User Image Cart Icon 0 Search Image
  • Home > Blog > Aldosterone & Obesity/hypertension

Aldosterone & Obesity/hypertension

  1. Aldosterone in obesity
  2. Resistant hypertension, obesity, sleep apnea, and Aldosterone: theory and therapy
  3. The role of Aldosterone in obesity-related hypertension
  4. Visceral obesity and insulin resistance are associated with plasma Aldosterone levels in women
  5. obesity, hypertension and Aldosterone: is leptin the link?
  6. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration
  7. Aldosterone production and signaling dysregulation in obesity
  8. Fibrosis and cardiac function in obesity: a randomised controlled trial of Aldosterone blockade
  9. Plasma Aldosterone, plasma lipoproteins, obesity and insulin resistance in humans
  10. The role of the renin-angiotensin-Aldosterone system in obesity-related renal diseases
  11. Adipocytes produce Aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus–associated obesity and vascular dysfunction
  12. Adipocytes, Aldosterone and obesity-related hypertension
  13. The link between the renin-angiotensin-Aldosterone system and renal injury in obesity and the metabolic syndrome
  14. Leptin-Aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity
  15. The renin–angiotensin–Aldosterone system as a link between obesity and coronavirus disease 2019 severity
  16. obesity, sleep apnea, Aldosterone, and hypertension
  17. Morbid obesity, hypertensive disease and the renin-angiotensin-Aldosterone axis
  18. Vasculometabolic and Inflammatory Effects of Aldosterone in obesity
  19. A critical review of the evidence supporting Aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension
  20. The regulation of Aldosterone secretion by leptin: implications in obesity-related cardiovascular disease
  21. The renin angiotensin Aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome
  22. obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of Aldosterone, neprilysin, and sodium-glucose …
  23. The association of Aldosterone with obesity-related hypertension and the metabolic syndrome
  24. The link between adipose tissue renin-angiotensin-Aldosterone system signaling and obesity-associated hypertension
  25. The involvement of Aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes
  26. Interaction of Aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review
  27. Fat cells may be the obesity–hypertension link: human adipogenic factors stimulate Aldosterone secretion from adrenocortical cells
  28. obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-Aldosterone system
  29. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and Aldosterone levels in morbid obesity
  30. Role of mineralocorticoid receptor and renin–angiotensin–Aldosterone system in adipocyte dysfunction and obesity
  31. Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity
  32. obesity-induced hypertension develops in young rats independently of the renin-angiotensin-Aldosterone system
  33. Differential effects of renin–angiotensin–Aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity …
  34. Role of renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
  35. Relationship between obesity, hypertension, and Aldosterone production in postmenopausal African American women: a pilot study
  36. Response to ‘renal injury in extreme obesity: the important role of Aldosterone‘
  37. Increased Aldosterone: mechanism of hypertension in obesity
  38. Changes in serum Aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults
  39. Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes
  40. Impact of obesity on the association of active renin and plasma Aldosterone concentrations, and Aldosterone-to-renin ratio with preeclampsia
  41. Reviving the use of Aldosterone inhibitors in treating hypertension in obesity
  42. Race, obesity, and the renin-angiotensin-Aldosterone system: treatment response in children with primary hypertension
  43. obesity and the renin–angiotensin–Aldosterone system
  44. PS 08-85 ASSOCIATION OF Aldosterone SYNTHASE (CYP11B2) GENE POLYMORPHISMS WITH obesity IN ESSENTIAL HYPERTENSIVE CHILDREN AND …
  45. Beneficial long-term effect of Aldosterone antagonist added to a traditional blockade of the renin–angiotensin–Aldosterone system among patients with obesity …
  46. Changes in Aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young …
  47. Insulin resistance and the renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
  48. The renin, angiotensin, Aldosterone, and obesity connection
  49. The renin-angiotensin-Aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity
  50. The Relationship between obesity, insulin resistance and Aldosterone levels
  51. Emerging role of Aldosterone in mediating the vicious cycle of obesity, insulin resistance and metabolic syndrome
  52. Distribution of genotypes and alleles of the Aldosterone-synthase gene in patients with abdominal obesity
  53. Targeting the Renin-Angiotensin-Aldosterone System in obesity
  54. Altered circadian plasma cortisol and Aldosterone group rhythms in Cushing’s syndrome versus obesity and health.
  55. Characteristics of the Renin-Angiotensin-Aldosterone System in Carriers of Polymorphic Variants of the VDR Gene With Arterial hypertension and obesity
  56. obesity-stimulated Aldosterone release is not related to an S1P-dependent mechanism
  57. ARTERIAL STIFFNESS, Aldosterone, CRP AND DIASTOLIC DYSFUNCTION IN PATIENTS WITH hypertension, obesity AND ATRIAL FIBRILLATION
  58. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND ARTERIAL hypertension
  59. Changes in excretion of Aldosterone in urine during absolute starvation in essential obesity.
  60. The Renin-Angiotensin-Aldosterone System as a Link Between obesity and Coronavirus Disease 2019 Severity
  61. Effect of Aldosterone receptor antagonist on obesity-related glomerulonephropathy
  62. Aldosterone Production and Signaling Dysregulation in obesity
  63. Adipocyte-derived Aldosterone And Cortisol Are Nox1/4 Dependent: Implications In obesity-associated Vascular Dysfunction.
  64. … efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal dysfunction
  65. Role of Aldosterone in obesity-induced endothelial dysfunction
  66. Aldosterone synthase gene polymorphism in alimentary obesity, metabolic syndrome components, some secondary forms of arterial hypertension, pathology of the …
  67. RELATIONSHIP BETWEEN obesity AND PLASMA Aldosterone IN ESSENTIAL hypertension: INFLUENCE OF GENDER: PP. 34.372
  68. Possible Interactions Among Fatty Acids, Other Lipids, and Aldosterone in the hypertension of obesity
  69. Influence of Race and obesity on the Renin-Angiotensin-Aldosterone System in Adolescents Born Preterm
  70. Does Renin‐Angiotensin‐Aldosterone System Inhibition Impact obesity as a Co–Risk Factor?
  71. P658Left ventricular function improvement by Aldosterone blockade in obesity: contribution of beneficial changes in collagen turnover
  72. BAS/BSCR35 Effects of Aldosterone and obesity on the anticontractile properties of perivascular adipose tissue in rat aortic rings
  73. Abstract MP009: Changes in Aldosterone are Associated With Changes in obesity-Related Factors in Normotensive Overweight/Obese Young Adults Undergoing …
  74. RENIN-ANGIOTENSIN-Aldosterone-SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND hypertension: PP. 26.334
  75. The relationship between renin-Aldosterone system and obesity in non-insulin dependent diabetes mellitus (NIDDM).
  76. Role of the adipose-tissue renin-angiotensin-Aldosterone system in obesity and obesity-associated hypertension.
  77. obesity, adipocytes, and the renin-angiotensin-Aldosterone axis.
  78. … of Aldosterone, Plasma Renin Activity (PRA) and Superoxide Dismutase (SOD) with Inflammation and Insulin Resistance in Adult Men with Central obesity
  79. Effect of obesity on Activation of the Renin Angiotensin-Aldosterone system in Patients with Moderate to Advanced Heart Failure
  80. Differential aspects of the dynamics of the renin-angiotensin-Aldosterone system in obesity with and without hypertension and in essential arterial hypertension
  81. … receptor agonists and antagonists of Aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity
  82. Hyperinsulinemia Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 …
  83. Function of the adrenal cortex in obesity. 6. Aldosterone secretion and excretion of its metabolites during some dynamic tests.
  84. Abstract A39: Gene-environment interactions between SNPs in the renin-angiotensin-Aldosterone system and hypertension, obesity, and blood pressure-related …
  85. Function of the adrenal cortex in obesity. 5. Daily secretion of Aldosterone.
  86. … : C-344T Aldosterone-SYNTHASE GENE POLYMORPHISM AND RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity
  87. … growth factor-23—klotho—vitamin D 3 axis and the renin—angiotensin—Aldosterone axis in the development and progression of obesity-related kidney disease
  88. PS 04-15 MICE LACKING Aldosterone SYNTHASE OR TREATED WITH EPLERENONE ARE RESISTANT TO DIET-INDUCED obesity
  89. Role of NADPH oxidase (Nox) 1/4 in adipocyte-derived Aldosterone production and in inflammation and fibrosis in obesity
  90. 6.1 hypertension Associated with obesity or Overweight: a Role for Aldosterone?
  91. The renin–angiotensin–Aldosterone system, glucose metabolism and diabetes
  92. Plasma Aldosterone concentration in the patient with diabetes mellitus Rapid Communication
  93. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
  94. Local renal Aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor
  95. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease
  96. Renin‐angiotensin‐Aldosterone system in diabetes and hypertension
  97. Diabetes mellitus, the renin-angiotensin-Aldosterone system, and the heart
  98. The role of the renin-angiotensin-Aldosterone system in diabetes and its vascular complications
  99. Selective Aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
  100. Renin‐angiotensin‐Aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA
  101. … role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, Aldosterone and catecholamines in type 1 (insulin-dependent) diabetes …
  102. Blockade of the renin–angiotensin–Aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
  103. Sodium, renin, Aldosterone, catecholamines, and blood pressure in diabetes mellitus
  104. Diabetes and reninangiotensin-Aldosterone system: implications for COVID-19 patients with diabetes treatment management
  105. Evidence for renoprotection by blockade of the renin–angiotensin–Aldosterone system in hypertension and diabetes
  106. Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus
  107. The crosstalk between insulin and renin-angiotensin-Aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention
  108. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–Aldosterone system in type 2 diabetes: a prospective study using …
  109. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus
  110. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic …
  111. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson Heart Study
  112. A systematic review of the role of renin angiotensin Aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy
  113. Increased Aldosterone levels in a model of type 2 diabetes mellitus
  114. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus
  115. Renin-angiotensin-Aldosterone system activation in long-standing type 1 diabetes
  116. Impact of the renin-angiotensin-Aldosterone-system on cardiovascular and renal complications in diabetes mellitus
  117. The renin-angiotensin-Aldosterone system and the eye in diabetes
  118. Big renin and biosynthetic defect of Aldosterone in diabetes mellitus
  119. The state and responsiveness of the renin-angiotensin-Aldosterone system in patients with type II diabetes mellitus
  120. Aldosterone and type 2 diabetes mellitus
  121. Renin-angiotensin-Aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes
  122. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study
  123. Blocking the renin-angiotensin-Aldosterone system to prevent diabetes mellitus
  124. Aldosterone responsiveness in patients with diabetes mellitus
  125. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated Aldosterone-induced renal fibrosis in mice with diabetes
  126. Renin-angiotensin-Aldosterone system in diabetes mellitus.
  127. Effect of renin–angiotensin–Aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review …
  128. Diabetes impairs the vascular effects of Aldosterone mediated by G protein-coupled estrogen receptor activation
  129. The renin-angiotensin-Aldosterone system is suppressed in adults with type 1 diabetes
  130. Determinants and changes associated with Aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy
  131. Cardiac Aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density
  132. The role of renin–angiotensin–Aldosterone system‐based therapy in diabetes prevention and cardiovascular and renal protection
  133. The role of Aldosterone in cardiovascular disease in people with diabetes and hypertension: an update
  134. Aldosterone induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant administration
  135. Renin–angiotensin–Aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients
  136. Higher screening Aldosterone to renin ratio in primary aldosteronism patients with diabetes mellitus
  137. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for Aldosterone involvement in the pathogenesis of renal dysfunction
  138. The tissue renin-angiotensin-Aldosterone system in diabetes mellitus
  139. Impact of aliskiren treatment on urinary Aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy
  140. Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of Aldosterone synthase
  141. The study of renin–angiotensin–Aldosterone in experimental diabetes mellitus
  142. Renin-angiotensin-Aldosterone system, electrolyte homeostasis and blood pressure in alloxan diabetes.
  143. The role of the tissue renin-angiotensin-Aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications
  144. Serum potassium is a predictor of incident diabetes in African Americans with normal Aldosterone: the Jackson Heart Study
  145. Renin angiotensin Aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
  146. Effect of renin-angiotensin-Aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on …
  147. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
  148. Responsiveness of plasma renin and Aldosterone in diabetes mellitus
  149. Glucose-induced hyperkalemia with normal Aldosterone levels: Studies in a patient with diabetes mellitus
  150. … between urinary sodium excretion and serum Aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–Aldosterone …
  151. Low plasma Aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation
  152. Ongoing treatment with renin-angiotensin-Aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population
  153. Associations between glycaemic control and activation of the renin-angiotensin-Aldosterone system in participants with type 2 diabetes mellitus and hypertension
  154. Individual variability in response to renin angiotensin Aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care …
  155. Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the Aldosterone/mineralocorticoid receptor system
  156. Decreases in renin and Aldosterone secretion in alloxan diabetes: an effect of insulin deficiency
  157. The renin‐Aldosterone axis in patients with diabetes insipidus
  158. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems
  159. Aldosterone-mediated apical targeting of ENaC subunits is blunted in rats with streptozotocin-induced diabetes mellitus
  160. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
  161. Renin-angiotensin-Aldosterone system blockade in diabetes: role of direct renin inhibitors
  162. Mechanistic and clinical aspects of renin-angiotensin-Aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease
  163. Reduced plasma Aldosterone concentrations in randomly selected patients with insulin‐dependent diabetes mellitus
  164. Increased integrated concentration of norepinephrine, epinephrine, Aldosterone, and growth hormone in patients with uncontrolled juvenile diabetes mellitus
  165. Effect of sodium glucose co-transporter-2 inhibition on the Aldosterone/renin ratio in type 2 diabetes mellitus
  166. Changes of Aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea–hypopnea syndrome before and after …
  167. Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
  168. Renin–angiotensin–Aldosterone–blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy
  169. … of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–Aldosterone system blockade in albuminuric hypertensive type 2 diabetes …
  170. Effect of acute hyperglycaemia on plasma potassium and Aldosterone levels in type 2 (non-insulin-dependent) diabetes
  171. Atrial natriuretic peptide and renin-angiotensin-Aldosterone system in non-insulin-dependent diabetes mellitus.
  172. Dissociation of renin and Aldosterone during dehydration: studies in a case of diabetes insipidus and adipsia
  173. Responsiveness of plasma Aldosterone to angiotensin II in patients with diabetes mellitus
  174. Aldosterone responses to angiotensin II, adrenocorticotropin, and potassium in chronic experimental diabetes mellitus in rats
  175. RU28318, an Aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes
  176. Renin angiotensin-Aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients—A Retrospective Study
  177. Add-on antihypertensive medications to angiotensin-Aldosterone system blockers in diabetes: a comparative effectiveness study
  178. Renin-Aldosterone responsiveness in uncomplicated juvenile-type diabetes mellitus
  179. Renin-Aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration
  180. … Renal Association clinical guidelines: hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or …
  181. … of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and Aldosterone …
  182. Blockade of the renin-angiotensin-Aldosterone system and renal protection in diabetes mellitus
  183. Renin‐Angiotensin‐Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria
  184. Altered relation of the renin-Aldosterone system and vasoactive peptides in type 2 diabetes: the KORA F4 study
  185. Renin-angiotensin-Aldosterone system antagonists and the prevention of type 2 diabetes mellitus
  186. Advanced glycation of high-density lipoprotein and the functionality of Aldosterone release in type 2 diabetes
  187. Renin angiotensin Aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism
  188. Responsiveness of plasma 18-hydroxycorticosterone and Aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus
  189. Production of Aldosterone in male rats with inherited diabetes insipidus (Brattleboro strain)
  190. … –Aldosterone system before and during submaximal bicycle exercise in relation to circulatory catecholamines in patients with Type 1 (insulin-dependent) diabetes …
  191. THE RENIN‐Aldosterone SYSTEM IN NEPHROGENIC DIABETES INSIPIDUS AND THE INFLUENCE OF HYDROCHLOROTHIAZIDE AND INDOMETHACIN
  192. Recurrent hyperkalemic renal tubular acidosis and hyponatremia in diabetes mellitus due to Aldosterone resistance
  193. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
  194. P153 Modulation of renin-angiotensin-Aldosterone system reverses adverse left atrial remodelling in type 2 diabetes
  195. Renoprotective effects of renin–angiotensin–Aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis
  196. Relationships between renin, Aldosterone, blood pressure and renal function in hypertensive insulin-dependent diabetes mellitus
  197. Aldosterone responsiveness to an acute potassium load in diabetes mellitus and chronic renal insufficiency
  198. Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-Aldosterone System
  199. Effects of amiloride on oral glucose loading, serum potassium, renin, and Aldosterone in diet‐controlled diabetes
  200. Glomerular hyperfiltration in insulin-dependent diabetes mellitus: no evidence for enhanced activity of the renin-angiotensin-Aldosterone system
  201. Renin–angiotensin–Aldosterone system blockade and urinary albumin excretion in community‐based patients with Type 2 diabetes: The Fremantle Diabetes Study
  202. Genetic polymorphism of renin-angiotensin-Aldosterone system in type 2 diabetes and in combination with arterial hypertension among Dagestan inhabitants
  203. The function of Aldosterone in patients with diabetes
  204. Renin-angiotensin-Aldosterone system in diabetes insipidus
  205. Diabetes insipidus after surgery of intracranial arterial aneurysms–with special reference to the human ADH and Aldosterone secretion (author’s transl)
  206. … angiotensin converting enzyme (ACE) insertion/deletion and Aldosterone synthase (CYP11B2)-344C/T polymorphisms in relation to type 2 diabetes mellitus risk in …
  207. The Role of Aldosterone in Diabetes-Related Vascular Disease: A New Therapeutic Target?
  208. Plasma renin and Aldosterone in youngsters with insulin-dependent diabetes mellitus
  209. The efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal …
  210. Azelnidipine Decreased Plasma Aldosterone andPlasminogen Activator Inhibitor Type 1 Levelsin the Hypertensive Patients with Type 2 Diabetes Mellitus―the Jikei …
  211. Relationship between Aldosterone and diabetes mellitus and its chronic complications
  212. Correlation Between Aldosterone and Gestational Diabetes Mellitus.
  213. Effects of Aldosterone, methylprednisolone and triiodothyronine on the response to water loading in the conscious hypothyroid rat with diabetes insipidus.
  214. Aldosterone excess: a rare non-nephrophathic cause of hypertension in type I diabetes.
  215. 538-P: Copeptin and Renin Angiotensin Aldosterone System (RAAS) Activation in Long-Standing Type 1 Diabetes (T1D)
  216. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
  217. Mineralocorticoid receptor and diabetes: in favour of other corticosteroids than Aldosterone
  218. Aldosterone prevents deleterious effects of diabetes in mouse hearts
  219. The effect of rosiglitazone combined with insulin on plasma Aldosterone in diabetes patients
  220. Aldosterone and Protein Disulfide Isomerase Activity in Diabetes
  221. Aldosterone Prevents Deleterious Effects of Diabetes in Mouse Hearts by a Proangiogenic Effect
  222. hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
  223. … , May 15, 10: 00 AM-12.00 PM: Rationale for Aldosterone receptor blockade in the treatment of cardiovascular diseases*: Aldosterone receptor antagonists in diabetes …
  224. Pancreatic Renin‐Angiotensin‐Aldosterone System in the Cardiometabolic Syndrome and Type 2 Diabetes Mellitus
  225. … of acid-releasing renal function of rats in the dynamics of experimental diabetes mellitus with underlying pharmacological blockade of renin-angiotensin-Aldosterone …
  226. Cardiovascular Complications in Diabetes: Role of Aldosterone and Mineralocorticoid Receptors
  227. Acute Aldosterone Administration Increases Vascular Resistance in Patients with Type 2 Diabetes
  228. The Increase of Plasma Aldosterone Concentrations Were Correlated with Insulin Resistance in Patients with Type 2 Diabetes Mellitus.
  229. Aldosterone antagonism in type 2 diabetes mellitus—a new therapeutic approach to diabetic macrovascular disease?
  230. N‐Acetylcysteine Attenuates Aldosterone induced Vasoconstriction in Individuals with Type 2 Diabetes
  231. Relationship Between Circulating Aldosterone and Adipocytokines or Oxidative Stress in Patients With Type 2 Diabetes
  232. Renin Angiotensin Aldosterone System (RAAS) Activation and Diabetic Nephropathy (DN) Resistor Status in Longstanding Type 1 Diabetes
  233. … Usage of Renin-Angiotensin-Aldosterone System Blocking Agents on Incidence of Contrast-Induced Nephropathy in Patients with Diabetes Mellitus and Renal …
  234. Comparison of the morphological changes in the capillaries and the state of the renin-angiotensin-Aldosterone system in diabetes mellitus
  235. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN DIABETES MELLITUS
  236. H003 Cardiac Aldosterone overexpression prevents harmful effects of diabetes in mouse heart by preserving capillary density
  237. Correlation between insulin resistance and renin-angiotensin-Aldosterone system in newly diagnosed type 2 diabetes mellitus
  238. Plasma and Urinary Aldosterone Levels in Rats with Non-Insulin Dependent Diabetes Mellitus-Association with Myocardial Fibrosis
  239. The role of the renin-angiotensin-Aldosterone system blockade in preventing type 2 diabetes
  240. G Protein-coupled Estrogen Receptor Contributes To The Vascular Effects Of Aldosterone And Type Two Diabetes-associated Vascular Dysfunction
  241. Ednit effects on activity of renin-angiotensin-Aldosterone system and renal function in hypertensive subjects with diabetes mellitus
  242. Effects of atenolol add-on treatment on plasma renin activity (PRA) and Aldosterone escape in hypertensive patients with diabetes receiving valsartan
  243. Are renin angiotensin Aldosterone system gene polymorphisms risk factors for hypertension and diabetes? A literature review report from Malaysia
  244. … ADHERENCE TO RENIN-ANGIOTENSIN-Aldosterone-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES: A …
  245. Orthostatic hypotension in complicated diabetes mellitus: study of the renin-angiotensin-Aldosterone system (author’s transl)
  246. Diabetes mellitus type-II related hypertension and cardiovascular diseases: involvement of impaired regulatory renin-angiotensin-Aldosterone system
  247. Abstract P632: Nlrp3/inflammasome Activation Contributes To Aldosterone-induced Vascular Dysfunction In Type 2 Diabetes.
  248. … autonomous Aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin-Aldosterone …
  249. Effect of sodium depletion on the renin-angiotensin-Aldosterone system and prostaglandins in patients with insulin-dependent diabetes mellitus
  250. Impaired Sodium Excretion during Water Immersion in Diabetes Mellitus: Observations on the Renin-Aldosterone System
  251. Renin‐angiotensin‐Aldosterone system blockade ameliorates myocardial and ventricular function of rats with diabetes mellitus
  252. … Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 Diabetes Mellitus
  253. Renin-Angiotensin-Aldosterone System of Local Organizations and Chronic Complications of Type 2 Diabetes
  254. Aldosterone, Not Leptin, is Correlated With High Sympathetic Activity in Resistant hypertension With or Without Type 2 Diabetes
  255. … with angiotensin converting enzyme inhibitor and Aldosterone antagonist on insulin sensitivity and serum leptin concentration in patients with type 2 diabetes …
  256. … NITRIC OXIDE SYNTHASE, ANGIOTENSINOGEN AND Aldosterone SYNTHASE GENE POLYMORPHISMS IN TYPE 2 DIABETES MELLITUS AND THEIR …
  258. The kidney in diabetes mellitus: urinary transfer in excretion, hypertension, the Renin-Angiotensin-Aldosterone system, and the role of angiotensin converting enzyme …
  259. PP. 09.11: ASSOCIATION OF PLASMA Aldosterone CONCENTRATION WITH PREVALENCE OF DIABETES MELLITUS IN SUSPECTED PRIMARY …
  260. CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System
  261. … irbesartan, and perindopril plus irbesartan on blood pressure, renal hemodynamics, proteinuria, renin angiotesin-Aldosterone system, and TGF-B1, in type 2 diabetes …
  262. A Nox4 Inhibitor, GKT 137831, Decreases Aldosterone Synthesis, Adiposity and Vascular Contractility in a Murine Model of Diabetes.
  263. Effect of 5-month guanfacine treatment on the renin-angiotensin-Aldosterone system and some metabolic factors in patients with diabetes mellitus type II and …
  264. S-423 Plasma Aldosterone level and its metabolic implications in patients with type 2 diabetes
  265. … CILNIDIPINE ON SYMPATHETIC NERVOUS SYSTEM AND PLASMA Aldosterone CONCENTRATION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES …
  266. … OF THE RENIN-ANGIOTENSIN SYSTEM AND PREVALENCE OF TYPE 2 DIABETES MELLITUS. A MODEST BUT SIGNIFICANT EFFECT OF Aldosterone …
  267. Aldosterone and arterial hypertension
  268. Mechanisms of hypertension: the expanding role of Aldosterone
  269. Serum Aldosterone and the incidence of hypertension in nonhypertensive persons
  270. Structural analysis and evaluation of the Aldosterone synthase gene in hypertension
  271. Genetic determination of plasma Aldosterone levels in essential hypertension
  272. Essential hypertension: renin and Aldosterone, heart attack and stroke
  273. Role of Aldosterone in left ventricular hypertrophy in hypertension
  274. hypertension: renin–angiotensin–Aldosterone system alterations
  275. Narrative review: the emerging clinical implications of the role of Aldosterone in the metabolic syndrome and resistant hypertension
  276. Aldosterone-receptor antagonism in hypertension
  277. Global-and renal-specific sympathoinhibition in Aldosterone hypertension
  278. Aldosterone, hypertension, and cardiovascular disease: an endless story
  279. Saline suppression of plasma Aldosterone in hypertension
  280. Plasma Aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension
  281. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension
  282. The renin-angiotensin-Aldosterone system: a specific target for hypertension management
  283. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and Aldosterone profiles
  284. ICV infusion of corticosterone antagonizes ICV-Aldosterone hypertension
  285. hypertension, increased Aldosterone secretion and low plasma renin activity relieved by dexamethasone
  286. Aldosterone Excretion Rate and Blood Pressure in Essential hypertension Are Related to Polymorphic Differences in the Aldosterone Synthase Gene CYP11B2
  287. Resistant hypertension, obstructive sleep apnoea and Aldosterone
  288. Aldosterone and the risk of hypertension
  289. Somatic mutations in ATP1A1 and ATP2B3 lead to Aldosterone-producing adenomas and secondary hypertension
  290. Aldosterone-to-renin ratio, arterial stiffness, and the response to Aldosterone antagonism in essential hypertension
  291. Intracerebroventricular infusion of Aldosterone induces hypertension in rats
  292. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome
  293. Aldosterone and the vasculature: mechanisms mediating resistant hypertension
  294. Association between increased plasma levels of Aldosterone and decreased systemic arterial compliance in subjects with essential hypertension
  295. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
  296. Aldosterone, inflammation, immune system, and hypertension
  297. Characterization of resistant hypertension: association between resistant hypertension, Aldosterone, and persistent intravascular volume expansion
  298. Severity of obstructive sleep apnea is related to Aldosterone status in subjects with resistant hypertension
  299. Central interactions of Aldosterone and angiotensin II in Aldosterone-and angiotensin II-induced hypertension
  300. Eplerenone, a selective Aldosterone blocker, in mild-to-moderate hypertension
  301. A chimaeric llβ-hydroxylase/Aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
  302. Influence of arterial blood pressure and Aldosterone on left ventricular hypertrophy in moderate essential hypertension
  303. Association of the C− 344T Aldosterone synthase gene variant with essential hypertension: a meta-analysis
  304. Increased cardiac types I and III collagen mRNAs in Aldosterone-salt hypertension.
  305. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-Aldosterone hypertension
  306. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of Aldosterone synthase
  307. Arterial pressure, left ventricular mass, and Aldosterone in essential hypertension
  308. Vascular complications in patients with Aldosterone producing adenoma in Japan: comparative study with essential hypertension
  309. Effects of the selective Aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
  310. Aldosterone is produced from ventricles in patients with essential hypertension
  311. Aldosterone antagonists in hypertension and heart failure.
  312. Aldosterone antagonist improves diastolic function in essential hypertension
  313. Molecular basis of salt sensitivity in human hypertension: evaluation of renin-angiotensin-Aldosterone system gene polymorphisms
  314. Aldosterone secretion and primary and malignant hypertension
  315. Experimental Aldosterone hypertension in the dog.
  316. Intracerebroventricular infusion of RU28318 blocks Aldosterone-salt hypertension
  317. Influence of antihypertensive medication on Aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism
  318. Variation at the Aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised Aldosterone-to-renin ratio
  319. Renin-Aldosterone Relationships in Pregnancy-Induced hypertension: An Alternative Viewpoint
  320. Molecular genetics of the renin-angiotensin-Aldosterone system in human hypertension.
  321. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, Aldosterone excess, and low plasma renin
  322. hypertension and severe hyperkalaemia associated with suppression of renin and Aldosterone and completely reversed by dietary sodium restriction
  323. Genetic variants in the epithelial sodium channel in relation to Aldosterone and potassium excretion and risk for hypertension
  324. Plasma renin activity and angiotensin I and Aldosterone concentrations in cats with hypertension associated with chronic renal disease.
  325. hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-Aldosterone systems.
  326. Myocardial ultrasonic backscatter in hypertension: relation to Aldosterone and endothelin
  327. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, Aldosterone and blood pressure levels.
  328. Brain sodium channels and ouabainlike compounds mediate central Aldosterone-induced hypertension
  329. … of congestive heart failure: vasopressin, Aldosterone, and angiotensin II: further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis
  330. … -responsive Aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension.
  331. Investigation of the role of Aldosterone in hypertension associated with spontaneous pituitary‐dependent hyperadrenocorticism in dogs
  332. Ratio of serum Aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism
  333. Assessment of the novel selective Aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
  334. Genetic polymorphism of the renin–angiotensin–Aldosterone system and arterial hypertension in the Italian population: the GENIPER Project
  335. Long-term safety and efficacy of the selective Aldosterone blocker eplerenone in patients with essential hypertension
  336. Haplotype analysis of Aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension
  337. Can the genetic factors influence the treatment of systemic hypertension? The case of the renin-angiotensin-Aldosterone system
  338. Incidence of primary aldosteronism uncomplicated essential hypertension: a prospective study with elevated Aldosterone secretion and suppressed plasma renin …
  339. Non-genomic actions of Aldosterone: role in hypertension
  340. Aldosterone-producing adenoma without hypertension: a report of two cases
  341. The control of Aldosterone secretion in normal and hypertensive man: abnormal renin-Aldosterone patterns in low renin hypertension
  342. Relation of renin, angiotensin II, and experimental renal hypertension to Aldosterone secretion
  343. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension
  344. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-Aldosterone …
  345. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, Aldosterone-producing adenoma, and pheochromocytoma
  346. Age versus urinary sodium for judging renin, Aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension
  347. Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-Aldosterone system
  348. Angiotensin, Aldosterone and human arterial hypertension
  349. Is Aldosterone the missing link in refractory hypertension?: Aldosterone-to-renin ratio as a marker of inappropriate Aldosterone activity
  350. Effect of chronic diuretic treatment on the plasma renin‐angiotensin‐Aldosterone system in essential hypertension.
  351. > VI. RENIN, Aldosterone, AND hypertension: The Intercurrent hypertension of Primary Aldosteronism
  352. Contrasting associations between Aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites
  353. Renin and Aldosterone levels and hypertension following envenomation in humans by the yellow scorpion Leiurus quinquestriatus
  354. Importance of the renin-angiotensin-Aldosterone system (RAS) in the physiology and pathology of hypertension
  355. Plasma Aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension
  356. Plasma Aldosterone-renin interrelationships in various forms of essential hypertension: studies using a rapid assay of plasma Aldosterone
  357. Production of experimental hypertension by Aldosterone
  358. hypertension and hypersalimentation. 1. Aldosterone hypertension.
  359. Renin, Aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of Goldblatt hypertension in conscious dogs
  360. Familial hyperpotassemia and hypertension accompanied by normal plasma Aldosterone levels: possible hereditary cell membrane defect
  361. Renin-angiotensin-Aldosterone system gene polymorphisms and hypertension in Hong Kong Chinese
  362. Abnormally sustained Aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity
  363. Essential hypertension and Aldosterone
  364. … of Aldosterone in man: Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension
  365. Serum Aldosterone level in patients with hypertension during treatment by acupuncture
  366. VI. RENIN, Aldosterone, AND hypertension: The Relationship Between Plasma Renin and Aldosterone in Normal Man
  367. Aldosterone metabolites and possible Aldosterone precursors in hypertension
  368. Aldosterone synthase (CYP11B2)− 344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension
  369. Influence of plasma Aldosterone on left ventricular geometry and diastolic function in treated essential hypertension
  370. Effect of fructose-induced hypertension on the renin-angiotensin-Aldosterone system and atrial natriuretic factor
  371. Further studies on urinary Aldosterone in human arterial hypertension.
  372. The cardiac structure-function relationship and the renin-angiotensin-Aldosterone system in hypertension and heart failure
  373. Impact of renin-angiotensin-Aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension
  374. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of Aldosterone in hypertension
  375. Familial hyperkalemia, hypertension, and hyporeninemia with normal Aldosterone levels: A tubular defect in potassium handling
  376. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-Aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension.
  377. Eplerenone: a selective Aldosterone receptor antagonist for hypertension and heart failure.
  378. Disparate patterns of Aldosterone response during diuretic treatment of hypertension
  379. Effect of atrial natriuretic factor on blood pressure, renin, and Aldosterone in Goldblatt hypertension.
  380. Results of adrenal surgery in patients with hypertension, Aldosterone excess, and low plasma renin concentration.
  381. Alterations in Aldosterone secretion and metabolism in low renin hypertension
  382. Regulation of cardiac output during Aldosterone-induced hypertension.
  383. Renin-Aldosterone profiling in hypertension
  384. Aldosterone studies in obese patients with hypertension
  385. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with Aldosterone and the increase in sodium-proton exchanger activity.
  386. Reversal of cardiovascular structural changes when treating essential hypertension: the importance of the renin-angiotensin-Aldosterone system
  387. Combining renin-angiotensin-Aldosterone system blockade with diuretic therapy for treatment of hypertension
  388. Functional derangements in the regulation of Aldosterone secretion in hypertension.
  389. Role of renin-angiotensin-Aldosterone system in salt-sensitive hypertension induced by sensory denervation
  390. Endothelin receptor blockade lowers plasma Aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension
  391. Aldosterone and specific Aldosterone receptor antagonists in hypertension and cardiovascular disease
  392. Possible mechanism of action for Aldosterone-induced hypertension
  393. Aldosterone antagonists in the treatment of hypertension and target organ damage
  394. Effect of nifedipine on plasma renin, Aldosterone and catecholamines in arterial hypertension
  395. Enhanced Aldosterone response to angiotensin II in human hypertension.
  396. Aldosterone and renin in essential hypertension.
  397. Role of the Aldosterone system in the salt-sensitivity of patients with benign essential hypertension
  398. Symptoms and the distress they cause: comparison of an Aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension
  399. Renin-angiotensin-Aldosterone and hypertension
  400. Electrolyte metabolism and Aldosterone secretion in benign and malignant hypertension
  401. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-Aldosterone system
  402. Aldosterone excretion in essential hypertension
  403. Calcium metabolism and the renin-Aldosterone system in essential hypertension.
  404. Does the renin-angiotensin-Aldosterone system modify cardiac structure and function in essential hypertension?
  405. The steroid content of adrenal adenomas and measurements of Aldosterone production in patients with essential hypertension and primary aldosteronism
  406. The role of Aldosterone in the development of hypertension in spontaneously hypertensive rats
  407. Malignant hypertension due to an Aldosterone producing adrenal adenoma
  408. Effect of corticotropin on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
  409. Role of renin and Aldosterone in hypertension due to a renin-secreting tumor
  410. Studies on Aldosterone: II. hypertension as a cumulative effect of Aldosterone administration
  411. Unexpected pressor responses to propranolol in essential hypertension: an interaction between renin, Aldosterone and sympathetic activity
  412. Low-renin, low-Aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child
  413. The role of the renin-angiotensin-Aldosterone system in circulatory control and hypertension.
  414. Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-Aldosterone system
  415. Influence of sodium intake on hydrochlorothiazide‐induced changes in blood pressure, serum electrolytes, renin and Aldosterone in essential hypertension
  416. Malignant hypertension: effect of therapy on renin and Aldosterone
  417. Role of Aldosterone in angiotensin II-induced hypertension in rats
  418. Effects of losartan on the renin-angiotensin-Aldosterone axis in essential hypertension.
  419. The influence of a heparin-like compound on hypertension, electrolytes and Aldosterone in man
  420. hypertension with Aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour
  421. Renin-angiotensin-Aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension
  422. Aldosterone diagnosis in hypertension: comparative evaluation of radioimmunoassays for urinary Aldosterone and 18-OH-corticosterone
  423. Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young‐Onset Essential hypertension
  424. Effects of glucocorticoid administration on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
  425. hypertension corrected and Aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible …
  426. Serum Aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension
  427. Renin, Aldosterone, sodium and hypertension
  428. Molecular variants in the P450c11AS gene as determinants of Aldosterone synthase activity in the Dahl rat model of hypertension
  429. Gene polymorphisms of the renin-angiotensin-Aldosterone system and essential arterial hypertension in childhood.
  430. Abnormal responsiveness of the renin Aldosterone system to acute stimulation in patients with essential hypertension
  431. hypertension induced by oral contraceptives containing estrogen and gestagen: effects on plasma renin activity and Aldosterone excretion
  432. Aldosterone secretion in hypertension
  433. Effects of biobehaviorally-assisted relaxation training on blood pressure, plasma renin, cortisol, and Aldosterone levels in borderline essential hypertension.
  434. Renin-angiotensin-Aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in …
  435. A decreased metabolic clearance rate of Aldosterone in benign essential hypertension
  436. Plasma renin activity and plasma Aldosterone concentrations in untreated Nigerians with essential hypertension.
  437. Adrenal sensitivity to angiotensin II and undiscovered Aldosterone stimulating factors in hypertension
  438. Renin-angiotensin-Aldosterone system and sodium balance in experimental renal hypertension
  439. Interaction between Aldosterone secretion, sodium and potassium balance, and angiotensin activity in man: studies in hypertension and cirrhosis
  440. Coronary microvascular fluid flux and permeability: influence of angiotensin II, Aldosterone, and acute arterial hypertension
  441. Sodium sensitivity in essential hypertension: role of the renin-angiotensin-Aldosterone system and predictive value of an intravenous frusemide test.
  442. Altered renin-angiotensin-Aldosterone relationships in normal renin essential hypertension.
  443. Maternal hypertension and progeny blood pressure: role of Aldosterone and 11β-HSD
  444. Dysregulation of Aldosterone secretion and its relationship to the pathogenesis of essential hypertension
  445. Artificial mutations in P450c11AS (Aldosterone synthase) can increase enzymatic activity: a model for low-renin hypertension?
  446. Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-Aldosterone system
  447. Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, Aldosterone, urinary metanephrines and response to thiazide …
  448. Renin-angiotensin-Aldosterone system during chronic thiazide therapy of benign hypertension
  449. Angiotensin and Aldosterone in renovascular hypertension
  450. Studies of the renin-angiotensin-Aldosterone system in patients with hypertension and in normal subjects
  451. Metabolic cardiovascular risk factors and the renin-Aldosterone system in essential hypertension.
  452. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-Aldosterone system
  453. Effects of angiotensin infusions on Aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders
  454. Response of Aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn’s syndrome, and …
  455. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in Aldosterone-induced hypertension
  456. Calcium sensitivity of isometric force in intact and chemically skinned aortas during the development of Aldosterone-salt hypertension in the rat.
  457. Effect of posture on the plasma concentrations of Aldosterone in hypertension and primary hyperaldosteronism
  458. Altered Aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension
  459. Aldosterone receptor antagonists for hypertension
  460. … of angiotensin converting enzyme inhibitors in essential and renal hypertension: effects of captopril and enalapril on renin-angiotensin-Aldosterone, renal function and …
  461. The role of ACTH in the episodic release of Aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism
  462. Low renin,“normal” Aldosterone and hypertension: Circadian rhythm of renin, Aldosterone, Cortisol and growth hormone
  463. Vascular responsiveness in rats resistant to Aldosterone-salt hypertension.
  464. hypertension with Aldosterone excess.
  465. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-Aldosterone system in patients with essential hypertension
  466. The promise of selective Aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure
  467. Long-term effects of irbesartan and atenolol on the renin-angiotensin-Aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular …
  468. hypertension caused by an Aldosterone-secreting adenoma: occurrence in a 7-year-old child
  469. A delayed suppression of the renin-Aldosterone axis following saline infusion in human hypertension.
  470. The effect of low and high sodium diets on plasma atrial natriuretic factor, the renin‐Aldosterone system and blood pressure in subjects with essential hypertension
  471. Renin-angiotensin-Aldosterone system in pregnancy-induced hypertension
  472. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma Aldosterone in essential hypertension
  473. Plasma renin activity (PRA) and Aldosterone (PA) in patients with chronic glomerulonephritis (GN) and hypertension.
  474. The renin—angiotensin—Aldosterone system and carotid artery disease in mild-to-moderate primary hypertension
  475. Renin-angiotensin-Aldosterone system, RR interval, and blood pressure variability during postural changes in borderline arterial hypertension
  476. Adenovirus-mediated human prostasin gene delivery is linked to increased Aldosterone production and hypertension in rats
  477. Aldosterone and corticosterone secretion rates in rats with experimental renal hypertension
  478. Aldosterone in sustained essential hypertension
  479. Rhythm characteristics of plasma renin, Aldosterone and cortisol in five subtypes of mesor-hypertension
  480. Triamterene-Induced Changes in Aldosterone and Renin Values in Essential hypertension: Evidence of a Role for Aldosterone in Preventing Blood Pressure …
  481. Renin and Aldosterone in essential hypertension
  482. Aldosterone and electrolyte balance in human hypertension
  483. Quadric analysis in the preoperative distinction between patients with and without adrenocortical tumors in hypertension with Aldosterone excess and low plasma …
  484. Body fluid volumes and the response of renin and Aldosterone to short‐and long‐term thiazide therapy of essential hypertension
  485. Aldosterone, the adrenal cortex, and hypertension
  486. hypertension and Aldosterone overproduction without renin suppression in Cushing’s syndrome from an adrenal adenoma
  487. Circadian changes in plasma renin activity and plasma Aldosterone concentration in two-kidney hypertension rats.
  488. Aldosterone-related genetic effects in hypertension
  489. Heritable abnormalities of the renin-angiotensin-Aldosterone system in essential hypertension.
  490. … hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary Aldosterone …
  491. Regulation of Aldosterone receptors in hypertension
  492. Plasma Renin Activity and in vitro Synthesis of Aldosterone by the Adrenal Glands of Rats with Spontaneous, Renal, or Pinealectomy‐Induced hypertension
  493. Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-Aldosterone system.
  494. Influence of Aldosterone vs endothelin receptor antagonism on renovascular function in liquorice‐induced hypertension
  495. Controlled study of circadian rhythm of blood pressure in patients with Aldosterone-producing adenoma compared with those with essential hypertension
  496. Different regulation of cardiac and renal corticosteroid receptors in Aldosterone-salt treated rats: effect of hypertension and glucocorticoids
  497. The Aldosterone to renin ratio in secondary hypertension
  498. Plasma deoxycorticosterone and Aldosterone in essential hypertension
  499. Urinary Aldosterone and hypertension
  500. Changes in the renin-angiotensin-Aldosterone system and in sodium and potassium balance during development of renal hypertension in rats
  501. Experimental Aldosterone hypertension in the rat
  502. The renin-angiotensin-Aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood …
  503. Activity of renin-angiotensin-Aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension
  504. … evidence on blocking the renin–angiotensin–Aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent …
  505. Aldosterone metabolic clearance is normal in low-renin essential hypertension
  506. Role of Aldosterone in the pathogenesis of hypertension
  507. Development of hypertension in rats treated with Aldosterone acetate
  508. Blunted Aldosterone responsiveness to angiotensin II in normotensive subjects with familial predisposition to essential hypertension.
  509. Relation between plasma renin activity, angiotensin, and Aldosterone and blood pressure in mild untreated hypertension.
  510. In vivo left ventricular function and collagen expression in Aldosterone/salt-induced hypertension
  511. Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular Aldosterone
  512. Unilateral Page kidney hypertension in man: Studies of the renin-angiotensin-Aldosterone system before and after nephrectomy
  513. Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I …
  514. … and calcium channel-blocking drugs on plasma Aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension
  515. hypertension and hypokalemic alkalosis associated with underproduction of Aldosterone
  516. Perspectives on the renin-angiotensin-Aldosterone system in hypertension
  517. Aldosterone suppression with dopamine infusion in low-renin hypertension.
  518. Dissociation of plasma renin activity and Aldosterone in essential hypertension
  519. The relationship of Aldosterone synthase gene polymorphism with hypertension and left ventricular hypertrophy
  520. Plasma immunoreactive gamma melanotropin in patients with idiopathic hyperaldosteronism, Aldosterone-producing adenomas, and essential hypertension.
  521. Modifications of myocardial Na+,K+-ATPase isoforms and Na+/Ca2+ exchanger in Aldosterone/salt-induced hypertension in guinea pigs
  522. Nomograms relating Aldosterone excretion to urinary sodium and potassium in the pediatric population: Their application to the study of childhood hypertension
  523. Characteristics of adrenal-regeneration and Aldosterone hypertension.
  524. Renin–angiotensin–Aldosterone system polymorphisms and essential hypertension: where are we?
  525. Failure of chronic Aldosterone infusion to increase arterial pressure in dogs with angiotensin-induced hypertension.
  526. Renin-angiotensin-Aldosterone system in experimental renal hypertension in the rabbit
  527. Relationship of plasma renin activity and Aldosterone levels with hemodynamic functions in essential hypertension
  528. The renin-Aldosterone system in pre-eclampsia, essential and transient hypertension during pregnancy, and normotensive pregnant and non-pregnant control …
  529. Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-Aldosterone and bradykinin profile in hypertension
  530. A study of urinary and intracellular sodium and potassium, renin, Aldosterone, and hypertension in blacks and Indians in Natal
  531. Dynamic Aldosterone and 18-hydroxydeoxycorticosterone studies in labile and stable benign essential hypertension
  532. Opposite associations of circulating Aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension
  533. Catecholamines and the renin-angiotensin-Aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
  534. Urinary Aldosterone and hypertension
  535. Effect of blood pressure angiotensin II and Aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with …
  536. The Role of Urinary PGE2 and Renin-Angiotensin-Aldosterone System in the Pathogenesis of Essential hypertension
  537. Dissociation in the excretion of different Aldosterone metabolites and unmetabolized (‘free’) Aldosterone in hypertension
  538. The Yucatan miniature swine: an improved pig model for the study of desoxycorticosterone-acetate (DOCA) and Aldosterone hypertension
  539. Relationship between plasma Aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment
  540. hypertension with inappropriate Aldosterone stimulation: a syndrome
  541. The integrated concentration of plasma renin activity and Aldosterone in essential hypertension.
  542. Reduced Aldosterone metabolites in hypertension
  543. Relations between renin, Aldosterone and experimental hypertension in rats
  544. The gerontological decline of the renin-Aldosterone system: a chronobiological approach extended to essential hypertension
  545. Circulatory volume in essential hypertension. Relationships with age, blood pressure, exchangeable sodium, renin, Aldosterone and catecholamines.
  546. Abnormal urinary kallikrein in hypertension is not related to Aldosterone or plasma renin activity.
  547. Short‐term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma Aldosterone in patients with essential hypertension
  548. … Renin Activity Ratio in Hypertensive Patients with Increases of 11-Deoxycorticosterone and 18-Hydroxy-ll-Deoxycorticosterone: A Subtype of Essential hypertension?
  549. Renal function, body fluid volumes, renin, Aldosterone, and noradrenaline during treatment of hypertension with pindolol.
  550. The adrenal cortex and hypertension: some observations on a possible role for mineralocorticoids other than Aldosterone
  551. Suppression of plasma renin and Aldosterone in stress-salt hypertension in dogs
  552. Suppression of the Renin—Aldosterone System in Mild Essential hypertension
  553. Response of plasma Aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension
  554. Dopaminergic regulation of circadian rhythms of blood pressure, renin and Aldosterone in essential hypertension
  555. The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and Aldosterone in hypertensive subjects
  556. Antihypertensive and Aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension.
  557. The Renin‐Aldosterone System and Renal Hemodynamics in Patients with Posttransplant hypertension
  558. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep
  559. High-renin malignant hypertension secondary to an Aldosterone-producing adenoma
  560. Sodium balance, plasma renin, and Aldosterone in hypertension.
  561. Effects of enalapril maleate on blood pressure, renin-angiotensin-Aldosterone system, and peripheral sympathetic activity in essential hypertension.
  562. Aldosterone and magnesium in essential arterial hypertension.
  563. The effects of sodium loading and deprivation on plasma renin and plasma and urinary Aldosterone in hypertension
  564. hypertension due to coexisting pheochromocytoma and Aldosterone-producing adrenal cortical adenoma
  565. The renin-angiotensin-Aldosterone system and hypertension in primary hyperparathyroidism
  566. Altered Ca-dependent fluxes of 42K in rat aorta during Aldosterone-salt hypertension.
  567. Effects of ACTH and posture on Aldosterone metabolism in essential hypertension
  568. … and indirect measurement of urinary kallikrein excretion in patients with essential hypertension and normotensives: relation to age and plasma renin and Aldosterone …
  569. Aldosterone secretion by dogs during the developmental phase of Goldblatt hypertension
  570. Effect of chlorothiazide upon Aldosterone excretion and sodium and potassium balance in essential hypertension
  571. Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, Aldosterone and arginine vasopressin in essential hypertension
  572. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects
  573. The renin-Aldosterone system and thiazide-induced depletion of total body potassium in essential hypertension
  574. … enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma Aldosterone in hypertensive diabetics compared to patients with essential hypertension.
  575. The renin-Aldosterone system in exaggerated natriuresis of essential hypertension
  576. Role of Aldosterone in the antihypertensive effect of spironolactone in essential hypertension
  577. Central and renal circulation, renin and Aldosterone in plasma during prazosin treatment in essential hypertension
  578. Plasma Aldosterone in essential hypertension with low renin activity
  579. … of nicardipine, a calcium‐entry blocker: Effects on renal function, plasma renin activity, and Aldosterone concentration in mild‐to‐moderate essential hypertension
  580. The effect of indomethacin on plasma renin activity and urinary Aldosterone of patients with essential hypertension
  581. Effect of an Aldosterone antagonist on electrolytes and juxtaglomerular granularity in adrenal regeneration hypertension
  582. Candesartan cilexetil in hypertension: Effects of six weeks’ treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-Aldosterone system
  583. The metabolic clearance of Aldosterone decreases similarly during infusion of angiotensin II in patients with essential hypertension and in normal subjects
  584. Malignant hypertension and Aldosterone secretion: Influence of reversal and progression of the syndrome in two cases
  585. Prostanoids and Aldosterone-induced mild experimental hypertension in rats.
  586. … paper: the renin-angiotensin-Aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyze different forms of hypertension
  587. Differences in adrenal cholesterol, ascorbic acid, circulating corticosterone and Aldosterone during the onset of hypertension in SHR vs WKy rats
  588. Responses of plasma catecholamines, renin-angiotensin-Aldosterone system, and atrial natriuretic peptide to exercise in patients with essential hypertension
  589. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma Aldosterone in idiopathic aldosteronism.
  590. … beta adrenergic blockade with orally administered labetalol in hypertension: Studies on blood volume, plasma renin and Aldosterone and catecholamine excretion
  591. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of Aldosterone-induced hypertension and cardiac fibrosis
  592. Renin, angiotensin II, Aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy
  593. The characterization of low renin hypertension by plasma renin activity and plasma Aldosterone concentration
  594. Plasma Aldosterone Response to Angiotensin II in Sodium‐Restricted Elderly Subjects with Essential hypertension
  595. Left ventricular hypertrophy and remodelling of resistance arteries: the role of activation of the renin–angiotensin–Aldosterone system in hypertension
  596. Blood volume and Aldosterone secretion in hypertension and primary aldosteronism.
  597. Solitary kidney and ageing as causes of low renin and Aldosterone concentrations: relevance to ‘low-renin’essential hypertension
  598. Effect of indapamide on the renin‐Aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.
  599. Renin-Aldosterone system suppression during water immersion in renovascular hypertension.
  600. Relationships between sodium clearance, plasma renin activity, plasma Aldosterone, renal hemodynamics and blood pressure in essential hypertension
  601. An association between mineral metabolism and the renin-Aldosterone system in human hypertension.
  602. Dexamethasone-responsive hypertension in young women with suppressed renin and Aldosterone
  603. Abnormal vasopressin and Aldosterone response to furosemide in essential hypertension
  604. Effects of intravenous labetalol on blood pressure, angiotensin II and Aldosterone in hypertension: comparison with propranolol
  605. Circadian rhythm of renin and Aldosterone in unilateral renovascular hypertension: pre-and post-operative studies
  606. … between plasma Aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension
  607. Factors for postoperative persistent hypertension in patients with Aldosterone-producing adenoma
  608. Effects of experimental renal hypertension on Aldosterone biosynthesis by rat adrenal tissue
  609. Biochemical correction in the syndrome of hypertension and hyperkalaemia by severe dietary salt restriction suggests renin‐Aldosterone suppression critical in …
  610. Abnormal norepinephrine and Aldosterone responses to upright posture in nonmodulating hypertension
  611. … plasma renin activity and plasma Aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension
  612. Aldosterone-Induced hypertension: Effects of a Kininase Inhibitor
  613. Mechanism of inhibition of Aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism
  614. hypertension and mineralocorticoids. Usefulness of renin and Aldosterone measurements
  615. Hypotensive and natriuretic effects of nifedipine in essential hypertension. Role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-Aldosterone systems.
  616. Captopril, Aldosterone and urinary kallikrein in primary hypertension
  617. Age-and sex-related differences in plasma Aldosterone in essential hypertension. Relationship to plasma renin activity
  618. The Renin-Angiotensin-Aldosterone System in hypertension.
  619. STRUCTURE‐FUNCTION RELATIONSHIPS OF Aldosterone SYNTHASE AND 11β‐HYDROXYLASE ENZYMES: IMPLICATIONS FOR HUMAN hypertension
  620. Effect of enalapril on renin, angiotensin converting enzyme activity, Aldosterone and prostaglandins in patients with hypertension.
  621. Aldosterone antagonism and hypertension
  622. The substitutive role of ACTH in supporting Aldosterone response to head-up tilt during acute renin suppression in patients with essential hypertension.
  623. Effect of a new mineralocorticoid antagonist mespirenone on Aldosterone-induced hypertension
  624. Functional aspects of the renin–angiotensin–Aldosterone system and angiotensin II receptor AT1 blockers in arterial hypertension
  625. Essential arterial hypertension: plasma and urinary Aldosterone alterations.
  626. Aldosterone responsiveness to angiotensin II after sodium restriction in subjects with low renin essential hypertension
  627. Renin-angiotension-Aldosterone system, urinary prostaglandins and kallikrein in pregnancy-induced hypertension: evidence for a dysregulation of the renin …
  628. Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-Aldosterone system, and blood pressure in essential hypertension.
  629. Aldosterone response to prolonged ACTH infusion in juvenile hypertension
  630. Adrenal Cortex, Aldosterone, and hypertension: Report of an International Workshop
  631. The role of Aldosterone in the response to treatment of primary hypertension
  632. Metabolism of Aldosterone in dogs with renovascular hypertension
  633. Renin-angiotensin-Aldosterone system in arterial hypertension.
  634. Effect of propranolol therapy on Aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension
  635. Renin-angiotensin and Aldosterone in Experimental hypertension
  636. Effects of the Calcium Antagonist Felodipine on the Sympathetic and Renin‐Angiotensin‐Aldosterone Systems in Essential hypertension
  637. Primary aldosteronism due to Aldosterone producing adenoma without hypertension
  638. The Acute and Chronic Effects of Betaxolol on Blood Pressure, Renin‐Aldosterone, and Renal Function in Essential hypertension
  639. Renin-hyporesponsiveness in essential hypertension dissociation between plasma renin and catecholamines or Aldosterone following furosemide
  640. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-Aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.
  641. Effect of angiotensin converting-enzyme inhibition on potassium-mediated Aldosterone secretion in essential hypertension
  642. … haemodynamics and the renin-angiotensin-Aldosterone system in normotensive subjects with a familial predisposition to hypertension: changes during increased salt …
  643. CAPTOPRIL IN PRIMARY hypertension: Effects related to the renin‐angiotensin‐Aldosterone and kallikrein‐kinin systems.
  644. … reduces Aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism
  645. Perinephritis hypertension in Macaca fascicularis (cynomolgus monkey): studies of the renin-angiotensin-Aldosterone axis and renal hemodynamic function.
  646. … -angiotensin-Aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
  647. Urinary excretion of renal prostaglandins, kallikrein, vasopressin and Aldosterone in essential hypertension
  648. Severe hypertension in a ten-year-old boy secondary to an Aldosterone-producing tumour identified by adrenal sonography.
  649. Aldosterone: clinical implications in essential hypertension
  650. Role of Aldosterone in the initial stage of two forms of experimental vasorenal hypertension
  651. The renin-angiotensin-Aldosterone system and arterial hypertension in patients with rheumatoid arthritis
  652. … for” Aldosterone” and” 18-hydroxycorticosterone” in unprocessed urine, and their use in screening to distinguish primary aldosteronism from hypertension.
  653. hypertension, angiotensin II, Aldosterone, and race
  654. Jejunal permeability to water and electrolytes in patients with chronic intrahepatic hypertension: evidence for a role of Aldosterone.
  655. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, Aldosterone, and electrolyte responses.
  656. Aldosterone regulation in essential hypertension: altered adrenal responsiveness to angiotensin II.
  657. Aldosterone metabolism in the isolated perfused liver of R and S hypertension-prone Dahl rats
  658. The relationship of Aldosterone to mild essential hypertension.
  659. Effect of oral labetalol on plasma catecholamines, renin and Aldosterone in patients with severe arterial hypertension
  660. Urinary sodium and Aldosterone excretion following portocaval shunts for cirrhosis of liver and portal hypertension: effect of end-to-side and side-to-side anastomoses …
  661. Three cases of malignant hypertension: the roles of endothelin-1 and the renin-angiotensin-Aldosterone system.
  662. Dopaminergic regulation of Aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension
  663. Aldosterone and hypertension
  664. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and Aldosterone in essential hypertension
  665. Responsiveness of the renin‐Aldosterone system during exercise in young patients with essential hypertension
  666. A simple method for definition of incomplete suppression of Aldosterone and its association with hypertension and hypokalaemia in man
  667. Remikiren (Ro 42-5892)—An orally active renin inhibitor in essential hypertension Effects on blood pressure and the renin-angiotensin-Aldosterone system
  668. hypertension, oedema, and suppressed renin Aldosterone system due to unsupervised salt administration.
  669. Low-Renin Essential hypertension: Diminution of Aldosterone Suppression?
  670. Angiotensin II in primary hypertension, relationship to plasma renin activity, Aldosterone and urinary electrolytes
  671. Effect of coffee on blood pressure and activity renin-angiotensin-Aldosterone system and catecholamines concentration in patients with essential hypertension
  672. Effect of one year of thiazide therapy on plasma volume, renin, Aldosterone, lipids and urinary metanephrines in systolic hypertension of elderly patients
  673. Renal hypertension with Elevated Aldosterone: Case Due to Muscular Hypertrophy Cured by Nephrectomy with Decline of Aldosterone Levels to Normal
  674. Aldosterone: possible roles in sustaining essential hypertension and in determining response to antihypertensive treatment
  675. … ON BLOOD PRESSURE, RENAL FUNCTION, PLASMA RENIN ACTIVITY, AND PLASMA Aldosterone IN MILD‐TO‐MODERATE ESSENTIAL hypertension
  676. Captopril in the long-term treatment of essential hypertension: changes in the renin-angiotensin-Aldosterone system
  677. Humoral mechanisms in the pathogenesis of arterial hypertension with emphasis on the renin-angiotensin-Aldosterone system and natriuretic substances
  678. Does industrial environment influence the prevalence of arterial hypertension, plasma cholesterol and uric acid concentration and activity of the renin-Aldosterone …
  679. Abnormalities in the renin–angiotensin–Aldosterone system in normotensive subjects with a positive family history of hypertension
  680. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, Aldosterone, arginine vasopressin, atrial …
  681. On the Role of Aldosterone to hypertension; Especially an Extent of Its Participation
  682. … effects of angiotensin II infusion and variations in salt intake on plasma Aldosterone levels in normal subjects, patients with essential hypertension and patients with …
  683. Role of renin-angiotensin-Aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease
  684. … of low-renin hypertension: Aldosterone response to sodium restriction and upright posture, angiotensin II, ACTH and potassium in patients with hypertension
  685. … pressure, Aldosterone and body fluids during enalapril treatment: a double‐blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension
  686. An Apraisal of the Role of Aldosterone and the Sympathetic Nervous System in Essential hypertension
  687. Effect of chronic beta-adrenergic blockade on blood pressure and release of renin, Aldosterone and cortisol in essential hypertension (author’s transl)
  688. Relationship between Plasma Renin-Angiotensin-Aldosterone and ANF Levels in Primary hypertension
  689. Morphological signs of hyperactivity of the renin-Aldosterone system in cadmium-induced experimental hypertension.
  690. Interrelations between plasma renin activity, Aldosterone, and sympathetic nervous system activity in essential hypertension.
  691. PLASMA RENIN ACTIVITY AND Aldosterone SECRETION RATE IN hypertension: The Distinction between Primary and Secondary Hyperaldosteronism
  692. hypertension due to a giant Aldosterone-secreting adenoma
  693. … –Aldosterone system in essential arterial hypertension in clinical practice. Activity of the renin-angiotensin-Aldosterone system during treatment of hypertension with …
  694. Aldosterone excess and essential hypertension
  695. The influence of a heparin-like compound on hypertension, electrolytes and Aldosterone in man.
  696. Relationship between vasopressin and the renin-angiotensin-Aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma …
  697. Correlation between propranolol in plasma and urine, renin-Aldosterone system and blood pressure in essential hypertension
  698. … Effects of Dopamine on the Renin-Angiotensin-Aldosterone System in Conscious Rats: THE 10th CONFERENCE ON THE PATHOGENESIS OF hypertension
  699. Enhanced response of plasma Aldosterone to metoclopramide in essential hypertension.
  700. … 52: Comparison of selective Aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminuria in systolic hypertension …
  701. Effects of celiprolol on plasma renin, Aldosterone, norepinephrine and epinephrine in primary hypertension
  702. Inhibitory effect of enalapril on serum Aldosterone in essential hypertension
  703. Effects of Aldosterone on intralymphocytic sodium and potassium in patients with essential hypertension
  704. … metabolism, plasma renin activity and serum Aldosterone: a double-blind pilot comparison against hydrochlorothiazide in patients with essential hypertension.
  705. Relation between somatostatin, atrial natriuretic peptide, beta-endorphin, Aldosterone and pregnancy induced hypertension
  706. Renin/angiotensin/Aldosterone system in malignant hypertension
  707. Effects of corticotropin-releasing factor (CRF) on Aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism
  708. The renin-angiotensin-Aldosterone system in primary and secondary hypertension
  709. Molecular genetics of the renin-angiotensin-Aldosterone system in human hypertension
  710. Aldosterone, sodium and potassium in essential hypertension
  711. The state of the renin-angiotensin-Aldosterone system in various clinical forms of hypertension in aging
  712. Aldosterone-binding globulin-induced hypertension in the rat. A new experimental model.
  713. Hypotensive effect of intensifying Aldosterone metabolism in dogs with vasorenal hypertension
  714. The renin-angiotensin system and Aldosterone in hypertension: a brief review of some aspects.
  715. Plasma human atrial natriuretic peptide, endothelin-1, Aldosterone and plasma-renin activity in pregnancy-induced hypertension
  716. Changes in renin activity, Aldosterone level and electrolytes in pregnancy-induced hypertension.
  717. Daily profiles of Aldosterone levels during normal, high and low sodium intake in patients with essential hypertension
  718. Renin-Angiotensin-Aldosterone System of a Woman with Bartter’s Syndrome: Juxtaglomerular Cell Hyperplasia without hypertension
  719. Plasma catecholamines, renin and Aldosterone during combined alpha-and beta-adrenoceptor blockade in patients with severe arterial hypertension.
  720. Circadian variation of Aldosterone urinary excretion in idiopathic hypertension.
  721. Effect of pressor agents on blood pressure, plasma renin activity and plasma Aldosterone concentration in essential hypertension
  722. Studies on Plasma Renin and Aldosterone in Essential hypertension
  723. Plasma concentration of Aldosterone, 18-hydroxy-deoxycorticosterone and cortisol in adrenal veins of patients with low-renin hypertension
  724. Reduced response of plasma Aldosterone to acute ACTH stimulation during long-term treatment with spironolactone in essential hypertension
  725. Physiopathology of arterial hypertension. Significance of the renin-angiotensin-Aldosterone system and structural changes
  726. … agonist cianergoline on blood pressure, the renin-angiotensin-Aldosterone axis and the sympathetic nervous system in patients with essential hypertension
  727. Hyperplastic changes and Aldosterone content in the adrenal cortex in essential hypertension and primary aldosteronism
  728. Molecular genetics of the renin angiotensin Aldosterone system in human hypertension
  729. Role of the renin-angiotensjon-Aldosterone system in the pathogenesis of arterial hypertension
  730. … traditional Chinese medicine differential types and plasma levels of renin, angiotension II, Aldosterone, atrial natriuretic factor in patients with essential hypertension
  731. … -relationship of sympathetic nervous system and renin-angiotensin-Aldosterone system in three renin subgroups of borderline and persistent essential hypertension
  732. Regulation of Aldosterone Secretion by a New Aldosterone Stimulating Factor: THE 11th CONFERENCE ON THE PATHOGENESIS OF hypertension
  733. Behavior of the renin-angiotensin-Aldosterone system and vasopressin secretion in patients with renovascular hypertension or small kidney
  734. Isolation of a polar Aldosterone-like substance from the urine and adrenal incubates of patients with arterial hypertension
  735. P-70: The selective Aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension
  736. Renin-angiotensin-Aldosterone system in essential hypertension. Inappropriately high plasma Aldosterone in young patients with severe hypertension and in older …
  737. Significance of the renin-angiotensin-Aldosterone system for pathogenesis and early diagnosis of pregnancy-induced hypertension with special reference to …
  738. The Relationship between the Upright Serum Aldosterone Level and the Left Ventricular Geometry in Essentioal hypertension
  739. The changes of serum-ACE, plasma renin activity and Aldosterone in the diabetics with hypertension
  740. Association between Aldosterone synthase gene polymorphism and primary hypertension in Chinese Han population [J]
  741. Arterial hypertension in acromegaly: altered dopaminergic control of Aldosterone secretion
  742. Effect of captopril on renal haemodynamics and the renin-angiotensin-Aldosterone and osmoregulatory systems in essential hypertension
  743. Altered coupling between aortic adrenergic-receptors and inositol phosphate accumulation in Aldosterone hypertension
  744. Restructuring of the collagen network in hypertension: role of the angiotensin-Aldosterone system
  745. … factor in high-altitude pulmonary hypertension: the influence of acute hypoxia on plasma atrial natriuretic factor, renin, and Aldosterone concentrations in highlanders …
  746. The acute effect of nicardipine on the renin-angiotensin-Aldosterone system in salt-sensitive essential hypertension
  747. Chronobiological evidence for an uncoupling of the Na, K-ATPase to Aldosterone in normal renin hypertension
  748. Selected components of the kallikrein-kinin system and of the renin-angiotensin-Aldosterone system in offspring of parents with hypertension
  749. Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-Aldosterone system.
  750. Essential hypertension and Aldosterone
  751. Aldosterone metabolism after prolonged ACTH administration in juvenile hypertension
  752. Dissociated Renin–Aldosterone Response to Acute Sodium Depletion in Patients with a Previous History of Pregnancy–Associated hypertension
  753. The level of plasma renin and plasma Aldosterone activity in normotensive women and in pregnancy-induced arterial hypertension in a group of women from …
  754. Effect of penbutolol on circadian blood pressure, and renin, Aldosterone and cortisol levels in patients with essential hypertension.
  755. Blood pressure, catecholamines, renin and Aldosterone during short and long-term treatnent of essential hypertension with verapamil
  756. Role of renin-angiotensin-Aldosterone system in pathogenesis of arterial hypertension in chronic renal failure
  757. Human salivary or plasma Aldosterone-and dehydroepiandrosterone-binding glycoprotein induces hypertension in the rat.
  758. Beta-adrenergic regulation of circadian rhythmicity of the renin-angiotensin-Aldosterone system in five subtypes of essential hypertension.
  759. The Role of Aldosterone in Pathogenesis of Artenal hypertension
  760. 14C-Aldosterone binding by plasma proteins in adolescents with primary arterial hypertension
  761. Genetic aspects of plasma Aldosterone binding globulins in families of patients with essential hypertension, including isolation of novel thermostable homologues from …
  762. Considerations of the renin-angiotensin Aldosterone system in the pathogenesis of hypertension in infancy
  763. hypertension with defective Aldosterone stimulation by sodium restriction: a new syndrome
  764. Aldosterone Receptors and Effector Mechanisms in Mononuclear Leukocytes in Different Forms of hypertension
  765. New frontiers in Aldosterone/mineralocorticoid biology: A reemerging force in target organ damage and hypertension
  766. Vasopressin and renin-Aldosterone system in patients with arterial hypertension
  767. Effects of losartan on the renin-angiotensin-Aldosterone system and erythrocytosis in patients with chronic obstructive pulmonary disease and systemic hypertension
  768. Changes in reactivity of the renin-angiotensin-Aldosterone system in old age as a risk factor in the development of hypertension
  769. Role of Aldosterone in the pathogenesis of hypertension
  770. Aldosterone secretion rate and electrolyte balance studies on three patients with hypertension: Influence of guanethidine, hydralazine and methyclothiazide
  771. Post-renal-transplant hypertension Urine volume, free water clearance and plasma concentrations of arginine vasopressin, angiotensin II and Aldosterone before and …
  772. Plasma renin activity, Aldosterone and cortisol levels during physical exercise in essential hypertension.
  773. Polymorphism of Aldosterone synthase gene CYP11B2 in hypertension in China
  774. Effects of various doses of captopril on plasma Aldosterone concentrations in patients with essential hypertension
  775. The renin-angiotensin-Aldosterone system and serum lipoproteins in patients with essential hypertension
  776. Role of Aldosterone in potassium secretion in chronic renal failure associated with hypertension (transtubular potassium gradient)
  777. Effect of Ac-SDKP on Cardiac and Renal Collagen Deposition in Aldosterone-Salt hypertension
  778. Determination of plasma atrial natriuretic peptide, angiotensin II, Aldosterone and efficacy of benazepril in patients with salt sensitive essential hypertension
  779. Role of steroids in hypertension: evaluation of plasma mineralocorticoid activity with Aldosterone receptors
  780. hypertension following subcutaneous and intraperitoneal injections of polyvinyl alcohol and the effect of Aldosterone
  781. The renin-angiotensin-Aldosterone system in hypertension of hypothalamic origin
  782. … on blood pressure, weight, plasma volume, the renin-angiotensin-Aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
  783. Renin-angiotensin-Aldosterone system and pulmonary hemodynamics in patients with pulmonary artery hypertension
  784. Urinary excretion of Aldosterone in patients with hypertension
  785. Aldosterone, Angiotensin, and hypertension
  786. Mineralocorticoid receptor activation by Aldosterone or corticosterone induces hypertension, myocardial infarction and proteinuria
  787. Deviation of plasmatic Aldosterone and significance of the stimulating (ACTH-cortrosyn) and inhibitory (propranolol) effects in hypertension and cardiovascular …
  788. … pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and Aldosterone in patients with essential hypertension.
  789. Changes of the renin-angiotensin-Aldosterone system under contraceptive steroids. Contribution to the etiology of hypertension under hormonal contraceptives
  790. The renin-angiotensin-Aldosterone system and the adrenergic system in normal pregnancy and hypertension induced by pregnancy
  791. Correlation of atrial natriuretic factor and renin-Aldosterone system with chronic pulmonary hypertension among residents in a high altitude
  792. Differential Effects of Acute and Chronic β-Adrenoreceptor Blockade on Blood Pressure and the Renin—Angiotensin—Aldosterone System in Essential hypertension
  793. Changes in the renin-Aldosterone system after unilateral portalization of adrenal and renal blood in patients with arterial hypertension
  794. Plasma Aldosterone and plasma renin activity in patients with essential and renal hypertension under acute stimulation with saline depletion and acute suppression …
  795. Development of a mouse hypertension model induced by Aldosterone excess
  796. The renin-Aldosterone profile in hypertension
  797. … central and peripheral sympathetic nervous system and the renin-Aldosterone system on the onset and maintenance of high blood pressure in essential hypertension
  798. The Relationship of Aldosterone to Mild Essential hypertension
  799. … BETWEEN Aldosterone SECRETION, SODIUM AND POTASSIUM BALANCE, AND ANGIOTENSIN ACTIVITY IN MAN: STUDIES IN hypertension AND …
  800. The renin-angiotensin-Aldosterone system and antidiuretic hormone secretion during plasmapheresis in patients with high arterial hypertension refractory to drug …
  801. Essential hypertension and left ventricular hypertrophy in cardiovascular disease: beyond overactivity of the renin–angiotensin–Aldosterone–sodium system
  802. Plasma Aldosterone concentration and vascular reactivity in hypertension
  803. Role of Aldosterone and the Aldosterone binding globulin in experimental and spontaneous hypertension
  804. Strategy for studying mineralocorticoids other than Aldosterone in arterial hypertension of hormonal origin
  805. Concentration of adrenocorticotrophic hormone and Aldosterone secretion in essential hypertension and hyperaldosteronism
  806. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and Aldosterone in hypertension.
  807. … on plasma renin activity, plasma Aldosterone concentration, urinary prostaglandin E excretion and blood pressure in patients with essential hypertension
  808. … increase of mineralocorticoids after furosemide in low-renin essential hypertension: Evidence for 18-hydroxycorticosterone to be a better marker than Aldosterone
  809. Erythrocyte cation transport in arterial hypertension: interrelation with the renin-angiotensin-Aldosterone system and the atrial natriuretic factor
  810. Role of Aldosterone in the initial stage of 2 forms of experimental vasorenal hypertension
  811. The kallikrein-kinin system in primary hypertension: dynamics of circulating components of the kallikrein-kinin system in relation to the renin-angiotensin-Aldosterone …
  812. Studies on kallikrein-kinin system in essential hypertension: urinary kallikrein-kinin system and renin-angiotensin-Aldosterone system (author’s transl)
  813. Kallikrein-kinin, enkephalin, renin-Aldosterone and catecholamine systems in the vanadate (as vanadyl)-induced arterial hypertension.
  814. The Relationship between the Upright Serum Aldosterone Level and the Left Ventricular Geometry in Essentioal hypertension.
  815. Plasma Renin and Aldosterone Profiles in Essential hypertension.
  816. … in peripheral venous distensibility and blood pressure modifications in borderline hypertension: evidence against a primary role for the renin-angiotensin-Aldosterone …
  817. Radioimmunologic determination of Aldosterone and renin in the blood in the diagnosis of different forms of arterial hypertension
  818. VI. RENIN, Aldosterone, AND hypertension: The Hepatic Metabolism of Renin and Aldosterone
  819. … renin-angiotensin-Aldosterone system and kinin system in hypertensive and normotensive youngsters with or without a family history of essential arterial hypertension
  820. Renin angiotensin Aldosterone system, urinary prostaglandins and kallikrein in pregnancy induced hypertension. Evidence for a disregulation of the renin-angiotensin …
  821. Negative noxiousness of Aldosterone analogue-induced hypertension and inhibition of Aldosterone by silver spike point electrical stimulation
  822. Effects of acebutolol on the renin-Aldosterone system in essential arterial hypertension
  823. Human Essential hypertension: Role of the Genes of the Renin-Aldosterone System
  824. The development and maintenance of experimental Aldosterone hypertension in the rat: evidence for a mechanism other than peripheral vascular …
  825. Radioimmunologic analysis of the state of the renin-angiotensin-Aldosterone-system in arterial hypertension
  826. Radioimmunologic analysis of the state of the renin-angiotensin-Aldosterone system in arterial hypertension
  827. Role of Aldosterone in essential arterial hypertension complicated by chronic renal insufficiency
  828. Factors for postoperative persistent hypertension in patients with Aldosterone producing adenoma
  829. hypertension: the role of renin, angiotensin and Aldosterone
  830. Plasma renin activity and Aldosterone in patients with essential hypertension
  831. Aldosterone reduces baroreceptor discharge in the dog. hypertension
  832. Aldosterone response to modulation of potassium in patients on dialysis or with essential hypertension.
  833. Rectal electrical potential difference and plasma Aldosterone in hyperaldosteronism and low-, normal-and high-renin hypertension
  834. Plasma renin activity and plasma Aldosterone in essential hypertension: effect of age and diastolic blood pressure
  835. Adrenal cancer with hypertension but low plasma renin and Aldosterone.
  836. Relationship between plasma Aldosterone and left ventricular structure and function in patients with essential hypertension
  837. Changes of Atrial Natriuretic Peptide and Aldosterone in Pregnancy-induced hypertension and Normal Pregnancy
  838. hypertension and the Renin-Angiotensin-Aldosterone Axis
  839. Saralasin-induced changes of blood pressure, renin and Aldosterone in essential and renal hypertension (author’s transl)
  840. Plasma renin activity, Aldosterone and adrenergic activity in patients with hypertension and in normotensives with a family history of hypertension
  841. Possible Implication of the Renin-Angiotensin-Aldosterone System in the hypertension of Phaeochromocytoma
  842. Hypotensive effect of intensification of Aldosterone metabolism in dogs with vasorenal hypertension
  843. Aldosterone Receptor Antagonism Normalizes Vascular Function in 11β-Hydroxysteroid Dehydrogenase Deficient hypertension
  844. The Renin-Angiotensin-Aldosterone System in hypertension its Biochemistry and Applications
  845. Plasma mineralocorticoids–Aldosterone and desoxycorticosterone–in patients with” low-renin” arterial hypertension
  846. Renin-angiotensin-Aldosterone system in hypertension patients who have had a cerebral stroke
  847. Changes in the renin-angiotensin-Aldosterone system in the development of hypertension in aging. 2
  848. Effects of Aldosterone antagonism on cardiac fibrosis in patients with essential hypertension
  849. Preliminary study on relationship between renin-angiotensin-Aldosterone system and hypertension in coal miners
  850. … de Recherche et d’Etudes sur les Genomes (GREG). Genetic determination of plasma Aldosterone levels in essential hypertension-comparison between urban and …
  851. P-489: Plasma renin activity and Aldosterone level in patients with essential hypertension
  852. Relations between blood insulin concentration, renin-angiotensin-Aldosterone system and clinical picture of hypertension
  853. Changes of the renin-angiotensin-Aldosterone system and immunologic parameters in essential and symptomatic arterial hypertension
  854. Alcohol and hypertension in sudden cardiac death, features of the status of the renin-angiotensin-Aldosterone system
  855. Renin-Aldosterone system in secretion of cortisol in patients with arterial hypertension in European North
  856. Low Renin hypertension: A State of Inappropriate Secretion of Aldosterone.
  857. The value of stimulation of the renin-angiotensin-Aldosterone system as a screening test for hypertension (author’s transl)
  858. A study on the serum angiotensin I angiotensin II atrial natriureticfactor and Aldosterone levels in essential hypertension
  859. Body fluid compartments, hypertension and the renin-angio-tensin-Aldosterone system (RAAS) in hemodialysed patients
  860. The effect of long-term treatment of arterial hypertension with Ca antagonists on the renin-angiotensin-Aldosterone system in diabetics. Hyporeninemic …
  861. VI. RENIN, Aldosterone, AND hypertension: Pseudo-primary Aldosteronism
  862. Effect of obzidan on hemodynamic indices and the renin and Aldosterone levels of the blood plasma in patients with juvenile hypertension
  863. Low renin variant of hypertension: functional relations of the renin-Aldosterone pressor system
  864. Aldosterone precursors and arterial hypertension with adrenal nodules not caused by aldosteronism
  865. Is there a relation between the renin-angiotensin-Aldosterone system and vasopressin secretion in essential hypertension?
  866. Levels of catecholamines and activity of the renin-Aldosterone system in women with hypertension in the period before and after menopause
  867. Essential’hypertension with hypokalemia: Caused by Aldosterone-secreting adrenal adenoma
  868. … –Aldosterone system in essential hypertension–hypotensive action of beta adrenergic blocking agents and variation of the renin-Aldosterone system (author’s transl)
  869. EVALUATION OF PRESSOR ASSAY, PLASMA RENIN ACTIVITY, AND Aldosterone EXCRETION IN RENAL VASCULAR hypertension.
  870. Behavior of the plasma renin activity and Aldosterone after salt restriction and upright posture in essential hypertension
  871. The renin-angiotensin-Aldosterone system in children and adolescents with nephrogenic hypertension
  872. Dopaminergic control of Aldosterone secretion is not mediated by atrial natriuretic factor in patients with essential hypertension.
  873. Observation of the Plasma Renin-Angiotensin-Aldosterone System and Prostaglandin System in Essential hypertension
  874. The renin-angiotensin-Aldosterone system in the diagnosis of renovascular arterial hypertension
  875. Clinical significance of renin-angiotensin-Aldosterone system, endothelin and nitric oxide in renal hypertension and adrenocorticoadenomas
  876. Basal and reactive renin and Aldosterone secretion in arterial hypertension of insulin dependent diabetics
  877. Continuous long-term treatment with diuretics of hypertension and the status of the renin-angiotensin-Aldosterone system
  878. Measurement and Significance of Calcitonin Gene-related Peptide. Neuropeptide Y and Aldosterone in Portal hypertension
  879. The correlation of atrial natriuretic peptide values with those of renin, angiotensin and Aldosterone in hypertension patients below and above 50
  880. Diazoxide test in the diagnosis of arterial hypertension: modifications in the levels of renin and Aldosterone in blood of patients with various restrains of the renal …
  881. The effects of capoten and nifedipine on plasma endothelin, renin activity, an-giotensin and Aldosterone in patients with essential hypertension
  882. Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and Aldosterone in essential hypertension
  883. 163 ROLE OF THE RENIN-Aldosterone SYSTEM IN hypertension COARCTATION OF THE AORTA
  884. … cardiopulmonary hematic centralization (by immersion in water) on hydrosaline elimination and on the renin-angiotensin-Aldosterone system in essential hypertension
  885. Atrial natriuretic peptide inhibits the Aldosterone response to metoclopramide in patients with glomerular disease and essential hypertension
  886. The renin-angiotensin-Aldosterone system in hypertensive subjects. III-The use of beta-blockers in reno-vascular hypertension (author’s transl)
  887. Relation of myocardial fibrosis to circulating Aldosterone and endothelin in primary and secondary human hypertension: an ultrasonic study by acoustic densitometry
  888. A study of urinary and intracellular sodium and potassium, renin, Aldosterone and hypertension in Africans and Indians in Natal.
  889. Effect of nifedipine treatment on the renin-Aldosterone system and secretion of cortisol and growth hormone in patients with essential hypertension
  890. Plasma renin activity and Aldosterone excretion in patients with essential hypertension, with hypertension in bilateral adrenal cortex hyperplasia and with Aldosterone …
  891. Renin-angiotensin-Aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol
  892. Acute combined alpha-and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and Aldosterone
  893. Adenovirus-mediated Human Prostasin Gene Delivery is Associated with Increased Aldosterone Production and hypertension in Rats
  894. The role of the kallikrein-kinin and renin-angiotensin-Aldosterone systems in the development of hypertension in glomerulonephritis
  895. Renin, Angiotensin and Aldosterone in Relation to Electrolyte Metabolism [Abridged] hypertension and Hyperaldosteronism with Low Plasma Renin …
  896. Inhibition of the renin-angiotensin-Aldosterone axis by low dose intravenous captopril as a treatment for accelerated phase hypertension.
  897. Blood level of free serotonin, catecholamines and the renin-angiotensin-Aldosterone system in patients with primary hypertension
  898. Behavior of Aldosterone and plasma renin activity after ACTH administration and insulin-induced hypoglycemia in patients with essential arterial hypertension
  899. Renin-Angiotensin-Aldosterone System and Adrenergic System in hypertension Induced by Pregnancy: Critical Role of the Stimulative Conditions and of the Lability …
  900. … -release nicardipine on blood pressure, renal function and the renin-angiotensin-Aldosterone system in patients with mild-to-moderate essential arterial hypertension
  901. Renin-Aldosterone and kallikrein-kinin systems in the patients with arterial hypertension who took part in elimination of aftereffects of the accident at Chernobyl Atomic …
  902. Atrial natriuretic peptide, left ventricular mass and renin-angiotensin-Aldosterone system in essential arterial hypertension of a mild or moderate degree
  903. … between atrial natriuretic factor and the renin-angiotensin-Aldosterone system in the renal reaction to acute volume loading in patients with essential hypertension
  904. Effects of pharmacological modulation of the renin-angiotensin-Aldosterone system on salt sensitivity in patients with borderline hypertension
  905. … of gene polymorphism of Aldosterone synthese gene CYP11B2 (-344T/C) on antihypertensive response to Valsartan in Han nationality essential hypertension …
  906. … –Aldosterone system, blood volume, serum uric acid and urinary excretion of prostaglandins and kallikrein in the arterial hypertension induced by pregnancy
  907. … /hypertension/Congestive Heart Failure: Angiotensin-Converting Enzyme Gene Polymorphism Has No Influence on the Circulating Renin-Angiotensin-Aldosterone …
  908. OR-78: White coat hypertension, microalbuminuria and renin-angiotensin-Aldosterone system gene variants in adolescents
  909. … , serum levels of sodium, potassium, Aldosterone, total catecholamines, 6-keto-PGF2alpha and plasma renin activity in patients with primary arterial hypertension …
  910. … to 9: 00 AM Aldosterone-A Common Link in Cardiac and Vascular Disorders*: Ability to selectively interfere with the effects of Aldosterone in patients with hypertension …
  911. … –Aldosterone system, sympathetic-adrenal system and the level of the 6-keto-PGF1 alpha metabolite of prostacyclin in patients with primary arterial hypertension
  912. … action by decreasing the production of angiotensin II and Aldosterone, are being extensively prescribed for the treatment of hypertension and congestive heart …
  913. P-243: Assessment of the novel selective Aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systemic hypertension: results from a …
  914. Case 39-1972: hypertension, Hypokalemia and Elevated Urinary Aldosterone Level
  915. (Supplementary) 19-Hydroxyandrostenedione, A New Amplifier of the Action of Aldosterone, in Low Renin Essential hypertension
  916. P-669: Screening for primary Aldosterone in older patients with hypertension
  917. P-392: Ultrasound tissue characterization in patients with primary and secondary hypertension: influence of the renin-angiotensin-Aldosterone system
  918. P-525: An interaction of insulin and renin-Aldosterone system responsible for left ventricular hypertrophy in patients with essential hypertension
  919. 736 Vascular hypertrophy and the renin-angiotensin-Aldosterone system in the initiation of hypertension caused by inhibition of nitric oxide synthesis
  920. 4. On the Role of Renin-Angiotensin System with Special Relation to Aldosterone for the Etiology of hypertension
  921. … of 5-month guanfacine treatment on the renin-angiotensin-Aldosterone system and some metabolic factors in patients with diabetes mellitus type II and hypertension
  922. P-387: Twenty-four hour pulse pressure, left ventricular mass, risk factors and Aldosterone in untreated essential hypertension
  923. Effect of a Single Dose of Ramipril (HOE 498) on the Renin Angiotensin-Aldosterone System in Essential Arterial hypertension
  924. 10 Dopaminergic Control of Aldosterone in Essential hypertension
  925. … OF NIFEDIPINE ON PLASMA RENIN ACTIVITY, PLASMA Aldosterone & CORTISOL CONCENTRATIONS IN PATIENTS WITH ESSENTIAL hypertension
  926. K+ channel mutations in adrenal Aldosterone-producing adenomas and hereditary hypertension
  927. Predictors of hyperkalemia risk following hypertension control with Aldosterone blockade
  928. Aldosterone in salt-sensitive hypertension and metabolic syndrome
  929. hypertension in blacks: individualized therapy based on renin/Aldosterone phenotyping
  930. Dysregulated renin–angiotensin–Aldosterone system contributes to pulmonary arterial hypertension
  931. Resistant hypertension and Aldosterone: an update
  932. Pathogenesis of hypertension: interactions among sodium, potassium, and Aldosterone
  933. The renin angiotensin Aldosterone system in hypertension: roles of insulin resistance and oxidative stress
  934. Aldosterone synthase inhibitors in hypertension: current status and future possibilities
  935. Sleep apnea, Aldosterone, and resistant hypertension
  936. Association of kidney function with residual hypertension after treatment of Aldosterone-producing adenoma
  937. Effects of a novel Aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 …
  938. Aldosterone, hypertension, and beyond
  939. The central role of the brain Aldosterone–“ouabain” pathway in salt-sensitive hypertension
  940. The effects of Aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies
  941. High prevalence of autonomous Aldosterone secretion among patients with essential hypertension
  942. Effectiveness of the selective Aldosterone blocker, eplerenone, in patients with resistant hypertension
  943. Therapeutic perspectives in hypertension: novel means for renin–angiotensin–Aldosterone system modulation and emerging device-based approaches
  944. … -angiotensin-Aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension
  945. hypertension, renin–angiotensin–Aldosterone system inhibition, and COVID-19
  946. Actions of circulating angiotensin II and Aldosterone in the brain contributing to hypertension
  947. Sex differences in angiotensin II-and Aldosterone-induced hypertension: the central protective effects of estrogen
  948. Role of brain Aldosterone and mineralocorticoid receptors in Aldosterone-salt hypertension in rats
  949. Stress-induced Aldosterone hyper-secretion in a substantial subset of patients with essential hypertension
  950. Recent update of renin-angiotensin-Aldosterone system in the pathogenesis of hypertension
  951. Aldosterone synthesis in the brain contributes to Dahl salt‐sensitive rat hypertension
  952. Aldosterone mediates cardiac fibrosis in the setting of hypertension
  953. Leptin induces hypertension and endothelial dysfunction via Aldosterone-dependent mechanisms in obese female mice
  954. The role of the renin-angiotensin-Aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)
  955. Aldosterone, hypertension and heart failure: insights from clinical trials
  956. Plasma Aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study
  957. Use of Aldosterone antagonists for treatment of uncontrolled resistant hypertension
  958. … enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–Aldosterone system inhibitors involving 158 998 …
  959. Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases
  960. Study of Aldosterone synthase inhibition as an add‐on therapy in resistant hypertension
  961. Aldosterone induces electrical remodeling independent of hypertension
  962. Spironolactone, eplerenone and the new Aldosterone blockers in endocrine and primary hypertension
  963. hypertension and renin-angiotensin-Aldosterone system inhibitors in patients with Covid-19
  964. Hypoadiponectinemia and Aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension
  965. The renin-angiotensin-Aldosterone system: a crossroad from arterial hypertension to heart failure
  966. Renal volume, renin-angiotensin-Aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease
  967. Long-term effects of Aldosterone blockade in resistant hypertension associated with chronic kidney disease
  968. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension
  969. Relation of dietary salt and Aldosterone to urinary protein excretion in subjects with resistant hypertension
  970. Association of the− 344C/T Aldosterone synthase (CYP11B2) gene variant with hypertension and stroke
  971. Renoprotective effect of renin-angiotensin-Aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia
  972. Role of Aldosterone blockade in resistant hypertension
  973. Lessons from Africa: the importance of measuring plasma renin and Aldosterone in resistant hypertension
  974. The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled …
  975. A randomized controlled study of CPAP effect on plasma Aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea
  976. Aldosterone contributes to sympathoexcitation in renovascular hypertension
  977. Salt, Aldosterone and hypertension
  978. hypertension and Aldosterone levels in women with early‐onset androgenetic alopecia
  979. Aldosterone excess or escape: Treating resistant hypertension
  980. Prospective validation of an automated chemiluminescence-based assay of renin and Aldosterone for the work-up of arterial hypertension
  981. Masked Uncontrolled hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion
  982. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–Aldosterone system
  983. High plasma Aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension
  984. Effect of Aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis
  985. hypertension in women: the role of progesterone and Aldosterone
  986. Aldosterone, hypertension, and antihypertensive therapy: insights from a general population
  987. Renin angiotensin Aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?
  988. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin–angiotensin–Aldosterone system …
  989. The renin–angiotensin–Aldosterone system in 2011: role in hypertension and chronic kidney disease
  990. Association of Aldosterone excess and apnea-hypopnea index in patients with resistant hypertension
  991. … the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension
  992. Effect of melatonin on the renin-angiotensin-Aldosterone system in L-NAME-induced hypertension
  993. Suppression of Aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension
  994. Sex differences and central protective effect of 17β-estradiol in the development of Aldosterone/NaCl-induced hypertension
  995. Effects of ARB or ACE-inhibitor administration on plasma levels of Aldosterone and adiponectin in hypertension
  996. Renin‐angiotensin‐Aldosterone system activity in hyperthyroid cats with and without concurrent hypertension
  997. Lack of suppression of Aldosterone production leads to salt-sensitive hypertension in female but not male balb/C mice
  998. Association between polymorphisms in the renin-angiotensin-Aldosterone system genes and essential hypertension in the Han Chinese population
  999. High plasma Aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations
  1000. Renin-angiotensin-Aldosterone profiles in pregnant women with chronic hypertension
  1001. Aldosterone-induced hypertension is sex-dependent, mediated by T cells and sensitive to GPER activation
  1002. Haplotype-based association of the renin-angiotensin-Aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan …
  1003. Are genetic polymorphisms in the renin–angiotensin–Aldosterone system associated with essential hypertension? Evidence from genome-wide association studies
  1004. Statins, the renin–angiotensin–Aldosterone system and hypertension–a tale of another beneficial effect of statins
  1005. Role of central nervous system Aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
  1006. Association between pituitary-adrenal axis dominance over the renin-angiotensin-Aldosterone system and hypertension
  1007. Salt, the renin–angiotensin–Aldosterone system and resistant hypertension
  1008. Aldosterone sensitivity: an opportunity for investigation into the pathogenesis of hypertension
  1009. Aldosterone synthase inhibition in hypertension
  1010. … dissection of sodium and potassium transport along the Aldosterone-sensitive distal nephron: importance in the control of blood pressure and hypertension
  1011. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-Aldosterone system plays an important role
  1012. The role of Aldosterone in mediating the dependence of angiotensin hypertension on IL-6
  1013. Renin–angiotensin–Aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and …
  1014. Primary aldosteronism and Aldosterone-associated hypertension
  1015. Activation of renin–angiotensin–Aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
  1016. Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans: a proof-of-concept study by cardiac magnetic resonance
  1017. Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
  1018. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
  1019. … in the renin-angiotensin-Aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure
  1020. Association between Aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis
  1021. Polymorphisms in genes of the renin‐angiotensin‐Aldosterone system and renal cell cancer risk: Interplay with hypertension and intakes of sodium, potassium and …
  1022. Programming of hypertension: associations of plasma Aldosterone in adult men and women with birthweight, cortisol, and blood pressure
  1023. Adrenal tissue-specific deletion of TASK channels causes Aldosterone-driven angiotensin II–independent hypertension
  1024. Renin and Aldosterone measurements in the management of arterial hypertension
  1025. Interpreting stimulated plasma renin and Aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating …
  1026. Effect of ivabradine on a hypertensive heart and the renin-angiotensin-Aldosterone system in L-NAME-induced hypertension
  1027. Role of brain corticosterone and Aldosterone in central angiotensin II–induced hypertension
  1028. hypertension, insulin resistance, and Aldosterone: sex‐specific relationships
  1029. … continuous positive airway pressure treatment on Aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled …
  1030. Association of Aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population
  1031. The efficacy and safety of the novel Aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study
  1032. Plasma Aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study
  1033. The kidneys and Aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension
  1034. Association of Aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population
  1035. Renal denervation attenuates Aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension
  1036. Bimodal Aldosterone distribution in low-renin hypertension
  1037. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of Aldosterone-producing adenoma
  1038. … receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in Aldosterone/salt-induced hypertension in female rats
  1039. Association of the-344T/C Aldosterone synthase gene variant with essential hypertension.
  1040. Circulating Aldosterone levels and disease severity in pulmonary arterial hypertension
  1041. Factors affecting complete hypertension cure after adrenalectomy for Aldosterone-producing adenoma: outcomes in a large series
  1042. Aldosterone, sodium, and hypertension: lessons from torcetrapib?
  1043. Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, Aldosterone level, and left ventricular structure
  1044. … of plasma renin concentration instead of plasma renin activity decreases the positive Aldosterone-to-renin ratio tests in treated patients with essential hypertension
  1045. Fluid retention, Aldosterone excess, and treatment of resistant hypertension
  1046. Central infusion of Aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats
  1047. Impact of Aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension
  1048. Contribution of four polymorphisms in renin-angiotensin-Aldosterone-related genes to hypertension in a Thai population
  1049. Influence of blood pressure control and application of renin‐angiotensin‐Aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
  1050. Association of Aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels
  1051. Endogenous ouabain and Aldosterone are coelevated in the circulation of patients with essential hypertension
  1052. Atrial natriuretic peptide and Aldosterone synthase gene in essential hypertension: A case–control study
  1053. … extract of Hibiscus sabdariffa on the renin-angiotensin-Aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study …
  1054. Synergistic effects of gene polymorphisms of the renin–angiotensin–Aldosterone system on essential hypertension in Kazakhs in Xinjiang
  1055. Modulation of Aldosterone levels by− 344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension
  1056. Renin-angiotensin-Aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis
  1057. Aldosterone and alterations of hypertension-related vascular function in African Americans
  1058. β‐Blocker withdrawal is preferable for accurate interpretation of the Aldosterone–renin ratio in chronically treated hypertension
  1059. … artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-Aldosterone …
  1060. Upregulation of the renin-angiotensin-Aldosterone-ouabain system in the brain is the core mechanism in the genesis of all types of hypertension
  1061. Does the ratio of serum Aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO
  1062. Crosstalk between the heme oxygenase system, Aldosterone, and phospholipase C in hypertension
  1063. K+ and the renin–angiotensin–Aldosterone system: new insights into their role in blood pressure control and hypertension treatment
  1064. Effect of renin-angiotensin-Aldosterone system blockade on long-term outcomes in postacute kidney injury patients with hypertension
  1065. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans
  1066. Aldosterone, inactive matrix gla-protein, and large artery stiffness in hypertension
  1067. … –Aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind …
  1068. Discovery of spirocyclic Aldosterone synthase inhibitors as potential treatments for resistant hypertension
  1069. What “Drives” the Link Between the Renin–Angiotensin–Aldosterone System and the Prothrombotic State in hypertension?
  1070. Renin-angiotensin-Aldosterone system in the pathogenesis of pregnancy-induced hypertension
  1071. CNS neuroplasticity and salt-sensitive hypertension induced by prior treatment with subpressor doses of ANG II or Aldosterone
  1072. Pathophysiology and treatment of resistant hypertension: the role of Aldosterone and amiloride-sensitive sodium channels
  1073. Endogenous ouabain and the renin–angiotensin–Aldosterone system: distinct effects on Na handling and blood pressure in human hypertension
  1074. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate Aldosterone/NaCl-induced hypertension in mice
  1075. Renin–angiotensin–Aldosterone system gene polymorphisms in gestational hypertension and preeclampsia: A case–control gene-association study
  1076. Management of resistant hypertension: Aldosterone antagonists or intensification of diuretic therapy?
  1077. Urinary Aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with Aldosterone-producing adenomas
  1078. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of Aldosterone status
  1079. Sodium pumps, ouabain and Aldosterone in the brain: A neuromodulatory pathway underlying salt-sensitive hypertension and heart failure
  1080. Persistent hypertension after adrenalectomy for an Aldosterone-producing adenoma: weight as a critical prognostic factor for Aldosterone‘s lasting effect on the cardiac …
  1081. Combination therapy with renin‐angiotensin‐Aldosterone receptor blockers for hypertension: how far have we come?
  1082. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy
  1083. The effect of catheter based renal synthetic denervation on renin-angiotensin-Aldosterone system in patients with resistant hypertension
  1084. … -and Aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension
  1085. CYP11B2 gene haplotypes independently and in concurrence with Aldosterone and Aldosterone to renin ratio increase the risk of hypertension
  1086. T allele of− 344C/T polymorphism in Aldosterone synthase gene is not associated with resistant hypertension
  1087. New drug therapies interfering with the renin–angiotensin–Aldosterone system for resistant hypertension
  1088. Effects of T-type calcium channel blockers on renal function and Aldosterone in patients with hypertension: a systematic review and meta-analysis
  1089. Clinical value of measuring the renin/Aldosterone levels: optimising the management of uncontrolled/resistant hypertension
  1090. β2-Adrenergic receptor genotype affects the renin-angiotensin-Aldosterone system response to the Dietary Approaches to Stop hypertension (DASH) dietary pattern
  1091. Clinical effects of eplerenone, a selective Aldosterone blocker, in Japanese patients with essential hypertension
  1092. Discovery of indazole Aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension
  1093. … Aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension
  1094. Common genetic variations of the renin–angiotensin–Aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension
  1095. Five Reasons for the Failure to Diagnose Aldosterone Excess in hypertension
  1096. Graz Endocrine Causes of hypertension (GECOH) study: a diagnostic accuracy study of Aldosterone to active renin ratio in screening for primary …
  1097. Relationship between− 344T/C polymorphism in the Aldosterone synthase gene and atrial fibrillation in patients with essential hypertension
  1098. Microalbuminuria and plasma Aldosterone levels in nondiabetic treatment-naïve patients with hypertension
  1099. Serum Aldosterone is related to left ventricular geometry and function in young adults with never-treated primary hypertension
  1100. Aldosterone-producing adrenocortical carcinoma without hypertension
  1101. Association of− 344C/T polymorphism in the Aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension
  1102. Targeting the Renin–Angiotensin–Aldosterone System to Prevent hypertension and Kidney Disease of Developmental Origins
  1103. Predictors of resolution of hypertension after adrenalectomy in patients with Aldosterone-producing adenoma
  1104. … of plasma renin, angiotensin, and Aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension
  1105. Oestrogen receptors and T cells determine how sex affects Aldosterone-induced hypertension
  1106. Relationship of Aldosterone synthase gene (C-344T) and mineralocorticoid receptor (S810L) polymorphisms with gestational hypertension
  1107. Decreased mortality of COVID-19 with renin-angiotensin-Aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis
  1108. Aldosterone and stress-dependent arterial hypertension
  1109. Role of Aldosterone, mitogenic growth factors, apoptosis inducers and pulmonary arterial hypertension in the formation and progression of chronic pulmonary …
  1110. hypertension and depressed symptomatology: a cluster related to the activation of the renin–angiotensin–Aldosterone system (RAAS). Findings from population …
  1111. Body mass index predicts 24-hour urinary Aldosterone levels in patients with resistant hypertension
  1112. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of Aldosterone in arterial hypertension
  1113. Association of elevated plasma Aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension
  1114. Association of post-saline load plasma Aldosterone levels with left ventricular hypertrophy in primary hypertension
  1115. … association and synergistic effect of human Aldosterone synthase (CYP11B2) gene polymorphisms causing susceptibility to essential hypertension in Indian patients
  1116. Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: A review
  1117. Secondary hypertension due to concomitant Aldosterone-producing adenoma and parathyroid adenoma
  1118. Aldosterone excess and resistant hypertension: investigation and treatment
  1119. hypertension and longevity: role of genetic polymorphisms in renin-angiotensin-Aldosterone system and endothelial nitric oxide synthase
  1120. Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in Aldosterone-salt-treated rats
  1121. Association between urine Aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension
  1122. Effect of postural changes on Aldosterone to plasma renin ratio in patients with suspected secondary hypertension
  1123. Arterial hypertension, Aldosterone, and Atrial Fibrillation
  1124. Associations of renin–angiotensin–Aldosterone system genes with blood pressure changes and hypertension incidence
  1125. … complex 1 subunit raptor by Aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension
  1126. … of Aldosterone blockade and diuretic reinforcement vs. dual renin–angiotensin blockade for left ventricular mass regression in patients with resistant hypertension
  1127. Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian hypertension Study
  1128. … trial of azilsartan and olmesartan comparing effects on the renin-angiotensin-Aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS …
  1129. … outcomes of laparoscopic‐based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral Aldosterone …
  1130. The role of the renin-angiotensin-Aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: diagnostic implications
  1131. … renin activity and Aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
  1132. Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-Aldosterone system inhibitors on the prognosis of COVID-19 …
  1133. Aldosterone-producing adrenal adenoma and idiopathic intracranial hypertension—a pathogenetic link for Aldosterone?
  1134. Unravelling drug-induced hypertension: molecular mechanisms of Aldosterone-independent mineralocorticoid receptor activation by posaconazole
  1135. Aldosterone a relevant factor in the beginning and evolution of arterial hypertension
  1136. Long-term effect of efonidipine therapy on plasma Aldosterone and left ventricular mass index in patients with essential hypertension
  1137. Serum potassium levels predict blood pressure response to Aldosterone antagonists in resistant hypertension
  1138. Association of the K173R variant and haplotypes in the Aldosterone synthase gene with essential hypertension
  1139. The Effects of Salt and Glucose Intake on Angiotensin II and Aldosterone in Obese and Nonobese Patients with Essential hypertension
  1140. Resistant hypertension characterized by increased Aldosterone levels and persistent intravascular volume expansion
  1141. … C-344T, angiotensin II type 1 receptor A1166C and 11-β hydroxysteroid dehydrogenase G534A gene polymorphisms and essential hypertension in the population of …
  1142. Predictors of hyperkalemia risk after hypertension control with Aldosterone blockade according to the presence or absence of chronic kidney disease
  1143. Clock genes and salt-sensitive hypertension: a new type of Aldosterone-synthesizing enzyme controlled by the circadian clock and angiotensin II
  1144. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in Aldosterone-induced hypertension and kidney damage in a model of hereditary …
  1145. Immune system alterations by Aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage
  1146. A novel haplotype of low-frequency variants in the Aldosterone synthase gene among northern Han Chinese with essential hypertension
  1147. Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with Aldosterone-producing adenomas
  1148. Role of renin-angiotensin-Aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney …
  1149. Abnormal regulation of renin angiotensin Aldosterone system is associated with right ventricular dysfunction in hypertension
  1150. Microalbuminuria and hypertension in pregnancy: role of Aldosterone and inflammation
  1151. Galectin-3 and Aldosterone as potential tandem biomarkers in pulmonary arterial hypertension
  1152. The association of plasma resistin with dietary sodium manipulation, the renin‐angiotensin‐Aldosterone system, and 25‐Hydroxyvitamin D3 in human hypertension
  1153. The role of Aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension
  1154. Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells …
  1155. Renal ischemia-reperfusion leads to hypertension and changes in proximal tubule Na+ transport and renin-angiotensin-Aldosterone system: Role of NADPH oxidase
  1156. Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin–angiotensin–Aldosterone system polymorphisms
  1157. An overview of the classical and tissue-derived renin-angiotensin-Aldosterone system and its genetic polymorphisms in essential hypertension
  1158. A not-so-modest proposal that a “modest” increase in Aldosterone causes hypertension and more
  1159. Role of angiotensinogen and relative Aldosterone excess in salt-sensitive hypertension
  1160. Paradoxical increase of 24-hour urinary Aldosterone levels in obese patients with resistant hypertension on a high salt diet
  1161. … angiotensin II and Aldosterone secretion in patients with pressure overloaded systemic right ventricles are similar to those observed in systemic arterial hypertension
  1162. Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis
  1163. Association of Aldosterone-to-renin ratio with hypertension differs by sodium intake: the Ohasama study
  1164. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin–angiotensin–Aldosterone system blockers
  1165. Aldosterone and hypertension in African Americans
  1166. Central endogenous angiotensin-(1–7) protects against Aldosterone/NaCl-induced hypertension in female rats
  1167. Difficult-to-control hypertension due to bilateral Aldosterone-producing adrenocortical microadenomas associated with a cortisol-producing adrenal …
  1168. Role of pendrin in the pathophysiology of Aldosterone-induced hypertension
  1169. … Aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension
  1170. Aldosterone antagonists or renin-guided therapy for treatment-resistant hypertension: a comparative effectiveness pilot study in primary care
  1171. Genetic and functional analyses of Aldosterone synthase gene C-344T polymorphism with essential hypertension
  1172. A systemic review of the relationship between Aldosterone synthase–344 C/T polymorphism and hypertension in Han
  1173. … approach to the management of high blood pressure: efficacy and tolerability of the Aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension
  1174. Resistant hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-Aldosterone system …
  1175. Plasma Aldosterone concentration is positively associated with pulse pressure in patients with primary hypertension
  1176. New therapeutic options in patients prone to hypertension: a focus on direct renin inhibition and Aldosterone blockade
  1177. Association between elevated plasma Aldosterone concentration and left atrial conduit function in hypertension
  1178. Low plasma renin activity and high Aldosterone/renin ratio are associated with untreated isolated systolic hypertension
  1179. Association of the Aldosterone synthase gene− 344T> C polymorphism with essential hypertension and glucose homeostasis: A case–control study in a Han Chinese …
  1180. Effects of Olmesartan on the Renin-angiotensin-Aldosterone System for Patients with Essential hypertension after Cardiac Surgery—Investigation Using a …
  1181. Polymorphism of genes of renin-angiotensin-Aldosterone system in the development of hypertension in workers exposed to physical factors
  1182. Renin-angiotensin-Aldosterone system and pathobiology of hypertension
  1183. Ins and outs of Aldosterone-producing adenomas of the adrenal: from channelopathy to common curable cause of hypertension
  1184. … administration on the relationship between renin-angiotensin-Aldosterone system activity and plasma glucose in patients with hypertension
  1185. Effect of Aldosterone antagonists on obstructive sleep apnea in patients with resistant hypertension: a systematic review and meta-analysis
  1186. The role of Aldosterone in hypertension
  1187. The role of Aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?
  1188. Sodium chloride and Aldosterone: harbingers of hypertension-related cardiovascular disease
  1189. Gene mutations that promote adrenal Aldosterone production, sodium retention, and hypertension
  1190. Elevated Renin and Aldosterone Levels in a Young Woman With hypertension
  1191. Endocrine causes of hypertension: Aldosterone
  1192. Acetaminophen increases Aldosterone secretion while suppressing cortisol and androgens: a possible link to increased risk of hypertension
  1193. Are” functionally related polymorphisms” of renin-angiotensin-Aldosterone system gene polymorphisms associated with hypertension?
  1194. Effect of felodipine on myocardial and renal injury induced by Aldosterone-high salt hypertension in uninephrectomized rats
  1195. Effect of electroacupuncture of different acupoints on blood pressure, plasma angiotensin II, Aldosterone and atrial natriuretic peptide in spontaneous hypertension …
  1196. The impact of an Aldosterone synthase (CYP11B2) polymorphism on vascular function and inflammatory biomarkers in essential hypertension
  1197. The Role of hypertension and Renin-angiotensin-Aldosterone System Inhibitors in Bleomycin-induced Lung Injury
  1198. Rates of hospitalization associated with the use of Aldosterone receptor antagonists in patients with pulmonary arterial hypertension
  1199. Differences of blood plasma renin activity, angiotensin II and Aldosterone levels in essential or secondary hypertension
  1200. The role of renin-angiotensin Aldosterone system related micro-ribonucleic acids in hypertension
  1201. Renin-angiotensin-Aldosterone system in the elderly: rational use of aliskiren in managing hypertension
  1202. A systematic review on randomized control trials on rennin angiotensin Aldosterone system inhibitors role in managing hypertension among hemodialysis patients
  1203. Gene expression profile of persistent postoperative hypertension patients with Aldosterone-producing adenomas
  1204. Increased plasma Aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension
  1205. Polymorphism of the Aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic …
  1206. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs Aldosterone …
  1207. What is the role of Aldosterone excess in resistant hypertension and how should it be investigated and treated?
  1208. Obstructive sleep apnea syndrome–related hypertension and sarcopenia: a brief glance on the renin-angiotensin-Aldosterone system
  1209. Of hammers and screws: renin–angiotensin–Aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension
  1210. Preeclampsia: the role of Aldosterone in hypertension and inflammation
  1211. CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension
  1212. Role of Nox2 and p22phox in persistent postoperative hypertension in Aldosterone-producing adenoma patients after adrenalectomy
  1213. Is renal denervation an alternative or a complement to Aldosterone antagonists in treatment of resistant hypertension?
  1214. … ‐based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral Aldosterone …
  1215. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary hypertension: Insights from the Veterans Affairs Clinical Assessment Reporting and …
  1216. … of Aldosterone on Senescence and Proliferation Inhibition of Endothelial Progenitor Cells Induced by Sirtuin 1 (SIRT1) in Pulmonary Arterial hypertension
  1217. The role of renin–angiotensin–Aldosterone system in etiology and pathogenesis of arterial hypertension and its systemic complications—what remains from Laragh …
  1218. Resistant hypertension in the elderly-second line treatments: Aldosterone antagonists, central alpha-agonist agents, alpha-adrenergic receptor blockers, direct …
  1219. … ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-Aldosterone …
  1220. Female sex hormones are associated with the reduction of serum sodium and hypertension complications in patients with Aldosterone-producing adenoma
  1221. Aldosterone, gut microbiome and hypertension: selected papers from APCH 2019
  1222. … of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: hypertension management and renin-angiotensin-Aldosterone system blockade in …
  1223. A cross-sectional study on factors associated with hypertension and genetic polymorphisms of renin-angiotensin-Aldosterone system in Chinese hui pilgrims …
  1224. Novel marker of myocardial remodeling ST2 and the influence of Aldosterone antagonist in patients with heart failure caused by hypertension and ischemic heart …
  1225. Untangling essential hypertension: the potential roles of Aldosterone and atrial natriuretic peptide
  1226. The role of Aldosterone receptor blocker therapy in hypertension and heart failure
  1227. Long-term use of Aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis
  1228. Role of vasopressin and Aldosterone in pulmonary arterial hypertension: A pilot study
  1229. Proinflammatory/profibrotic effects of Aldosterone in Gitelman’s syndrome, a human model opposite to hypertension
  1230. Progression of renal insufficiency in patients with essential hypertension treated with renin angiotensin Aldosterone system blockers: an electrocardiographic …
  1231. Polymorphic variation of CYP11B2 predicts postoperative resolution of hypertension in patients undergoing adrenalectomy for Aldosterone‐producing adenomas
  1232. Association of Aldosterone synthase (CYP11B2) gene-344T/C polymorphism with essential hypertension in Mongolian nationality
  1233. Estrogen receptor-beta (ERβ) in the PVN and RVLM plays an essential protective role in Aldosterone/salt-induced hypertension in female rats
  1234. Regulators of Epithelial Sodium Channels in Aldosterone-Sensitive Distal Nephrons (ASDN): Critical Roles of Nedd4L/Nedd4-2 and Salt-Sensitive hypertension
  1235. Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice
  1236. Cardiovascular responses to chronic baroreflex activation in Aldosterone hypertension
  1237. Blind spots in the new International Society of hypertension guidelines: physiologically individualized therapy for resistant hypertension based on renin/Aldosterone …
  1238. hypertension and the renin-angiotensin-Aldosterone system
  1239. Synergic effects of renin and Aldosterone on right ventricular function in hypertension: a tissue Doppler study
  1240. Aldosterone-salt hypertension depends on the SFO, central Aldosterone synthase and MR specifically in the PVN
  1241. … effects of renin-angiotensin-Aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta …
  1242. … regulation of blood pressure: focus on “Role of central nervous system Aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt …
  1243. Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with hypertension: A Nationwide Cohort Study
  1244. RENIN, Aldosterone, THE Aldosterone-TO-RENIN RATIO AND INCIDENT ARTERIAL hypertension AMONG NORMOTENSIVE SUBJECTS FROM THE …
  1245. Blockers of renin-angiotensin-Aldosterone system in the treatment of arterial hypertension: classics versus the modern
  1246. High Aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?
  1247. P3486 Cytokine profile, renin-angiotensin Aldosterone system and left ventricular remodelling in essential arterial hypertension comorbid with chronic obstructive …
  1248. … the renin–angiotensin–Aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension
  1249. SAT-224 Recurrent Co-Driver Mutation in CTNNB1-Mutant Aldosterone-producing Adenomas (APA), Causing Reversible hypertension in Puberty, Pregnancy or …
  1250. Stimulation of Aldosterone synthesis by angiotensin II in the brain: support for positive feedback in hypertension?
  1251. Na+-Cl− cotransporter-mediated chloride uptake contributes to hypertension and renal damage in Aldosterone-infused rats
  1252. Role of relative Aldosterone excess in salt-sensitive hypertension among African ancestry
  1253. Hormones other than Aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism
  1254. P3568 The relationship between plasma renin and Aldosterone levels and the reduction of blood pressure with spironolactone in patients with resistant hypertension
  1255. Role of Aldosterone Antagonists in Treatment of Refractory hypertension [J]
  1256. INTERACTION OF Aldosterone AND SODIUM AFFECTS PREVALENCE OF ATRIAL FIBRILLATION IN PATIENTS WITH RESISTANT hypertension
  1257. Oxidative Stress in hypertension and Cardiovascular-Renal Remodeling: Focus on the Renin-Angiotensin-Aldosterone System
  1258. Evaluating the relationship of blood pressure, plasma angiotensin peptides and Aldosterone with cognitive functions in patients with hypertension
  1259. JS ISH-ECCR-4 The plasma Aldosterone/angiotensin II ratio for the screening of secondary hypertension
  1260. … characteristics of subclinical target organ damage in urban adult residents with hypertension in Tianjin and its relationships with renin-angiotensin-Aldosterone …
  1261. PRINCIPAL COMPONENTS OF POLYSOMNOGRAPHY POTENTIALLY EFFECT ON Aldosterone-RENIN-RATIO IN SNORERS WITH hypertension
  1262. Impaired Aldosterone response to the saline infusion test in patients with resistant hypertension and obstructive sleep apnea
  1263. Deficiency of T-type Ca2+ channels Cav3.1 and Cav3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma Aldosterone in mice
  1264. Aldosterone, hypertension, and Cardiovascular Disease
  1265. GW29-e0446 The Biomarker of Atrial Fibrillation in Patients with Essential hypertension–Aldosterone
  1266. Effects of Interactions among Gene Polymorphisms of the Renin–Angiotensin-Aldosterone System on hypertension in Turkish People from Southeast Anatolia
  1267. Effect of sodium–glucose cotransporter-2 inhibitors on Aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study
  1268. Aldosterone renin ratio in patients with resistant hypertension
  1269. Aldosterone escape in treatment of essential hypertension with RAS blockers [J]
  1270. Association of Urine Na: K with Renin and Aldosterone at Baseline in Pediatric hypertension
  1271. Diagnosis of Primary Aldosteronism and Usefulness of Aldosterone/Renin Ratio in Secondary hypertension
  1272. Increased Aldosterone release during head-up tilt in early primary hypertension
  1273. Polymorphic variants of the renin-angiotensin-Aldosterone system genes associated with the risk of hypertension development
  1274. Aldosterone-Renin Ratio Is Determinant of Arterial Stiffness in Large Cohort of Patients With Severe Essential hypertension: Pp. 10.410
  1275. Renin-angiotensin-Aldosterone inhibitors for treatment of hypertension with abnormal circadian rhythm of blood pressure
  1276. Direct versus enzymatic renin measurement for the calculation of Aldosterone/renin ratio in patients with essential hypertension and with primary hyperaldosteronism
  1277. Estimation of Serum Aldosterone and Electrolytes in Pregnancy Induced hypertension
  1278. Choice of an Optimal Blocker of the Renin-Angiotensin-Aldosterone System in Patients With Concomitant Arterial hypertension and Chronic Obstructive Pulmonary …
  1279. … Global Versus Renal-Specific Sympathoinhibition in Aldosterone-Induced hypertension: Implications for Medical Device-Based Treatment of Resistant hypertension
  1280. ALISKIREN, BOTH AS MONOTHERAPY AND IN COMBINATION WITH VALSARTAN, REDUCES PLASMA Aldosterone IN PATIENTS WITH hypertension: PP …
  1281. Estimation of the renin-angiotensin-Aldosterone system, water and electrolyte imbalance and endothelial function in newborns of women with chronic hypertension
  1282. … Chronic kidney disease progression in patients with resistant hypertension subject to two therapeutic strategies: intensification with loop diuretics vs Aldosterone …
  1283. Renin-angiotensin-Aldosterone System Blockers, hypertension and Clinical Outcomes
  1284. COVID‐19, hypertension, and renin‐angiotensin‐Aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
  1285. Roles of Aldosterone Receptor Antagonists in Heart Failure, hypertension, and Chronic Kidney Disease
  1286. Is there truly a sympathetic component to Aldosterone hypertension?
  1287. Aldosterone Biosynthesis: Genetic Control and Contribution to the Development of Arterial hypertension
  1288. Letter by Zhou and Zhou Regarding Article,“hypertension: Renin–Angiotensin–Aldosterone System Alterations”
  1289. A5917 Principal Component Analysis and Correlated Effect on Aldosterone-renin-ratio in Snorers with hypertension
  1290. The blockade of renin-angiotensin-Aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy
  1291. Aldosterone-Producing Cell Clusters in Essential hypertension
  1292. Abstract MP13: TRPM7 Downregulation Contributes To Cardiovascular Injury And hypertension Induced By Aldosterone And Salt
  1293. P1872 Fixed combinations of renin-angiotensin-Aldosterone system inhibitors and calcium channel blockers in relation of patients adherence in hypertension
  1294. … between Chronic Use of Renin–Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with hypertension
  1295. Vascular and endothelial function in human hypertension, and the importance of the renin-angiotensin-Aldosterone system
  1296. Association between polymorphism of the angiotensin-converting enzyme gene and the Aldosterone synthase gene in pedigreed primary hypertension.
  1297. Aldosterone synthase, polymorphism of its CYP11B2 gene in arterial hypertension and cardiovascular diseases associated with it (literature review)
  1298. Regulation of Biogenesis and Fusion/Fission Processes of Vascular Mitochondria In Aldosterone-Induced hypertension
  1299. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in hypertension: The MESA Study
  1300. Serum Aldosterone Levels in hypertension
  1301. Plasma renin activity, serum Aldosterone concentration and selected organ damage indices in essential arterial hypertension
  1302. Steroidogenic acute regulatory protein/Aldosterone synthase participates in signaling of angiotensin II/Aldosterone-induced aortic remodeling and hypertension
  1303. A6748 The Effect of Physiological Phenotyping with Plasma Renin and Aldosterone on Uncontrolled hypertension
  1304. Gender Differences in the Aldosterone Level of Young Obese Patients With hypertension
  1305. hypertension with Metabolic Alkalosis and Hypokalaemia-Could it be Aldosterone?
  1306. Abstract P249: Central Nervous System Control of Plasma Aldosterone and Endogenous Ouabain in Angiotensin II-Salt hypertension
  1307. Central injections of adeno‐associated virus‐siRNA gene to silence estrogen receptor beta (ERβ) augment Aldosterone‐induced hypertension in female rats
  1308. A14580 Predictors of the results of the diagnostic tests for the primary hyperaldosteronism in patients with hypertension and an Aldosterone-to-renin ratio greater than …
  1309. Roles of Aldosterone, mineralocorticoid inhibition and G6PD activity in microvascular endothelial dysfunction in African Americans with hypertension
  1310. Contribution of rennin-angiotensin-Aldosterone system genes and NO synthase gene to the development of arterial hypertension
  1311. Aldosterone–Renin Ratio and Side-Selective Renal Perfusion in Essential hypertension
  1312. A2074 FAILURE OF SUPPRESSION OF THE RENIN ANGIOTENSIN Aldosterone SYSTEM A POSSIBLE MECHANISM OF ESSENTIAL hypertension
  1313. Optimising Renin-Angiotensin-Aldosterone System Inhibitor Therapy In Heart Failure And Resistant hypertension: Challenges And Solutions
  1314. Response to Letter to Regarding Article,“Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary hypertension: Results of a Randomized, Double …
  1315. The role of Aldosterone and Aldosterone blockade in hypertension
  1316. PREGNANCY INDUCED hypertension AND ITS RELATION TO VITAMIN D AND Aldosterone IN IRAQI PREGNANT WOMEN
  1317. G PROTEIN-COUPLED ESTROGEN RECEPTORS: NOVEL THERAPEUTIC TARGETS IN Aldosterone/SALT-INDUCED hypertension?
  1318. Aldosterone METABOLITES AND POSSIBLE Aldosterone PRECURSORS IN hypertension
  1319. Brain natriuretic peptide counteracting the Renin-angiotensin-Aldosterone system in accelerated malignant hypertension
  1320. Renin–angiotensin–Aldosterone system inhibitors may benefit patients with comorbid hypertension and COVID-19
  1321. A8790 nocturnal hypertension renin-angiotensin-Aldosterone activation target organ damage
  1322. Mutation of an anti‐aging gene klotho causes hypertension via upregulation of plasma Aldosterone levels
  1323. Relationship between Aldosterone escape phenomena and left ventricular hypertrophy in essential hypertension treated by RAS blocker
  1324. Role of Aldosterone in postmenopausal hypertension
  1325. Aldosterone antagonists in the treatment of hypertension
  1326. Relationship between the CYP11B_2-344T/C polymorphism of Aldosterone synthase gene and essential hypertension in Uygur, Han and Kazak population in …
  1327. Letter by Keidar and Gamliel-Lazarovich Regarding Article,“Effects of A Novel Aldosterone Synthase Inhibitor for Treatment of Primary hypertension: Results of a …
  1328. A5791 Analysis of biochemistry and angiotensin I, angiotensin II and Aldosterone in Kazakh and Uygur primary hypertension in Xinjiang
  1329. Mutation of Anti-aging Gene Klotho Causes hypertension via Upregulation of CYP11B2 Expression and Aldosterone Syhthesis
  1330. A11744 Parameters of carotid structure and renin-Aldosterone system in patients with resistance hypertension
  1331. Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial hypertension
  1332. … the parameters of the renin-angiotensin-Aldosterone system, water-electrolyte metabolism, and endothelial function in newborns of women with chronic hypertension
  1333. The Role of Aldosterone in Pulmonary Venous hypertension
  1334. … ) polymorphism as a component of the renin-angiotensin-Aldosterone system in the pathogenesis of myocardial hypertrophy in hypertension: literature review and own …
  1335. OS 29-05 renal denervation attenuates Aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension
  1336. The Role of Aldosterone in Pulmonary Venous hypertension: Response
  1337. The relationship between blood levels of Aldosterone and procollagen type Ⅲ amino-terminal peptide with Left ventricular geometry in essential hypertension patients
  1338. Association of the-344T/C polymorphism of Aldosterone synthase gene CYP11 B2 with essential hypertension in Xinjiang uygur isolated group
  1339. … AGES, OFFICE BLOOD PRESSURE, EGFR, RENIN, Aldosterone, METANEPHRYLS LEVELS IN PATIENTS WITH RESISTANT hypertension
  1340. Na+-Cl− cotransporter-mediated chloride uptake contributes to hypertension and renal damage in Aldosterone-infused rats 2
  1341. Are Aldosterone antagonists effective for treating hypertension?
  1342. Pulmonary hypertension and Right Ventricular Dysfunction Identify Subgroups of Patients With HFpEF That Benefit From Aldosterone Antagonist Therapy
  1343. … control with additive administration of eplerenone, an Aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty
  1344. Elevated Plasma Renin Activity Caused by Accelerated-malignant hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal …
  1345. A10337 Intervention of Aldosterone antagonist on immune inflammatory injury in patients with essential hypertension
  1346. Abstract P313: Age and Response of Plasma Aldosterone to Saline Infusion in Primary hypertension
  1347. … AND THE RENIN ANGIOTENSIN Aldosterone SYSTEM: DISTINCT EFFECTS ON NA HANDLING AND BLOOD PRESSURE IN HUMAN hypertension: 2C. 04
  1348. Correlation between Aldosterone and hypertension among resistant hypertensive patients
  1349. … promotes apoptosis resistance in pulmonary artery smooth muscle cells to modulate adverse pulmonary vascular remodeling in pulmonary arterial hypertension
  1350. TRPM7 is Cardiovascular Protective in Aldosterone-Induced hypertension
  1351. Aldosterone levels and the-344t/c Aldosterone synthase in individuals with a family history of hypertension
  1352. … of renin-aniotensin-Aldosterone system is associated with improved left ventricular function in STEMI survivors without previous hypertension: a two dimensional …
  1353. Comparison of Aldosterone/plasma rennin activity ratio among hypertension patients in different posture
  1354. The relation of hypertension and Aldosterone-renin ratio with the severity of coronary artery disease in non-diabetic patients
  1355. Challenging hypertension: M-Atrial Natriuretic Peptide Enhances Antihypertensive Actions of Furosemide and Attenuates the Activation of Aldosterone
  1356. PP. 26.08: MANAGEMENT OF RESISTANT hypertension (RHT): Aldosterone ANTAGONISTS OR INTENSIFICATION OF DIURETIC THERAPY?
  1357. P4561 Patients adherence with fixed dose combinations of renin-angiotensin-Aldosterone system inhibitors in hypertension
  1358. Sacubitril/Valsartan Mitigates “Aldosterone Breakthrough” in Rats With Arterial hypertension While Valsartan and Enalapril Do Not
  1359. Effect of 3-month CPAP treatment on blood pressure and serum Aldosterone concentration in patients with resistant hypertension
  1360. Effects of irbesartan on the Aldosterone escape in essential hypertension
  1361. … six-month combination therapy using indapamide with amlodipine and renin-angiotensin-Aldosterone system blockers in patients with high-risk essential hypertension
  1362. Cholecalciferol supplementation is able to modulate hypertension and plasma Aldosterone in SHRSP rats.
  1363. Arterial hypertension progression and changing activity of reninangiotensin-Aldosterone and sympatho-adrenal systems
  1364. P616BNP and BMP4, two novel targets of Aldosterone in hypertension
  1365. Abstract P113: Early Life Stress-Induced Increases in Urinary Aldosterone Precedes Renal Dysfunction and hypertension in Male Mice Fed a High Fat Diet
  1366. Abstract P163: Masked Uncontrolled hypertension in Treated Hypertensive Patients Have Heightened Out-Of-Clinic Aldosterone Levels
  1367. Central blockade of Aldosterone synthase (AS) and lesion of the subfornical organ (SFO) attenuate subcutaneous (sc) Aldosterone‐induced hypertension
  1368. CHAPTER IV-Activation of the renal Aldosterone/MR system in aging and hypertension
  1369. Plasma Aldosterone, ANP, hypertension and Stage A and B Heart Failure in the General Community
  1370. Structural and Functional Insights into Aldosterone Synthase Interaction with Ligands and Redox Partner Proteins for Enhanced Treatment of hypertension
  1371. Study of the relationship between the depressurization of Aldosterone antagonists and plasma Aldosterone renin activity ratio (ARR) in refractoriness hypertension …
  1372. The Use of Renin and Aldosterone Profiling in the Treatment of Complex hypertension
  1373. Role of cardiac Aldosterone on the development of cardiac fibrosis in response to hypertension
  1374. Suppression of Aldosterone Mediates Left Ventricular Hypertrophy Regression in Patients With hypertension
  1375. Central AT1R stimulation increases hypothalamic Aldosterone: further evidence for a pivotal role of hypothalamic Aldosterone in Ang II induced hypertension
  1376. Leptin‐induced hypertension is Aldosterone Dependent in Obese Females
  1377. The Expression of Renin-angiotensin-Aldosterone System in Primary hypertension
  1378. G protein-coupled estrogen receptors: novel therapeutic targets in Aldosterone-induced hypertension?
  1379. Abstract P328: Evaluation of Hyperkalemia and the Use of Aldosterone Antagonists in Resistant and Secondary hypertension in a hypertension Referral Center
  1380. Decreased klotho expression in early Aldosterone‐induced hypertension
  1381. The Correlation between Essential hypertension and Renin-angiotensin-Aldosterone System
  1382. ALTERATION OF Aldosterone RESPONSE TO SALT OVERLOAD THROUGH CHRONIC KIDNEY DISEASE IN PATIENTS WITH hypertension
  1383. Severity of obstructive sleep apnea dependent upon Aldosterone status in subjects with resistant hypertension
  1384. Leptin-mediated Aldosterone Secretion Causes hypertension in Obese Females
  1385. Cilnidipine Decreases Insulin Resistance and Aldosterone Levels in Essential hypertension
  1386. An increased Aldosterone-to-renin ratio in patients with non-dipper hypertension
  1387. SEVERITY OF OBSTRUCTIVE SLEEP APNEA RELATED TO Aldosterone LEVELS IN SUBJECTS WITH RESISTANT hypertension: PP. 32.274
  1388. Response by Danser and van den Meiracker to Letter by Zhou and Zhou Regarding Article,“hypertension: Renin–Angiotensin–Aldosterone System Alterations”
  1389. Correction of Aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases
  1390. Oxidative Stress is Related to Increased Sodium-Aldosterone Product and Left Ventricular Dysfunction in Resistant hypertension
  1391. The measurement of the renin-angiotensin-Aldosterone system in patients with adrenal tumors with arterial hypertension
  1392. Autonomous Aldosterone secretion as a significant cause of arterial hypertension: the effectiveness of targeted therapy
  1393. Aldosterone‐Induced hypertension is T Lymphocyte‐Dependent and Attenuated by Activation of the G Protein‐Coupled Estrogen Receptor 1
  1394. Vascular Aging In Aldosterone Associated hypertension: Role Of NADPH Oxidase 1
  1395. Vascular Aging in Aldosterone Associated hypertension: Role of NADPH Oxidase 1
  1396. Metabolic disorders and the state of the renin–angiotensin–Aldosterone system in obese patients with resistant hypertension
  1397. OS 02-01 ROLE OF Aldosterone AND NADPH OXIDASE 1 IN hypertension-ASSOCIATED VASCULAR AGING
  1398. Absoluter Aldosteronexzess, Bluthochdruck und koronare Herzerkrankung/Arterial hypertension and cardiovascular disease–absolute Aldosterone excess is the tip of …
  1399. Variation of plasma Aldosterone level and histological ultrastructure change of adrenal gland in stress-induced hypertension rats
  1400. Relation between cardiac hemodynamics and Aldosterone content two years after myocardial infarction depending on arterial hypertension
  1401. Study of relationship between fibrinogen, Aldosterone and left ventricular mass index in patients with essential hypertension
  1402. … by Calhoun et al1 in which the authors tested the effect of a novel Aldosterone synthase inhibitor, LCI699, for treatment of primary hypertension. An 8-week …
  1403. Determination of Aldosterone Hormone and Alpa Feto-Protein Concentrations in Normal Pregnant Women and in Pregnancy Induced hypertension
  1404. Effects of Impaired Aldosterone Secretion on hypertension Development in the Spontaneously Hypertensive Rat (SHR).
  1405. Response to “role of relative Aldosterone excess in salt-sensitive hypertension in people of african ancestry”
  1406. The role of [ldquo] stress [rdquo] in Aldosterone-mediated hypertension: circumstantial evidence from the [ldquo] stress subtraction [rdquo] experiment of adrenal vein …
  1407. The role of central ROS and NO in Aldosterone (ALDO)/salt‐induced hypertension
  1408. AN INCREASED Aldosterone TO RENIN RATIO IN PATIENTS WITH NON-DIPPER hypertension: PP. 24.477
  1409. Somatic mutations in ATP1A1 and ATP2B3 lead to Aldosterone-producing adenomas and secondary hypertension
  1410. Association of the-344T/C Aldosterone synthase gene variant with essential hypertension
  1411. … OF QUINAPRIL ADD-ON TREATMENT ON Aldosterone BREAKTHROUGH IN PATIENTS WITH ESSENTIAL hypertension RECEIVING VALSARTAN: PP …
  1412. Aldosterone/Renin Ratio is a Predictor of Cardiovascular Events in Patients with Essential hypertension
  1413. Diagnostic accuracy of the Aldosterone to active renin ratio in detecting primary aldosteronism: the graz endocrine causes of hypertension (GECOH) study
  1414. Renin-Angiotensin-Aldosterone and Other Neurohumoral Factors in the Pathogenesis of Pulmonary hypertension
  1415. Response to Role of Angiotensinogen and Relative Aldosterone Excess in Salt-Sensitive hypertension
  1416. Aldosterone/renin Ratio is a Long-term Predicter of Cardiovascular Events in Patients With Essential hypertension
  1417. Aldosterone synthase gene polymorphism in patients with hypertension combined ischemic heart disease with in various left ventricular mass
  1418. RELATIONSHIPS OF SERUM URIC ACID WITH PLASMA RENIN ACTIVITY AND PLASMA Aldosterone IN PRIMARY hypertension.
  1419. Synthesis of Aldosterone in the brain contributes to the hypertension in the Dahl salt sensitive rat
  1420. Analysis of Renin-Angiotensin-Aldosterone System Gene Polymorphisms in Essential hypertension in Javanese Indonesian
  1421. Effect of Qingre Jiangya Granules on Plasma Angiotensin Ⅱ and Aldosterone in Spontaneous hypertension Rats [J]
  1422. GW25-e0782 Association between plasma Aldosterone with KCNJ5 gene polymorphisms in primary hypertension patients
  1423. Regulation of the Aldosterone synthase gene-role in human hypertension and adrenal corticosteroid production
  1424. 26 PREDICTORS OF COMPLETE RESOLUTION OF hypertension AFTER ADRENALECTOMY AMONG JAPANESE PATIENTS WITH Aldosterone …
  1425. The Influence of Juteng Capsule on Blood Pressure and Plasma Aldosterone and Catecholamine of Stress-induced hypertension in Rats
  1426. Blood Pressure Control and Dipping Patterns in Patients With Resistant hypertension: Combined Effects of Aldosterone and Sodium
  1427. Effects of Reduced Aldosterone Secretion on hypertension Development in the Spontaneously Hypertensive Rat (SHR) as Measured by Remote Monitoring
  1428. Aldosterone: With an Unhealthy Diet (High Sodium, Low Potassium) a Little Extra May Go a Long Way Toward Development of hypertension
  1429. Effects of Aldosterone Hormone on Endothelial Function With Carotid Intima-media Thickness Among Resistant and Early Onset hypertension Patients
  1430. Effect of Qingxuan Jiangya decoction on renin-angiotensin-Aldosterone system of primary hypertension patients
  1431. Study on the association of plasma rennin angiotensin, angiotensin II and Aldosterone in sleep apnea hypopnea syndrome patients with hypertension
  1432. Albumin may prevent hypertension by inhibiting renin angiotensin Aldosterone system
  1433. Impact of Polymorphisms in the Renin-Angiotensin-Aldosterone System on Vascular Alterations in Essential hypertension
  1434. Gender differences renin-angiotensin-Aldosterone system and its relation to humoral factors in patients with arterial hypertension
  1435. … response to mineralocorticoid-receptor blockade in aldosteronisms: primary hyperaldosteronism vs Aldosterone-associated hypertension/low-renin hypertension
  1436. … Impact of hypertension and Chronic Kidney Disease on the Acute Myocardial Infarction: Pathogenic Interactions of Cardiac Remodeling Using Aldosterone …
  1437. Target levels of renin-angiotensin-Aldosterone system components and their role in cardiovascular event development among patients with arterial hypertension
  1438. Magnesium supplementation attenuates Aldosterone‐induced hypertension, kidney damage and oxidative stress in genetically hypomagnesemic mice
  1439. Elevated Plasma Aldosterone/Renin Ratio Is Associated with Future Stroke in Japanese Patients with Essential hypertension
  1440. Abstract P027: Associations of Renin-Angiotensin-Aldosterone System Genes with Blood Pressure changes and hypertension Incidence: The GenSalt Study
  1441. Circulating Inactive Matrix Gla-Protein is Associated With High Aldosterone Levels and Arterial Stiffness in hypertension
  1442. Comparison of the role of the renin-angiotensin Aldosterone system in the genesis of hypertension between two groups of nonhunting dogs and hunting dogs
  1443. PLASMA Aldosterone LEVELS ON NORMAL, LOW AND HIGH SODIUM INTAKE IN PATIENTS WITH ESSENTIAL hypertension WITH NORMAL AND LOW …
  1444. Studies of Aldosterone renin ratio and genetic variation at the CYP11B1/CYP11B2 locus in human essential hypertension
  1445. Endocrine hypertension, Adrenal Steroids and Development of a Saliva Based Aldosterone Assay as a Potential Screening Method
  1446. Relationship between angiotensin converting enzyme and Aldosterone synthase gene polymorphisms and essential hypertension in Qiqihar Han population
  1447. Leptin Induces hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice
  1448. Twenty-four hour urine Aldosterone level predicts left ventricular hypertrophy in patients with primary aldosteronism and essential hypertension
  1449. Aldosterone and Salt Induces hypertension Associated with Increased Oxidative Stress in the Brain of Apolipoprotein E Knockout Mice
  1450. … Antagonists Regulate Mitochondrial Dynamics and Local Aldosterone Production Attenuating Right Ventricular Remodeling in Pulmonary Arterial hypertension
  1451. Baseline Aldosterone/Renin Ratios Predict Responses to Thiazide in Essential hypertension, Particularly for Already-Treated Patients
  1452. Aldosterone AND hypertension IN OVARIECTOMIZED FEMALE DAHL SALT SENSITIVE RATS ON LOW SALT DIET
  1453. Malignant hypertension Leading to a Diagnosis of an Aldosterone and Cortisol Co-Secreting Adrenal Tumor
  1454. Aldosterone-RECEPTOR ANTAGONISTS LEAD TO PROLONGED BLOOD PRESSURE REDUCTION IN UNCONTROLLED hypertension: A …
  1455. IRB Protocol: Rates of Practitioner Use of Aldosterone Antagonists for Resistant hypertension in an Academic Quaternary Referral Ambulatory Clinic Setting A …
  1456. Abstract P280: Butyric Acid Protects Against Aldosterone-salt-induced hypertension and Renal Injury via Suppression of (Pro) Renin Receptor
  1457. ZD100: BP Lowering, Renal Enhancing and Aldosterone Suppressing Properties via pGC-A in Human Resistant “Like” hypertension-A First in Human Study
  1458. Renin-angiotensin-Aldosterone system gene variants and their association with left ventricular function and vascular properties in essential hypertension
  1459. Aldosterone Targets Raptor to Promote Pulmonary Smooth Muscle Cell Proliferation and Modulate Pulmonary Arterial hypertension
  1460. Serum potassium levels predict blood pressure response to Aldosterone antagonists in resistant hypertension
  1461. Angiotensinogen Gene M235T Polymorphism and Serum Renin, Aldosterone Hormones Levels among Sudanese patients with Essential hypertension
  1462. Upregulation of Renin Angiotensin Aldosterone System (RAAS) by Methylglyoxal: Role in hypertension
  1463. Dietary Iron Restriction Attenuates hypertension and Renal Injury in Aldosterone/Salt-Induced Hypertensive Mice
  1464. The activity of the renin-Aldosterone system and arterial hypertension creation in patients with congenital vesicoureteral reflux and reflux nephropathy
  1465. … ACTIVATION OF MINERALCORTICOID RECEPTOR-SGK1 SYSTEMS IN URINARY EPITHELIUM FOR THE MODEL OF SODIUM SENSITIVE hypertension: PP …
  1466. Abstract P276:(Pro) Renin Receptor-dependent Renal Generation of Aldosterone Contributes to ENaC Activation During Angiotensin II-induced hypertension
  1467. THE CHANGES OF PLASMA RENIN AND Aldosterone LEVELS IN RESISTANT hypertension PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA …
  1468. Anti-aging Gene Klotho Deficiency Causes hypertension Via Upregulation of CYP11B2 Expression and Aldosterone Synthesis
  1469. Endothelial function, the renin-angiotensin-Aldosterone axis (RAAS) and hypertension: the therapeutic role of potassium supplementation
  1470. CNS blockade of Aldosterone synthase prevents sympathetic hyperactivity and hypertension by central Na+ loading in Wistar rats
  1471. The induction of salt‐sensitiive hypertension (HTN) in rats by sensitizing pre‐treatments with either angiotensin II (ANG II) or Aldosterone (ALDO)
  1472. Influence of antihypertensive medication on the screening parameter Aldosterone to renin ratio in patients with essential hypertension and primary aldosteronism
  1473. Disruption of the WNK/SPAK pathway attenuates angiotensin II, but enhances Aldosterone‐induced hypertension (1136.3)
  1474. Resistant hypertension, Elevated Aldosterone/Renin Ratio and Reduced RGS2: A Pathogenetic Link Deserving Further Investigations?
  1475. A Study of a Proposed Molecular Mechanism for Idiopathic Cases of hypertension: Detection of Aldosterone-receptor Complex at Period Homolog 1 (Per1) Promoter …
  1476. TRPM7-kinase Modulates Renal and Splenic Macrophage and T-lymphocyte Infiltration in Aldosterone-salt-induced hypertension
  1477. Function of dynamically stimulated endothelium and renin–angiotensin–Aldosterone system in normotensive subjects with a family history of hypertension
  1478. Effect of Circadian Variability of Dipper Blood Pressure Induced by Irbesartan in Patients with Non-Dipper Essential hypertension on Levels of Aldosterone
  1479. Aldosterone Activates Raptor to Promote Pulmonary Artery Smooth Muscle Cell Proliferation and Pulmonary Arterial hypertension
  1480. The changes of plasma renin and Aldosterone levels in resistant hypertension patients with obstructive sleep apnea syndrome before and after continuous positive …
  1481. Renin-angiotensin-Aldosterone System Polymorphisms-based Risk Score In Resistant Arterial hypertension And Adverse Cardiovascular Events: The Genhart-rio …
  1482. Dyssynchrony and Fibrosis in a Canine Model of hypertension Correlates with Aldosterone-Mediated Depletion in Circulating Progenitor Cell Counts
  1483. Primary Prevention of Atrial Fibrillation Using Renin-Angiotensin-Aldosterone System Inhibitors among Medicare Beneficiaries with hypertension
  1484. Endothelial function, the renin-angiotensin-Aldosterone axis (RAAS) and hypertension: diagnostic strategies and therapeutic role of potassium supplementation
  1485. Effect of renin-angiotensin-Aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
  1486. Aldosterone Inactivates the Endothelin-B Receptor via a Thiol Redox Switch to Modulate Pulmonary Arterial hypertension
  1487. … of Pulmonary Artery Endothelial Catechol-o-methyltransferase Activity by Aldosterone Increases Norepinephrine Levels in Pulmonary Arterial hypertension
  1488. Effects of chronic receptor blockade on intracardiac angiotensin II and Aldosterone content in an angiotensin II-infused model of hypertension
  1489. 5972 The renin and Aldosterone levels at resistant hypertension and its connection with other clinical features
  1490. Association and Interrelation of Angiotensinogen, ACE, ACE-2, and Aldosterone Synthase Gene Polymorphism in Essential hypertension
  1491. Selective Aldosterone Blocker Enhances Protective Effects of Calcium Channel Blocker (CCB) Against Salt-sensitive hypertension-induced Cardiovascular Injury …
  1492. Aldosterone (Aldo) Interacts with PKA, MAPKs and PLC Pathway to Sensitize Angiotensin (ANG) II‐Induced hypertension
  1493. … Prevents the Arterial Stiffness Elevation Resulting in the Amelioration of Inappropriate Cardiovascular Response During Exercise in Patients With hypertension
  1494. … Peripheral Blood 18-oxo-cortisol Can Differentiate the Patients With Aldosterone Producing Adenoma From Those With Essential hypertension.-omitting many steps …
  1495. … CATHETER BASED RENAL SYMTHETIC DENERVATION ON RENIN-ANGIOTENSION-Aldosterone SYSTEM IN PATIENTS WITH RESISTANT hypertension
  1496. … et al,“The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin hypertension and Elevated Aldosterone …
  1497. Novel description of Aldosterone synthase CYP11B2 -344 T>C gene polymorphism related to hypertension in Mexican Amerindians: Teenek, Mixtec and Mayans
  1498. … Application of a New Chemiluminescent Method for Direct Renin Measurement to the Calculation of Aldosterone/Renin Ratio in Patients with Essential hypertension
  1499. PVN injections of adeno‐associated virus‐siRNA to silence either NOX2 or NOX4 attenuates Aldosterone/NaCl‐induced hypertension in mice
  1500. Relationship between Aldosterone and complement c1q tumor necrosis factor-related protein 1 in sleep apnea-related hypertension
  1501. … -ATPASE INHIBITION WITH SALT-SENSITIVITY OF BLOOD PRESSURE IN RESISTANT hypertension AND EFFECTS OF Aldosterone ANTAGONIST: 8A. 06
  1502. … injections of adeno‐associated virus‐siRNA to silence estrogen receptor β (ERβ) produces augmentation of Aldosterone/NaCl‐induced hypertension in female rats
  1503. … Acute Regulatory Protein (StAR) is Associated With Connective Tissue Growth Factor-Mediated Pulmonary Vascular Fibrosis in Pulmonary Arterial hypertension In …
  1504. … the Endothelin-B Receptor to Decrease Pulmonary Endothelial Nitric Oxide Levels and Promote Pulmonary Vascular Remodeling in Pulmonary Arterial hypertension
  1505. … Modification of Endothelin-B Receptor Cysteinyl Thiol (s) by Aldosterone Decreases Pulmonary Endothelial Nitric Oxide Levels in Pulmonary Arterial hypertension
  1506. … AND EXPRESSION OF ATRIAL NATRIURETIC PEPTIDE AND Aldosterone SYNTHASE GENE IN PATIENTS WITH ESSENTIAL hypertension
  1507. … SYSTEM WITH COMBINATIONS OF ALISKIREN AND AMLODIPINE, RAMIPRIL AND AMLODIPINE IN PATIENTS WITH ESSENTIAL hypertension
  1508. … ,“The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin hypertension and Elevated Aldosterone …
  1509. … -OXO-CORTISOL PRACTICALLY DIFFERENTIATE Aldosterone PRODUCING ADENOMA FROM BILATERAL HYPERPLASIA AND PRIMARY hypertension …
  1510. 1020 EFFECTS OF Aldosterone BLOCKADE ON LIPIDS, GLUCOSE AND VISCERAL FAT IN PATIENTS WITH ESSENTIAL hypertension
  1511. 9.11 Association between Plasma Aldosterone, Metabolic Syndrome and Left Ventricular Mass in Essential hypertension
  1512. … IN ANGIOTENSIN II RECEPTOR GENES WITH POSTOPERATIVE hypertension RISK FOR Aldosterone PRODUCING ADENOMA PATIENTS
  1513. … HIGH Aldosterone-RENIN RATIO (ARR) IS ASSOCIATED WITH THE DEVELOPMENT OF ESSENTIAL hypertension FROM WHITE COAT hypertension
  1514. 1c. 12: Dietary salt intake and Aldosterone-related organ damage in hypertension
  1515. … patients with uncomplicated hypertension/EY Choi, JW Ha, SJ Yoon [et al.]//Am. Soc. Echocardiogr.–2008.–Vol. 21, N 3.–P. 251–256. 19. Jonar S. Aldosterone …
  1516. … OF DNA POLYMORPHISMS WITHIN CYP11B2/CYP11B1 LOCUS AND POSTOPERATIVE hypertension RISK IN THE PATIENTS WITH Aldosterone …
  1517. … D AND PARATHYROID HORMONE WITH AMBULATORY hypertension AND THEIR INTERACTIONS WITH SERUM Aldosterone AND SALT INTAKE
  1518. Lipocalin‐2 Deficiency Protects against Aldosterone‐Induced hypertension and Organ Damages by Inhibiting Mineralocorticoid Receptor Signaling
  1519. 2 Renin-angiotensin-Aldosterone profiles predictive of superimposed preeclampsia: Chronic hypertension
  1520. … LAND: CLINICAL STUDIES IN PULMONARY hypertension: Galectin-3 And Aldosterone As Potential Tandem Biomarkers In Pulmonary Arterial hypertension
  1521. PP. LB01. 20: PROSPECTIVE ASSESSMENT OF THE DIRECT RENIN AND Aldosterone ASSAY IN THE WORK-UP OF ARTERIAL hypertension
  1522. … -47 EFFECTS OF RENIN-ANGIOTENSIN-Aldosterone SYSTEM BLOCKADE MEDICATIONS ON COGNITION FUNCTION IN hypertension: HEAD-TO-HEAD …
  1523. MicroRNA‐21 Overexpression Attenuates Aldosterone‐Mediated Cardiac Injury and hypertension
  1524. LBOS 02-01 hypertension, Aldosterone AND EPC-MEDIATED ENDOTHALIAL INJURY REPAIR
  1525. … CARDIOVASCULAR REMODELING EFFECTS OF Aldosterone: INSIGHTS FROM GITELMAN SYNDROME, A HUMAN MODEL OPPOSITE TO hypertension
  1526. … 17-38 CORRELATION OF Aldosterone-RENIN RATIO AND NIGHTTIME BLOOD PRESSURE AND TARGET ORGAN DAMAGE IN ESSENTIAL hypertension
  1527. A3401 A case report of a 33-year-old man with resistant hypertension and slightly elevated cortisol and Aldosterone
  1528. Effects of Lysine-specific Demethylase 1 Deficiency on Aldosterone Production and Salt-sensitive hypertension in Female Mice
  1529. … OF GALECTIN-3 AND Aldosterone ON DIFFERENT CLINICAL CHARACTERISTICS IN MALE AND FEMALE PATIENTS WITH ARTERIAL hypertension.
  1530. 301 ADIPONECTIN AND Aldosterone LEVELS IS ASSOCIATED WITH ARTERIAL STIFFNESS IN RESISTANT hypertension
  1531. [PP. 17.24] THE RESPONSE OF PLASMA Aldosterone TO SALINE INFUSION IS UNDER THE INFLUENCE OF AGE IN PRIMARY hypertension
  1532. … PLASMA RENIN ACTIVITY, PLASMA Aldosterone AND SELECTED ASYMPTOMATIC ORGAN DAMAGE INDICES IN ESSENTIAL ARTERIAL hypertension
  1533. … activation induces the expression of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in dendritic cells in vitro and during the Aldosterone-dependent hypertension
  1534. … The renin–angiotensin–Aldosterone system and superimposed pre-eclampsia in women with chronic kidney disease and chronic hypertension: Chronic hypertension
  1535. Intracerebroventricular injections of adeno‐associated virus‐siRNA gene to silence angiotensin type 1 receptors (AT1) prevent Aldosterone‐induced hypertension
  1536. PS-82 GENDER FEATURES OF THE RENIN-ANGIOTENSIN-Aldosterone SYSTEM (RAAS) IN PATIENTS WITH ARTERIAL hypertension IN UZBEKISTAN.
  1537. 32 Premature vascular ageing in hypertension: role of Aldosterone and nadph oxidases
  1538. … aldosteronism in the COAR and SIE cohorts. To compare the numbers of patients who showed positive hormonal results or had hypertension between the COAR and …
  1539. PP. 32.15: POST-SALINE LOAD PLASMA Aldosterone LEVEL IS A DETERMINANT OF LEFT VENTRICULAR MASS IN ESSENTIAL hypertension
  1540. Deficiency of the T‐type Calcium Channel Cav 3.1 attenuates Plasma Aldosterone and Cardiac Hypertrophy despite similar Ang II‐induced hypertension
  1541. 1091 CLOCK GENE, Aldosterone AND hypertension
  1542. PS 17-65 THE C344T GENE POLYMORPHISM OF Aldosterone SYNTHASE IS RISK FACTOR OF EARLY RENAL DAMAGE IN hypertension IN A CHINESE …
  1543. Kir5. 1‐Mediated Changes in Renin‐Angiotensin‐Aldosterone System Balance in Salt Sensitive hypertension
  1544. Galectin-3 And Aldosterone As Potential Tandem Biomarkers In Pulmonary Arterial hypertension
  1545. 6.9 Plasma Aldosterone and Albumin Urinary Excretion in hypertension
  1546. … :[PP. 04.11] RELATIONSHIP BETWEEN PLASMA Aldosterone LEVELS AND LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN ESSENTIAL hypertension
  1547. MPS 14-03 Effects of Azilsartan medoxomil compared to other angiotensin II receptor blocker on plasma Aldosterone levels in patients with essential hypertension
  1548. 9B. 07: EFFECT OF POSTURAL CHANGES ON Aldosterone TO PLASMA RENIN RATIO IN PATIENTS WITH SUSPECTED SECONDARY hypertension
  1549. … OF THE RENIN ANGIOTENSIN Aldosterone SYSTEM AND ITS IMPACT ON KIDNEY OXIDATIVE STRESS, RENAL FUNCTION AND hypertension IN …
  1550. … IMPROVE ENDOTHELIAL GLYCOCALYX AND PWV AFTER 1 YEAR SUCCESSFUL TREATMENT IN UNTREATED PATIENTS WITH ESSENTIAL hypertension
  1551. GPER is involved in the stimulatory effects of Aldosterone in breast cancer cells and breast tumor-derived endothelial cells
  1552. Aldosterone mediates metastatic spread of renal cancer via the G protein‐coupled estrogen receptor (GPER)
  1553. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/Aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks
  1554. Renin-angiotensin-Aldosterone system-based antihypertensive agents and the risk of colorectal cancer among medicare beneficiaries
  1555. Primary hyperparathyroidism associatiated with Aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene
  1556. Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
  1557. Aldosterone-and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer
  1558. Urinary excretion of components of the renin-angiotensin-Aldosterone system in patients having localized renal cancer.
  1559. RETRACTED: Relationship Between Aldosterone Synthase CYP1A1 MspI Gene Polymorphism and Prostate Cancer Risk
  1560. Drugs affecting renin-angiotensin-Aldosterone system and the cancer risk: A meta-analysis of nested case-control studies.
  1561. Cancer progression in COVID-19: integrating the roles of renin angiotensin Aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial …
  1562. … use of renin-angiotensin-Aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional …
  1563. Aldosterone-Producing Adrenal Cortical Cancer
  1564. Effect of Aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
  1565. Aldosterone mediates a mineralocorticoid receptor‐mediated increase in prostate cancer cell migration
  1566. Resistance to Antihypertensive Drugs Targeting Renin Angiotensin Aldosterone System in Cancer patients: A Case Series
  1567. Treatment-related Aldosterone changes in cancer of the middle part of the larynx
  1568. Blood-ACTH, cortisole and Aldosterone levels following complex radiation treatment for cancer of the uterine cervix
  1569. Regulation of mineralocorticoid receptor and its downstream targets by estrogen and Aldosterone in breast cancer
  1570. The effect of combined radiotherapy on blood levels of ACTH, cortisol and Aldosterone in cervical cancer
  1571. … -10: Glucocorticoid and Aldosterone mimic progestin-induction of a therapy-resistant cytokeratin-5 positive cell population in estrogen receptor-positive breast cancer …
  1572. The Aldosterone Antagonist Spironolactone Improves Cardiac Function in Experimental Cancer Cachexia
  1573. Lower Aldosterone–renin ratio is a risk factor for total and cancer death in Japanese individuals: the Takahata study
  1574. The changes of serum cortisol and Aldosterone in patients with cancer of vestibular section of larynx after irradiation and with and without surgery
  1575. Levels of growth hormone, prolactin, cortisone, Aldosterone and insulin in the blood of patients with stomach cancer, before and after gastrectomy
  1576. Postoperative change of atrial natriuretic peptide and renin-angiotensin-Aldosterone system after pulmonary resection for lung cancer
  1577. … between SNPs in the renin-angiotensin-Aldosterone system and hypertension, obesity, and blood pressure-related dietary exposures regarding renal cell cancer risk
  1578. Enhanced Aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors
  1579. Relationship between visceral fat and plasma Aldosterone concentration in patients with primary aldosteronism
  1580. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice
  1581. Periarterial fat from two human vascular beds is not a source of Aldosterone to promote vasoconstriction
  1582. Significant association of Aldosterone and liver fat among HIV-infected individuals with metabolic dysregulation
  1583. Increased Aldosterone among HIV-infected women with visceral fat accumulation
  1584. Role of potassium excretion and percent body fat on ethnic differences in plasma Aldosterone levels
  1585. Aldosterone levels in patients on haemodialysis: Relationship with body fat mass and adipocytokines
  1586. System renin-Aldosterone in fat tissue and other organ and tissues
  1587. The renin-angiotensin-Aldosterone system (RAAS)-new pathogenetic and therapeutic aspects Part. I. Prorenin and renin and its receptors, convertase 2 of angiotensin …
  1588. Aldosterone production by the mouse adrenal gland is compromised by a high fat diet and 11 [beta]-hydroxysteroid dehydrogenase type 1 deficiency
  1589. … and glucagon-like peptide-1 and 2 receptors expression in stable patients with multivessel coronary artery disease: an association with renin-angiotensin-Aldosterone …
  1590. Neuropeptide Y (NPY) receptor 2 deletion in adipocytes blunts fat‐derived Aldosterone production in female mice exposed to chronic stress
  1591. Primary aldosteronism
  1592. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
  1593. High incidence of primary aldosteronism in 199 patients referred with hypertension.
  1594. Primary aldosteronism
  1595. Primary aldosteronism: diagnostic evaluation
  1596. Presidential address: part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome
  1597. Primary aldosteronism: diagnosis, localization, and treatment
  1598. The changing clinical spectrum of primary aldosteronism
  1599. Factors influencing outcome of surgery for primary aldosteronism
  1600. Primary aldosteronism: diagnosis and treatment
  1601. Cardiovascular complications in patients with primary aldosteronism
  1602. High prevalence of primary aldosteronism in the Tayside hypertension clinic population
  1603. Primary aldosteronism, a new clinical entity
  1604. The diagnosis of primary aldosteronism and separation of two major subtypes
  1605. Reliability of screening methods for the diagnosis of primary aldosteronism
  1606. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism
  1607. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore
  1608. Potentially high prevalence of primary aldosteronism in a primary-care population
  1609. Further evaluation of saline infusion for the diagnosis of primary aldosteronism.
  1610. Suppression of plasma renin activity in primary aldosteronism: distinguishing primary from secondary aldosteronism in hypertensive disease
  1611. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism
  1612. Primary aldosteronism: update on diagnosis and treatment.
  1613. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma
  1614. Primary aldosteronism. Results of surgical treatment.
  1615. Clinical and pathological diversity of primary aldosteronism, including a new familial variety
  1616. Normokalemic primary aldosteronism: a detectable cause of curable essential hypertension
  1617. Primary aldosteronism: A common and curable form of hypertension.
  1618. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.
  1619. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension
  1620. Outpatient screening tests for primary aldosteronism
  1621. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype
  1622. Hypokalemia in the hypertensive patient: with observations on the incidence of primary aldosteronism
  1623. Primary aldosteronism: hypertension with a genetic basis
  1624. Association of hypokalemia, aldosteronism, and renal cysts
  1625. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital
  1626. Primary aldosteronism: adrenal venous sampling
  1627. Single dose captopril as a diagnostic test for primary aldosteronism
  1628. Successful surgical treatment of a cat with primary aldosteronism
  1629. Plasma renin activity in primary aldosteronism: importance in differential diagnosis and in research of essential hypertension
  1630. Pheochromocytoma and primary aldosteronism: diagnostic approaches
  1631. Primary aldosteronism: learning from the study of familial varieties
  1632. Albuminuria in untreated patients with primary aldosteronism or essential hypertension.
  1633. Hemodynamic characteristics of primary aldosteronism
  1634. Calcium metabolism and parathyroid function in primary aldosteronism
  1635. Glucocorticoid-remediable aldosteronism
  1636. Primary aldosteronism. Issues in diagnosis and management.
  1637. Laparoscopic adrenalectomy for primary aldosteronism: a new operative method
  1638. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism
  1639. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism.
  1640. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?
  1641. Screening for primary aldosteronism with a logistic multivariate discriminant analysis*
  1642. Primary aldosteronism (Conn’s syndrome) in a cat; a case report and review of comparative aspects
  1643. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism
  1644. Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism
  1645. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
  1646. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism
  1647. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for …
  1648. Renal changes in primary aldosteronism
  1649. Success of surgery for primary aldosteronism judged by residual autonomous Aldosterone production
  1650. Correctable subsets of primary aldosteronism Primary adrenal hyperplasia and renin responsive adenoma
  1651. Adjustment of the osmostat in primary aldosteronism
  1652. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism?
  1653. CT in the diagnosis of primary aldosteronism: sensitivity in 29 patients.
  1654. Primary aldosteronism
  1655. Primary aldosteronism—some genetic, morphological, and biochemical aspects of subtypes
  1656. Aldosteronism and hypertension: primary aldosteronism versus hypertensive disease with secondary aldosteronism
  1657. Normotensive primary aldosteronism: report of a case
  1658. Circadian rhythm of plasma Aldosterone concentration in patients with primary aldosteronism
  1659. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of Aldosterone-producing adenoma
  1660. Therapeutic effect of calcium channel blockade in primary aldosteronism
  1661. The syndrome of primary aldosteronism
  1662. Pathology of primary aldosteronism
  1663. Primary aldosteronism: Photoscanning of tumors after administration of 131I-19-iodocholesterol
  1664. Control of plasma Aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia
  1665. Commentary on incidence of primary aldosteronism: current estimations based on objective data
  1666. Use of the saline infusion test to diagnose the cause of primary aldosteronism
  1667. Aldosteronism in Man: Some Clinical and Climatological Aspects Part I
  1668. Use of computed tomography in diagnosing the cause of primary aldosteronism
  1669. Laparoscopic adrenalectomy for primary aldosteronism: report of initial ten cases.
  1670. Glucocorticoid-remediable aldosteronism and pregnancy
  1671. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism
  1672. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of Aldosterone …
  1673. Normokalemic Primary Aldosteronism: Its Masquerade as Essential hypertension
  1674. Primary aldosteronism: clinical staff conference at the National Institutes of Health
  1675. Left ventricular systolic function in primary aldosteronism and hypertension
  1676. Effect of ketanserin in primary aldosteronism.
  1677. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism
  1678. Increased disorderliness and amplified basal and pulsatile Aldosterone secretion in patients with primary aldosteronism
  1679. Primary aldosteronism: clinical management
  1680. Evolution of the surgical management of primary aldosteronism.
  1681. Non-tumorous” primary” aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism).
  1682. Is Aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism?
  1683. Primary aldosteronism in pregnancy
  1684. Aldosteronism in man: some clinical and climatological aspects Part II
  1685. Primary reninism: hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors
  1686. Aldosteronism in hypertension: Spironolactone Response Test.
  1687. Primary aldosteronism with malignant hypertension
  1688. Diagnosis and treatment of primary aldosteronism
  1689. Primary aldosteronism in pregnancy
  1690. Primary aldosteronism presenting as myoglobinuric acute renal failure
  1691. Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients
  1692. Pregnancy and primary aldosteronism
  1693. The prediction of anatomical morphology of primary aldosteronism using serum 18-hydroxycorticosterone levels
  1694. Circadian rhythm and effect of posture on plasma Aldosterone concentration in primary aldosteronism
  1695. Primary aldosteronism due to adrenal hyperplasia: Occurrence in a boy aged 10 years
  1696. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension?
  1697. Postoperative studies of adrenal function in primary aldosteronism
  1698. The regulation of Aldosterone secretion in primary aldosteronism
  1699. Diagnosis and surgical treatment of primary aldosteronism in pregnancy: a case report
  1700. Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy
  1701. Suppression of Aldosterone by cyproheptadine in idiopathic aldosteronism
  1702. Possibility of normokalaemic primary aldosteronism as reflected in the frequency of adrenal cortical adenomas
  1703. Evolution of primary aldosteronism as a highly specific clinical entity
  1704. Renal function in primary aldosteronism
  1705. An association of primary aldosteronism and adrenaline-secreting phaeochromocytoma.
  1706. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis
  1707. Normotensive primary aldosteronism.
  1708. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism
  1709. Leptin levels are suppressed in primary aldosteronism
  1710. Diagnosis and localization in primary aldosteronism
  1711. Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension
  1712. Pseudohypo-aldosteronism and cholelithiasis: coincidence or pathogenetic correlation?
  1713. Primary aldosteronism
  1714. Impaired potassium-stimulated Aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism
  1715. Studies on the expanded extracellular fluid and the responses to various stimuli in primary aldosteronism
  1716. Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension
  1717. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism
  1718. Clinical implications of primary aldosteronism with resistant hypertension.
  1719. Spironolactone as a nonspecific treatment for primary aldosteronism
  1720. Secondary aldosteronism
  1721. Activation of Aldosterone secretion in primary aldosteronism
  1722. Normotensive primary aldosteronism
  1723. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension
  1724. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia
  1725. Useful parameters in the diagnosis of primary aldosteronism
  1726. Plasma Aldosterone response to ACTH in subtypes of primary aldosteronism
  1727. Primary aldosteronism.
  1728. Spironolactone-induced inhibition of Aldosterone biosynthesis in primary aldosteronism: morphological and functional studies
  1729. Primary aldosteronism: changing concepts in diagnosis and management
  1730. Primary aldosteronism due to unilateral adrenal hyperplasia
  1731. New insights into the medical management of primary aldosteronism.
  1732. Abnormalities of renal function and circulatory reflexes in primary aldosteronism
  1733. Paralytic myopathy–a leading clinical presentation for primary aldosteronism in Taiwan
  1734. Normotensive primary aldosteronism
  1735. The detection of adrenal tumors and hyperplasia in patients with primary aldosteronism: comparison of scintigraphy, CT, and MR imaging
  1736. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism.
  1737. Idiopathic aldosteronism in pregnancy.
  1738. Intralymphocyte free magnesium in patients with primary aldosteronism: Aldosterone and lymphocyte magnesium homeostasis
  1739. Glucocorticoid-remediable aldosteronism
  1740. Scintigraphic localization of adrenal lesions in primary aldosteronism
  1741. Clinical evaluation of the captopril screening test for primary aldosteronism
  1742. Prevalence of extracranial carotid artery lesions at duplex in primary aldosteronism
  1743. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity
  1744. Preoperative diagnosis of primary aldosteronism: Including a comparison of operative findings and preoperative tumor localization by adrenal phlebography
  1745. Circulating factor with ouabain-like immunoreactivity in patients with primary aldosteronism
  1746. Plasma Aldosterone-plasma renin activity ratio A simple test to identify patients with primary aldosteronism
  1747. Severe hypertension in primary aldosteronism and good response to surgery
  1748. Primary aldosteronism: pathophysiology, diagnosis and treatment
  1749. Selection of patients and operative approach in primary aldosteronism.
  1750. Primary aldosteronism: a new understanding
  1751. Identification and differentiation of surgically correctable hypertension due to primary aldosteronism
  1752. Adrenalectomy in primary aldosteronism: a long-term follow-up study
  1753. Primary aldosteronism: experience with current diagnostic criteria and surgical treatment in fourteen patients.
  1754. Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison.
  1755. Diagnosis of primary aldosteronism
  1756. IN VIVO AND IN VITRO STUDIES OF ADRENAL SECRETIONS IN CUSHING’S SYNDROME AND PRIMARY ALDOSTERONISM
  1757. A Kindred with Familial Glucocorticoid–Suppressible Aldosteronism
  1758. The blood pressure response to unilateral adrenalectomy in primary aldosteronism
  1759. Laparoscopic adrenalectomy for Cushing’s syndrome: comparison with primary aldosteronism.
  1760. Identifying the adrenal lesion in primary aldosteronism
  1761. Primary aldosteronism
  1762. Primary aldosteronism: implications of a new familial variety
  1763. Primary aldosteronism as a cause of severe postpartum hypertension in two women
  1764. Hormone and blood pressure relationships in primary aldosteronism
  1765. Aldosterone: review of its physiology and diagnostic aspects of primary aldosteronism
  1766. Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients
  1767. Familial forms broaden the horizons for primary aldosteronism
  1768. Myopathy and primary aldosteronism: electronmicroscopic study
  1769. Primary aldosteronism: how hard should we look?
  1770. Primary aldosteronism with unusual secretory pattern
  1771. Primary aldosteronism in a hypertensive acromegalic patient
  1772. Primary aldosteronism and its variants
  1773. Primary aldosteronism in a 9-year-old child
  1774. Primary aldosteronism: a review of medical literature from 1955 to June 1958
  1775. Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism
  1776. Primary aldosteronism: preoperative tumor visualization by scintillation scanning
  1777. Physiologic and surgical problems in the management of primary aldosteronism
  1778. Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adenoma.
  1779. Primary Aldosteronism Diagnosis and Surgical Treatment
  1780. Pregnancy complicated by primary aldosteronism.
  1781. Adrenal arteriography and venography in primary aldosteronism
  1782. Low Renin Essential hypertension: A Variant of Classic Primary Aldosteronism?
  1783. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects …
  1784. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and Aldosterone in primary aldosteronism
  1785. Observations on a case of primary aldosteronism
  1786. Primary aldosteronism: an endocrine perspective.
  1787. Acute and chronic effect of nifedipine in primary aldosteronism
  1788. Triamterene‐thiazide combination: Alternative therapy for primary aldosteronism
  1789. Laparoscopic adrenalectomy for primary aldosteronism
  1790. Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-Sectional Primary Aldosteronism and Heart Italian Multicenter …
  1791. Hypokalemic myopathy associated with primary aldosteronism and glycyrrhizine-induced pseudoaldosteronism
  1792. Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma
  1793. Stimulation and suppression of Aldosterone in plasma of normal man and in primary aldosteronism
  1794. Primary adrenocortical carcinoma causing aldosteronism
  1795. Plasma adrenomedullin in patients with primary aldosteronism
  1796. Differential diagnosis in primary aldosteronism
  1797. Selective hypoaldosteronism despite prolonged pre-and postoperative hyperreninemia in primary aldosteronism
  1798. Primary aldosteronism: A study in contrasts
  1799. Myocardial scintigraphic characteristics in patients with primary aldosteronism.
  1800. Primary Aldosteronism due to Unilateral Adrenal Hyperplasia Report of Two Cases and Review of the Literature
  1801. Postoperative transient aldosteronism
  1802. Intra-adrenal hemorrhage as a complication of adrenal venography in primary aldosteronism
  1803. Plasma renin activity and blood volume in uncontrolled diabetes: ketoacidosis, a state of secondary aldosteronism
  1804. Long-term results of surgical and conservative treatment of patients with primary aldosteronism
  1805. Variation of phenotype in patients with glucocorticoid remediable aldosteronism.
  1806. Primary aldosteronism
  1807. Primary aldosteronism is comprised of primary adrenal hyperplasia and adenoma.
  1808. Malignant hypertension in association with primary aldosteronism
  1809. Primary aldosteronism: report of a case and discussion of the pathogenesis
  1810. Primary aldosteronism: experience with thirty-eight patients
  1811. Laparoscopic adrenalectomy in patients with primary aldosteronism.
  1812. Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands
  1813. Impaired baroreflex function and arterial compliance in primary aldosteronism
  1814. Primary aldosteronism
  1815. Primary aldosteronism due to an adrenal carcinoma
  1816. A preliminary evaluation for primary aldosteronism
  1817. Is single oral administration of captopril beneficial in screening for primary aldosteronism?
  1818. Clinical implications of renal cyst in primary aldosteronism
  1819. Primary aldosteronism
  1820. Surgical management of primary aldosteronism
  1821. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma
  1822. Aldosterone to renin ratios in the evaluation of primary aldosteronism.
  1823. Glucocorticoid-suppressible aldosteronism: a disorder of the adrenal transitional zone
  1824. Preoperative lateralisation of Aldosterone-producing tumours in primary aldosteronism
  1825. Evaluation of plasma Aldosterone to plasma renin activity ratio in patients with primary aldosteronism
  1826. Asymptomatic normotensive primary aldosteronism. Case report.
  1827. Plasma β-endorphin levels in primary aldosteronism
  1828. In primary aldosteronism the circadian blood pressure rhythm is similar to that in primary hypertension
  1829. Primary aldosteronism: diagnosis and noninvasive lateralization procedures
  1830. Some Aldosterone-producing adrenal tumours also secrete cortisol, but present clinically as primary aldosteronism.
  1831. A case of primary aldosteronism with chronic renal failure undergoing hemodialysis treatment
  1832. Primary aldosteronism: treatment with trilostane
  1833. Plasma levels of atrial natriuretic peptide in man in primary aldosteronism, in Gordon’s syndrome and in Bartter’s syndrome.
  1834. Nature of renal escape from the sodium-retaining effect of Aldosterone in primary aldosteronism and in normal subjects
  1835. Genetics of primary aldosteronism
  1836. Intermittent aldosteronism in periodic paralysis: Dependence of attacks on retention of sodium, and failure to induce attacks by restriction of dietary sodium
  1837. Primary aldosteronism in pregnancy—should it be treated surgically?
  1838. Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia
  1839. Synthesis and separation of 18β-glycyrrhetyl monoglucuronide from serum of a patient with glycyrrhizin-induced pseudo-aldosteronism
  1840. The Salivary Sodium-Potassium Ratio: A Useful Screening Test for Aldosteronism in Hypertensive Subjects
  1841. PRIMARY ALDOSTERONISM: OBSERVATIONS IN SIX CASES AND REVIEW OF DIAGNOSTIC PROCEDURES: 1
  1842. Primary aldosteronism.
  1843. Erythrocytosis and primary aldosteronism
  1844. Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration
  1845. Episodic secretion of Aldosterone in primary aldosteronism: relationship to cortisol
  1846. The sympathetic nervous system and hypertension in primary aldosteronism.
  1847. Primary aldosteronism
  1848. Plasma renin activity and Aldosterone secretion in a pregnant woman with primary aldosteronism
  1849. … human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism
  1850. Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism
  1851. The dexamethasone-modified adrenal scintiscan in hyporeninemic aldosteronism (tumor versus hyperplasia). A comparison with adrenal venography and adrenal …
  1852. Primary aldosteronism: diagnosis and differentiation of subtypes
  1853. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism
  1854. Circadian rhythm of blood pressure in primary aldosteronism and renovascular hypertension: analysis by the cosinor method
  1855. A Case of Normotensive Primary Aldosteronism Comparison with 13 Previously Experienced Cases with hypertension
  1856. Aldosteronism and precocious puberty due to an ovarian androblastoma (Sertoli cell tumor)
  1857. Submaxillary potassium concentration in true and pseudoprimary aldosteronism
  1858. Primary aldosteronism
  1859. Glucocorticoid-remediable aldosteronism.
  1860. Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter’s syndrome)
  1861. Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets—Bartter’s syndrome or …
  1862. Primary aldosteronism: its diagnosis and surgical management
  1863. The management of patients with primary aldosteronism
  1864. Primary aldosteronism in a patient with familial adenomatous polyposis
  1865. Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension
  1866. Primary aldosteronism with cortisol overproduction from bilateral multiple adrenal adenomas
  1867. Primary aldosteronism aggravated during peripartum period
  1868. Primary aldosteronism detected after renal transplantation
  1869. Diagnosis of an Aldosterone-producing adenoma in primary aldosteronism: an evaluative maneuver
  1870. DOCA test for aldosteronism: its usefulness and implications.
  1871. Aldosterone regulation in primary aldosteronism: differences between adenoma and bilateral hyperplasia
  1872. Differential response to thiazides and spironolactone in primary aldosteronism
  1873. Laparoscopic adrenalectomy for primary aldosteronism: clinical experience in 12 patients.
  1874. Are calcium antagonists helpful in the management of primary aldosteronism?
  1875. Free and conjugated dopamine in pheochromocytoma, primary aldosteronism and essential hypertension.
  1876. The Gordon Wilson Lecture. Some Clinical and Climatological Aspects of Aldosteronism in Man
  1877. Pre-operative evaluation of the prognosis of hypertension in primary aldosteronism owing to adenoma
  1878. Observations on a presumptive case of primary aldosteronism
  1879. Unilateral adrenal hyperplasia as a cause of primary aldosteronism.
  1880. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism
  1881. Hormonal characteristics of primary aldosteronism due to unilateral adrenal hyperplasia
  1882. Spectral characteristics of heart rate and blood pressure variability in primary aldosteronism
  1883. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients
  1884. Screening for primary aldosteronism
  1885. Glucocorticoid-remediable aldosteronism
  1886. Primary aldosteronism: new approaches to diagnosis and management.
  1887. Medical treatment of low-renin aldosteronism
  1888. Primary aldosteronism and primary reninism
  1889. The evolution of primary aldosteronism from 1954 to 1960
  1890. hypertension due to renal artery occlusion simulating primary aldosteronism
  1891. The relationship of adrenal gland iodomethylnorcholesterol uptake to zona glomerulosa function in primary aldosteronism
  1892. Studies of impaired Aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism.
  1893. Primary aldosteronism with uncommon complications.
  1894. Diagnosis and treatment of primary aldosteronism
  1895. Adrenal transitional zone steroids, 18‐oxo and 18‐hydroxycortisol, useful in the diagnosis of primary aldosteronism, are ACTH‐dependent
  1896. Primary aldosteronism and malignant adrenocortical neoplasia.
  1897. Surgical treatment of primary aldosteronism.
  1898. Thyrotoxic periodic paralysis complicated with primary aldosteronism
  1899. Reduced Aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case
  1900. A case of normoreninemic, normotensive primary aldosteronism associated with essential hypertension and nephrocalcinosis
  1901. Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure
  1902. Effects of sodium intake on the captopril test for primary aldosteronism
  1903. Primary aldosteronism: A case with severe hypertension
  1904. Endoscopic adrenalectomy by retroperitoneal approach for primary aldosteronism
  1905. Lateralization procedures in primary aldosteronism
  1906. Primary aldosteronism
  1907. Primary aldosteronism: preoperative preparation with spironolactone
  1908. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism
  1909. Relationship between postoperative blood pressure change and renal pathophysiology in primary aldosteronism
  1910. Endothelin stimulates Aldosterone secretion in vitro from normal adrenocortical tissue, but not adenoma tissue, in primary aldosteronism
  1911. … -secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism.
  1912. Coronary artery aneurysms, aortic dissection, and hypertension secondary to primary aldosteronism: A rare triad: A case report
  1913. Functional black adenoma of the adrenal cortex: a rare cause of primary aldosteronism
  1914. Comparison of five modalities in localization of primary aldosteronism.
  1915. Primary aldosteronism with Aldosterone-producing adrenal adenoma in a pregnant woman
  1916. Incidence of suppressed renin activity and of normokalemic primary aldosteronism in hypertensive negro patients
  1917. Screening for surgically correctable hypertension caused by primary aldosteronism
  1918. Elevation of plasma renin activity during pregnancy and rupture of a dissecting aortic aneurysm in a patient with primary aldosteronism
  1919. Primary aldosteronism associated with chronic renal failure
  1920. Urinary free Aldosterone in healthy people and in patients with primary aldosteronism
  1921. Primary aldosteronism and its importance to the anaesthetist.
  1922. Solving the adrenal lesion (s) of primary aldosteronism
  1923. Calcium channel blockade with nifedipine in primary aldosteronism
  1924. Aldosteronism in pregnancy: association with virilization of female offspring.
  1925. Pseudoprimary aldosteronism from the topical application of 9-alpha-fluorprednisolone to the skin.
  1926. Dietary sodium change in primary aldosteronism. Atrial natriuretic factor, hormonal, and vascular responses.
  1927. Primary aldosteronism and its relationship to diabetes mellitus
  1928. Primary aldosteronism: inability to differentiate unilateral from bilateral adrenal lesions by various routine clinical and laboratory data and by peripheral plasma …
  1929. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism
  1930. Aldosteronism
  1931. Existence of a slowly exchangeable pool of body sodium in normal subjects and its diminution in patients with primary aldosteronism
  1932. Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism.
  1933. Effect of saline infusions on Aldosterone secretion and electrolyte excretion in normal subjects and patients with primary aldosteronism
  1934. Preoperative tumor localization by adrenal venography in patients with primary aldosteronism: a comparison with operative findings
  1935. Primary aldosteronism due to a malignant ovarian tumour
  1936. Coexisting renal artery stenosis and primary aldosteronism.
  1937. Primary aldosteronism: review of the anaesthetic experience in sixty patients
  1938. Prominent peripheral edema associated with primary aldosteronism due to an adrenocortical adenoma
  1939. Association of accelerated (malignant) hypertension in a patient with primary aldosteronism
  1940. Multiple plasma steroid responses to graded ACTH infusions in patients with primary aldosteronism
  1941. Problems related to aldosteronism during cesarean section
  1942. High Plasma Renin Activities in Primary Aldosteronism with Malignant hypertension A Case Report
  1943. … of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism
  1944. Surgical treatment of aldosteronism: Combined experiences at the Massachusetts Memorial and the Peter Bent Brigham Hospitals
  1945. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension
  1946. Adrenal adenomata causing primary aldosteronism
  1947. Concurrence of primary aldosteronism and renal artery stenosis.
  1948. Heterotopic adrenocortical adenoma producing primary aldosteronism
  1949. Primary aldosteronism
  1950. In vitro studies in primary aldosteronism
  1951. Primary aldosteronism in general practice
  1952. Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism
  1953. Primary aldosteronism: Study of twenty-six operated cases
  1954. Idiopathic aldosteronism masquerading as discrete Aldosterone-secreting adrenal cortical neoplasms among patients with primary aldosteronism
  1955. Primary aldosteronism: computerized tomography in preoperative evaluation.
  1956. PRODUCTION OF 18‐OXO‐CORTISOL IN SUBTYPES OF PRIMARY ALDOSTERONISM
  1957. Primary aldosteronism: the etiologic spectrum of disorders and their clinical differentiation
  1958. A case of secondary aldosteronism induced by pheochromocytoma
  1959. Non-tumorous” primary” aldosteronism: II. Type not relieved by glucocorticoid.
  1960. Autosomal dominant polycystic kidney disease complicated by primary aldosteronism
  1961. Aldosteronism and arterial hypertension
  1962. Changes in salivary electrolytes following treatment of primary aldosteronism
  1963. Improvement of growth hormone response to stimulation in primary aldosteronism with correction of potassium deficiency
  1964. The syndrome of hypertension, hyperreninemia and secondary aldosteronism associated with renal juxtaglomerular cell tumor (primary reninism)
  1965. Childhood primary aldosteronism due to an adrenal adenoma: Preoperative localization by adrenal vein catheterization
  1966. Surgical treatment of hypertension—primary aldosteronism: a review of 13 cases
  1967. Mechanism of impaired urinary concentrating ability in normokalemic primary aldosteronism.
  1968. A study of the juxtaglomerular body in primary aldosteronism
  1969. Normal sympathetic vasomotor and cardiac parasympathetic activities in patients with primary aldosteronism: assessment by spectral analysis
  1970. Primary aldosteronism with bilateral adrenal adenomas
  1971. Management of primary aldosteronism: evaluation of potassium and sodium balance, technic of adrenalectomy and operative results in 24 cases.
  1972. Absorption and secretion of water and electrolytes by the intact colon in a patient with primary aldosteronism.
  1973. The effect of tyramine, noradrenaline, and angiotensin on the blood pressure in hypertensive patients with aldosteronism and low plasma renin
  1974. Increased gain in baroreceptor-heart rate reflex in patients with primary aldosteronism.
  1975. Efficacy of iodine-131 6β-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism
  1976. Aldosteronism updated
  1977. Renal kininases in primary aldosteronism.
  1978. Aldosterone regulation in primary aldosteronism: influence of salt balance, posture and ACTH
  1979. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism
  1980. Primary aldosteronism
  1981. Effect of a spirolactone on plasma and urinary Aldosterone in primary aldosteronism
  1982. Outpatient screening procedures for primary aldosteronism
  1983. … prolactin stimulation of Aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin …
  1984. Primary aldosteronism with normal Aldosterone levels in blood and urine
  1985. Exaggerated natriuresis in primary aldosteronism.
  1986. Bilateral adrenal tumours in primary aldosteronism: localization of a unilateral aldosteronoma by dexamethasone suppression scan
  1987. Primary aldosteronism treated by trilostane (3, β-hydroxysteroid dehydrogenase inhibitor)
  1988. Primary Aldosteronism: A Follow‐up Study of 28 Cases of Surgically Treated Aldosterone‐producing Adenomas
  1989. Study on uric acid metabolism in patients with primary aldosteronism
  1990. Primary aldosteronism: remission and development of adrenal insufficiency after adrenal venography
  1991. ACTH-dependent Aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism
  1992. Steroid hormone production in a case of Cushing’s syndrome with electrolyte changes simulating primary aldosteronism
  1993. Clinical implications of postoperative transient aldosteronism
  1994. Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia
  1995. Simple screening procedure for the diagnosis of primary aldosteronism
  1996. Adrenal scintigraphy in primary aldosteronism
  1997. Abolished nocturnal blood pressure fall in a boy with glucocorticoid-remediable aldosteronism
  1998. Primary aldosteronism due to bilateral nodular hyperplasia: CT demonstration.
  1999. Normotensive primary aldosteronism due to adrenocortical carcinoma
  2000. A syndrome resembling primary aldosteronism (Conn syndrome) in untreated HIV disease
  2001. Primary aldosteronism due to adrenal cortical carcinoma
  2002. Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications
  2003. Usefulness of atrial natriuretic peptide assay in primary aldosteronism
  2004. Decreased blood pressure variability at rest in patients with primary aldosteronism
  2005. Action of antidiuretic hormone in potassium-depleted rats; relation to aldosteronism
  2006. Pheochromocytoma and primary aldosteronism
  2007. Sodium transport parameters in erythrocytes of patients with primary aldosteronism.
  2008. Does prolonged pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism?
  2009. Plasma renin in primary aldosteronism
  2010. Hyper‐responsiveness of Aldosterone to metoclopramide in aldosteronism
  2011. Estimation of the intrarenal hemodynamics in patients with primary aldosteronism
  2012. Primary aldosteronism with diabetes mellitus
  2013. The electrocardiogram and potassium metabolism: electrocardiographic abnormalities in primary aldosteronism and familial periodic paralysis
  2014. Dopaminergic regulation of Aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism
  2015. Childhood primary aldosteronism with bilateral adrenocortical hyperplasia: Plasma renin activity as an aid to diagnosis
  2016. Primary aldosteronism due to adrenal carcinomas
  2017. Unilateral hypersecretion of Aldosterone associated with adrenal hyperplasia as a cause of primary aldosteronism
  2018. Idiopathic aldosteronism: a possible disease of the intermediate lobe of the pituitary
  2019. Screening for aldosteronism
  2020. Primary aldosteronism CT, MRI, scintigraphic correlation
  2021. Regulation of Aldosterone secretion in primary aldosteronism
  2022. Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism
  2023. Therapeutic results of primary aldosteronism with special reference to renal or renovascular lesions
  2024. Increased Na+-H+ Exchange in Red Blood Cells of Patients With Primary Aldosteronism
  2025. The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas
  2026. Primary Aldosteronism with Ipsilateral Adrenal Cyst Report of a Case
  2027. Adrenal vein epinephrine levels: a useful aid in venous sampling for primary aldosteronism
  2028. Glucocorticoid-remediable aldosteronism
  2029. Are plasma Aldosterone surges in primary aldosteronism due to a loss of an inhibitory dopaminergic control?
  2030. Fludrocortisone suppression test in normal subjects, in patients with essential hypertension and in patients with various forms of aldosteronism
  2031. Primary aldosteronism associated with a primary double cancer of the thyroid and rectum: report of a case
  2032. Effect of verapamil on Aldosterone secretion in primary aldosteronism
  2033. Experience with primary aldosteronism
  2034. Adrenal venous sampling analysis of primary aldosteronism: value of ACTH stimulation in the differentiation of adenoma and hyperplasia
  2035. Interference by spironolactone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronism.
  2036. Primary aldosteronism caused by Aldosterone-producing adenoma in pregnancy–complicated by EPH gestosis.
  2037. Primary tumorous aldosteronism due to a black adrenal adenoma: a light and electron microscopic study.
  2038. Localization of Aldosterone‐producing tumours in primary aldosteronism by adrenal and renal vein catheterization
  2039. Hypokalemia, aldosteronism, and renal cysts
  2040. Pathophysiology and diagnosis of primary aldosteronism
  2041. Is aldosteronism important in the maintenance of arterial blood pressure and electrolyte balance during sodium depletion?
  2042. Effect of metoclopramide on plasma Aldosterone in normal subjects, primary aldosteronism and hypopituitarism
  2043. The effect of heparin on Aldosterone secretion and metabolism in primary aldosteronism (1)
  2044. Ultrastructural studies of adrenal adenoma causing primary aldosteronism
  2045. Parallel biochemical and histochemical studies of an adrenocortical adenoma from a patient with primary aldosteronism
  2046. A reappraisal of the diagnostic criteria for primary aldosteronism
  2047. Pseudoprimary Aldosteronism.
  2048. Increased adrenal medullary atrial natriuretic polypeptide synthesis in patients with primary aldosteronism.
  2049. Left ventricular myocardial structure and function in patients with primary aldosteronism
  2050. High resolution MRI of adrenal glands in patients with primary aldosteronism.
  2051. Captopril before and after spironolactone therapy in primary aldosteronism
  2052. Significance of renal kininases in patients with primary aldosteronism
  2053. Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushing’s syndrome and primary aldosteronism.
  2054. An easy diagnostic approach to primary aldosteronism
  2055. Potassium-losing nephritis and primary aldosteronism
  2056. Renin gene expression in the adrenal and kidney of patients with primary aldosteronism
  2057. Plasma atrial natriuretic peptide concentration in patients with primary aldosteronism
  2058. Lobular pattern of choriocapillaris in pre-eclampsia with aldosteronism.
  2059. Primary aldosteronism due to unilateral adrenal hyperplasia: a case report.
  2060. Adrenocortical adenoma with primary aldosteronism in culture
  2061. Erythrocyte Na+‐H+ exchanger and Na+‐Li+ countertransport activity in primary aldosteronism
  2062. Low dose atrial natriuretic factor in primary aldosteronism: renal, hemodynamic, and vascular effects.
  2063. Effects of Aldosterone on intralymphocytic sodium and potassium in patients with primary aldosteronism
  2064. Some observations on the mechanism of postoperative transient aldosteronism with special reference to early changes in serum electrolyte levels
  2065. Study of the predictive factors of postoperative blood pressure in cases with primary aldosteronism
  2066. Primary aldosteronism: a review of 8 cases
  2067. Postoperative improvement of hypertension in primary aldosteronism and Cushing’s syndrome
  2068. Aldosterone response to adrenocorticotrophin and furosemide in primary aldosteronism after prolonged spironolactone treatment
  2069. Dopaminergic regulation of Aldosterone secretion in primary aldosteronism: a clinical study
  2070. A case of normotensive primary aldosteronism with hypopituitarism, epilepsy, and medullary sponge kidney
  2071. Effect of α-human atrial natriuretic peptide in low renin essential hypertension and primary aldosteronism
  2072. Unusual renal function associated with saluresis accompanying water loading in a case of primary aldosteronism
  2073. Evaluation of the localizing procedures of primary aldosteronism
  2074. A novel low-activity form of carbonic anhydrase I in erythrocytes of patients with primary aldosteronism. Evidence for the presence of a mixed disulfide with glutathione.
  2075. A case of primary aldosteronism with renovascular hypertension
  2076. hypertension: when to suspect underlying pheochromocytoma or aldosteronism
  2077. Surgical management of primary aldosteronism (Conn’s syndrome), a correctable cause of hypertension
  2078. … article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By …
  2079. Failure to visualize bilateral adrenal glands in a patient with primary aldosteronism
  2080. Metabolic and hormonal studies in a patient with primary aldosteronism, presenting with acute hypokalaemic paresis induced by chlorothiazide
  2081. Prognostic factors of primary aldosteronism.
  2082. Primary aldosteronism with bilateral multiple Aldosterone-producing adrenal adenomas
  2083. The adrenal cortex (excluding aldosteronism)
  2084. Aldosteronism
  2085. Single oral administration of captopril may not bring an improvement in screening of primary aldosteronism
  2086. Isolated primary aldosteronism in a patient with adrenal carcinoma and XY/XXY mosaic Klinefelter’s syndrome
  2087. Aldosterone regulation in primary aldosteronism
  2088. Primary aldosteronism caused by adrenal cortical carcinoma
  2089. Atrial Natriuretic Peptide Infusion in Primary Aldosteronism: Renal, Hemodynamic and Hormonal Effects
  2090. Primary aldosteronism by carcinoma of the adrenal cortex
  2091. Captopril Test in the Evaluation of Primary Aldosteronism.
  2092. Aldosteronism after severe trauma.
  2093. Effects of change in body posture on plasma and serum electrolytes in normal subjects and in primary aldosteronism
  2094. Renal and adrenal sparing surgery for patients with primary aldosteronism and primary reninoma
  2095. Variant forms of primary aldosteronism: reconsideration of the differential diagnosis and treatment
  2096. Primary aldosteronism: Observations on water and electrolyte changes during partial immersion
  2097. The kidney in endocrine hypertension: Cushing’s syndrome, pheochromocytoma, and aldosteronism
  2098. Evidence for a defect in urinary concentrating ability in primary aldosteronism and its reversal by adrenal surgery
  2099. Two uncommon causes of mineralocorticoid excess: syndrome of apparent mineralocorticoid excess and glucocorticoid-remediable aldosteronism
  2100. Use of amiloride in preoperative management of a patient with primary aldosteronism
  2101. Effect of spironolactone on urinary excretion of immunoreactive prostaglandin E in essential hypertension and primary aldosteronism
  2102. Manipulation by corticotropin and cortisol of Aldosterone secretion in primary aldosteronism
  2103. Localization of Aldosterone-producing adenoma: venous sampling in primary aldosteronism
  2104. Plasma renin activity in primary aldosteronism
  2105. Cytosolic free calcium concentration in platelets in patients with renovascular hypertension and primary aldosteronism.
  2106. Infusion of Chlorothiazide in a Patient With Primary Aldosteronism: Observations on Potassium Clearance
  2107. Primary Aldosteronism Associated with Acute Intermittent Porphyria: Report of a Case
  2108. Adrenal venography and sampling in the diagnosis and treatment of primary aldosteronism.
  2109. Abnormality of Aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism
  2110. The syndrome of juxtaglomerular hyperplasia with aldosteronism, hypokalemic alkalosis and normal blood pressure.
  2111. … in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral …
  2112. The Diagnostic Implication of Restriction of Salt Intake and Adminitstration of Various Drugs in Primary Aldosteronism
  2113. Adrenal imaging with iodomethyl-norcholesterol (I-131) in primary aldosteronism.
  2114. Plasma ouabain-like activity in essential hypertensive patients and in subjects with primary aldosteronism.
  2115. Glucocorticoid-remediable aldosteronism.
  2116. Primary aldosteronism: diagnosis, surgical management, and report of two cases operated upon
  2117. Lack of Aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies
  2118. Non-surgical therapy of primary aldosteronism: transcatheter arterial infusion of ethanol into an aldosteronoma
  2119. Renal dopaminergic activity in patients with primary aldosteronism
  2120. Ultrastructural types of cell in adrenal cortical adenoma with primary aldosteronism.
  2121. Hypokalemic alkalosis, hyperreninemia, aldosteronism, normal blood pressure and normal juxtaglomerular apparatus–a new syndrome of renal alkalosis.
  2122. Coexistence of Primary Aldosteronism and Pheochromocytoma in a Vietnamese Patient.
  2123. … of electrolyte excretion in normal and hypertensive subjects before and after saline infusions: a simple electrolyte formula for the diagnosis of primary aldosteronism
  2124. The effect of adrenal surgery on plasma atrial natriuretic factor and sodium escape phenomenon in patients with primary aldosteronism
  2125. Treatment of primary aldosteronism
  2126. Adrenal scintiscanning and aldosteronism
  2127. Spironolactone Prevents Na+/H+ Exchange Enhancement in Primary Aldosteronism
  2128. Nocturnal, daytime, and postural changes of plasma Aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism
  2129. Secondary aldosteronism documented by plasma renin and Aldosterone circadian rhythm in subjects with kidney or heart transplantation
  2130. Renal electrolyte cycles and mechanism of nocturia in primary aldosteronism
  2131. Effect of naloxone on the adrenal cortex in primary aldosteronism
  2132. Effects of stilbestrol on the renal pressor system as modified by adrenalectomy and secondary aldosteronism
  2133. A simulation study on renin and Aldosterone secretions in primary aldosteronism.
  2134. Adrenocortical carcinoma manifesting pure primary aldosteronism: a case report and analysis of steroidogenic enzymes
  2135. Immunohistochemical localization of atrial natriuretic peptide in primary aldosteronism.
  2136. Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma Aldosterone concentration
  2137. Isolated primary aldosteronism in adrenocortical carcinoma: a case report and review of literature
  2138. Influence of unilateral adrenalectomy on renin-angiotensin-Aldosterone system in primary aldosteronism
  2139. A case of bilateral adrenal cortical adenomas causing Cushing’s syndrome and primary aldosteronism
  2140. The molecular basis of a hereditary form of hypertension, glucocorticoid-remediable aldosteronism
  2141. A rare case of primary aldosteronism due to bilateral functioning adrenocortical adenomas
  2142. Anorexia nervosa, secondary aldosteronism and angiopathy
  2143. α-h-ANP injection in normals, low renin hypertension and primary aldosteronism
  2144. A new diagnostic test for primary aldosteronism
  2145. A case of primary aldosteronism presenting hypokalemic myopathy induced by benidipine hydrochloride; a dihydropyridine calcium channel blocker
  2146. Aldosteronism associated with adrenal cortical adenoma
  2147. Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes
  2148. Primary aldosteronism
  2149. Adrenocortical carcinoma presenting as primary aldosteronism in a young man
  2150. Impaired vasopressin suppression and enhanced atrial natriuretic hormone release following an acute water load in primary aldosteronism
  2151. Increased plasma renin activity, secondary aldosteronism, and hypertension
  2152. A case of primary aldosteronism due to unilateral multiple adrenal adenomas
  2153. A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism
  2154. Primary aldosteronism: case observed in a patient subjected previously to thoracolumbar sympathectomy
  2155. Primary aldosteronism in a patient with an Aldosterone-producing adenoma
  2156. Urinary kallikrein excretion in patients with primary aldosteronism: differentiation of adrenal adenoma from idiopathic adrenal hyperplasia
  2157. Reduced renal extraction of atrial natriuretic peptide in primary aldosteronism
  2158. Primary Aldosteronism
  2159. I027: Saline infusion test in the diagnosis of primary aldosteronism
  2160. Diagnosis of primary aldosteronism
  2161. Comparative study of diagnosis for location of adrenal adenoma in patients with primary aldosteronism (author’s transl)
  2162. Primary aldosteronism. A report of 2 cases.
  2163. Withdrawal of endogenous sympathetic drive lowers blood pressure in primary aldosteronism
  2164. Multiple forms of immunoreactive renin in human adrenocortical tumour tissue from patients with primary aldosteronism
  2165. A SIMPLIFIED SCREENING TEST FOR DIFFERENTIATING PRIMARY ALDOSTERONISM FROM ESSENTIAL HYPERTENTION WITH LOW PLASMA RENIN …
  2166. Evaluation of select criteria for the diagnosis of primary aldosteronism in normokalemic hypertension
  2167. Primary aldosteronism: Importance of the level of plasma renin as an adjunct in diagnosis
  2168. Syncope as a manifestation of primary aldosteronism
  2169. Activity of [des-Aspartyl1]-Angiotensin II in Primary Aldosteronism
  2170. Glucocorticoid-remediable aldosteronism
  2171. Endogenous dopaminergic inhibition of Aldosterone and prolactin secretion is apparently not increased in primary aldosteronism
  2172. Surgical management of primary aldosteronism–progress in localization studies and operative treatment
  2173. Detection of primary aldosteronism by the 6-hour integrated Aldosterone/renin ratio.
  2174. Approach to a patient with suspected primary aldosteronism.
  2175. Diagnosis and Treatment of Primary Aldosteronism (120 Cases Report)
  2176. Primary aldosteronism due to hyperplasia of zona glomerulosa: failure of suppression by DOCA or stimulation by angiotensin
  2177. Importance of atrial natriuretic hormone in an exaggerated natriuresis during acute sodium load in primary aldosteronism
  2178. Clinical and pathological aspects of primary aldosteronism
  2179. Adrenal Imaging with 131I-19-Iodocholesterol in the Diagnostic Evaluation of Patients with Aldosteronism
  2180. Macronodule associated with bilateral adrenal hyperplasia. A rare misleading cause of primary aldosteronism (two cases)
  2181. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism
  2182. … ROLE OF HYPOKALEMIA IN THE MANIFESTATION OF HIGH QRS VOLTAGE AND SINUS RADYCARDIA IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2183. Cyproheptadine in Idiopathic Aldosteronism
  2184. A case of primary aldosteronism, nephrotic syndrome and chronic renal failure: a diagnostic dilemma
  2185. Regulation of Atrial Natriuretic Peptide in Primary Aldosteronism and in Cushing’s Disease
  2186. A case report of obstructive sleep apnea syndrome associated with primary aldosteronism
  2187. Three cases of primary aldosteronism including one case with postoperative ventricular tachycardia
  2188. Aldosteronism
  2189. Restoration of renin-Aldosterone dynamics to normal following surgery in primary aldosteronism
  2190. Anesthetic Experience of Adrenalectomy with Primary Aldosteronism-Report of two cases.
  2191. Diagnosing primary aldosteronism with frusemide stimulation test in hypertensive patients with raised Aldosterone to renin ratio
  2192. Captopril v Aldosterone to plasma renin activity ratio in screening for primary aldosteronism
  2193. Lateralisation of Aldosterone-producing adenoma in primary aldosteronism
  2194. … of glutathione-peroxidase (GSH-PO) in human adrenal gland–studies on adrenocortical adenomas associated with primary aldosteronism and Cushing’s syndrome.
  2195. Primary aldosteronism in pregnancy
  2196. Plasma cortisol and primary aldosteronism
  2197. Comparison of steroidogenesis in adrenal tissue and adrenal adenoma from a case of primary aldosteronism
  2198. Evaluation of a test using saralasin to differentiate primary aldosteronism due to an Aldosterone-producing adenoma from idiopathic hyperaldosteronism
  2199. Anesthetic Management of a patient with Primary Aldosteronism caused by Adrenal Adenoma.
  2200. Salt loading in renal aldosteronism before and after nephrectomy
  2201. Urinary excretion of catecholamines in patients with primary aldosteronism before and after unilateral adrenalectomy.
  2202. Adrenal adenoma with primary aldosteronism in a child: a case report.
  2203. Anesthetic management of adrenalectomy in a patient with aldosteronism complicated with hypertrophic cardiomyopathy
  2204. Concomitant laparoscopic treatment for primary aldosteronism and cholelithiasis
  2205. Glucocorticoid remediable aldosteronism: a case report.
  2206. Pituitary peptides other than ACTH may not be Aldosterone secretagogue in primary aldosteronism
  2207. Urinary citrate excretion in primary aldosteronism
  2208. Morphofunctional characteristics of endocrine nephropathy in primary aldosteronism
  2209. A Cardiac Arrest during Surgery for Adrenal Tumor Causing Primary Aldosteronism.
  2210. Simplified screening procedures for primary aldosteronism. Studies on the mechanism of the hyper-responsiveness to furosemide and standing
  2211. A case of normotensive primary aldosteronism in association with non-functioning adenoma and Aldosterone producing adenoma in ipsilateral adrenal gland
  2212. In primary aldosteronism hypertensive patients endothelial dysfunction is caused by an impairment in no availability
  2213. Diagnosis, localization, and treatment of primary aldosteronism.
  2214. Secretory regulation and episodic secretion of Aldosterone in patients with primary aldosteronism (author’s transl)
  2215. Plasma concentration and urinary excretion of arginine-vasopressin in primary aldosteronism during the fluid deprivation tests
  2216. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism
  2217. Biosynthesis of various steroids in vitro by isolated adrenal cells in primary aldosteronism, Cushing’s syndrome, and adrenogenital syndrome due to adrenocortical …
  2218. Faecal sodium/potassium ratio and aldosteronism in experimental hypertension in the rat
  2219. British Medical Association (Mashonaland branch): Primary syndromes of aldosteronism
  2220. STUDY ON CLINICAL CHARACTERISTICS OF hypertension IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2221. Diagnostic value of imaging in localizing primary aldosteronism
  2222. 19-Nor-deoxycorticosterone excretion in primary aldosteronism and low renin hypertension
  2223. Does a digoxin-like substance participate in vascular and pressure control during dietary sodium changes in patients with primary aldosteronism?
  2224. Image diagnosis of adrenal disorders–I. CT images of control subjects and image diagnosis of primary aldosteronism
  2225. Elevated ‘free’18-hydroxy-corticosterone excretion as a possible indicator for early diagnosis of primary aldosteronism
  2226. Enzyme histocytochemical studies in human adrenocortical adenomas.[I]. Primary aldosteronism.
  2227. Effect of captopril on Aldosterone response to potassium infusion in primary aldosteronism.
  2228. A case of neurinoma of the pancreas in a patient with primary aldosteronism
  2229. Studies on the in vitro production of Aldosterone and other corticoids in the adrenal adenoma of a primary aldosteronism
  2230. Expression of cytochrome P-450 mRNAs in steroidogenesis of adrenocortical adenomas from patients with primary aldosteronism
  2231. Primary Aldosteronism
  2232. Anesthesiological management of a patient with primary aldosteronism complicated with hypertrophic cardiomyopathy
  2233. Pattern classification of renal electrolyte cycles in primary aldosteronism
  2234. Effects of metoclopramide, a dopamine antagonist, on secretion of Aldosterone and renin release in patients with primary aldosteronism
  2235. … natriuretic peptide responses to upright posture and furosemide administration in patients with normal-, low renin essential hypertension and primary aldosteronism
  2236. Fecal and salivary electrolytes in the diagnosis of primary aldosteronism
  2237. Primary aldosteronism
  2238. Primary aldosteronism-A Report of 26 cases
  2239. Primary aldosteronism at Henry Ford Hospital in the 1980s
  2240. A case of secondary aldosteronism similar to Bartter’s syndrome with no abnormality in renal chloride reabsorption
  2241. Adrenal scintigraphy in primary aldosteronism
  2242. In vivo and in vitro studies on steroid metabolism in a case of primary aldosteronism with multiple lesions of adenoma and nodular hyperplasia
  2243. Hypertensive crisis during the resection of an adrenal tumor in primary aldosteronism
  2244. Renin content of the kidney in primary aldosteronism
  2245. Hyperpigmentation on Cortisone After Adrenalectomy for Primary Aldosteronism
  2246. Night-Day Variations of Renin-Activity in Primary Aldosteronism
  2247. … on clinical and endocrine characteristics of dexamethasone-suppressible hyperaldosteronism compared with those in primary aldosteronism owing to Aldosterone …
  2248. Primary aldosteronism in childhood due to primary adrenal hyperplasia
  2249. When To Hospitalize for Primary Aldosteronism
  2250. Primary Aldosteronism Caused by Unilateral Adrenal Hyperplasia
  2251. Urinary Arginine Esterase Activity in the Patients with hypertension, Chronic Nephritis and Primary Aldosteronism
  2252. Effects of salt restriction, spironolactone, and ammonium chloride on acid-base relations in a case of primary aldosteronism
  2253. Change in plasma renin activity by cold storage of plasma in normal subjects and patients with essential hypertension and primary aldosteronism
  2254. Primary aldosteronism caused by an adrenal tumor: a correctable cause of hypertension.
  2255. Plasma renin in primary aldosteronism
  2256. Conn’s syndrome: case report and a review of the syndrome of primary aldosteronism (SOPA)
  2257. Heterogeneous blood pressure response to furosemide and captopril in primary aldosteronism.
  2258. Primary Aldosteronism, Recumbent Posture, and Salt Loading Are Associated with Higher Levels of Atrial Natriuretic Peptide
  2259. Primary Aldosteronism
  2260. Primary Aldosteronism
  2261. Primary Aldosteronism
  2262. Primary Aldosteronism and the Effects of Two Mineralocorticoid Inhibitors—Triamterene and Spironolactone (Aldactone)
  2263. Primary aldosteronism
  2264. Report: Primary Aldosteronism.
  2265. Primary aldosteronism due to adrenocortical adenoma (Conn’s syndrome)
  2266. Ultrastructural and biochemical studies in human adrenocortical adenomas associated with primary aldosteronism.
  2267. Therapy of primary aldosteronism with trilostane
  2268. Secondary Aldosteronism
  2269. Primary Aldosteronism: 13 Cases Analysis
  2270. A case of nephrotic syndrome with diabetes mellitus and primary aldosteronism
  2271. Surgery of primary aldosteronism
  2272. TWO CASES OF PRIMARY ALDOSTERONISM
  2273. The syndrome of primary aldosteronism: a case study.
  2274. Screening for Aldosteronism
  2275. Renin in aldosteronism: relating kidney and adrenal
  2276. Primary Aldosteronism: A Challenging Case
  2277. Bilateral renal artery stenosis with aldosteronism
  2278. Primary Aldosteronism and Other Mineralocorticoid Excess Syndromes in hypertension: Incidence, Screening, and Diagnosis
  2279. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism
  2280. General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy
  2281. Diurnal variation and responses of corticoids to dexamethasone and ACTH before and after adrenal surgery in primary aldosteronism
  2282. Synchronous changes in active and inactive renin secretion after furosemide in patients with primary aldosteronism
  2283. Adrenal Scintigraphy in Primary Aldosteronism Caused by an Aldosterone Producing Adenoma
  2284. Diagnosis and treatment of primary aldosteronism
  2285. Primary aldosteronism. Diagnostic aspects and treatment
  2286. The spitting image of primary aldosteronism
  2287. Primary Aldosteronism: Report of 38 Cases
  2288. The syndrome of mineralocorticoid excess: Primary aldosteronism
  2289. Pathological and clinical studies on primary aldosteronism
  2290. Plasma Aldosterone concentration in patients with primary aldosteronism in the last decade
  2291. Computer tomographic localisation in primary aldosteronism. Comparison with adrenal scintigraphy (author’s transl)
  2292. Primary Reninism: hypertension, Hyperreninaemia and Secondary Aldosteronism Due to Juxtaglomerular Renal Cell Tumours
  2293. Diagnosis of Primary Aldosteronism: Clinical Analysis of 26 Cases
  2294. Diagnosis and Treatment of Primary Aldosteronism
  2295. Formation of steroid hormones in the adrenal adenoma and adjacent adrenal tissue of a patient with primary aldosteronism
  2296. Effects on muscle electrolytes of potassium and magnesium infusions, spironolactone medication and operation in a case of primary aldosteronism
  2297. Intravenously Administered Chlorothiazide For Aldosteronism
  2298. Surgical management of primary aldosteronism: Experience of 9 cases
  2299. Primary Aldosteronism─ Clinical Experiences and Literature Review
  2300. Surgical Therapy of Primary Aldosteronism
  2301. Urinary 18, 19-dihydroxycorticosterone and 18-hydroxy-19-norcorticosterone excretion in patients with primary and secondary aldosteronism
  2302. Primary aldosteronism in general practice
  2303. Kinins in relation to renin activity in renal and inferior caval veins in normal individuals and patients with primary aldosteronism
  2304. A direct enzyme immunoassay for 18-hydroxycortisol in urine: a new tool for screening primary aldosteronism
  2305. … system: studies on histological changes in adrenal and renal tissue; a follow-up study of postoperative blood pressure in primary and idiopathic aldosteronism
  2306. The plasma Aldosterone/plasma renin activity ratio at different salt intakes has a limited value for the diagnosis of primary aldosteronism.
  2307. Eccrine sweat gland sensitivity to catecholamines in patients with pheochromocytoma and primary aldosteronism
  2308. Differences between adrenal adenoma causing primary aldosteronism and other adrenal tissues in the incorporation of labeled steroid precursors into their products
  2309. PREGNANCY AND PRIMARY ALDOSTERONISM
  2310. An Autopsy Case of Primary Aldosteronism
  2311. Endocrine characterization of the adrenal adenomas in a case of primary aldosteronism.
  2312. Suppressed Plasma Renin Activity in Hypertensive Patients-Its Evaluation for the Diagnosis of Primary Aldosteronism
  2313. ATYPICAL ALDOSTERONISM
  2314. Primary Aldosteronism: Changing Concepts in Diagnosis and Management
  2315. M010: Primary aldosteronism: A clinical profile based in 294 cases
  2316. Current concepts of primary aldosteronism
  2317. Intracellular sodium and potassium concentrations in erythrocytes of patients with primary aldosteronism
  2318. … adrenal steroid biosynthesis, on blood pressure, plasma Aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism …
  2319. Is the Aldosterone-renin ratio useful in screening for primary aldosteronism?
  2320. Primary Aldosteronism by Adenoma 1 Case
  2321. Anesthetic Experience with Primary Aldosteronism: Report of a case.
  2322. Primary Aldosteronism with Uncommon Complications
  2323. An Anesthetic Experience with Primary Aldosteronism.
  2324. Primary aldosteronism and adrenal incidentaloma.
  2325. Primary aldosteronism: complete remission after adrenal venography
  2326. Inactive form of carbonic anhydrase I in erythrocytes from primary aldosteronism.
  2327. Effect of dibutyryl cyclic AMP on plasma renin activity in normal men and patients with primary aldosteronism
  2328. Primary aldosteronism–screening, diagnosis and therapy.
  2329. Fallacy of the Aldosterone: renin ratio (ARR) used to screen for primary aldosteronism
  2330. The Recognition, Confirmation, and Course of Primary Aldosteronism.
  2331. CLINICOPATHOLOGIC STUDIES OF PRIMARY ALDOSTERONISM
  2332. Multiple calcified adrenal myelolipoma suggestive of association of primary aldosteronism: report of a case
  2333. Utility of Iodocholesterol Scanning in Primary Aldosteronism
  2334. Therapeutic experience of primary aldosteronism associated with chronic renal failure
  2335. Screening for primary aldosteronism in hypertensive patients
  2336. Determination of urinary 18-hydroxycortisol in the diagnosis of primary aldosteronism
  2337. Primary Aldosteronism: A Clinical Profile Based in 294 Cases: P1. 75
  2338. Aldosteronism after hypokalemia in diuretic therapy of systemic arterial hypertension
  2339. Circulatory reflexes in primary aldosteronism (author’s transl)
  2340. … : Effect of the Antihypertensive Agent Diazoxide on Plasma Renin Activity and its Clinical Application, especially in Screening Primary Aldosteronism and its Similar …
  2341. Direct radioimmunoassays for” Aldosterone” and” 18-hydroxycorticosterone” in unprocessed urine, and their use in screening to distinguish primary aldosteronism …
  2342. Cardiac Arrest Induced by Primary Aldosteronism
  2343. I004: Diagnostic value of the post-captopril test in primary aldosteronism
  2344. Renal kininase I, kininase II and neutral endopeptidase 24.11 activities in patients with essential hypertension, primary aldosteronism and Cushing’s syndrome
  2345. Asymptomatic Normotensive Primary Aldosteronism
  2346. Primary aldosteronism and arterial hypertension
  2347. Systemic hemodynamics in primary aldosteronism
  2348. … antibodies specific for 18-hydroxycortisol and their use in an enzyme immunoassay for human urinary 18-hydroxycortisol for diagnosis of primary aldosteronism
  2349. Detection of primary aldosteronism using the captopril test
  2350. M011: A follow-up study of patients with primary aldosteronism treated medically
  2351. Unexpected incidence of low blood pressure 2 years after unilateral adrenalectomy for primary aldosteronism
  2352. Prolactin in primary aldosteronism
  2353. Studies on Curable hypertension: Special Reference to Renovascular hypertension and Primary Aldosteronism: Panel Discussion on Some Problems in the …
  2354. Some Recent Contributions to Pathogenesis and Diagnosis of The Syndrome of Primary Aldosteronism
  2355. Some remaining problems of aldosteronism from personal case
  2356. Studies on abnormalities of adrenal steroidogenesis in essential hypertension, primary aldosteronism and renovascular hypertension: responses of plasma steroids to …
  2357. A CASE OF GRAVES’DISEASE ASSOCIATED WITH PRIMARY ALDOSTERONISM TREATED BY SIMULTANEOUS SUBTOTAL THYROIDECTOMY AND …
  2358. Aldosterone and Aldosteronism
  2359. PLASMA RENIN IN ALDOSTERONISM.
  2360. USE OF COMPUTED TOMOGRAPHY IN DIAGNOSING THE CAUSE OF PRIMARY ALDOSTERONISM
  2361. Crisis of arterial hypertension in patients with primary aldosteronism
  2362. Primary aldosteronism is an independent determinant of albumin excretion.
  2363. Insulin resistance and abnormal glucose metabolism in patients with primary aldosteronism
  2364. Effect of SK&F-12185 [dl-2(p-Aminophenyl)-2-phenylethylamine] on Adrenocortical Function in Primary Aldosteronism
  2365. Aldosteronism and Spironolactone
  2366. Changes of urinary kallikrein excretion and plasma natriuretic factor in a patient with primary aldosteronism with special reference to adrenal histology
  2367. … ADRENOCORTICAL GLOMERULAR ZONE BY INCOMPLETE LIGATION OF BILATERAL URETERS OF RATS: An Experimental Model for Secondary Aldosteronism
  2368. 21-DeoxyAldosterone excretion in patients with primary aldosteronism and 21-hydroxylase deficiency
  2369. DEXAMETHASONE SUPPRESSION SCINTISCAN IN PRIMARY ALDOSTERONISM WITH SCINTADREN
  2370. Investigation of the prevalence and genetic characterisation of patients with glucocorticoid remediable aldosteronism
  2371. Primary aldosteronism due to adrenal carcinomas. Klin Wochenschr.
  2372. Plasma Renin Activity in Primary Aldosteronism-Reply
  2373. I-131 NP-59 adrenal cortical scintigraphy in suspected primary aldosteronism.
  2374. Radioimmunoassay of urinary 21-deoxytetrahydroAldosterone in primary aldosteronism and 21-hydroxylase deficiency
  2375. Crisis of arterial hypertension in patients with primary aldosteronism. Krizovoe techenie arterial’noj gipertonii u bol’nykh pervichnym al’dosteronizmom
  2376. Aldosterone and Aldosteronism
  2377. Presidential address: Part I. Painting background part II primary aldosteronism, a new clinical syndrome
  2378. Use of the Saline Infusion Test to Diagnose the Cause of Primary Aldosteronism
  2379. Computer tomographic localisation in primary aldosteronism. Comparison with renal scintigraphy
  2380. A SUCCESSFUL CASE OF ADRENALECTOMY FOR PRIMARY ALDOSTERONISM
  2381. The clinical use of captopril in the diagnosis and treatment of primary aldosteronism
  2382. Coexisting primary aldosteronism and pheochromocytoma (report of 4 cases)
  2383. hypertension Controlled by Adrenalectomy: A Case of Primary Aldosteronism
  2384. Localization of te Adrenal Lesions in Primary Aldosteronism
  2385. … of single-administration captopril on plasma and urinary vasopressin in normotensive subjects and patients with essential hypertension and primary aldosteronism
  2386. Aldosterone-producing microadenoma in a patient with primary aldosteronism.
  2387. Suppressed plasma renin activity and primary aldosteronism.
  2388. The diagnosis and surgical management of primary aldosteronism: Joseph C. Cerny, Detroit, Michigan
  2389. The significance of sodium intake in postoperative aldosteronism
  2390. Clinical study on primary aldosteronism–localization of adrenal tumors
  2391. … the hypochloremic state and postural change (from supine posture to standing and walking)–new diagnostic criteria for primary aldosteronism (with normal potassium …
  2392. The prediction of blood pressure after adrenalectomy in primary aldosteronism
  2393. Twenty-Four Hour Blood Pressure Profile in Subjects with Different Subtypes of Primary Aldosteronism
  2394. Five cases of primary aldosteronism: a comparative study on diagnosis for localization of adrenal tumor
  2395. Effect of spironolactone on circadian rhythm of plasma renin activity, plasma Aldosterone and cortisol in primary aldosteronism
  2396. Primary aldosteronism: diagnosis, laterality and regulation of hormone secretion
  2397. Anesthetic Experience of Adrenalectomy with Primary Aldosteronism.
  2398. Significance of single-dose captopril test in the differential diagnosis of primary aldosteronism
  2399. PRIMARY ALDOSTERONISM RELATIONS BETWEEN PATHOLOGICAL FINDINGS AND LOCALIZATION OF THE TUMOR AND FOLLOW-UP RESULTS
  2400. Anesthetic Experience of a Patient with Primary Aldosteronism Complicated with Aortic Dissection: A case report.
  2401. Primary Aldosteronism: An Anesthetic Experience with Adrenalectomy.
  2402. ANALYSIS OF THE DIURNAL BLOOD PRESSURE VARIATION IN PRIMARY ALDOSTERONISM: P1. 133
  2403. I002: Primary aldosteronism; a community based survey in 3 ethnic communities in cape town, south africa
  2404. The circadian rhythm of serum Aldosterone in the diagnostics of primary aldosteronism
  2405. Clinical study of one Chinese pedigree with glucocorticoid-remediable aldosteronism
  2406. Primary Aldosteronism and Effects of Two Mineralocorticoid Inhibitors
  2407. … suppression test and long-PCR of chimeric gene for the diagnosis of glucocorticoid-remediable aldosteronism (GRA) in patients with primary aldosteronism (PA)
  2408. M012: Positive screening for primary aldosteronism in blacks and whites with essential hypertension
  2409. Corticoids secretion in primary aldosteronism. I. Diurnal variation and the effect of dexamethasone (author’s transl)
  2410. Scintigraphic Localization of Adrenal Lesions in Primary Aldosteronism
  2411. Fimilial primary aldosteronism with delayed glucocorticoid responsiveness: A new sndrome
  2412. D016: Aldosterone synthase gene polymorphisms in primary aldosteronism
  2413. Localization of adrenal adenomas in primary aldosteronism
  2414. A Case Report of Primary Aldosteronism with Sustained hypertension After Adrenalectomy
  2415. Primary Aldosteronism Versus Other Forms of hypertension Associated with Hypokalemia.
  2416. A case of primary aldosteronism with severe hypokalemic myopathy
  2417. Diurnal Blood Pressure Changes in Primary Aldosteronism-A Study of Ambulatory Blood Pressure Monitoring and Neurohormonal Changes
  2418. Radioimmunological determination of Aldosterone in the serum. New method for the localization of aldosteronism
  2419. Isolated Clinical Syndrome of Primary Aldosteronism in Four Patients With Adrenocortical Carcinoma
  2420. Nuclear medicine diagnostic localization in primary aldosteronism and Cushing syndrome
  2421. Nonnokalemic Primary Aldosteronism. A Detectable Cause of Curable Essential hypertension
  2422. Plasma Levels of Atrial Natriuretic Peptide in Primary Aldosteronism and Essential hypertension
  2423. The role of endogenous dopamine on mineralocorticoids secretion in normal subjects, patients with primary aldosteronism, and idiopathic hyperaldosteronism
  2424. CLINICAL SIGNIFICANCE OF CHANGES OF ATRIAL NATRIURETIC POLYPEPTIDE (ANP) IN PRIMARY ALDOSTERONISM AND THEIR RELATION WITH THE
  2425. Plasma Aldosterone and electrolytes in primary and secondard aldosteronism (author’s transl)
  2426. A possible role for intermediate lobe peptides in the pathogenesis of idiopathic aldosteronism.
  2427. Variations in severity of hypertension in a large pedigree with glucocorticoid-remediable aldosteronism
  2428. … -Adosterol (NCL-6-131I) by Diverging and Pinhole Methods III. Comparative Studies of Baseline and Dexamethasone Suppression Imaging in Aldosteronism
  2429. Whole body computed tomographic findings of each one case with primary aldosteronism and Cushing syndrome
  2430. The x-ray endovascular treatment of renin-dependent arterial hypertension with secondary aldosteronism in patients without vasorenal involvement
  2431. Studies on the mechanism of secretion of adrenal steroid hormones from adenomas of primary aldosteronism and Cushing’s syndrome (author’s transl)
  2432. M014: Identification of the aetiology of primary aldosteronism (PA) with adrenal vein sampling (AVS) in a CT and MRI era: Results in 104 consecutive cases
  2433. PLASMA Aldosterone RESPONSE TO LONG TERM SPIRONOLACTONE TREATMENT IN PRIMARY ALDOSTERONISM
  2434. Response of several adrenal steroids to rapid ACTH stimulation test in essential hypertension and primary aldosteronism (author’s transl)
  2435. Abnormality of circulatory reflex and Aldosterone response during head-up tilting in patients with primary aldosteronism
  2436. ROLE OF NATRIURETIC FACTORS IN MINERALOCORTICOID ESCAPE PHENOMENON IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2437. Hyperkalaemia secondary to hypo-aldosteronism-a report of 2 cases differentiating hyperreninaemic from hyporeninaemic hypo-aldosteronism
  2438. Dietary sodium change in primary aldosteronism. Atrial natriuretic factor, hormonal, and vascular responses. hypertension.
  2439. Prevalence and determinants of non-rheumatic Atrial Fibrillation (AF) in patients with primary aldosteronism
  2440. Effect of captopril on Aldosterone response to potassium infusion in primary aldosteronism
  2441. Clinical analysis on 40 cases of primary aldosteronism–long-term follow-up of blood pressure
  2442. Corticoid secretion in primary aldosteronism. II. The renin releasing test and the angiotensin II analog infusion test (author’s transl)
  2443. Effects of surgical treatment on circadian variations of arterial pressure in patients with primary aldosteronism and renovascular hypertension
  2444. A CASE OF PRIMARY ALDOSTERONISM TREATED BY ADRENAL ARTERY EMBOLIZATION USING ABSOLUTE ETHANOL
  2445. A Case of Primary Aldosteronism due to Bilateral Adrenal Hyperplasia with Hidden Undiagnosed Adrenal Adenoma for Eight Years
  2446. Prostaglandin E2 and the renin-angiotensin system in primary aldosteronism and Cushing’s syndrome
  2447. Multiple Endocrine Neoplasia Type I: A Case of Parathyroid Adenoma, Colloid Nodules and Aldosteronism
  2448. Glucocorticoid remediable aldosteronism: a rare hereditary form of adrenocorticotropic hormone regulated mineralocorticoid hypertension
  2449. Adrenal venous sampling analysis of primary aldosteronism: value of ACTH stimulation in the differentiation of adenoma and hyperplasia
  2450. Diagnosis and roentgeno-endovascular treatment of patients with renin-dependent arterial hypertension and secondary aldosteronism without damage to the main …
  2451. Morphology of the juxtaglomerular appartus in Bartter’s syndrome (hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension)
  2452. An unexpected rise in plasma Aldosterone to furosemide-upright test in primary aldosteronism due to Aldosterone producing adenoma.
  2453. Current problems in primary aldosteronism–4 cases of normokalemic primary aldosteronism (1st degree) caused by adenoma and 3 cases of aldosteronism, 1st …
  2454. … and dopamine on Aldosterone secretion in cultured adrenocortical adenoma cells and adjacent non-adenoma cells from patients with primary aldosteronism
  2455. … and Urinary Aldosterone Excretion in Hypertensive Patients: with Special Reference to Incidence of Normokalemic Primary Aldosteronism in Essential hypertension
  2456. A clinicopathological and ultrastructural study on 147 cases of primary aldosteronism
  2457. Endocrinopathies of hyperfunction: Cushing’s syndrome and aldosteronism
  2458. DIAGNOSTIC APPROACH TO 144 PATIENTS WITH PRIMARY ALDOSTERONISM: P2. 130
  2459. Results of Treatment in 68 Patients with Idiopathic Aldosteronism in Japan
  2460. DIAGNOSTIC AND THERAPEUTIC UNDERSTANDING OF 37 CASES OF PRIMARY ALDOSTERONISM [J]
  2461. 1 Case of Primary Aldosteronism Caused by Adrenal Hyperplasia
  2462. … 131/I-adosterol (NCL-6-/sup 131/I) by diverging and pinhole methods, 3. Comparative studies of baseline and dexamethasone suppression imaging in aldosteronism
  2463. Clinical observation of 12 cases of primary aldosteronism, special reference to the diagnostic problem (author’s transl)
  2464. 24 hours ambulatory blood pressure in primary aldosteronism
  2465. Follow up of 123 patients submitted to adrenalectomy in primary aldosteronism
  2466. A clinical analysis of 146 cases of primary aldosteronism
  2467. Analysis of the Pre and Post operative Blood Pressure and Blood Biochemical Changes in 40 Cases of Primary Aldosteronism
  2468. The diagnosis of unilateral adrenal adenoma in 123 patients with primary aldosteronism
  2469. The Diagnostic Value of Urinary Free 18-Hydroxycorticosterone in Primary Aldosteronism
  2470. 60 Primary Aldosteronism-Treatment with Trilostane, an Inhibitor of Steroid Biosynthesis
  2471. Adrenal scintigraphy with 131I-19-iodocholesterol in primary aldosteronism
  2472. 1.4 Characteristics of patients with glucocorticoid remediable aldosteronism in the North East of Scotland
  2473. 109 Improvement of arterial baroreflex function by adrenalectomy and its effect on the variability of arterial pressure in primary aldosteronism
  2474. Primary aldosteronism: renaissance of a syndrome
  2475. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
  2476. Primary aldosteronism: diagnostic and treatment strategies
  2477. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
  2478. Primary aldosteronism and hypertensive disease
  2479. Renal damage in primary aldosteronism: results of the PAPY Study
  2480. Minireview: primary aldosteronism—changing concepts in diagnosis and treatment
  2481. Cardiovascular outcomes in patients with primary aldosteronism after treatment
  2482. A review of the medical treatment of primary aldosteronism
  2483. Diagnosis and management of primary aldosteronism
  2484. Update in primary aldosteronism
  2485. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism
  2486. Primary aldosteronism—careful investigation is essential and rewarding
  2487. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents
  2488. A comprehensive review of the clinical aspects of primary aldosteronism
  2489. Long-term renal outcomes in patients with primary aldosteronism
  2490. Comparison of confirmatory tests for the diagnosis of primary aldosteronism
  2491. Primary aldosteronism: an update on screening, diagnosis and treatment
  2492. Insulin sensitivity in patients with primary aldosteronism: a follow-up study
  2493. Primary aldosteronism: management issues
  2494. Role for adrenal venous sampling in primary aldosteronism
  2495. Primary aldosteronism: cardiovascular, renal and metabolic implications
  2496. The current epidemic of primary aldosteronism: causes and consequences
  2497. Primary aldosteronism
  2498. Psychological aspects of primary aldosteronism
  2499. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline
  2500. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature
  2501. Guidelines for the diagnosis and treatment of primary aldosteronism-The Japan Endocrine Society 2009
  2502. Primary aldosteronism: factors associated with normalization of blood pressure after surgery
  2503. Diagnosis and treatment of primary aldosteronism
  2504. Laboratory investigation of primary aldosteronism
  2505. Diagnosis of primary aldosteronism: from screening to subtype differentiation
  2506. Observational study mortality in treated primary aldosteronism: the German Conn’s registry
  2507. Aldosteronism and hypertension
  2508. Prevalence and diagnosis of primary aldosteronism
  2509. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism
  2510. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol
  2511. Bone involvement in aldosteronism
  2512. Confirmatory testing in primary aldosteronism
  2513. Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary Aldosteronism
  2514. Risk factors associated with a low glomerular filtration rate in primary aldosteronism
  2515. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism
  2516. Primary aldosteronism: current knowledge and controversies in Conn’s syndrome
  2517. Kidney impairment in primary aldosteronism
  2518. Glucocorticoid-remediable aldosteronism
  2519. Relative glomerular hyperfiltration in primary aldosteronism
  2520. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism
  2521. Primary aldosteronism and metabolic syndrome
  2522. A clinical prediction score to diagnose unilateral primary aldosteronism
  2523. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’screening of hypertensive patients
  2524. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry
  2525. Drug effects on Aldosterone/plasma renin activity ratio in primary aldosteronism
  2526. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies
  2527. Primary aldosteronism: are we diagnosing and operating on too few patients?
  2528. Psychological assessment of primary aldosteronism: a controlled study
  2529. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment
  2530. Comorbidities in primary aldosteronism
  2531. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)
  2532. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry
  2533. Long-term follow-up after adrenalectomy for primary aldosteronism
  2534. Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism
  2535. Response to Is There an Unrecognized Epidemic of Primary Aldosteronism?(Pro)
  2536. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?
  2537. Primary aldosteronism in diabetic subjects with resistant hypertension
  2538. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma Aldosterone-renin ratio
  2539. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study
  2540. Confirmatory tests in the diagnosis of primary aldosteronism
  2541. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism
  2542. Inappropriate left ventricular mass in patients with primary aldosteronism
  2543. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism
  2544. Intrarenal hemodynamics in primary aldosteronism before and after treatment
  2545. Hyperparathyroidism and the calcium paradox of aldosteronism
  2546. Use of plasma Aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature.
  2547. Cautions over the current epidemic of primary aldosteronism.
  2548. Role of radiology in the management of primary aldosteronism
  2549. Captopril suppression versus salt loading in confirming primary aldosteronism
  2550. Loss of bone minerals and strength in rats with aldosteronism
  2551. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism
  2552. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study
  2553. Adiponectin and insulin sensitivity in primary aldosteronism
  2554. A possible association between primary aldosteronism and a lower β-cell function
  2555. Relationships of plasma renin levels with renal function in patients with primary aldosteronism
  2556. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study
  2557. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience
  2558. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication?
  2559. hypertension of Kcnmb1−/− is linked to deficient K secretion and aldosteronism
  2560. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma Aldosterone concentration to plasma renin activity
  2561. Primary hyperparathyroidism with concurrent primary aldosteronism
  2562. Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group)
  2563. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication
  2564. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension
  2565. Treatment of primary aldosteronism
  2566. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients
  2567. Progress in primary aldosteronism: present challenges and perspectives
  2568. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings …
  2569. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism
  2570. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects
  2571. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism
  2572. Surgically correctable hypertension caused by primary aldosteronism
  2573. Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension
  2574. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism
  2575. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism
  2576. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes
  2577. The metabolic syndrome in primary aldosteronism
  2578. The challenge of more robust and reproducible methodology in screening for primary aldosteronism
  2579. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?
  2580. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism
  2581. … -blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
  2582. Primary aldosteronism in normokalemic patients with adrenal incidentalomas
  2583. The role of aldosteronism in causing obesity-related cardiovascular risk
  2584. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism
  2585. Primary aldosteronism: diagnosis and treatment
  2586. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism
  2587. Adrenalectomy improves arterial stiffness in primary aldosteronism
  2588. Screening for membrane hormone receptor expression in primary aldosteronism
  2589. High prevalence of primary aldosteronism using postcaptopril plasma Aldosterone to renin ratio as a screening test among Italian hypertensives
  2590. Oxidative stress in aldosteronism
  2591. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism
  2592. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism
  2593. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to Aldosterone-producing adenoma
  2594. Diagnostic value of the post-captopril test in primary aldosteronism
  2595. Differential diagnosis of primary aldosteronism subtypes
  2596. Resistant hypertension and aldosteronism
  2597. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism
  2598. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an Aldosterone/renin ratio above 25 as a …
  2599. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study
  2600. Variability in the renin/Aldosterone profile under random and standardized sampling conditions in primary aldosteronism
  2601. Captopril test can give misleading results in patients with suspect primary aldosteronism
  2602. Aldosteronism and resistant hypertension
  2603. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling
  2604. Diagnosis and treatment of primary aldosteronism
  2605. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface
  2606. Clinicopathological features of primary aldosteronism associated with subclinical Cushing’s syndrome
  2607. Validity of the Aldosterone-renin ratio used to screen for primary aldosteronism
  2608. Primary aldosteronism: revival of a syndrome
  2609. Primary aldosteronism: who should be screened?
  2610. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism
  2611. Renin-angiotensin-Aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism
  2612. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests
  2613. Predictors of successful outcome after adrenalectomy for primary aldosteronism
  2614. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases
  2615. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype
  2616. The genetic basis of primary aldosteronism
  2617. Diagnosis and management of primary aldosteronism
  2618. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism
  2619. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients
  2620. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  2621. Within-patient reproducibility of the Aldosterone: renin ratio in primary aldosteronism
  2622. The genetics of primary aldosteronism
  2623. Primary aldosteronism–treatment options
  2624. Primary aldosteronism
  2625. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism
  2626. Calcium paradox of aldosteronism and the role of the parathyroid glands
  2627. What we still do not know about adrenal vein sampling for primary aldosteronism
  2628. Genetics of primary aldosteronism
  2629. Evaluation of primary aldosteronism
  2630. A diagnostic algorithm—the holy grail of primary aldosteronism
  2631. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of Aldosterone oversecretion in primary aldosteronism patients
  2632. Screening for primary aldosteronism
  2633. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy
  2634. Diagnosis and management of primary aldosteronism in pregnancy: case report and review of the literature
  2635. Detecting and treating primary aldosteronism
  2636. Aldosterone to renin ratio–a reliable screening tool for primary aldosteronism?
  2637. Primary aldosteronism: from genesis to genetics
  2638. Urinary tetrahydroAldosterone as a screening method for primary aldosteronism: a comparative study
  2639. Primary aldosteronism: part II: subtype differentiation and treatment
  2640. Diuretics and bone loss in rats with aldosteronism
  2641. The Aldosterone-to-renin ratio as a screening test for primary aldosteronism.
  2642. Active renin versus plasma renin activity to define Aldosterone-to-renin ratio for primary aldosteronism
  2643. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different …
  2644. Aldosterone-and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism
  2645. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism
  2646. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates
  2647. Trends in the prevalence of primary aldosteronism, Aldosterone-producing adenomas, and surgically correctable Aldosterone-dependent hypertension
  2648. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to Aldosterone-producing adenoma
  2649. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood
  2650. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment
  2651. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes
  2652. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience
  2653. Primary aldosteronism-part I: prevalence, screening, and selection of cases for adrenal vein sampling
  2654. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of Aldosterone excess baseline and after adrenocorticotropic …
  2655. Peripheral arterial stiffness in primary aldosteronism.
  2656. Subclinical primary aldosteronism
  2657. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis
  2658. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment
  2659. Response to Is There an Unrecognized Epidemic of Primary Aldosteronism?(Con)
  2660. Primary aldosteronism
  2661. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism
  2662. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study
  2663. The phosphorylated sodium chloride cotransporter in urinary exosomes is superior to prostasin as a marker for aldosteronism
  2664. Primary aldosteronism: the case for screening
  2665. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary Aldosterone metabolites
  2666. Aldosteronism and a Proinflammatory Vascular Phenotype: Role of Mg2+, Ca2+, and H2O2 in Peripheral Blood Mononuclear Cells
  2667. Aldosterone-to-renin ratio as a screening test for primary aldosteronism–the Dutch ARRAT Study
  2668. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism
  2669. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women
  2670. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our …
  2671. Diagnosis and management of primary aldosteronism
  2672. Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used
  2673. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree
  2674. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study
  2675. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III
  2676. Diagnosis and management of primary aldosteronism
  2677. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for Aldosterone vasculopathy and prognosis
  2678. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism
  2679. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism
  2680. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area
  2681. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation
  2682. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study
  2683. A screening procedure for primary aldosteronism based on the Diasorin Liaison® automated chemiluminescent immunoassay for direct renin
  2684. Primary aldosteronism in pregnancy
  2685. Screening for primary aldosteronism: implications of an increased plasma Aldosterone/renin ratio
  2686. Screening for primary aldosteronism-normal ranges for Aldosterone and renin in three South African population groups
  2687. Eplerenone use in primary aldosteronism during pregnancy
  2688. Primary aldosteronism: evidence against a second epidemic
  2689. Atrial fibrillation in primary aldosteronism
  2690. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and Aldosterone
  2691. Vascular disturbances in primary aldosteronism: clinical evidence
  2692. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism
  2693. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study
  2694. Primary aldosteronism: results of adrenalectomy for nonsingle adenoma
  2695. Aldosteronism revisited: perspectives on less well-recognized actions of Aldosterone
  2696. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?
  2697. Cardiovascular complications of patients with aldosteronism associated with autonomous cortisol secretion
  2698. Bone loss in rats with aldosteronism
  2699. Cardiac remodeling in patients with primary aldosteronism
  2700. Primary aldosteronism: are we missing the wood for the trees?
  2701. Primary aldosteronism, diagnosis and treatment in Japan
  2702. Integrating genetics and genomics in primary aldosteronism
  2703. Captopril suppression: limitations for confirmation of primary aldosteronism
  2704. Management of primary aldosteronism: its complications and their outcomes after treatment
  2705. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets
  2706. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment
  2707. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism
  2708. Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients
  2709. Primary aldosteronism.
  2710. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants
  2711. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating Aldosterone secretion?
  2712. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning
  2713. Myocardial and aortic stiffening in the early course of primary aldosteronism
  2714. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism
  2715. Screening tests and diagnostic examinations of hypertensives for primary aldosteronism
  2716. The Aldosterone–renin ratio in screening for primary aldosteronism
  2717. Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing’s syndrome
  2718. Progress in primary aldosteronism
  2719. The association of serum potassium level with left ventricular mass in patients with primary aldosteronism
  2720. Case Report: Laparoscopic Adrenalectomy on a Patient with Primary Aldosteronism during Pregnancy
  2721. Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism
  2722. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension
  2723. Primary aldosteronism, a common entity? The myth persists
  2724. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism
  2725. Would wider screening for primary aldosteronism give any health benefits?
  2726. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism
  2727. Aberrant hormone receptors in primary aldosteronism
  2728. Familial varieties of primary aldosteronism
  2729. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene …
  2730. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?
  2731. The role of adrenal venous sampling in the surgical management of primary aldosteronism
  2732. A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism
  2733. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
  2734. Primary aldosteronism: the role of confirmatory tests
  2735. Primary aldosteronism associated with severe rhabdomyolysis due to profound hypokalemia
  2736. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis
  2737. Single-center outcome of laparoscopic unilateral adrenalectomy for patients with primary aldosteronism: lateralizing disease using results of adrenal venous sampling
  2738. Primary aldosteronism: a common and important problem A practical guide to the diagnosis and treatment
  2739. Evidence for a Role of Vasopressin in the Control of Aldosterone Secretion in Primary Aldosteronism: in Vitro and in Vivo Studies
  2740. Plasma and urine Aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism
  2741. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives
  2742. A German family with glucocorticoid-remediable aldosteronism
  2743. Pseudo‐aldosteronism’induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients
  2744. New concepts in adrenal vein sampling for Aldosterone in the diagnosis of primary aldosteronism
  2745. Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results
  2746. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI
  2747. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy
  2748. Primary aldosteronism: rare bird or common cause of secondary hypertension?
  2749. Treatment of primary aldosteronism: Where are we now?
  2750. The role of adrenal scintigraphy in the preoperative management of primary aldosteronism
  2751. QT interval in patients with primary aldosteronism and low-renin essential hypertension
  2752. Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity
  2753. New aspects on primary aldosteronism
  2754. Primary aldosteronism: from bench to bedside
  2755. Left ventricular changes in primary aldosteronism
  2756. Primary aldosteronism can alter peripheral levels of transforming growth factor β and tumor necrosis factor α
  2757. Primary aldosteronism in 2011: towards a better understanding of causation and consequences
  2758. Is it possible to extirpate cardiovascular events in primary aldosteronism after surgical treatment
  2759. Familial or genetic primary aldosteronism and Gordon syndrome
  2760. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy
  2761. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it?
  2762. Long-term effects of surgical correction of adrenal hyperplasia and adenoma causing primary aldosteronism
  2763. Primary aldosteronism: what consensus for the diagnosis
  2764. Prediction of successful outcome in patients with primary aldosteronism
  2765. Idiopathic intracranial hypertension with primary aldosteronism: report of 2 cases
  2766. Recent advances in diagnosis and treatment of primary aldosteronism.
  2767. A case of primary aldosteronism due to unilateral adrenal hyperplasia
  2768. Genetic alterations in patients with primary aldosteronism
  2769. Active renin mass concentration to determine Aldosterone-to-renin ratio in screening for primary aldosteronism
  2770. Primary aldosteronism: actual epidemics or false alarm?
  2771. Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism
  2772. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism
  2773. Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism
  2774. Mitochondria-targeted cardioprotection in aldosteronism
  2775. Is primary aldosteronism underdiagnosed in clinical practice?
  2776. Primary aldosteronism with Aldosterone-producing adenoma consisting of pure zona glomerulosa-type cells in a pregnant woman
  2777. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene
  2778. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate
  2779. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone
  2780. Primary Aldosteronism—One Picture Is Not Worth a Thousand Words
  2781. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy
  2782. Prolongation of the QT interval in primary aldosteronism
  2783. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting
  2784. … /renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum Aldosterone concentration for primary aldosteronism screening in different age …
  2785. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients
  2786. Primary aldosteronism
  2787. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension
  2788. Somatic Mutations in the KCNJ5 Gene Raise the Lateralization Index: Implications for the Diagnosis of Primary Aldosteronism by Adrenal Vein Sampling
  2789. The pharmacological treatment of primary aldosteronism
  2790. Left heart morphology and function in primary aldosteronism
  2791. Diurnal blood pressure pattern in patients with primary aldosteronism
  2792. Spontaneous remission of idiopathic aldosteronism after long‐term treatment with spironolactone: results from the German Conn’s Registry
  2793. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy
  2794. … Endocrine Causes of hypertension (GECOH) study: a diagnostic accuracy study of Aldosterone to active renin ratio in screening for primary aldosteronism
  2795. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension
  2796. Combined primary aldosteronism and preclinical Cushing’s syndrome: an unusual case presentation of adrenal adenoma
  2797. Recurrent calcium nephrolithiasis associated with primary aldosteronism
  2798. Authors’ Response: Prevalence of Primary Aldosteronism in Unselected Hypertensive Populations—Screening and Definitive Diagnosis
  2799. Is primary aldosteronism rare or common among hypertensive patients?
  2800. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements
  2801. Primary aldosteronism: A contrarian view
  2802. Functional tests for primary aldosteronism: value of captopril suppression
  2803. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism
  2804. Coexistence of normotensive primary aldosteronism in two patients with Gitelman’s syndrome and novel thiazide-sensitive Na-Cl cotransporter mutations.
  2805. Establishment of reference values for endocrine tests. III: primary aldosteronism
  2806. Problems in diagnostics of primary aldosteronism-analysis of the own data
  2807. Primary aldosteronism: clinical lateralization and costs
  2808. Value of adrenal venous sampling for lesion localization in primary aldosteronism
  2809. Life-threatening arrhythmia caused by primary aldosteronism
  2810. Chromogranin a measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism
  2811. Treatment of primary aldosteronism
  2812. Is there an epidemic of primary aldosteronism?
  2813. 131I-6β-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results
  2814. Clinical characteristics of Aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism
  2815. Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests justified?
  2816. Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B2 Receptor and α-Adducin Gene Polymorphisms
  2817. A case with primary aldosteronism due to unilateral multiple adrenocortical micronodules
  2818. The cutoff value of Aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine
  2819. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism
  2820. A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern
  2821. Prevalence and role of a raised Aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice
  2822. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism
  2823. Reverse remodeling and recovery from cachexia in rats with aldosteronism
  2824. Primary aldosteronism: a practical approach to diagnosis and treatment
  2825. Sporadic solitary Aldosterone-and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism
  2826. Primary aldosteronism: a pictorial essay
  2827. Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism
  2828. Primary aldosteronism
  2829. A case of primary aldosteronism revealed after renal transplantation
  2830. The genetics of primary aldosteronism: chapter two
  2831. Screening and diagnosis of primary aldosteronism
  2832. High prevalence of thyroid ultrasonographic abnormalities in primary aldosteronism
  2833. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol
  2834. Contrast‐enhanced MRI index of diffuse myocardial fibrosis is increased in primary aldosteronism
  2835. Coexistence of primary aldosteronism and Hashimoto’s thyroiditis
  2836. Adrenal Venous Sampling for Primary Aldosteronism and Clinical Outcomes After Unilateral Adrenalectomy: A Single‐Center Experience
  2837. Primary aldosteronism
  2838. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism
  2839. Selection of patients for surgery for primary aldosteronism.
  2840. … with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism
  2841. Evolution of diagnostic criteria for primary aldosteronism: why is it more common in” drug-resistant” hypertension today?
  2842. Current diagnosis and treatment of primary aldosteronism
  2843. Long-term results of laparoscopic adrenalectomy for primary aldosteronism
  2844. Diagnosis of primary aldosteronism: for medical management, not just surgery
  2845. Pathophysiological roles of the adrenal renin-angiotensin system in patients with primary aldosteronism
  2846. The prevalence of primary aldosteronism in diabetic patients
  2847. Tissue 65Zinc translocation in a rat model of chronic aldosteronism
  2848. Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass
  2849. Twenty-four hour blood pressure profile in subjects with different subtypes of primary aldosteronism
  2850. Primary aldosteronism combined with preclinical Cushing’s syndrome in an elderly patient
  2851. Paralysis as first manifestation of primary aldosteronism
  2852. Coexistence of three distinct adrenal tumors in the same adrenal gland in a patient with primary aldosteronism and preclinical Cushing’s syndrome
  2853. Progress in primary aldosteronism 2
  2854. Primary aldosteronism associated with severe hypokalemic rhabdomyolysis
  2855. Discrepant results of adrenal venous sampling in seven patients with primary aldosteronism
  2856. Responses in extracellular and intracellular calcium and magnesium in aldosteronism
  2857. Retroperitoneal laparoscopic management of primary aldosteronism with report of 130 cases
  2858. … for detecting precisely functional state of various lesions in unilateral and bilateral adrenal disorders, inducing primary aldosteronism with subclinical Cushing’s …
  2859. A rare case of primary hyperparathyroidism associated with primary aldosteronism, Hürthle cell thyroid cancer and meningioma
  2860. Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism
  2861. Primary aldosteronism: diagnostic and therapeutic considerations
  2862. Caution about the overdiagnosis of primary aldosteronism
  2863. Primary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stress
  2864. Primary aldosteronism: the most frequent form of secondary hypertension?
  2865. Combined primary aldosteronism and Gushing’s syndrome due to a single adrenocortical adenoma complicated by Hashimoto’s thyroiditis
  2866. Prevalence of primary aldosteronism in hypertensive patients and its effect on the heart
  2867. Usefulness of adrenal vein sampling in the evaluation of aldosteronism
  2868. Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration
  2869. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism
  2870. Role of K+ Channels in the Pathophysiology of Primary Aldosteronism
  2871. Analysis of unilateral adrenal hyperplasia with primary aldosteronism from the aspect of messenger ribonucleic acid expression for steroidogenic enzymes: a …
  2872. Primary aldosteronism: comparison between guidelines of the Japanese and the US Endocrine Society
  2873. Diagnosis of glucocorticoid-remediable aldosteronism in hypertensive children
  2874. Japanese family with glucocorticoid-remediable aldosteronism diagnosed by long-polymerase chain reaction
  2875. 11 C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism
  2876. Assessment of serum sodium to urinary sodium divided by (serum potassium) ² to urinary potassium as a screening tool for primary aldosteronism
  2877. QT interval is prolonged but QT dispersion is maintained in patients with primary aldosteronism
  2878. Primary aldosteronism and a Texas two-step
  2879. Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism
  2880. Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion
  2881. Primary aldosteronism and hypercortisolism due to bilateral functioning adrenocortical adenomas
  2882. A clinical observation on twelve cases of primary aldosteronism
  2883. Aldosterone/renin ratio in the diagnosis of primary aldosteronism
  2884. Efficacy of screening for primary aldosteronism by adrenocortical scintigraphy without discontinuing antihypertensive medication
  2885. Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability
  2886. Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism
  2887. Some considerations about evolution of idiopathic primary aldosteronism
  2888. Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension
  2889. Animal models of primary aldosteronism
  2890. Cautions over idiopathic aldosteronism
  2891. Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases
  2892. Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism
  2893. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoid-remediable aldosteronism.
  2894. Genetic forms of primary aldosteronism
  2895. A case of primary aldosteronism with rhabdomyolysis
  2896. Primary aldosteronism: evolving concepts in diagnosis and treatment
  2897. More fuel to the debate on the “epidemics of primary aldosteronism”
  2898. Single-incision laparoscopic adrenalectomy for primary aldosteronism: report of a case
  2899. Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism
  2900. Primary aldosteronism
  2901. Possibly simultaneous primary aldosteronism and preclinical Cushing’s syndrome in a patient with double adenomas of right adrenal gland
  2902. One-hour upright posture is an ideal position for serum Aldosterone concentration and plasma renin activity measuring on primary aldosteronism screening
  2903. Prevalence of primary aldosteronism among Bulgarian hypertensive patients
  2904. Renal function in primary aldosteronism
  2905. Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism?
  2906. Have main types of primary aldosteronism different phenotype?
  2907. Primary aldosteronism and pregnancy: report of 2 cases
  2908. A case of primary aldosteronism associated with renal artery stenosis and preclinical Cushing’s syndrome
  2909. Multiple intracerebral microhemorrhages associated with primary aldosteronism: a case report
  2910. Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience
  2911. Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism
  2912. Analytical variation in plasma renin activity: implications for the screening of primary aldosteronism
  2913. Misdiagnosis of two cases of primary aldosteronism owing to failure of computed tomography to detect adrenal microadenoma
  2914. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism
  2915. Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients
  2916. Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism
  2917. Diagnosis of surgically-treatable forms of primary aldosteronism
  2918. The Aldosterone-renin ratio and primary aldosteronism/In reply
  2919. Diagnostic procedures for primary aldosteronism/diagnostische methoden für den primären hyperaldosteronismus
  2920. Salivary Aldosterone as a diagnostic aid in primary aldosteronism
  2921. Primary aldosteronism. A risk factor for aortic dissection?
  2922. Recurrence of primary aldosteronism after percutaneous ethanol injection
  2923. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion
  2924. Aldosterone and aldosteronism
  2925. A case of primary aldosteronism with end stage renal disease
  2926. Malignant hypertension and hypertensive encephalopathy in primary aldosteronism caused by adrenal adenoma
  2927. Effects of hypokalemia and left ventricular hypertrophy on QT interval in patients with primary aldosteronism
  2928. About an epidemic of primary aldosteronism
  2929. Primary aldosteronism caused by unilateral adrenal hyperplasia: rethinking the accuracy of imaging studies
  2930. Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism
  2931. Primary aldosteronism due to unilateral adrenal microadenoma in an elderly patient: efficacy of selective adrenal venous sampling
  2932. Primary aldosteronism with ventricular fibrillation: a case report
  2933. Diagnosis of primary aldosteronism in chronic kidney disease by I-131 NP-59 SPECT/CT imaging.
  2934. Primary aldosteronism takes (KCNJ) five!
  2935. Primary aldosteronism simulating polymyositis
  2936. A case of primary aldosteronism caused by multiple adrenocortical macronodules
  2937. Genetic screening for glucocorticoid-remediable aldosteronism (GRA): experience of three clinical centres in Poland
  2938. The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism
  2939. Surgical management of primary aldosteronism. not everything that shines is gold
  2940. Metabolic dysfunction in primary aldosteronism
  2941. Change in the pattern of adrenal venous sampling over time in patients with primary aldosteronism
  2942. Overt diabetes mellitus in a patient with combined primary aldosteronism and Cushing’s syndrome
  2943. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient
  2944. Primary aldosteronism: the case against screening
  2945. Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
  2946. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism
  2947. Case of ruptured multiple cerebral aneurysms associated with primary aldosteronism
  2948. Screening for primary aldosteronism in a cohort of Brazilian patients with resistant hypertension
  2949. Experience of retroperitoneoscopic adrenalectomy in 195 patients with primary aldosteronism
  2950. Primary aldosteronism
  2951. Simultaneous surgery for chronic aortic dissection and adrenal adenoma with primary aldosteronism
  2952. Hypertensive Complications in Patients with Primary Aldosteronism.
  2953. Successful treatment of primary aldosteronism due to computed tomography‐negative microadenoma
  2954. Response to renal function in primary aldosteronism: is glomerular hyperfiltration a hallmark of primary aldosteronism? Further results from the Primary Aldosteronism …
  2955. Morning plasma Aldosterone predicts the subtype of primary aldosteronism independant of sodium intake
  2956. Glucocorticoid-remediable aldosteronism
  2957. Primary aldosteronism with right-dominant heart failure
  2958. Clinical characteristics and surgery outcomes of unilateral nodular adrenal hyperplasia in primary aldosteronism: study of 145 cases
  2959. hypertension due to primary aldosteronism
  2960. Episodic rage associated with primary aldosteronism resolved with adrenalectomy
  2961. Aortic dissection-a rare complication of primary aldosteronism-a case report
  2962. A case of primary aldosteronism accompanied by rhabdomyolysis
  2963. Primary aldosteronism and resistant arterial hypertension
  2964. Comparison of target organ damages between primary aldosteronism and essential hypertension
  2965. The neuroendocrine-immune interface gone awry in aldosteronism
  2966. Plasma Aldosterone to renin ratio predicts treatment response in primary aldosteronism: Is volume loading needed?
  2967. Characteristics of left ventricular structural damage in patients with primary aldosteronism
  2968. A rare case of primary aldosteronism caused by bilateral functioning adrenocortical adenomas with renal cell carcinoma
  2969. A case of primary aldosteronism in childhood
  2970. Acute cerebral hemorrhage normalized plasma renin activity in a patient with primary aldosteronism
  2971. Metabolic syndrome and primary aldosteronism: time for reappraisal?
  2972. Clinical relevance of dietary salt intake on Aldosterone and the Aldosterone-to-renin ratio as screening parameters for primary aldosteronism
  2973. Aortic cell apoptosis in rat primary aldosteronism model
  2974. Cushing’s syndrome by left adrenocortical adenoma synchronously associated with primary aldosteronism by right adrenocortical adenoma: report of a case
  2975. Primary Aldosteronism
  2976. Left ventricular hypertrophy in patients with primary aldosteronism
  2977. Primary aldosteronism
  2978. Should primary aldosteronism be diagnosed among normotensive subjects during general health check-up and/or at general outpatient clinics?
  2979. New diagnostic procedure for primary aldosteronism: adrenal venous sampling under adrenocorticotropic hormone and angiotensin II receptor blocker—application to …
  2980. Value of saline load test in diagnosis of primary aldosteronism [J]
  2981. Screening for primary aldosteronism: progress and frustration
  2982. Diagnosis and management of primary aldosteronism
  2983. TREATMENT OF PRIMARY ALDOSTERONISM: SHORT AND MIDDLE-TERM EFFECTS OF MEDICAL AND SURGICAL THERAPY IN PRIMARY …
  2984. Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism
  2985. Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report
  2986. Primary aldosteronism presented with intracranial hemorrhage
  2987. Is primary aldosteronism a benign disorder? Old evidence reconfirmed
  2988. … producing adrenal adenoma associated with a latent aldosteronoma: usefulness of the ACTH loading test for the detection of covert aldosteronism in overt Cushing …
  2989. A case of primary aldosteronism with aortic dissection
  2990. Risk factors of decreased glomerular filtration rate in patients with primary aldosteronism
  2991. A possible association between primary aldosteronism and a lower β-cell function
  2992. 100 cases of primary aldosteronism: careful choice of patients for surgery using adrenal venous sampling and CT imaging results in excellent blood pressure and …
  2993. Evolution features of hypertensive patients with primary aldosteronism-Prospective Study
  2994. The Clinical Implication and Problems of Adrenal Vein Sampling in Patients with Primary Aldosteronism.
  2995. Cautions over idiopathic aldosteronism
  2996. The current epidemic of primary aldosteronism: causes and consequences
  2997. Primary aldosteronism in diabetic subjects with resistant hypertension: response to Umpierrez et al.
  2998. Diagnosis of primary aldosteronism-debate continues. Part I
  2999. Primary aldosteronism presenting as bibrachial paralysis
  3000. Adrenal cortex scintigraphy with and without dexamethasone suppression in the study of primary aldosteronism
  3001. Primary Aldosteronism: The Surgical Perspective
  3002. Potassium supplementation improves the natriuretic response to central volume expansion in primary aldosteronism
  3003. Primary Aldosteronism and public health: new definitions, new challenges
  3004. Anesthesia and laparoscopic adrenalectomy for primary aldosteronism.
  3005. Factors influencing outcome of surgical treatment for primary aldosteronism
  3006. Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor
  3007. Use of gadolinium contrast adrenal venography for the assessment of primary aldosteronism in a patient with iodine allergy
  3008. PREVALENCE OF PRIMARY ALDOSTERONISM (PA) IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS: RESULTS OF A NATIONWIDE SURVEY IN ITALY: 5B. 3
  3009. A patient with concurrent primary aldosteronism and Page kidney
  3010. Primary aldosteronism importance to the
  3011. Diagnosis and treatment of primary aldosteronism (report of 46 cases)
  3012. Primary aldosteronism complicated with chronic renal failure
  3013. A case of nephrocalcinosis associated with primary aldosteronism
  3014. Anterior ischemic optic neuropathy associated with idiopathic aldosteronism and hypertension
  3015. Animal models of primary aldosteronism
  3016. Medical Management of Primary Aldosteronism
  3017. Laparoscopic management of primary aldosteronism: a report of 227 cases
  3018. Diagnosis of adenomatous primary aldosteronism in a patient with severe hypertension
  3019. Insulin signaling in adipose tissue of patients with primary aldosteronism
  3020. Adrenalectomy for Primary Aldosteronism
  3021. Biomarkers of endothelial dysfunction and risk of early organ damage: a comparison between patients with primary aldosteronism and essential hypertension
  3022. Bilateral aldosteronoma associated with secondary aldosteronism in a chronic hemodialysis subject
  3023. Adrenal venous sampling crucial in primary aldosteronism?
  3024. A case of adrenocortical carcinoma with concurrent Cushing’s syndrome and primary aldosteronism
  3025. Development of pseudo-aldosteronism depends on amount of glycyrrhizae radix in each individual
  3026. Primary aldosteronism with HIV infection: important considerations when using the Aldosterone: renin ratio to screen this unique population
  3027. Long‐term follow‐up of a girl with primary aldosteronism: Effect of potassium supplement
  3028. Primary Aldosteronism Due to Aldosterone Producing Adenama in the Presence of Contralateral Nonfunctioning Adenama.
  3029. Adrenal venous sampling but not computed tomography is essential before undertaking adrenalectomy for primary aldosteronism
  3030. Surgical Operation of Primary Aldosteronism [J]
  3031. Improving adrenal venous sampling in primary aldosteronism
  3032. A case of primary aldosteronism accompanied by hypokalemic rhabdomyolysis
  3033. Diagnosis and management of primary aldosteronism in cats
  3034. … Role for P450 scc in the Overproduction of Aldosterone in Aldosterone-Producing Adenoma and Idiopathic Hyperaldosteronism in Patients with Primary Aldosteronism
  3035. A new method of super-selective acth-stimulated adrenal venous sampling is revolutionarily useful for treatment of primary aldosteronism: PP. 18.179
  3036. Laboratory Test of Primary Aldosteronism
  3037. Primary aldosteronism and diabetes mellitus
  3038. Response to More Fuel to the Debate on the “Epidemic of Primary Aldosteronism”
  3039. Interpretation of clinical practice guidelines of primary aldosteronism.
  3040. The study of screening rates of primary aldosteronism in obstructive sleep apnea syndrome with hypertension as the blood pressure classification
  3041. Gender difference in QT interval in patients with primary aldosteronism
  3042. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism
  3043. Prevalence of metabolic syndrome in patients with primary aldosteronism
  3044. Primary aldosteronism in type 1 diabetes mellitus
  3045. Primary aldosteronism in a patient after surgical treatment of primary hyperparathyroidism
  3046. Observation on the prevalence of primary aldosteronism in the in-patients in Xinjiang [J]
  3047. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism
  3048. Response to the Article:“Primary Aldosteronism: Are We Missing the Wood for the Trees?”
  3049. HIGH EXPRESSION OF THE PRO-RENIN RECEPTOR IN Aldosterone PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM: 4D. 02
  3050. Time to normalization of blood pressure after an adrenalectomy for patients with primary aldosteronism
  3051. Prevalence of glucose metabolism disturbance in primary aldosteronism
  3052. … PRESSURE AND POTASSIUM EFFECTS OF THE NEW DIRECT Aldosterone SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM …
  3053. Adrenal venous sampling revisited-Crucial role in the management of primary aldosteronism patients
  3054. … adrenal incidentalomas from normotensive and hypertensive patients: Distinguishing subclinical or atypical primary aldosteronism from adrenal incidentaloma
  3055. Diagnosis and treatment of primary aldosteronism
  3056. Kidney in primary aldosteronism: A key determinant of treatment outcome
  3057. Primary Aldosteronism
  3058. Association of renovascular hypertension and primary aldosteronism
  3059. Myasthenia gravis complicated with primary aldosteronism and hypokalemic myopathy
  3060. A possible association between primary aldosteronism and a lower β-cell function
  3061. Anesthetic management for electroconvulsive therapy (ECT) in a patient with primary aldosteronism
  3062. OR-39: Prevalence of unrecognized primary aldosteronism in essential hypertension
  3063. Treatment of primary aldosteronism-debate continues. Part II
  3064. Clinical significance of Aldosterone to renin ratio in screening primary aldosteronism
  3065. Primary Aldosteronism
  3066. A Case Study of Primary Aldosteronism
  3067. Adrenalectomy for primary aldosteronism
  3068. Role of adrenal venous sampling in the treatment strategy for primary aldosteronism
  3069. Clinical Analysis of Primary Aldosteronism
  3070. Primary aldosteronism
  3071. K001 Is primary aldosteronism a channelopathy?
  3072. Primary Aldosteronism
  3073. Misleading diagnosis of renal artery stenosis by magnetic resonance angiography in a patient with primary aldosteronism
  3074. Primary Aldosteronism Complicated by Severe Hypokalemic Myopathy
  3075. HORMONAL EFFECTS OF THE NEW DIRECT Aldosterone SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C. 06
  3076. Will the lessons from primary aldosteronism change the treatment of hypertension and left ventricular hypertrophy?
  3077. Factors Influencing Outcome of Surgical Treatment for Primary Aldosteronism
  3078. Primary aldosteronism
  3079. Nonprimary Aldosteronism
  3080. Surgical treatment of primary aldosteronism [J]
  3081. Diagnosis and surgical Treatment of primary Aldosteronism
  3082. aldosteronism. Some, possibly many, normokalemic
  3083. Analysis of diagnosis and treatment of primary aldosteronism:(Report of 63 cases)
  3084. Primary aldosteronism: analysis of a series of 54 patients
  3085. The evolution of primary aldosteronism
  3086. Long-term consequences of primary aldosteronism
  3087. Primary aldosteronism: an update
  3088. Hypokalemic paralysis in a young woman with thyrotoxicosis and primary aldosteronism
  3089. Diagnosis and treatment of primary aldosteronism
  3090. Evaluation of High-Dose Spironolactone in the Preoperative Preparation of Primary Aldosteronism
  3091. Glucolipid metabolism characteristics analysis of primary aldosteronism
  3092. A brief history of diagnosis and treatment of primary aldosteronism.
  3093. Diagnosis and Treatment of Primary Aldosteronism
  3094. Surgical treatment of primary aldosteronism.
  3095. Is confirmation of an adrenal adenoma in patients with primary aldosteronism sufficient for indication of adrenalectomy?
  3096. Estimation of the efficacy of the measurement of plasma renin activity and direct renin in diagnostics of primary aldosteronism
  3097. The diagnosis and treatment of primary aldosteronism (report of 507 cases)
  3098. Primary aldosteronism presenting with hypertension and quadriparesis
  3099. Controversies on the Diagnosis of Primary Aldosteronism
  3100. Clinical Features of Patients with Primary Aldosteronism
  3101. Studies of diagnosis and differential diagnosis in primary aldosteronism
  3102. Seeing is Believing—Just not in Primary Aldosteronism
  3103. Primary Aldosteronism and Pregnancy: A Case Report
  3104. Current opinion on primary aldosteronism
  3105. Characteristics of glucolipid metabolism and analysis of related factors in patients with primary aldosteronism [J]
  3106. Supracentrimetric nodule on computed tomography does not exclude adrenal venous sampling before surgery for primary aldosteronism
  3107. The Aldosterone-Renin Ratio and Primary Aldosteronism: In Response
  3108. Diagnosis and treatment of primary aldosteronism. An analysis of 18 cases
  3109. Diagnosis and Treatment of Primary Aldosteronism (Report of 14 Cases)[J]
  3110. Normokalaemic primary aldosteronism due to an Aldosterone-producing adrenal adenoma–Case 06/2009
  3111. Genomic profile in primary aldosteronism
  3112. Differential diagnosis of subtypes in primary aldosteronism
  3113. How to screen for pheochromocytoma, primary aldosteronism and Cushing’s syndrome
  3114. Primary aldosteronism-why is the diagnosis difficult?
  3115. Response to About an Epidemic of Primary Aldosteronism
  3116. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  3117. CLINICAL AND BIOLOGICAL ASPECTS OF PRIMARY ALDOSTERONISM: 18 CASES: P3. 115
  3118. New index of using serum sodium and potassium and urine sodium and potassium jointly in screening primary aldosteronism in hypertensive patients
  3119. Primary aldosteronism: from genesis to genetics q
  3120. Progress in medications of primary aldosteronism.
  3121. Response to Metabolic Dysfunction in Primary Aldosteronism
  3122. Evaluation of Aldosterone to renin concentration ratio as a reliable screening parameter for primary aldosteronism applying currently available assays
  3123. Altered heart rate variability but preserved temporal relationship with sleep stages in a patient with primary aldosteronism
  3124. Primary Aldosteronism: An Update on Screening, Diagnosis and Treatment
  3125. Patient Guide to Detection, Diagnosis and Treatment of Primary Aldosteronism
  3126. Recent progress of diagnosis and treatment of primary aldosteronism
  3127. Cardiovascular complications in patients with primary aldosteronism
  3128. Endocrine—Primary Aldosteronism
  3129. Endocrine—Primary Aldosteronism
  3130. Clinical significance of determination of SAC/PRA value in patients with primary aldosteronism
  3131. … ON LEFT VENTRICULAR MASS INDEX AND BLOOD PRESSURE IN PATIENTS WITH PRIMARY ALDOSTERONISM–RETROSPECTIVE ANALYSIS: 5B. 4
  3132. Delayed Arterial Switch Operation for D-Transposition of the Great Arteries and Glucocorticoid Remediable Aldosteronism
  3133. Non-surgical therapy of primary aldosteronism
  3134. Ratio of plasma Aldosterone concentration to renin activity in screening for primary aldosteronism: the current situation and influencing factors.
  3135. 6.15 Roles of Clinical Criteria, CT Scan and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes
  3136. Application of captopril test in the diagnosis of primary aldosteronism
  3137. The value of CT in the etiological classification of primary aldosteronism
  3138. METABOLIC DIFFERENCES BETWEEN MAIN TYPES OF PRIMARY ALDOSTERONISM: PP. 18.188
  3139. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism
  3140. Primary aldosteronism during 2007-2011 in Iceland
  3141. Aberrant receptor expression in primary aldosteronism
  3142. To stimulate or not to stimulate: the differential diagnosis of aldosteronism revisited
  3143. Primary aldosteronism in newly diagnosed hypertensive patients
  3144. Comparison of strategies for biochemical diagnosis of primary aldosteronism in German academic centres
  3145. Screening and diagnosis of primary aldosteronism
  3146. The laparoscopic surgical treatment of primary aldosteronism
  3147. Screening for primary aldosteronism in a secondary care diabetes population
  3148. Atypical clinical manifestations of primary aldosteronism.
  3149. Adrenal venous sampling (AVS) is essential for detecting unilateral or bilateral adrenal lesions in primary aldosteronism
  3150. … OF BLOOD PRESSURE AND LEFT VENTRICULAR (LV) GEOMETRY AFTER ADRENALECTOMY OR MEDICAL TREATMENT FOR PRIMARY ALDOSTERONISM …
  3151. Demonstration of Blood Pressure-Independent Non Infarct Myocardial Fibrosis in Primary Aldosteronism: A Cardiac MRI Study
  3152. PREVALENCE OF PRIMARY ALDOSTERONISM AMONG HYPERTENSIVE PATIENTS: P 774
  3153. Imaging diagnosis of primary aldosteronism.
  3154. The confirmatory Tests of primary aldosteronism should be selected in each countries-the analysis of 83 patients in our hospital
  3155. OR-46: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension
  3156. Role of imaging diagnosis in surgical treatment of primary aldosteronism
  3157. Recent progress in the treatment of idiopathic aldosteronism
  3158. Partial Adrenalectomy in Patients with Primary Aldosteronism
  3159. AN EXPERIENCE OF SURGICAL TREATMENT FOR PRIMARY ALDOSTERONISM ASSOCIATED WITH CHRONIC RENAL FAILURE
  3160. Treatment of primary aldosteronism with retroperitoneal laparoscopic surgery [J]
  3161. Primary Aldosteronism And Inappropriateness Of Left Ventricular Mass
  3162. Retroperitoneal laparoscopic surgery for primary aldosteronism (report of 90 cases)
  3163. Female patients with primary aldosteronism are diagnosed earlier and have a better outcome
  3164. Endocrine hypertension due to primary aldosteronism
  3165. Vitamin D deficiency in primary aldosteronism
  3166. Pseudo-hypo aldosteronism: Type II
  3167. ANALYSING THE RELATIVE FACTORS THAT INFLUENCE GLOMERULAR FILTRATION RATE IN PRIMARY ALDOSTERONISM.
  3168. A Case of Primary Aldosteronism after Renal Transplantation
  3169. A case of nephrocalcinosis with primary aldosteronism
  3170. PSYCHOLOGICAL ASSESSMENT OF PRIMARY ALDOSTERONISM. A CONTROLLED STUDY: PP. 39.279
  3171. Prevalence of primary aldosteronism among hypertensive patients (preliminary results)
  3172. Michał Lityński, MD-the author of the first description in the world literature of primary aldosteronism-after 50 years
  3173. Investigating children of glucocorticoid remediable aldosteronism patients
  3174. Glucocorticoid-remediable aldosteronism: Report of a family and literature review
  3175. Clinical Significance of Strengthening Screening and Diagnosis of Primary Aldosteronism
  3176. Periodic paralysis: an uncommon complication of primary aldosteronism
  3177. Prevalence of primary aldosteronism in hypertensive subjects with hyperglycaemia
  3178. Renal function in patients with primary aldosteronism: comparison with essential hypertension
  3179. Guidelines for diagnosis and treatment of primary aldosteronism
  3180. PREVALENCE OF PRIMARY ALDOSTERONISM AMONG UNSELECTED HYPERTENSIVE PATIENTS: P2. 104
  3181. Potassium channels in primary aldosteronism
  3182. Investigation and Management of Primary Aldosteronism-A Review of Cases and Audit of Outcomes in a Tertiary Referral Centre
  3183. Left ventricular mass in patients with primary aldosteronism after etiologic treatment
  3184. Severe hypokalemia-associated rhabdomyolise and unusual poliuria in patient with primary aldosteronism: A case presentation
  3185. Combined primary aldosteronism and preclinical Cushing
  3186. Primary Aldosteronism: Current Concepts of Epidemic, Diagnosis, and Treatment.
  3187. The influence of the ovarian cycle on the first-step laboratory screening for primary aldosteronism
  3188. PERIPHERAL ARTERIAL STIFFNESS IN PRIMARY ALDOSTERONISM: 8D. 03
  3189. Osteopontin in patients with primary aldosteronism
  3190. Treating Primary Aldosteronism with New Aldosterone Receptor Antagonists
  3191. Moleculan Genetics of Glucocorticoid Remediable Aldosteronism.
  3192. Primary aldosteronism and sleep apnea syndrome.
  3193. Primary Aldosteronism Screening and Diagnosis in Primary Health Care
  3194. DIFFERENCES IN PULSE WAVE VELOCITY BETWEEN MAIN TYPES OF PRIMARY ALDOSTERONISM: 8D. 04
  3195. TRANSCRIPTIONAL AND PATHOLOGICAL ANALYSIS OF PRIMARY ALDOSTERONISM: 4D. 01
  3196. Evaluation of renal function of primary aldosteronism between pre-and post-treatment
  3197. THE COMPARISON OF CLINICAL FEATURES BETWEEN HYPOKALEMIC AND NORMOKALEMIC PRIMARY ALDOSTERONISM PATIENTS: 8D. 05
  3198. Retrospective analysis of diagnostic and treatment outcomes of primary aldosteronism
  3199. Clinical analysis of 330 patients with primry aldosteronism
  3200. Factors Associated with Amelioration of Blood Pressure after Surgery for Primary Aldosteronism
  3201. Metabolic syndrome among patients with primary aldosteronism: a common feature?
  3202. Evaluation of cardiac structure and function changes with tissue Doppler echocardiography in primary aldosteronism patients
  3203. Predicting factors of the post-surgical decline in renal function in patients with primary aldosteronism
  3204. Aortic Intramural Hematoma Associated with Primary Aldosteronism.
  3205. Screening for peptide hormone receptor expression in primary aldosteronism
  3206. Factors Associated with Normal Blood Pressure after Surgery To Treat Primary Aldosteronism
  3207. Glucocorticoid remediable aldosteronism. A Northern Ireland experience
  3208. Anxiety and depressive symptoms in patients with primary aldosteronism in a longitudinal study
  3209. Primary Aldosteronism: Rare or Common Condition in Hypertensive Patients and Normotensive Individuals?
  3210. RELATIVE HYPERFILTRATION IN PRIMARY ALDOSTERONISM: OP 146
  3211. Comparing the Prevalence of Primary Aldosteronism in Hypertensive Diabetic and Non-diabetic Patients.
  3212. P-628: Primary Aldosteronism (PA) Prevalence in Italy (PAPY) study: Results of a nationwide survey
  3213. Primary aldosteronism due to right adrenal adenoma case report.
  3214. Primary aldosteronism: renal effects compared with primary hypertension
  3215. Study on significance of serum level of high-sensitivity C-reactive protein in patients with primary aldosteronism
  3216. Prevalence of primary aldosteronism in Chinese patients with resistant hypertension
  3217. Screening for aberrant peptide hormone responsiveness in primary aldosteronism
  3218. Gene polymorphisms related to metabolic and cardiac complications in patients with primary aldosteronism
  3219. Plasma and urine Aldosterone to PRA ratio in the diagnosis of Primary Aldosteronism
  3220. Adrenal venous sampling in the differential diagnosis of primary aldosteronism
  3221. THE KIDNEY AS TARGET ORGAN IN PRIMARY ALDOSTERONISM: 4B. 7
  3222. Analysis of left ventricular hypertrophy in patients with unilateral and bilateral primary aldosteronism
  3223. Primary aldosteronism screening: What is the Aldosterone: renin test?
  3224. Simultaneous presentation of Brugada syndrome and primary aldosteronism
  3225. INCREASED DIAGNOSIS OF PRIMARY ALDOSTERONISM, INCLUDING SURGICALLY CORRECTABLE FORMS, IN CENTERS FROM FIVE CONTINENTS: P2. 102
  3226. Predictors for cure and normotension after adrenalectomy for primary aldosteronism
  3227. Metabolic disturbance and cardiovascular events in primary aldosteronism: recent advance.
  3228. IS RELYING ON CT-SCAN FOR SUBTYPING OF PRIMARY ALDOSTERONISM REALLY THAT BAD? A FOLLOW-UP BASED APPROACH: PP. 18.180
  3229. Primary aldosteronism associated with subclinical Cushing syndrome
  3230. Daily profiles of Aldosterone secretion in primary aldosteronism
  3231. Incidence of metabolic disorders in patients with essential hypertension and patients with primary aldosteronism
  3232. Primary aldosteronism due to unilateral adrenal hyperplasia: report of a case and review of the literature
  3233. Audit of adrenal vein sampling for primary aldosteronism
  3234. Adrenal venous sampling in the differential diagnosis of primary aldosteronism
  3235. Cornell product left ventricular hypertrophy in electrocardiogram in patients with primary aldosteronism
  3236. The difficulties in differential diagnosis of primary aldosteronism subtypes in women with strokes at a young age
  3237. Retroperitoneal laparoscopic surgery vs open adrenalectomy for primary aldosteronism [J]
  3238. Usefulness of FDG-PET for detecting primary aldosteronism in patient who have bilateral adrenal incidentaloma
  3239. Aldosterone/plasma renin activity ratio is a sensitive parameter for screening patients with primary aldosteronism
  3240. Retroperitoneal laparoscopic surgery for primary aldosteronism as compared with open adrenalectomy
  3241. A case of The Primary Aldosteronism with Hypokalemic Periodic Paralysis
  3242. Primary Aldosteronism in Diabetic Subjects With Resistant hypertension: Response to Ng et al.
  3243. Human primary aldosteronism; investigation of the mechanism leading to autonomous Aldosterone excess
  3244. Postoperative Outcomes in Patients Undergoing Adrenalectomy for Primary Aldosteronism
  3245. The Diagnosis Value of Plasma Aldosterone/renin Activity Ratio in Primary Aldosteronism [J]
  3246. HUMORAL AND CELL-MEDIATED AUTOIMMUNITY MECHANISMS IN THE PATHOGENESIS OF PRIMARY ALDOSTERONISM: PP. 39.286
  3247. Incidental primary aldosteronism and incidental Cushing’s syndrome
  3248. Comparison of Three Different Doses of ACTH Stimulation During AVS For Primary Aldosteronism
  3249. PREVALENCE OF PRIMARY ALDOSTERONISM IN RESISTANT hypertension AND ITS ASSOCIATION WITH EARLY VASCULAR DAMAGE: PP. 18.197
  3250. Use of the 250mcg short synacthen test to differentiate between patients with primary aldosteronism and essential hypertension
  3251. Pathophysiological significance of CYP11B2 immunohistochemical staining in primary aldosteronism
  3252. PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension: ASSESSMENT OF THE GLOBAL CARDIOVASCULAR RISK AT DIAGNOSIS AND FOLLOW-UP …
  3253. Primary aldosteronism and secondary hyperparathyroidism of the vitamin D deficiency
  3254. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal imaging findings
  3255. Metabolic parameters in patients with primary aldosteronism: relation to snps of the adiponectin gene
  3256. CONCURRENT PRIMARY ALDOSTERONISM AND SUBCLINICAL CORTISOL HYPERSECRETION. A PERSPECTIVE STUDY: PP. 39.278
  3257. Intrathoracic blood volume during laparoscopic adrenectomy for primary aldosteronism under general anesthesia
  3258. Arterial stiffness, intima-media thickness and fibrosis of carotid arteries in patients with primari aldosteronism
  3259. Regulation of Aldosterone synthase expression in normal adrenal and primary aldosteronism
  3260. Adrenal Vein Sampling for Identification of the Subtypes of Primary Aldosteronism: Results on 2635 Cases of the Avis Study
  3261. Significance of Aldosterone/plasma renin activity ratio in diagnosis of primary aldosteronism with ROC curve
  3262. Expressions and significance of two kinds of vascular endothelial growth factors of different origin in adrenocortical lesions of primary aldosteronism
  3263. Sympathetic Overactivity in Hypertensive Patients With Primary Aldosteronism
  3264. Usefulness of the Aldosterone-to-Renin Ratio for Screening Primary Aldosteronism
  3265. Diagnostic evaluation of plasma Aldosterone concentration to plasma renin activity ratio in primary aldosteronism
  3266. Secondary hypertension Caused by Endocrine Disorders Except Primary Aldosteronism and Pheochromocytoma
  3267. A-006 PRIMARY ALDOSTERONISM: CYSTATIN C AND ENDOTHELIAL DYSFUNCTION
  3268. Long-Term Regression of Left Ventricular Hypertrophy Through Inward Remodeling with Specific Treatment of Primary Aldosteronism
  3269. ABNORMALITIES OF THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS IN PRIMARY ALDOSTERONISM: P2. 129
  3270. ADRENALECTOMY IMPROVES COMMON CAROTID INTIMA-MEDIA THICKNESS IN PRIMARY ALDOSTERONISM: PP. 39.290
  3271. BLOOD PRESSURE REDUCTION FOLLOWING ADRENALECTOMY IN PRIMARY ALDOSTERONISM: A RETROSPECTIVE FOLLOW-UP STUDY: PP. 18.174
  3272. Two Case of Primary Aldosteronism Induced by Aldosterone Producing Adrenal Adenoma in a Family.
  3273. Adiponectin gene polymorphisms in primary aldosteronism and their relation to the metabolic syndrome
  3274. Control study of clinical effect in retroperitoneal laparoscopic adrenalectomy and open surgery for primary aldosteronism
  3275. Low detection Rate of Primary Aldosteronism when Screening Among Hypertensive Patients with Ongoing Medication
  3276. Adrenal venous sampling should be performed before adrenalectomy in primary aldosteronism?
  3277. Using plasma renin concentration to screen primary aldosteronism in hypertensive patients and to observe the effect of posture
  3278. Lipoprotein (a) is Elevated in Patients with Renovascular hypertension, but not in Patients with Primary Aldosteronism
  3279. A unique case of recurrent malignant hypertension after removal of an adrenal tumor for primary aldosteronism
  3280. Demonstration of blood pressure-independent diffuse cardiac fibrosis in Primary Aldosteronism-a cardiac MRI study
  3281. … APNEA SYNDROME IN HYPERTENSIVE PATIENTS REFERRED TO A SPECIALIZED OUTPATIENT CLINIC AND ASSOCIATION WITH PRIMARY ALDOSTERONISM …
  3282. New quick cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  3283. Percutaneous Transluminal Adrenal Ablation for Aldosteronism: Report of Initial Three Cases
  3284. ACUTE AORTIC DISSECTION COMPLICATING CLINICAL COURSE OF PRIMARY ALDOSTERONISM DUE TO Aldosterone PRODUCING ADENOMA: P1. 300
  3285. Plasma Aldosterone/renin ratio——a sensitive screening test and parameter for primary aldosteronism
  3286. Primary aldosteronism is very frequent in resistant hypertension and is associated to early renal vascular damage
  3287. The effectiveness on screening for primary aldosteronism in patients with hypertension by using the urinary potassium to (serum potassium)~ 2 ratio
  3288. Salivary Aldosterone to cortisol ratio: Potential screening tool for primary aldosteronism
  3289. A Case of Primary Aldosteronism due to Remnant Adenoma after Adrenalectomy in Pregnant Woman
  3290. Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone
  3291. Influential factors on the ratio of plasma Aldosterone concentration to plasma renin activity in screening primary aldosteronism
  3292. Renal complications of aldosteronism and diabetes: role of oxidative stress and protective effects of polyphenol extract
  3293. … -TERM CHANGES OF LEFT VENTRICULAR DIASTOLIC FUNCTION AFTER ADRENALECTOMY OR MEDICAL TREATMENT FOR PRIMARY ALDOSTERONISM: PP …
  3294. Pseudo-aldosteronism induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients
  3295. Inhibitory effect of carbamazepine on hypotensive action of spironolactone in primary aldosteronism
  3296. primary aldosteronism and (2) the probable hyper-secretion of renin secondary to hypertrophy of the
  3297. Research advance of plasma Aldosterone concentration to plasma renin activity ratio-the screening index of primary aldosteronism
  3298. P-559: Prevalence of primary aldosteronism among unselected hypertensive patients
  3299. Adrenal Adenoma Removal Improves Glucose Control in A Diabetic Patient with Primary Aldosteronism: A Case Report and Literature Review
  3300. Differential diagnosis of primary aldosteronism by peripheral plasma levels of 18-oxo-cortisol: a noninvasive method with a high specificity
  3301. The sodium to urinary sodium to potassium to urinary potassium (SUSPUP) ratio in primary aldosteronism
  3302. Long-term changes of left ventricular (LV) structure and function after adrenalectomy or medical treatment for primary aldosteronism
  3303. EFFECTS OF FEMALE SEX HORMONES AND CONTRACEPTIVE PILL ON THE DIAGNOSTIC WORK-UP FOR PRIMARY ALDOSTERONISM: PP. 18.181
  3304. SUBTLE HYPERPARATHYROIDISM: A NOVEL FEATURE OF PRIMARY ALDOSTERONISM THAT IS CORRECTED BY ADRENALECTOMY: PP. 39.272
  3305. Hyper Transcardiac Extraction of Aldosterone Promote Ventricular Remodeling and Cardiac Mass in Patients with Primary Aldosteronism
  3306. SENSITIVITY, SPECIFICITY AND REPRODUCIBILITY OF THE Aldosterone-TO-RENIN-RATIO AS A SCREENING TEST FOR PRIMARY ALDOSTERONISM: PP …
  3307. Assessing the quality of studies on screening primary aldosteronism by using plasma Aldosterone to renin activity ratio
  3308. DIFFERENTIAL DIAGNOSIS OF PRIMARY ALDOSTERONISM SUBTYPES USING ADRENAL VEIN SAMPLING: EVALUATION OF THE GERMANS CONN’S …
  3309. The accuracy of combining Aldosterone to renin ratio and low renin level in diagnosing primary aldosteronism
  3310. INTRA-OPERATIVE CORTISOL ASSAY IMPROVES THE SUCCESS RATE OF ADRENAL VENOUS SAMPLING FOR PRIMARY ALDOSTERONISM: PP. 18.198
  3311. The effectiveness on screening for primary aldosteronism in patients with hypertension by using the urinary potassium to (serum potassium) ratio.
  3312. Long-term modifications in left ventricular structure and function after adrenalectomy or medical treatment in patients with primary aldosteronism
  3313. Aldosterone elevation during the luteal phase of the menstrual cycle may suggest primary aldosteronism in hypertensive women
  3314. P-534: Predictive value of the Aldosterone-renin ratio in screening for primary aldosteronism
  3315. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism following adrenalectomy
  3316. Sporadic solitary Aldosterone-and cortisol-cosecreting adenomas: a subtype of primary aldosteronism
  3317. 49 HYPOZINCEMIA AND OXIDATIVE STRESS IN RATS WITH CHRONIC ALDOSTERONISM.
  3318. Cardiovascular effects of unilateral adrenalectomy are superior to those of Aldosterone antagonist treatment in primary aldosteronism
  3319. GENETIC PROFILING OF OMENTAL ADIPOSE TISSUE IN PATIENTS WITH PRIMARY ALDOSTERONISM AND CANDIDATE GENES FOR CARDIOMETABOLIC …
  3320. Simultaneous occurrence of hypokalemic periodic paralysis and rhabdomyolysis as complications of hypokalemia with primary aldosteronism
  3321. Aldosterone REDUCTION BY UNILATERAL ADRENALECTOMY REDUCES SALT APPETITE IN PATIENTS CURED OF PRIMARY ALDOSTERONISM: LB2. 4
  3322. Aldosterone-PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM ARE CHARACTERISED BY UNDER-EXPRESSION OF THE TWIK …
  3323. 18-Hydroxycorticosterone, 18-hydroxycortisol and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes
  3324. … Adrenal Vein Sampling International Study (Avis) on Use and Interpretation of Adrenal Vein Sampling for Differentiating the Major Subtypes of Primary Aldosteronism …
  3325. In primary aldosteronism, plasma Aldosterone concentration is an independent risk factor for albuminuria, and the higher baseline urinary albumin excretion predicts …
  3326. Mutations in the KCNJ5 Gene Imply a Higher Lateralization Index at Adrenal Vein Sampling for Primary Aldosteronism
  3327. Oxidative Stress, Mitochondrial Permeability Pore Opening and Cardiac Hypertrophy With Fibrosis in Aldosteronism: Response to Supplemental Zinc
  3328. SHOULD MANAGEMENT OF PRIMARY ALDOSTERONISM BE BASED ON ADRENAL VEIN SAMPLING OR ADRENAL CT-SCAN? A RETROSPECTIVE STUDY OF …
  3329. Anger and anxiety in patients with primary aldosteronism treated with amiloride hydrochloride or spironolactone or adrenalectomy
  3330. … DOES NOT AFFECT ADRENAL CORTISOL AND CHROMOGRANIN A RELEASE: IMPLICATIONS FOR THE DIAGNOSIS OF PRIMARY ALDOSTERONISM: PP …
  3331. … Aldosterone EFFECTS OF Aldosterone SYNTHASE INHIBITION VS. MINERALOCORTICOID BLOCKADE IN PATIENTS WITH PRIMARY ALDOSTERONISM …
  3332. 201 CYTOSOLIC CALCIUM AND ZINC IN CARDIOMYOCYTES OF RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE AND AMLODIPINE …
  3333. P-567: Prevalence of primary aldosteronism (PA) nationwide in Italy in newly diagnosed hypertensive patients
  3334. 636 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3335. P-592: Active renin concentration and the Aldosterone/renin ratio in screening primary aldosteronism
  3336. 7.20 Adiponectin Gene Variants in the Metabolic Syndrome of Patients with Primary Aldosteronism and Essential hypertension
  3337. Aldosterone regulation for 18 years in a case of primary aldosteronism
  3338. OR-12: No association between primary aldosteronism and two CYP11B2 polymorphisms in a well-characterized Australian sample
  3339. P-640: Prevalence of primary aldosteronism among hypertensive patients
  3340. P-598: Prevalence of primary aldosteronism among hypertensive patients
  3341. 73 BONE LOSS IN ALDOSTERONISM. RESCUE WITH HYDROCHLOROTHIAZIDE AND SPIRONOLACTONE.
  3342. 53 CYTOSOLIC AND MITOCHONDRIAL CALCIUM IN RAT CARDIOMYOCYTES: RESPONSE TO ALDOSTERONISM AND COTREATMENT WITH …
  3343. 642 INFLUENCE OF AGING ON THE SCREENING TEST OF PRIMARY ALDOSTERONISM DIAGNOSIS
  3344. 657 RE-EVALUATION OF THE SALINE INFUSION TEST FOR PRIMARY ALDOSTERONISM: DURATION, THE SUBTYPE CLASSIFICATION AND CUT-OFF LIMITS …
  3345. AS-248: Primary Aldosteronism: Treated by Superselecive Adrenal Arterial Embolization
  3346. 84 Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure 88 Primary aldosteronism: cardiovascular, renal and metabolic implications
  3347. 46 URINARY ZINC LOSSES IN RATS WITH ALDOSTERONISM: PREVENTION BY ACETAZOLAMIDE.
  3348. 21 PRIMARY ALDOSTERONISM IN A PATIENT WITH IDIOPATHIC INTRACRANIAL hypertension
  3349. P-568: Apparent prevalence of primary aldosteronism in a referral practice: a retrospective study
  3350. 7. Young W, Stanson A, Thompson G, et al. Role for adrenal ve-nous sampling in primary aldosteronism. Surgery 2004; 136: 1227–1235. 8. Kahn S, Angle J. Adrenal …
  3351. U-004 PRIMARY ALDOSTERONISM: CHANGES IN CYSTATIN C-BASED KIDNEY FILTRATION, PROTEINURIA, AND RENAL DUPLEX INDICES WITH TREATMENT
  3352. 9.13 Metabolic Alterations in Patients with Primary Aldosteronism (PA): Role of Adipokines
  3353. 641 EFFECT OF AGING ON VARIOUS CONFIRMATORY TESTS AND ADRENAL VEIN SAMPLING FOR PRIMARY ALDOSTERONISM DIAGNOSIS
  3354. 5.1 Adiponectin and Insulin Sensitivity in Primary Aldosteronism
  3355. 57 OBSTRUCTIVE SLEEP APNEA IS PREVALENT IN PRIMARY ALDOSTERONISM: 3D MAGNETIC RESONANCE IMAGING TO STUDY IMPROVEMENT WITH …
  3356. 166 ZINC DYSHOMEOSTASIS IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE.
  3357. P-667: Circadian rythm of blood pressure in patients with primary aldosteronism compared with essential hypertension patients
  3358. 178 ZINC DYSHOMEOSTASIS IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE.
  3359. CLINICAL CHARACTERISES OF 224 CASES WITH NORMOKALEMIC AND HYPERTENSIVE PRIMARY ALDOSTERONISM
  3360. P-611: The application of the Aldosterone/PRA ratio (ARR) in the diagnosis of primary aldosteronism
  3361. 71 CALCIUM AND MAGNESIUM HOMEOSTASIS IN ALDOSTERONISM: RESPONSE TO DIURETICS
  3362. 44 ONGOING KIDNEY IMPAIRMENT IN JAPANESE PATIENTS WITH PRIMARY ALDOSTERONISM: PREDICTORS OF NEW-ONSET CHRONIC KIDNEY DISEASE …
  3363. 51 STRUCTURAL REMODELING OF THE HEART IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE OR DIETARY ZINC SUPPLEMENT.
  3364. … (NP-59) uptake per unit volume of adrenal adenoma for differentiation between patients with Cushing’s syndrome, primary aldosteronism, and non-hypersecreting …
  3365. 6.4 Cardiac Modifications in Patients with Primary Aldosteronism Before and After Specific Treatment
  3366. P-593: Drug effects on Aldosterone/plasma renin activity ratio in primary aldosteronism
  3367. 2.30 Diagnostic workup of primary aldosteronism
  3368. P-627: Does the availability of Adrenal Vein Sampling (AVS) affect the diagnosis of the adrenocortical pathology underlying Primary Aldosteronism (PA)? Results of …
  3369. A-004 ENDOTHELIAL PROGENITOR CELLS IN PRIMARY ALDOSTERONISM: A BIOMARKER OF SEVERITY FOR Aldosterone VASCULOPATHY AND …
  3370. P-601: Long-term management of hypertensive patients with primary aldosteronism
  3371. Insulin sensitivity in 32 patients with primary aldosteronism
  3372. … ACID-SENSITIVE K+ CHANNEL 2 (TASK-2) GENE IS A HALLMARK OF Aldosterone PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM …
  3373. … EVALUATION OF STRUCTURAL AND FUNCTIONAL CHANGES IN THE HEART AND LARGE ARTERIES IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3374. Serum 18 hydroxycortisol identifies aldosteronoma in the differential diagnosis of primary aldosteronism
  3375. 6.12 Long-Term Effects of Pharmacological and Surgical Treatment on Cardiovascular Parameters in Patients with Primary Aldosteronism
  3376. P-560: Low prevelence of primary aldosteronism in hypertensive diabetics
  3377. 4.26 Left Ventricular Mass Appropriateness in Patients with Primary Aldosteronism
  3378. U-002 DISSECTED AORTIC ANEURYSM: UNCOMMON INITIAL PRESENTATION OF PRIMARY ALDOSTERONISM
  3379. 5.4 Vascular Remodelling in Carotid Arteries of Patients with Primary Aldosteronism by Backscatter Signal and Peripheral Vascular Stiffness Analysis
  3380. P-674: Adrenal catecholamines venous sampling in primary aldosteronism
  3381. OR-13: Serum inflammatory cytokines in patients with primary aldosteronism
  3382. P-532: Identification of hypertensive patients with normokaliemic primary aldosteronism
  3383. 44 SKELETAL MUSCLE ATROPHY, BONE LOSS, AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3384. A-005 MYOCARDIAL ULTRASOUND TISSUE CHARACTERIZATION IN PATIENTSWITH PRIMARY ALDOSTERONISM
  3385. P. 097 ADRENALECTOMY IS MORE EFFECTIVE THAN SPIRONOLACTONE IN REDUCING ARTERIAL STIFFNESS IN PRIMARY ALDOSTERONISM☆
  3386. 637 PREVALENCE OF PRIMARY ALDOSTERONISM IN HYPERTENSIVE SUBJECTS WITH HYPERGLYCEMIA
  3387. 47 SPIRONOLACTONE IN THE TREATMENT OF HYPOZINCEMIA FOUND IN RATS WITH ALDOSTERONISM.
  3388. Characteristics of 330 cases with primary aldosteronism
  3389. 45 SPIRONOLACTONE IN THE PREVENTION OF SKELETAL MUSCLE ATROPHY AND BONE LOSS IN RATS WITH ALDOSTERONISM.
  3390. 18-Oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism
  3391. 5.6 Assessment of the Selectivity and Lateralisation Index for Adrenal Vein Sampling in Primary Aldosteronism
  3392. 12.16 Primary Aldosteronism and Endothelial Progenitor Cell Bioavailability
  3393. 6.16 Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism
  3394. Use of the 250 mcg short synacthen test in the diagnosis of primary aldosteronism
  3395. 6.2 Comparison of Three Different Doses of ACTH Stimulation During Adrenal Vein Sampling (AVS) in the Work-Up of Primary Aldosteronism
  3396. P-600: Primary aldosteronism with and without hypertensive urgency: Clinical and biochemical features
  3397. 367 ALDOSTERONISM: A PROINFLAMMATORY PHENOTYPE SECONDARY TO CALCIUM OVERLOAD
  3398. … HYPERPARATHYROIDISM AND THE RECOVERY OF FALLEN EXTRACELLULAR CALCIUM AND MAGNESIUM IN RATS WITH CHRONIC ALDOSTERONISM.
  3399. THE COMPLEMENT C1Q TUMOUR NECROSIS FACTOR-RELATED PROTEIN 1 LEVEL IN PATIENTS WITH SLEEP APNOEA AND PRIMARY ALDOSTERONISM
  3400. P-358: Cardiovascular and non-cardiovascular events in patients with primary aldosteronism
  3401. 4 PARATHYROIDECTOMY PREVENTS CALCIUM LOADING AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3402. 624 A NEED TO RE-FOCUS ON PRECISION OF SCREENING AND DIAGNOSTIC TESTS IN PRIMARY ALDOSTERONISM
  3403. 4.6 QT Interval in Patients with Primary Aldosteronism and Low-Renin Essential hypertension
  3404. Clinical nursing experience of 8 patients with primary aldosteronism
  3405. Report of 27 cases of primary aldosteronism
  3406. 1.7 Carotid Intima-Media Thickness and Prevalence of Plaques in Patients with Primary Aldosteronism and With Essential hypertension
  3407. 131 PARATHYROIDECTOMY PREVENTS CALCIUM LOADING AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3408. 70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM
  3409. Adrenal vein sampling in 22 patients with primary aldosteronism
  3410. 279 SECONDARY HYPERPARATHYROIDISM, INTRACELLULAR CALCIUM OVERLOADING, AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3411. P-562: Atrial and brain natriuretic peptides as markers for afterload and volume retention in primary aldosteronism
  3412. 54 CARDIOMYOCYTE EXPRESSION OF METALLOTHIONEIN AND ZINC TRANSPORTER 1 IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE …
  3413. … including saliva-type amylase-secreting secondary parathyroid hyperplasia (SPTH) and insulinoma with adrenal adenoma (AA) showing primary aldosteronism
  3414. O-19: Primary aldosteronism in a referral hypertension center
  3415. P-164: Primary aldosteronism may be associated with albuminuria and hyperfiltration
  3416. Q-008 THE METABOLIC SYNDROME DOES DIFFERENCES IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3417. 643 COSYNTROPIN STIMULATION TEST IS USEFUL IN DISTINGUISHING UNILATERAL FROM BILATERAL PRIMARY ALDOSTERONISM
  3418. A-008 THE ASSOCIATION OF HYPERFILTRATION AND LEFT VENTRICULAR MASS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3419. 652 LONG-TERM TREATEMENT WITH Aldosterone BLOCKER CAN CAUSE SPONTANEOUSLY REMISSION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3420. 1090 INTEGRATING GENETICS AND GENOMICS IN PRIMARY ALDOSTERONISM
  3421. … Aldosterone EXCESS BETWEEN BASELINE AND ACTH STIMULATION IN THE ADRENAL VEIN SAMPLING OF PATIENTS WITH PRIMARY ALDOSTERONISM
  3422. 632 SENSITIVITY, SPECIFICITY AND REPRODUCIBILITY OF THE Aldosterone-TO-RENIN-RATIO AS A SCREENING TEST FOR PRIMARY ALDOSTERONISM
  3423. P-664: The captopril test for the screening of primary aldosteronism
  3424. P-497: Biochemical profile of severe obstructive sleep apnea can mimic primary aldosteronism
  3425. … SODIUM DIVIDED BY (SERUM POTASSIUM) 2 TO URINARY POTASSIUM (SUSPPUP RATIO) AS A SCREENING TOOL FOR PRIMARY ALDOSTERONISM: PP …
  3426. U-007 THE INFLUENCE OF HYPOKALEMIA ON VASCULAR STIFFNESS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3427. 648 ANALYSIS OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3428. 656 COMPARISON OF VARIOUS CONFIRMATORY TESTS FOR FINAL DIAGNOSIS OF PRIMARY ALDOSTERONISM
  3429. 646 GUIDELINES MAY IMPROVE CLINICAL PRACTICE FOR DIAGNOSIS OF PRIMARY ALDOSTERONISM IN JAPAN
  3430. 42 COST-EFFECTIVE AND FEASIBLE SCREENING OF PRIMARY ALDOSTERONISM WITH POTASSIUM EXCRETION CAPACITY/BODY MASS INDEX RATIO
  3431. … EFFECT AFTER TRANSUMBILICAL LAPAROSCOPIC SINGLE-SITE ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM: A MATCHED CASE …
  3432. P-344: Unusual phenotype in a family affected by glucocorticoid remediable aldosteronism
  3433. … ASSOCIATED WITH PHYSIOLOGICAL INTERMEDIATE PHENOTYPES IN PATIENTS WITH ESSENTIAL hypertension, BUT NOT PRIMARY ALDOSTERONISM
  3434. P-333: Primary aldosteronism and cushing’s syndrome treated by CT-guided radiofrequency thermal ablation in SR-Adenomas
  3435. … OF Aldosterone AND CORTISOL BY HPLC-TANDEM MASS SPECTROMETRY: COULD THIS IMPROVE DECISION MAKING IN PRIMARY ALDOSTERONISM?
  3436. 992 Proceedings ofthe Royal Society ofMedicine mation on everything from aldosteronism to Cushing’s disease, and from the minutia of the history of chemistry of the …
  3437. 659 USEFULNESS OF NEW QUICK CORTISOL ASSAY DURING ADRENAL VEIN SAMPLING IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3438. 647 DIURNAL VARIATION OF ADRENAL VENOUS Aldosterone CONCENTRATION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3439. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study
  3440. Primary aldosteronism: practical approach to diagnosis and management
  3441. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice
  3442. Diagnosis and management of primary aldosteronism: an updated review
  3443. Primary Aldosteronism and ARMC5 Variants
  3444. Diagnosis and management of primary aldosteronism
  3445. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline
  3446. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment
  3447. An update on novel mechanisms of primary aldosteronism
  3448. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism
  3449. Long term outcome of aldosteronism after target treatments
  3450. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
  3451. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe
  3452. Update in primary aldosteronism
  3453. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
  3454. CACNA1H mutations are associated with different forms of primary aldosteronism
  3455. Age-related autonomous aldosteronism
  3456. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension
  3457. Systematic review of surgery and outcomes in patients with primary aldosteronism
  3458. Primary aldosteronism: the next five years
  3459. Continuum of renin-independent aldosteronism in normotension
  3460. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis
  3461. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism
  3462. Old and new concepts in the molecular pathogenesis of primary aldosteronism
  3463. Management of hypertension in primary aldosteronism
  3464. Laboratory challenges in primary aldosteronism screening and diagnosis
  3465. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan
  3466. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study
  3467. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes
  3468. Nuclear imaging in the diagnosis of primary aldosteronism
  3469. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy
  3470. Primary aldosteronism: emerging trends
  3471. Risk of fracture in primary aldosteronism: a population‐based cohort study
  3472. Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations
  3473. Case detection and diagnosis of primary aldosteronism–the consensus of Taiwan Society of Aldosteronism
  3474. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study
  3475. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism
  3476. Progress in the management of primary aldosteronism
  3477. Outcome of surgical treatment of primary aldosteronism
  3478. SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook
  3479. Is primary aldosteronism still largely unrecognized?
  3480. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney
  3481. Primary aldosteronism: challenges in diagnosis and management
  3482. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 2: first diagnostic steps
  3483. Update in diagnosis and management of primary aldosteronism
  3484. Bone and mineral metabolism in patients with primary aldosteronism
  3485. Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism
  3486. Subtyping of patients with primary aldosteronism: an update
  3487. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol
  3488. Renal outcomes in medically and surgically treated primary aldosteronism
  3489. Treatment of primary aldosteronism and organ protection
  3490. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an …
  3491. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly
  3492. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
  3493. Primary aldosteronism and salt
  3494. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study
  3495. Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms
  3496. Oxidative stress in patients affected by primary aldosteronism
  3497. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years
  3498. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism
  3499. Role of KCNJ5 in familial and sporadic primary aldosteronism
  3500. Primary aldosteronism: diagnosis and management
  3501. Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited
  3502. Primary aldosteronism and pregnancy
  3503. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system
  3504. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing
  3505. Primary aldosteronism as a cause of secondary osteoporosis
  3506. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling
  3507. Somatic and germline CACNA1D calcium channel mutations in Aldosterone-producing adenomas and primary aldosteronism
  3508. Recent developments in primary aldosteronism
  3509. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism
  3510. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism
  3511. Potential effects of age on screening for primary aldosteronism
  3512. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term
  3513. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial
  3514. Prevalence of primary aldosteronism in primary care: a cross-sectional study
  3515. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism
  3516. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study
  3517. Adrenal histopathology in primary aldosteronism: is it time for a change?
  3518. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment
  3519. The time has come for systematic screening for primary aldosteronism in all hypertensives
  3520. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism
  3521. Primary aldosteronism: a common cause of resistant hypertension
  3522. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry
  3523. Can screening and confirmatory testing in the management of patients with primary aldosteronism be improved?
  3524. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism
  3525. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea
  3526. Somatic and inherited mutations in primary aldosteronism
  3527. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry
  3528. Glucocorticoid-remediable aldosteronism
  3529. Primary aldosteronism and obstructive sleep apnea: is this a bidirectional relationship?
  3530. Genetic and histopathologic intertumor heterogeneity in primary aldosteronism
  3531. Glucose metabolism in primary aldosteronism
  3532. Development and validation of subtype prediction scores for the workup of primary aldosteronism
  3533. Mouse models of primary aldosteronism: from physiology to pathophysiology
  3534. The influence of aging on the diagnosis of primary aldosteronism
  3535. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China
  3536. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism
  3537. Role of ACTH and other hormones in the regulation of Aldosterone production in primary aldosteronism
  3538. Primary aldosteronism as a risk factor for vertebral fracture
  3539. Update in adrenal venous sampling for primary aldosteronism
  3540. … Efficacy of Adrenal Vein Sampling and Imaging Findings in Predicting Clinical Outcomes Following Unilateral Adrenalectomy for Primary Aldosteronism
  3541. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism
  3542. Health-related quality of life and mental health in primary aldosteronism: a systematic review
  3543. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases
  3544. Mass spectrometry–based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism
  3545. Approach to the surgical management of primary aldosteronism
  3546. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism
  3547. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes
  3548. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000–2015)
  3549. Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?
  3550. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism
  3551. Disordered CYP11B2 expression in primary aldosteronism
  3552. Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy
  3553. An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism
  3554. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism
  3555. Subtype diagnosis of primary aldosteronism: is adrenal vein sampling always necessary?
  3556. Unanswered questions in the genetic basis of primary aldosteronism
  3557. Immunohistochemistry of Aldosterone synthase leads the way to the pathogenesis of primary aldosteronism
  3558. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism
  3559. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions
  3560. New advances in the diagnostic workup of primary aldosteronism
  3561. An individualized approach to the evaluation and management of primary aldosteronism
  3562. Test characteristics of the Aldosterone-to-renin ratio as a screening test for primary aldosteronism
  3563. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
  3564. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism
  3565. Anxiety, depression, and impaired quality of life in primary aldosteronism: why we shouldn’t ignore it!
  3566. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension
  3567. Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism
  3568. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients
  3569. Evaluation of the saline infusion test and the captopril challenge test in Chinese patients with primary aldosteronism
  3570. Primary aldosteronism and pregnancy
  3571. Voltage-gated calcium channels in the human adrenal and primary aldosteronism
  3572. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study
  3573. Primary aldosteronism and impaired natriuresis in mice underexpressing TGFβ1
  3574. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment
  3575. Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis
  3576. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis
  3577. Effects of treating primary aldosteronism on renal function
  3578. Diagnostic accuracy of Aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism
  3579. Local control of Aldosterone production and primary aldosteronism
  3580. Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness
  3581. hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis
  3582. A subtype prediction score for primary aldosteronism
  3583. Risk of sepsis in patients with primary aldosteronism
  3584. Primary aldosteronism in the primary care setting
  3585. Comparative genomics and transcriptome profiling in primary aldosteronism
  3586. Basal and post-ACTH Aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism
  3587. Autoimmune mechanisms activating the angiotensin AT1 receptor in’primary’aldosteronism
  3588. Optimum position of left adrenal vein sampling for subtype diagnosis in primary aldosteronism
  3589. Changes in the clinical manifestations of primary aldosteronism
  3590. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies
  3591. Clinical management of primary aldosteronism
  3592. Clinical management and outcomes of adrenal hemorrhage following adrenal vein sampling in primary aldosteronism
  3593. Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism
  3594. … of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of Aldosterone in primary aldosteronism
  3595. Does contralateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study
  3596. Overview of the genetic determinants of primary aldosteronism
  3597. Dissecting the molecular pathways of primary aldosteronism
  3598. Primary aldosteronism: functional histopathology and long‐term follow‐up after unilateral adrenalectomy
  3599. Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism?
  3600. Outcomes of drug-based and surgical treatments for primary aldosteronism
  3601. The molecular basis of primary aldosteronism: from chimeric gene to channelopathy
  3602. … mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism
  3603. Primary aldosteronism as a public health issue
  3604. Development of a novel nomogram to predict hypertension cure after laparoscopic adrenalectomy in patients with primary aldosteronism
  3605. Does ACTH improve the diagnostic performance of adrenal vein sampling for subtyping primary aldosteronism?
  3606. In primary aldosteronism, mineralocorticoids influence exosomal sodium-chloride cotransporter abundance
  3607. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone
  3608. Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: pro side of the argument
  3609. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan
  3610. Epicardial fat thickness and primary aldosteronism
  3611. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism
  3612. Idiopathic intracranial hypertension associated with either primary or secondary aldosteronism
  3613. A novel phenotype of familial hyperaldosteronism type III: concurrence of aldosteronism and Cushing’s syndrome
  3614. Genetic characterization of GnRH/LH-responsive primary aldosteronism
  3615. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta‐analysis
  3616. Defining contralateral adrenal suppression in primary aldosteronism: implications for diagnosis and outcome
  3617. KCNJ5 Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism
  3618. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism
  3619. Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations.
  3620. Diagnosing unilateral primary aldosteronism–comparison of a clinical prediction score, computed tomography and adrenal venous sampling
  3621. Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: con side of the argument
  3622. Quantitative value of Aldosterone‐renin ratio for detection of Aldosterone‐producing adenoma: the Aldosterone‐Renin Ratio for Primary Aldosteronism (AQUARR) …
  3623. Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism
  3624. Clinical characteristics of Aldosterone-and cortisol-coproducing adrenal adenoma in primary aldosteronism
  3625. Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (The SPARTACUS Trial) a critique
  3626. Impact of new quick gold nanoparticle-based cortisol assay during adrenal vein sampling for primary aldosteronism
  3627. Correlation between lateralization index of adrenal venous sampling and standardized outcome in primary aldosteronism
  3628. Primary aldosteronism associated with subclinical Cushing syndrome
  3629. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism
  3630. Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay
  3631. Primary aldosteronism: Seismic shifts
  3632. Adrenal venous sampling for primary aldosteronism: laboratory medicine best practice
  3633. Primary aldosteronism in hypertensive patients: clinical implications and target therapy
  3634. Potassium channels related to primary aldosteronism: Expression similarities and differences between human and rat adrenals
  3635. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism
  3636. Importance of contralateral Aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism
  3637. Is it time to screen all patients with hypertension for primary aldosteronism?
  3638. Inflammatory markers in primary aldosteronism
  3639. Cardiac dysfunction in association with increased inflammatory markers in primary aldosteronism
  3640. … -specific monoclonal antibodies against 3β-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism
  3641. Age-related cutoffs of plasma Aldosterone/renin concentration for primary aldosteronism screening
  3642. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery
  3643. Primary aldosteronism and thyroid disorders in atrial fibrillation: A Swedish nationwide case–control study
  3644. The impact of Connshing’s syndrome-mild cortisol excess in primary aldosteronism drives diabetes risk
  3645. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?
  3646. Medical versus surgical treatment of primary aldosteronism
  3647. Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale …
  3648. Genetics of primary aldosteronism
  3649. The latest developments of functional molecular imaging in the diagnosis of primary aldosteronism
  3650. High‐probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false‐positive diagnoses
  3651. Prevelence of primary aldosteronism in an urban hypertensive population
  3652. Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity
  3653. Cardiovascular risk markers in patients with primary aldosteronism: a systematic review and meta-analysis of literature studies
  3654. A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable
  3655. Plasma Aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism
  3656. Contralateral suppression of Aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism
  3657. Clinicopathologic correlates of primary aldosteronism
  3658. Primary aldosteronism and cardiovascular risk, before and after treatment
  3659. Sequential comparison of Aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism
  3660. Role of adrenal vein sampling in primary aldosteronism: impact of imaging, localization, and age
  3661. Sodium infusion test for diagnosis of primary aldosteronism in chinese population
  3662. … somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism
  3663. Comparisons of microvascular and macrovascular changes in aldosteronism-related hypertension and essential hypertension
  3664. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by Aldosterone excess
  3665. Primary aldosteronism: New answers, new questions
  3666. Genetic disorders in primary aldosteronism—familial and somatic
  3667. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?
  3668. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension
  3669. Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies
  3670. The occurrence of apparent bilateral Aldosterone suppression in adrenal vein sampling for primary aldosteronism
  3671. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism
  3672. A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism
  3673. Subtyping of primary aldosteronism with adrenal vein sampling: hormone-and side-specific effects of cosyntropin and metoclopramide
  3674. Diagnosis of primary aldosteronism in the hypertension specialist centers in Italy: a national survey
  3675. The renaissance of primary aldosteronism: what has it taught us?
  3676. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation—long-term results and recurrence rate
  3677. Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy
  3678. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography–tandem mass spectrometry determinations of plasma Aldosterone concentration
  3679. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism
  3680. A Renin-ssance in Primary Aldosteronism Testing: Obstacles and Opportunities for Screening, Diagnosis, and Management
  3681. Current pattern of primary aldosteronism diagnosis: Delayed and complicated
  3682. Assay characteristics influence the Aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn’s registry
  3683. New insights into Aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5
  3684. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism
  3685. Human red blood cells alterations in primary aldosteronism
  3686. Adrenal vein sampling in primary aldosteronism: concordance of simultaneous vs sequential sampling
  3687. Adrenal venous sampling in patients with positive screening but negative confirmatory testing for primary aldosteronism
  3688. Primary aldosteronism and low-renin hypertension: a continuum?
  3689. Suppression of Aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism
  3690. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal Aldosterone production can be used in clinical …
  3691. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography
  3692. Aldosterone to active renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading
  3693. Dietary salt intake is a determinant of cardiac changes after treatment of primary aldosteronism: a prospective study
  3694. Macrolides for KCNJ5–mutated Aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism
  3695. obesity and the diagnostic accuracy for primary aldosteronism
  3696. Unadjusted plasma renin activity as a “first‐look” test to decide upon further investigations for primary aldosteronism
  3697. Preoperative masked renal damage in J apanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after …
  3698. Somatic KCNJ5 mutation occurring early in adrenal development may cause a novel form of juvenile primary aldosteronism
  3699. Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization
  3700. Prevalence of primary aldosteronism in hypertensive subjects with hyperglycemia
  3701. Diagnosis and treatment of unilateral forms of primary aldosteronism
  3702. Mineralocorticoid receptor antagonists in primary aldosteronism
  3703. Post-saline infusion test Aldosterone levels indicate severity and outcome in primary aldosteronism
  3704. Effect of Aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism
  3705. Mineralocorticoid receptor antagonists and clinical outcomes in primary aldosteronism: as good as surgery?
  3706. A new clinical prediction criterion accurately determines a subset of patients with bilateral primary aldosteronism before adrenal venous sampling
  3707. Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein
  3708. Minireview: potassium channels and Aldosterone dysregulation: is primary aldosteronism a potassium channelopathy?
  3709. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage
  3710. Combination of LC–MS/MS Aldosterone and automated direct renin in screening for primary aldosteronism
  3711. Reversible heart rhythm complexity impairment in patients with primary aldosteronism
  3712. Primary aldosteronism and cerebrovascular diseases
  3713. The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism
  3714. Subclinical primary aldosteronism
  3715. Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling
  3716. Impact of Aldosterone-producing cell clusters on diagnostic discrepancies in primary aldosteronism
  3717. … of strict criteria in adrenal venous sampling increases the proportion of missed patients with unilateral disease who benefit from surgery for primary aldosteronism
  3718. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism
  3719. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism
  3720. Risk of ischemic stroke in primary aldosteronism patients
  3721. Does concomitant autonomous adrenal cortisol overproduction have the potential to confound the interpretation of adrenal venous sampling in primary aldosteronism …
  3722. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant …
  3723. Regulation of Aldosterone production by ion channels: from basal secretion to primary aldosteronism
  3724. Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1–24) ACTH may increase apparent failure rate
  3725. Cost-effectiveness analysis of the diagnosis and treatment of primary aldosteronism in Japan
  3726. Aldosterone excess may inhibit insulin secretion: a comparative study on glucose metabolism pre-and post-adrenalectomy in patients with primary aldosteronism
  3727. An adverse pregnancy-associated outcome due to overlooked primary aldosteronism
  3728. Myocardial ultrasound tissue characterization of patients with primary aldosteronism
  3729. Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function
  3730. Parathyroid gland function in primary aldosteronism
  3731. Renal resistive index predicts postoperative blood pressure outcome in primary aldosteronism
  3732. Genetics of primary aldosteronism
  3733. Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes
  3734. Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism
  3735. Factors affecting parathyroid hormone levels in different types of primary aldosteronism
  3736. A short review of primary aldosteronism in a question and answer fashion
  3737. Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism?
  3738. Immunohistochemistry of the adrenal in primary aldosteronism
  3739. The subtyping of primary aldosteronism by adrenal vein sampling: sequential blood sampling causes factitious lateralization
  3740. Prevalence of primary aldosteronism without hypertension in the general population: results in Shika study
  3741. How to escape from primary aldosteronism? News and views on an adrenal disorder of salt retention
  3742. Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism
  3743. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China
  3744. Novel approach to establishing an Aldosterone: renin ratio cutoff for primary aldosteronism
  3745. Prevalence of malignancies in patients with primary aldosteronism
  3746. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era
  3747. Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay system
  3748. Genetic and potential autoimmune triggers of primary aldosteronism
  3749. … of peripheral blood mononuclear cells reveal transcriptional signatures as novel biomarkers of cardiac remodeling in rats with aldosteronism and hypertensive heart …
  3750. Clinical Practice Guideline for Management of Primary Aldosteronism: What is New in the 2016 Update?
  3751. Dual adrenal venous phase contrast-enhanced MDCT for visualization of right adrenal veins in patients with primary aldosteronism
  3752. The potential of ACTH in the genesis of primary aldosteronism
  3753. Characteristics predicting clinical improvement and cure following laparoscopic adrenalectomy for primary aldosteronism in a large cohort
  3754. Primary aldosteronism and potassium channel mutations
  3755. Role of endogenous ACTH on circadian Aldosterone rhythm in patients with primary aldosteronism
  3756. Liddle syndrome misdiagnosed as primary aldosteronism resulting from a novel frameshift mutation of SCNN1B
  3757. Subtype diagnosis of primary aldosteronism: Approach to different clinical scenarios
  3758. Circadian hemodynamic characteristics in hypertensive patients with primary aldosteronism
  3759. Sleep quality in patients with primary aldosteronism
  3760. Primary aldosteronism and its various clinical scenarios
  3761. Prevalence of primary aldosteronism among patients with type 2 diabetes
  3762. Optimization of left adrenal vein sampling in primary aldosteronism: coping with asymmetrical cortisol secretion
  3763. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: genetic diagnosis of primary aldosteronism
  3764. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score
  3765. Adrenal vein sampling in primary aldosteronism: sensitivity and specificity of basal adrenal vein to peripheral vein cortisol and Aldosterone ratios to confirm …
  3766. Medication adherence during laboratory workup for primary aldosteronism: pilot study
  3767. Saline Infusion Test highly associated with the incidence of cardio-and cerebrovascular events in primary aldosteronism
  3768. Role of adrenal vein sampling in primary aldosteronism: the M onash H ealth experience
  3769. Psychological symptoms and well-being after treatment for primary aldosteronism
  3770. Shortened saline infusion test for subtype prediction in primary aldosteronism
  3771. Right adrenal venography findings correlated with C-arm CT for selection during C-arm CT-assisted adrenal vein sampling in primary aldosteronism
  3772. Diagnosis of primary aldosteronism
  3773. Eplerenone use in primary aldosteronism during pregnancy
  3774. Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications
  3775. Association of primary aldosteronism with chronic thyroiditis
  3776. Association of the variations in the HSD3β gene with primary aldosteronism
  3777. Screening for primary aldosteronism in a primary care unit
  3778. Novel genes in primary aldosteronism
  3779. Cost‐Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant hypertension
  3780. Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre
  3781. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism
  3782. Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders
  3783. Worsening of lipid metabolism after successful treatment of primary aldosteronism
  3784. Case detection in primary aldosteronism: high-diagnostic value of the Aldosterone-to-renin ratio when performed under standardized conditions
  3785. A case of primary aldosteronism combined with acquired nephrogenic diabetes insipidus
  3786. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism
  3787. Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism
  3788. Evaluation of insulin sensitivity and secretion in primary aldosteronism
  3789. Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism
  3790. Progress in primary aldosteronism: translation on the move
  3791. Deciphering the role of vasopressin in primary aldosteronism
  3792. Clinical utility of the adrenocorticotropin stimulation test with/without dexamethasone suppression for definitive and subtype diagnosis of primary aldosteronism
  3793. Despite limited specificity, computed tomography predicts lateralization and clinical outcome in primary aldosteronism
  3794. Volumetric and densitometric evaluation of the adrenal glands in patients with primary aldosteronism
  3795. Non-stimulated adrenal venous sampling using Dyna computed tomography in patients with primary aldosteronism
  3796. Evaluation of right adrenal vein anatomy by Dyna computed tomography in patients with primary aldosteronism
  3797. Bilateral Aldosterone suppression and its resolution in adrenal vein sampling of patients with primary aldosteronism: analysis of data from the WAVES‐J study
  3798. Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study
  3799. The many faces of primary aldosteronism and cushing syndrome: a reflection of adrenocortical tumor heterogeneity
  3800. Adrenal vein sampling versus CT scanning in primary aldosteronism
  3801. Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism
  3802. A useful tool to improve the case detection rate of primary aldosteronism: the Aldosterone–renin ratio (ARR)-App
  3803. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: a meta-analysis
  3804. Primary aldosteronism: a channelopathy?
  3805. Hypokalemia may mask primary aldosteronism: a case series
  3806. NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism
  3807. Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism
  3808. Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24‐h urinary Aldosterone
  3809. The relationship among cardiac structure, dietary salt and Aldosterone in patients with primary aldosteronism
  3810. Factors associated with resolution of hypertension after adrenalectomy in patients with primary aldosteronism
  3811. Transcriptome analysis of primary aldosteronism in adrenal glands and controls
  3812. Analysis of postoperative biochemical values and clinical outcomes after adrenalectomy for primary aldosteronism
  3813. Aldosterone to renin ratio as a screening instrument for primary aldosteronism in a middle-aged population with atrial fibrillation
  3814. Twenty-four-hour urinary Aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism
  3815. Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism
  3816. A late diagnosis of primary aldosteronism
  3817. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of Aldosterone-producing adenoma
  3818. Relationship of ocular microcirculation, measured by laser speckle flowgraphy, and silent brain infarction in primary aldosteronism
  3819. The role of urinary Aldosterone for the diagnosis of primary aldosteronism
  3820. … of the TWIK-Related Acid-Sensitive K+ Channel 2 (TASK-2) Gene Is a Hallmark of Aldosterone-Producing Adenoma Causing Human Primary Aldosteronism
  3821. Body mass index and contralateral ratio predict outcome following unilateral adrenalectomy in primary aldosteronism
  3822. The third case report a patient with primary aldosteronism, seizures, and neurologic abnormalities (PASNA) syndrome de novo variant mutations in the CACNA1D …
  3823. A case of primary aldosteronism caused by unilateral multiple adrenocortical micronodules presenting as muscle cramps at rest: the importance of functional …
  3824. Visualizing adrenal steroids in primary aldosteronism: the expected and the unexplained
  3825. … rise in IVC Aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism
  3826. A case of monozygotic twins with primary aldosteronism: a case report
  3827. Primary aldosteronism: a field on the move
  3828. Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism.
  3829. Fully automated chemiluminescence vs RIA Aldosterone assay in primary aldosteronism work-up
  3830. Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications
  3831. Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism
  3832. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients
  3833. Electrical and myocardial remodeling in primary aldosteronism
  3834. Hypokalemic myopathy in primary aldosteronism: A case report
  3835. Rational Approach to a Patient with Suspected Primary Aldosteronism.
  3836. Screening for primary aldosteronism in an argentinian population: a multicenter prospective study
  3837. Ambulatory blood pressure monitoring–derived short‐term blood pressure variability in primary aldosteronism
  3838. Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism
  3839. Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report
  3840. Primary aldosteronism with type 2 diabetes mellitus requires more antihypertensive drugs for blood pressure control: a retrospective observational study
  3841. The clinical value of salivary Aldosterone in diagnosis and follow-up of primary aldosteronism
  3842. Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism
  3843. PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid antagonist treatment for Aldosterone-producing adenoma
  3844. ACTH stimulation test and computed tomography are useful for differentiating the subtype of primary aldosteronism
  3845. Adrenal vein sampling in the diagnosis of aldosteronism
  3846. Genetic characterization of a mouse line with primary aldosteronism
  3847. Enhanced soluble serum CD40L and serum P-selectin levels in primary aldosteronism
  3848. Implication of aortic calcification on persistent hypertension after laparoscopic adrenalectomy in patients with primary aldosteronism
  3849. Prevalence of angiotensin II type 1 receptor (AT1R)–activating autoantibodies in primary aldosteronism
  3850. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.
  3851. Heterogeneous machine learning system for improving the diagnosis of primary aldosteronism
  3852. Primary aldosteronism: from case detection to histopathology with up to 6 years of follow‐up
  3853. Reversing the established order: Should adrenal venous sampling precede cross‐sectional imaging in the evaluation of primary aldosteronism?
  3854. Reassessment of the cosyntropin stimulation test in the confirmatory diagnosis and subtype classification of primary aldosteronism
  3855. Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: sequential changes in the GFR during preoperative eplerenone treatment to …
  3856. Primary Aldosteronism or Not Primary Aldosteronism: Is This Now the Question in Normotension?
  3857. Simultaneous occurrence of primary aldosteronism due to aldosteronoma and ectopic meningioma in the adrenal gland: a case report
  3858. Comparison of 24-h urinary Aldosterone level and random urinary Aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism
  3859. Prognostic value of semiquantification NP-59 SPECT/CT in primary aldosteronism patients after adrenalectomy
  3860. Response to effectiveness of adrenalectomy and Aldosterone antagonists for long-term treatment of primary aldosteronism
  3861. A normotensive patient with primary aldosteronism
  3862. Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis
  3863. Persistent primary aldosteronism despite iatrogenic adrenal hemorrhage after adrenal vein sampling
  3864. A case of Adrenocoricotrophic hormone-independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism
  3865. Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: a meta-analysis
  3866. Delayed diagnosis of primary aldosteronism in patients with autosomal dominant polycystic kidney diseases
  3867. Biological diagnosis of primary aldosteronism: summary of new French and international guidelines
  3868. Clinical characteristics and long-term outcome of primary aldosteronism in a Norwegian population
  3869. The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old
  3870. Hypokalemia correlated with arterial stiffness but not microvascular endothelial function in patients with primary aldosteronism
  3871. Assessment of postoperative changes in antihypertensive drug consumption in patients with primary aldosteronism using the defined daily dose
  3872. Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism
  3873. Are catecholamine-derived indexes in adrenal venous sampling useful for judging selectivity and laterality in patients with primary aldosteronism?
  3874. Aldosterone-renin ratio in the assessment of primary aldosteronism
  3875. Diagnosing and managing primary aldosteronism in hypertensive patients: a case-based approach
  3876. Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism
  3877. Aldosterone-induced oxidative stress: a potential mechanism of Aldosterone autonomy in primary aldosteronism
  3878. Adrenal androgen measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism
  3879. Investigation of primary aldosteronism in patients with resistant hypertension–Authors’ reply
  3880. Confirmatory testing for primary aldosteronism
  3881. Primary aldosteronism as a public health issue–Authors’ reply
  3882. Subtype prediction of primary aldosteronism by combining Aldosterone concentrations in the left adrenal vein and inferior vena cava: a multicenter collaborative study …
  3883. Rapid diagnosis of primary Aldosteronism: oxymoron or one small step?
  3884. Downregulated serum 14, 15-epoxyeicosatrienoic acid is associated with abdominal aortic calcification in patients with primary aldosteronism
  3885. The spectrum of subclinical primary aldosteronism and incident hypertension
  3886. The application of captopril challenge test in the diagnosis of primary aldosteronism
  3887. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism
  3888. Issues in the diagnosis and treatment of primary aldosteronism
  3889. A multi-institutional comparison of adrenal venous sampling in patients with primary Aldosteronism: caution advised if successful bilateral adrenal vein sampling is not …
  3890. An app for the diagnosis of primary aldosteronism
  3891. A prediction model for primary aldosteronism when the salt loading test is inconclusive
  3892. Primary Aldosteronism and Cardiovascular Events: It is time to take guideline recommendations seriously
  3893. Association of polymorphisms in AGTR1 and AGTR2 genes with primary aldosteronism in the Chinese Han population
  3894. A case of glucocorticoid remediable aldosteronism and thoracoabdominal aneurysms
  3895. The relation between the degree of left ventricular mass regression and serum potassium level change in patients with primary aldosteronism after adrenalectomy
  3896. Diagnosis and management of primary aldosteronism
  3897. Hypokalemia-induced rhabdomyolysis by primary aldosteronism coexistent with sporadic inclusion body myositis
  3898. Unmasked chronic renal function deterioration after unilateral adrenalectomy in patients with primary aldosteronism
  3899. Comment on “Body mass index and contralateral ratio predict outcome following unilateral adrenalectomy in primary aldosteronism”
  3900. Effect of body mass index on the location of the right adrenal vein in patients with primary aldosteronism
  3901. Primary Aldosteronism
  3902. Primary aldosteronism—not just about potassium and blood pressure
  3903. Call for screening for primary aldosteronism: an underdiagnosed and treatable disease
  3904. Bone health among patients with primary aldosteronism: a systematic review and meta-analysis.
  3905. hypertension in the course of primary aldosteronism during pregnancy
  3906. Clinical outcomes following unilateral adrenalectomy in patients with primary aldosteronism
  3907. Pathophysiology and clinical features of primary aldosteronism
  3908. GATA6, SF1, NGFIB and DAX1 in the remodeled subcapsular zones in primary aldosteronism
  3909. The potential role of primary care in case detection/screening of primary aldosteronism
  3910. Evaluation of angiotensin II type‐1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role
  3911. Primary Aldosteronism Presenting with an Atypical Aldosterone-renin Ratio in the Acute Phase of Cerebral Hemorrhage
  3912. Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine pH, sex, and serum K+
  3913. Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH‐dependent …
  3914. Unmasked renal impairment and prolonged hyperkalemia after unilateral adrenalectomy for primary aldosteronism coexisting with primary …
  3915. The association between glomerular hyperfiltration and left ventricular structure and function in patients with primary aldosteronism
  3916. 2016 Endocrine Society guidelines update for the diagnosis of primary aldosteronism: are the proposed Aldosterone-to-renin ratio cut-off values relevant in the era of …
  3917. Stroke disclosing primary aldosteronism: Report on three cases and review of the literature
  3918. The value of plasma renin concentration in diagnosis of primary aldosteronism
  3919. OS 35-04 The AA2-Ratio: Towards improved screening for primary aldosteronism in hypertension
  3920. The importance of not overlooking curable hypertension: primary aldosteronism rarely screened for reflecting poor uptake of Endocrine Society Guidelines
  3921. Predictors of malignancy in primary aldosteronism
  3922. Adrenal venous sampling for differentiating unilateral from bilateral primary aldosteronism: still the best, but could be better
  3923. The prevalence of primary aldosteronism (PA) in a group of 350 hypertensive patients
  3924. Increased urinary excretion of the epithelial Na channel activator prostasin in patients with primary aldosteronism
  3925. Primary aldosteronism
  3926. C-arm computed tomography-assisted adrenal venous sampling improved right adrenal vein cannulation and sampling quality in primary aldosteronism
  3927. Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor
  3928. Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism
  3929. Clinical value of captopril test for primary aldosteronism diagnosis
  3930. Systolic heart failure in a patient with primary aldosteronism
  3931. Can Aldosterone break your heart? Takotsubo cardiomyopathy in a patient with newly diagnosed primary aldosteronism
  3932. Isolation of human parathyroid cell type as a tool for investigating the mechanisms of human primary aldosteronism
  3933. Adrenal venous sampling in primary aldosteronism: multinomial regression modeling to detect Aldosterone secretion lateralization when right adrenal sampling is …
  3934. … of the ratio of plasma Aldosterone to rennin concentration measured by an automated chemiluminescent immunoassay in screening for primary aldosteronism
  3935. Diagnosis and management of primary aldosteronism
  3936. … benefits of administering super-selective segmental adrenal venous sampling and performing adrenal sparing surgery in the patients with primary aldosteronism
  3937. Comparison between Aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay for the diagnosis of primary aldosteronism
  3938. Rhabdomyolysis in Primary Aldosteronism: A Case Report and Review of the Literature
  3939. Urine steroid metabolomics as a diagnostic tool in primary aldosteronism
  3940. Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone
  3941. Impact of electrocardiographic findings for diagnosis of left ventricular hypertrophy in patients with primary aldosteronism
  3942. Studies on the optimal diagnostic criteria of primary aldosteronism in captopril challenge test
  3943. The importance of knowing the timing within the menstrual cycle in nonmenopausal hypertensive women in the diagnostic workup for primary aldosteronism.
  3944. Management of primary aldosteronism in patients with adrenal hemorrhage following adrenal vein sampling: a brief review with illustrative cases
  3945. Familial aggregation and heritability of primary Aldosteronism with Cardiovascular events: a population-based family cohort study
  3946. Primary aldosteronism in AF patients: To screen or not to screen?
  3947. Case Report: A case report of acromegaly associated with primary aldosteronism
  3948. Mutations of the Twik-Related Acid-Sensitive K+ Channel 2 Promoter in Human Primary Aldosteronism
  3949. The Effect of Adrenalectomy on Exercise Response of the Renin-Angiotensin-Aldosterone System and Exercise Tolerance in Primary Aldosteronism
  3950. Genetic alterations in primary aldosteronism
  3951. Alteration of left ventricular longitudinal systolic function in 2D-strain in primary aldosteronism: A new target organ damage marker
  3952. Is aldosteronism really a relatively common cause of hypertension?
  3953. Case of primary aldosteronism with discordant hormonal and computed tomographic findings
  3954. Clinical Evaluation of Primary Aldosteronism with Subclinical Cushing’s Syndrome
  3955. Predictors of hypertension urgency in primary aldosteronism patients during the first 24 hours after surgery
  3956. Update on the Aldosterone resolution score and lateralization in patients with primary aldosteronism
  3957. Primary Aldosteronism and Its Various Scenarios
  3958. High-sensitive C-reactive protein in primary aldosteronism
  3959. Clinical significance of contralateral adrenal suppression during adrenal vein sampling in primary aldosteronism
  3960. A case of adrenal vein sampling in primary aldosteronism with homolateral suppression
  3961. Primary Aldosteronism of Late Onset: A Case Report
  3962. … evaluated by pulse wave velocity is not predictive of the improvement in hypertension after adrenal surgery for primary aldosteronism: a multicentre study …
  3963. A challenging case of primary aldosteronism presenting in pregnancy
  3964. Primary hyperparathyroidism in a patient with primary aldosteronism
  3965. Primary Aldosteronism: Molecular Mechanisms and Diagnosis
  3966. Investigation of primary aldosteronism in patients with resistant hypertension
  3967. The association of serum parathyriod hormone and calcium levels with primary aldosteronism: a meta-analysis.
  3968. Laparoscopic adrenalectomy due to primary aldosteronism during pregnancy
  3969. Intracranial aneurysm in a patient with glucocorticoid-remediable aldosteronism
  3970. PRIMARY ALDOSTERONISM AND PREGNANCY
  3971. Primary aldosteronism diagnosed in a patient with severe renal disease.
  3972. Serum dehydroepiandrosterone sulfate concentration is lower in women with primary aldosteronism
  3973. A case of primary aldosteronism who experienced cardiopulmonary arrest, was resuscitated and cured
  3974. Adrenal vein sampling for primary aldosteronism: A 2-week protocol for withdrawal of renin-stimulating antihypertensives
  3975. Annals On Call-Primary Aldosteronism: How Often Are We Missing It?
  3976. SY 14-3 primary aldosteronism IN resistant hypertension
  3977. Diagnosis and treatment of primary aldosteronism in 2017: Did we achieve our goals?
  3978. Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?
  3979. Adrenal venous sampling in dye-allergic primary aldosteronism patients: prevalence, pitfalls and a possible solution
  3980. Asymmetric dimethylarginin (adma) as a marker of endothelial dysfunction in primary aldosteronism
  3981. Assessment of the quantitative value usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study
  3982. New germline mutation in CACNA1H calcium channel causing primary aldosteronism
  3983. Effects of gender on screening value of Aldosterone-renin ratio for primary aldosteronism
  3984. CLCN2 chloride channel mutations in primary aldosteronism
  3985. Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
  3986. Primary aldosteronism: progress in diagnosis, therapy, and genetics
  3987. A case of resistant hypertension secondary to primary aldosteronism
  3988. Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease
  3989. Association of KCNJ5 gene rs3740835 (C/A) and rs2604204 (A/C) polymorphism with unilateral and bilateral primary aldosteronism
  3990. A13186 Primary Aldosteronism in Klinefelter’s Syndrome: Two Cases Report
  3991. Endocrine Surgery Review Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic …
  3992. OS 22-08 Prevalence of primary aldosteronism and its cardio-metabolic factors Chinese hypertensive patients in Xinjiang of China
  3993. The prevalence of hypertension after adrenalectomy in patients with primary aldosteronism
  3994. Neuroglobin correlates with cryptochrome-1 in obstructive sleep apnea with primary aldosteronism
  3995. Oxidative stress in patients affected by primary aldosteronism
  3996. Screening for Primary Aldosteronism in Resistant hypertension
  3997. Ankylosing spondylitis associated with primary aldosteronism in a middle-aged woman
  3998. A11218 A normotensive patient with primary aldosteronism: a case report
  3999. Diagnostic accuracy of three confirmatory tests for primary aldosteronism: a prospective study and systematic review
  4000. NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging …
  4001. A15382 Primary Hyperparathyroidism in a Patient with Primary Aldosteronism
  4002. Effects of Altered Calcium Metabolism on Cardiac Parameters in Primary Aldosteronism
  4003. Plasma galectin-3 concentrations in patients with primary aldosteronism
  4004. Renin assay interference may conceal the diagnosis of primary aldosteronism
  4005. A case of primary aldosteronism presenting as non-ST elevation myocardial infarction
  4006. Primary aldosteronism during long-term ulcerative colitis: a diagnostic challenge
  4007. CONFIRMATORY AND SUBTYPE TESTING IN PATIENTS WITH SUSPECTED PRIMARY ALDOSTERONISM
  4008. Adrenal cortical scintigraphy for lateralization of bilateral adrenal nodules in primary aldosteronism
  4009. Primary Aldosteronism at Prapokklao Hospital
  4010. Lower physical fitness in patients with primary aldosteronism is linked to the severity of hypertension and kalemia
  4011. Primary aldosteronism
  4012. P5402 Evidence for an increased prevalence of aldosteronism among patients with coronary artery disease during the time of military conflict in Donbass region
  4013. 7d. 11: Retinal Arteriolar Structure in Patients with Primary Aldosteronism
  4014. Molecular mechanisms in primary aldosteronism
  4015. Comparison on metabolic disorders and uric acid levels between patients with primary aldosteronism and essential hypertension
  4016. hypertension, Atrial Fibrillation and Aldosteronism-A study of interplay, predictors and outcome
  4017. CARDIOVASCULAR EVENTS AND TARGET ORGAN DAMAGE IN PRIMARY ALDOSTERONISM: A SYSTEMATIC REVIEW AND META-ANALYSIS
  4018. Primary Aldosteronism
  4019. Prevalence and Clinical Phenotype of Primary Aldosteronism in Primary Care Hypertensives
  4020. Primary Aldosteronism
  4021. A CASE OF PRIMARY ALDOSTERONISM
  4022. Monozygotic twins discordant for primary aldosteronism: a case report
  4023. Primary Aldosteronism
  4024. Genetic aspects in primary aldosteronism
  4025. DO WE HAVE TO SCREEN PATIENTS WITH ADRENAL INCIDENTALOMA FOR PRIMARY ALDOSTERONISM?
  4026. Primary aldosteronism: making the diagnosis and why it matters
  4027. Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report
  4028. ASSESSEMENT OF MYOCARDIAL MECHANOENERGETIC EFFICIENCY IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4029. Primary Aldosteronism
  4030. The infradiagnosis of primary aldosteronism as a public health problem
  4031. Isolated unilateral leg weakness as the presenting symptom of primary aldosteronism: a case report
  4032. Genetics of primary aldosteronism
  4033. The importance of adrenal vein sampling in primary aldosteronism. Necessary examination for many patients as computed tomography can lead to errors
  4034. The Identification of Primary Aldosteronism
  4035. Editorial Comment from Dr Nishikawa et al. to Preoperative masked renal damage in Japanese patients with primary aldosteronism: Identification of predictors for …
  4036. Evaluation of the (1–24) adrenocorticotropin stimulation test for the diagnosis of primary aldosteronism
  4037. A8196 Both Medical and Surgical Treatment leads to Marked Improvement of hypertension in Patients with Primary Aldosteronism (PA)
  4038. Adrenal vein sampling versus CT scanning in primary aldosteronism
  4039. A12871 Saline suppression test may predict bilateral subtypes of primary aldosteronism
  4040. The therapeutic effect of bromocriptine in combination with spironolactone in patients with primary aldosteronism: a hypothesis generating pilot study
  4041. Medical Treatment of Primary Aldosteronism
  4042. Value of combination strategy based on plasma Aldosterone/renin concentration ratio in screening of primary aldosteronism
  4043. Surgical outcomes of patients with primary aldosteronism lateralized with I-131-6 β-iodomethyl-norcholesterol single photon emission/computed tomography …
  4044. Primary Aldosteronism (Conn Syndrome)
  4045. MDT treatment for primary aldosteronism
  4046. Subclinical Cushing’s syndrome with primary aldosteronism with the developing symptom of complications: a case report
  4047. Analysis of the influencing factors for screening primary aldosteronism
  4048. Diagnosis, treatment and progress of primary aldosteronism in China
  4049. Primary Aldosteronism: From Genetic Causes to Clinical Guidelines
  4050. Origins of primary aldosteronism
  4051. Application of SUSPPUP ratio in patients with primary aldosteronism
  4052. Setting up a primary aldosteronism program: an Australian experience
  4053. Seated saline suppression testing for the diagnosis of primary aldosteronism. A validation study
  4054. Primary Aldosteronism in Hypertensive Patients
  4055. Progress on genetic basis of primary aldosteronism
  4056. obesity and the Diagnostic Accuracy for Primary Aldosteronism
  4057. CIRCADIAN HAEMODYNAMIC CHARACTERISTICS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4058. … : assessment of the raas-status using triple-a-testing: combining molecular profiling of hypertension with advanced screening for primary aldosteronism in a single …
  4059. Quality-of-Life Aspects of Primary Aldosteronism
  4060. Do patients with primary aldosteronism have cardiovascular damage at time of diagnosing hypertension in primary care?
  4061. 22-Year-old patient with malignant hypertension associated with primary aldosteronism
  4062. Outcomes of Drug-Based and Surgical Treatments for Primary Aldosteronism
  4063. A12864 Ambulatory Blood Pressure Monitoring May Unveil Primary Aldosteronism
  4064. ADRENAL VENOUS SAMPLING: THE GOLD-STANDARD FOR SURGICAL INDICATION IN PRIMARY ALDOSTERONISM
  4065. Adrenal vein catecholamine levels and ratios: reference intervals derived from patients with primary aldosteronism
  4066. The long-term effect of adrenal arterial embolization for unilateral primary aldosteronism on cardiorenovascular protection, blood pressure, and the endocrinological …
  4067. Primary aldosteronism-management can be challenging and complex
  4068. A1960 Ablation of the adrenal artery can treat primary aldosteronism
  4069. Glucocorticoid‐remediable aldosteronism in a young adult with a family history of Conn’s syndrome
  4070. VALUE OF PLASMA RENIN ACTIVITY CHANGES WITH DIFFERENT POSTURE ON IDENTIFICATION OF PRIMARY ALDOSTERONISM
  4071. 2Study heterogeneity and estimation of prevalence of primary aldosteronism
  4072. Revised guidelines for finding and treating primary aldosteronism
  4073. MEDICATION ADHERENCE AND UNREPORTED DRUG USE DURING WORKUP FOR PRIMARY ALDOSTERONISM
  4074. Primary aldosteronism in Western Norway. Studies of diagnostic approach and treatment outcome
  4075. Routine Versus Selective Adrenal Vein Sampling for Primary Aldosteronism
  4076. EP31: Primary Aldosteronism–results from the first Portuguese multicentre study
  4077. Time to change the focus with a new treatment for primary aldosteronism
  4078. GW26-e2487 Clinical Analysis of Primary Aldosteronism with hypertension
  4079. Abstract P612: The AA2-Ratio: Towards Improved Screening for Primary Aldosteronism
  4080. How should we treat patients with primary aldosteronism to prevent new-onset diabetes mellitus?
  4081. Os 35-05 measurement of angiotensin II at equilibrium in the diagnostic workup of primary aldosteronism-impact of patient positioning and ACE inhibitor treatment
  4082. A UNIQUE CASE OF TAKOTSUBO CARDIOMYOPATHY ASSOCIATED WITH PRIMARY ALDOSTERONISM
  4083. A7140 Layer-specific Strain Analysis of Myocardial Dysfunction by Speckle Tracking Echocardiography in Patients with Primary Aldosteronism
  4084. Decrease in serum potassium levels post saline suppression test in primary aldosteronism: an under-recognised phenomenon?
  4085. Primary aldosteronism in general practice: organ damage, epidemiology, and treatment
  4086. Hyperglycemia in patients with primary aldosteronism
  4087. Papilledema in Patient with Primary Aldosteronism: an Unusual Case Report
  4088. Application of a novel equilibrium angiotensin II assay in screening and confirmatory testing for primary aldosteronism: a pilot study
  4089. Primary aldosteronism: new insights into familial forms
  4090. A3370 The outcome comparisons of patients with primary aldosteronism and resistant hypertension after adrenalectomy or medical treatment
  4091. Corrigendum: Long term outcome of Aldosteronism after target treatments
  4092. Primary Aldosteronism in the Primary Care Clinic: Rife or Rare?
  4093. … to Potassium in Adrenocorticotropin Stimulation Test is a Possible New Index for Diagnosis of Aldosterone-producing Adenoma in Patients with Primary Aldosteronism
  4094. Cardiovascular Complications Associated With Primary Aldosteronism
  4095. Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism
  4096. Autosomal dominant polycystic kidney disease and hypertension masquerading primary aldosteronism
  4097. A18459 Research of KCNJ5 gene mutation and cardiac damage in patients with primary aldosteronism
  4098. Re-evaluation of screening and confirmatory tests in primary aldosteronism
  4099. The influence of aging on the diagnosis of primary aldosteronism
  4100. Microalbuminuria in primary aldosteronism
  4101. … OF LEFT VENTRICULAR FUNCTION BY GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension
  4102. Epidemiologic study of primary aldosteronism in northern Jiangsu
  4103. Os 35-06 comparison of n-terminal pro-b-type natriuretic peptide level in primary aldosteronism and essential hypertension
  4104. A16434 Antiplatelet and Anticoagulant therapies in Patients with Primary Aldosteronism: Results of the PA Sendai Study registry
  4105. Primary aldosteronism: more common than once thought: Two clinical cases
  4106. Prevalance of primary aldosteronism in hypertensive patients: epidemiological data from a tertiary centre
  4107. A2830 Serum soluble (pro) renin receptor concentration is correlated with organ dysfunctions in patients with primary aldosteronism
  4108. Primary aldosteronism-results from the first Portuguese multicentre study
  4109. A9431 Characteristics of cardiac structural changes and cardiac arrhythmias in patients with primary aldosteronism
  4110. A case of primary aldosteronism and Hashimoto
  4111. … Aldosterone: comparison of liquid chromatography-tandem mass spectrometry with radioimmunoassay in screening and confirmatory testing for primary aldosteronism
  4112. PROSPECTIVE APPRAISAL ON THE PREVALENCE OF PRIMARY ALDOSTERONISM AND ITS SUTYPES IN HYPERTENSIVE PATIENTS PRESENTING WITH …
  4113. No difference between CT and AVS for determining treatment options in primary aldosteronism
  4114. Genetic mutations cause primary aldosteronism
  4115. PP. 09.27: genetic abnormalities in lateralized multinodular primary aldosteronism
  4116. Biventricular Cardiac Hypertrophy in a Patient with Primary Aldosteronism and Atrial Septal Defect
  4117. Changes of parathyroid hormone in primary aldosteronism and its effects
  4118. Abstract P333: Effect of Autonomous Cortisol Secretion on Cerebrovasuclular Events in Patients With Primary Aldosteronism
  4119. The Predictive Value of Left Versus Right Adrenal Volume Ratio (L/Rv) in Discrimination between AVS Confirmed Unilateral and Bilateral Primary Aldosteronism
  4120. Patient selection for confirmatory tests of primary aldosteronism (PA) using the PA discrimination score
  4121. A11374 RAAS Triple A-Testing: LC-MS/MS Based Molecular Profiling of hypertension and Advanced Screening for Primary Aldosteronism
  4122. Characteristics of patients with normal adrenal imaging in primary aldosteronism
  4123. Glucocorticoid production in primary aldosteronism-from mechanisms to clinical implications
  4124. A9910 Correlation between vitamin D and plasma Aldosterone concentration in Primary aldosteronism patients
  4125. Four Cases of Hypovolemic Renin-Aldosterone Axis Deficiency Without Hyperkalemia Following Unilateral Adrenalectomy for Primary Aldosteronism
  4126. Utility of F-18 FDG-PET in detecting primary aldosteronism in patients with bilateral adrenal incidentalomas
  4127. Primary Aldosteronism with Rhabdomyolysis: A Case Report
  4128. Target Organ Damage and Treatment of Primary Aldosteronism
  4129. Primary Aldosteronism in Iceland, nationwide results from 2012-2016
  4130. Metabolic and hormonal profile in primary aldosteronism as compared with essential hypertension
  4131. Sleep quality in patients with primary aldosteronism
  4132. Primary Aldosteronism in a Patient with Autosomal Dominant Polycystic Kidney Disease Associated with Polycystic Liver Disease
  4133. Progress in the identification of responsible genes and molecular mechanisms in primary aldosteronism
  4134. PRIMARY ALDOSTERONISM IN YOUNG PATIENT WITH RECURRENT RESISTANT hypertension AFTER SOLITARY ADRENAL ADENOMA SURGICAL …
  4135. Response to ‘Oxidative stress in patients affected by primary aldosteronism’
  4136. Primary Aldosteronism: Molecular Genetics, Endocrinology, and Translational Medicine
  4137. … A-TESTING: COMBINING LC-MS/MS BASED MOLECULAR PROFILING OF hypertension AND ADVANCED SCREENING FOR PRIMARY ALDOSTERONISM
  4138. The value of high effective liquid chromatography in the diagnosis of primary aldosteronism
  4139. Glucocorticoid axis in patients with primary aldosteronism
  4140. Confirmatory tests for diagnosis of primary aldosteronism among Chinese hypertensives
  4141. New diagnostic methods for primary aldosteronism with specific antibodies
  4142. ACTH stimulation test for study of primary aldosteronism
  4143. Prevalence of AT1R-activating autoantibodies in primary aldosteronism: AT1R autoantibodies in primary aldosteronism
  4144. Laboratory challenges in primary aldosteronism screening and diagnosis
  4145. Prevalence of neoplasms in patients with primary aldosteronism
  4146. Primary aldosteronism–prevalence and prognosis in primary care
  4147. A2006 Ablation of the adrenal artery can treat idiopathic aldosteronism
  4148. Molecular Derangements in Sporadic Primary Aldosteronism
  4149. Treatment strategy and outcome with primary aldosteronism: a nationwide longitudinal cohort based study
  4150. Significance and utility of selective tributary sampling for accurate diagnosis of unilateral primary aldosteronism.
  4151. Expression and Functional Role of The Prorenin Receptor in Human Primary Aldosteronism
  4152. Prevalence and clinical correlates of CACNA1D mutations in primary aldosteronism
  4153. Is adrenal computed tomography accurate for the diagnosis of unilateral primary aldosteronism? A retrospective international cohort study
  4154. Primary aldosteronism is an underdiagnosed cause of hypertension. Important to find undiagnosed patients–effective treatment available
  4155. Method verification for Aldosterone and renin assay-a reliable screening test for primary aldosteronism
  4156. Patients with primary aldosteronism have lower circulating adenosine levels but similar susceptibility to ischemia-reperfusion compared to patients with essential …
  4157. Complete remission of hypertension in a hemodialysis patient after adrenalectomy for primary aldosteronism and renal transplantation
  4158. Abstract MP12: The AA2-Ratio: A Novel Screening Test for Primary Aldosteronism in Hypertensive Patients
  4159. Validation of Aldosterone-to-Renin Ratio Cut-offs in Screening for Primary Aldosteronism
  4160. Predictors of the Long-Term Outcomes in Patients With Secondary hypertension Caused by Primary Aldosteronism
  4161. Parathyroid Hormone Levels Are Positively Correlated With Left Ventricular Hypertrophy in Patients With Primary Aldosteronism
  4162. Intermittent Primary Aldosteronism-Another Hurdle in the Conn’s Story?
  4163. Normotensive hypokalemic primary aldosteronism: How is this Possible?
  4164. TDM-guided screening for primary aldosteronism cost saving
  4165. A0996 downregulated serum 14, 15-EET is associated with abdominal aortic calcification in patients with primary aldosteronism
  4166. Intermittent primary aldosteronism-another hurdle in the Conn
  4167. Os 35-01 the prevalence of sleep apnea syndrome in primary aldosteronism
  4168. Hair cortisol in patients with primary aldosteronism
  4169. Re-evaluation of the optimal cutoff of saline infusion test in the diagnosis of primary aldosteronism
  4170. CD3 ALDOSTERONISM, HEART AND VESSELS
  4171. Role of adrenal venous sampling in differential diagnosis of subtypes in primary aldosteronism
  4172. Aspects of diagnostic and management of bilateral adrenal gland’s lesions associated with primary aldosteronism
  4173. Cardiovascular complications during medication adjustment for the diagnosis of primary aldosteronism
  4174. Glucose and lipid metabolism characteristics in the male primary aldosteronism patients
  4175. THE LOCATION SPECTRUM OF THE ORIFICE OF RIGHT ADRENAL VEIN IN PATIENTS WITH PRIMARY ALDOSTERONISM: THE EXPERIENCE BASED ON 575 …
  4176. A case of primary aldosteronism with the subclinical Cushing
  4177. 4114Adrenal venous sampling in primary aldosteronism: cosyntropin infusion increases the success rate of the procedure but can mask the lateralization of …
  4178. The Detection Rate and Characteristics of Primary Aldosteronism in Hypertensive Patients
  4179. Adrenal vein sampling vs imaging in primary aldosteronism
  4180. Primary aldosteronism due to adrenocortical adrenal tumor in child: clinical case and literature review
  4181. Primary Aldosteronism Presenting as Hypokalemia and Rhabdomyolysis
  4182. Clinical and biochemical outcomes in surgically treated patients with primary aldosteronism. A multicentric retrospective study
  4183. The Urinary Aldosterone in the Diagnosis of Primary Aldosteronism
  4184. Application of captopril challenge test in the diagnosis of primary aldosteronism
  4185. Adrenal Venous Sampling in Patients with Primary Aldosteronism: Which Is the Best Evaluation Method for Laterality Assessments?
  4186. Persistent Hyperkalemia Status Postadrenalectomy for Primary Aldosteronism
  4187. OS 33-06 In patients with primary aldosteronism, obstructive sleep apnoea improves with treatment by adrenalectomy or medical therapy
  4188. Role of adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes
  4189. Assessing the new Primary Aldosteronism guidelines recommendation to omit confirmatory testing in selected patients-severity of hypokalaemia may be included
  4190. Investigation of the prevalence of primary aldosteronism among newly diagnosed patients with hypertension
  4191. Identification of Aldosterone production sites in primary aldosteronism
  4192. Adrenal venous sampling vs imaging for primary aldosteronism
  4193. Abstract P451: Cerebrovasuclular Events in Patients With Primary Aldosteronism: Results of the PA Sendai Study Registry
  4194. Posterior reversible encephalopathy syndrome (PRES) in a patient with primary aldosteronism
  4195. Postural orthostatic tachycardia syndrome unmasked by successful treatment of primary aldosteronism
  4196. The New Cholesterol Treatment Guidelines Represents a Paradigm Shift for Primary Aldosteronism Patients
  4197. Diagnostic Value of Saline Load Test in Patients With Primary Aldosteronism
  4198. The usage of computed tomography and serum potassium in determining the subtypes of primary aldosteronism
  4199. A9099 Diagnostic Significance of Contralateral Suppression Index of the Adrenal Venous Sampling in Primary Aldosteronism Subtyping
  4200. Role of imaging and adrenal venous sampling techniques in the diagnosis of primary aldosteronism
  4201. Captopril challenge test-is it useful for the diagnosis of primary aldosteronism?
  4202. … in Response to the Correspondence by Damien Denimal Entitled:” Comments on French SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, Part 2: Diagnosis …
  4203. Prolactinoma and primary aldosteronism: is there a causal link?
  4204. Use of NP-59 SPECT/CT imaging in atypical primary aldosteronism
  4205. Reversal of Arterial Stiffness in Patients with Primary Aldosteronism after Treatment
  4206. Abstract P117: Blood Pressure Outcomes in Patients With Primary Aldosteronism after Adrenalectomy versus Medical Management in Relation to the New 2017 ACC …
  4207. Discordance between imaging and adrenal vein sampling in primary aldosteronism
  4208. Renin: a possible novel marker for the efficacy of pharmacological treatment of primary aldosteronism
  4209. Differential diagnosis of primary aldosteronism by measurement of hybrid steroids using mass spectrometry
  4210. Prevalence of primary aldosteronism among hypertensive population in Trabzon City, Turkey
  4211. Adrenal vein sampling versus CT scanning in primary aldosteronism–Authors’ reply
  4212. Glucocorticoid-Remediable Aldosteronism: An Uncommon and Often Overlooked Cause of Adrenal hypertension
  4213. Aortic root dilatation in primary aldosteronism: is treatment effective in reducing aortic damage?
  4214. Against-Adrenal venous sampling vs. imaging for primary aldosteronism: beware of the caveats!
  4215. Long-term outcome from unilateral adrenalectomy in patients with primary aldosteronism
  4216. Genetic Steroid Disorders: Chapter 6C. Glucocorticoid-Remediable Aldosteronism
  4217. Primary aldosteronism: The role of plasma free metanephrines as a lateralization marker in adrenal vein sampling and its concordance with CT-scan.
  4218. Amplified Screening and Workup Protocol for Primary Aldosteronism: A Strategy to Improve New Zealand’s Woefully Low
  4219. Value of adrenal venous sampling in the subtype diagnosis of primary aldosteronism
  4220. [OP. 4B. 06] FREQUENCY OF PRIMARY ALDOSTERONISM IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA–OSA-PA STUDY
  4221. Intraoperative hypertensive crisis as a key symptom in a normotensive patient with primary aldosteronism-clinical case
  4222. COINCIDENCE OF PRIMARY ALDOSTERONISM AND RENAL ARTERY STENOSIS–A RARE CAUSE OF hypertension
  4223. Primary aldosteronism and the occurrence of hyperparathyroidism in the German Conn’s registry
  4224. Female patients with primary aldosteronism are diagnosed earlier and have a better cardiovascular outcome after treatment
  4225. In Focus Primary aldosteronism and low-renin hypertension: a continuum?
  4226. Primary Aldosteronism—An Endocrine Society Clinical Practice Guideline
  4227. Selective adrenal venous sampling is not always useful in primary aldosteronism
  4228. 9B. 08: CARDIAC AND VASCULAR DAMAGE IN PATIENTS WITH PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension
  4229. GW24-e2371 The association between KCNJ5 gene polymorphism and primary aldosteronism
  4230. Efficacy of Screening and Confirmatory Tests of Primary Aldosteronism in Diagnosing Aldosterone Producing Adenoma
  4231. Primary aldosteronism associated with a giant coronary aneurysm after drug-eluting stent implantation
  4232. A case of subclinical primary aldosteronism and subclinical Cushing
  4233. Role of adrenal venous sampling in primary aldosteronism: Salford royal NHS foundation trust experience
  4234. Paradoxical worsening of lipid metabolism after successful treatment of primary aldosteronism
  4235. Is steroid profiling using LC-MS/MS useful in the diagnostic work-up of primary aldosteronism?
  4236. West Australian experience with adrenal venous sampling studies in the diagnosis of primary aldosteronism
  4237. Rapid reduction in left ventricular mass in primary aldosteronism after treatment; a prospective cardiac MRI study
  4238. A Fisher discriminant model to predict the outcome of postoperative blood pressure in primary aldosteronism
  4239. Dissociation of subtype diagnosis by various criteria on adrenal venous samplings in primary aldosteronism
  4240. Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
  4241. Association of polymorphisms in angiotensin Ⅱ receptor gene with primary aldosteronism
  4242. Clinical and biochemical outcome after unilateral adrenalectomy in primary aldosteronism
  4243. Rating the blood pressure outcome after adrenalectomy for unilateral primary aldosteronism.
  4244. Hyperreninemic Aldosteronism in Caucasian and African-American Patients With Apparent Resistant hypertension
  4245. Primary aldosteronism studies on screening, outcome of adrenalectomy and functional pathology
  4246. Pregnancy, Primary Aldosteronism and Somatic CTNNB1 Mutations in the Adrenal
  4247. … reply: The importance of knowing the timing within the menstrual cycle in nonmenopausal hypertensive women in the diagnostic workup for primary aldosteronism.
  4248. Pathogenic Origins of Fibrosis in the Hypertensive Heart Disease that Accompanies Aldosteronism
  4249. Adrenal vein sampling for subtype classification of primary aldosteronism in British Columbia: insights and challenges
  4250. Application of endothelial markers detection in early target organ damage degree determination for patients with primary aldosteronism
  4251. Laparoscopic Partial Adrenalectomy for Primary Aldosteronism Combined with Cushing’s Syndrome: Report of a Case
  4252. Several Types of Somatic Mutations Induce Autonomous Production of Aldosterone in Primary Aldosteronism
  4253. Specificity of the posture test for subtyping of primary aldosteronism, a 10 year nationwide summary in Iceland
  4254. Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of hypertension Caused by Primary Aldosteronism
  4255. Case Report: A case report of acromegaly associated with primary aldosteronism [version 1; referees: 2 approved]
  4256. Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism
  4257. GW26-e2276 Relationship between Serum β2-microglobulin and Arteriosclerosis in Primary Aldosteronism
  4258. Long-term survival of a feline with primary aldosteronism secondary to an adrenal carcinoma.
  4259. Posture-responsive primary aldosteronism-the utility of seated saline suppression test
  4260. Successful treatment of primary aldosteronism with partial adrenalectomy, facilitated by the use of 11C-Metomidate PET/CT
  4261. A case of primary aldosteronism with secondary hyperparathyroidism and bilateral adrenal tumors
  4262. The Aldosterone Renin Ratio (ARR) APP as Tool to Enhance the Detection Rate of Primary Aldosteronism
  4263. GW26-e0139 The relationship between the KCNJ5 gene polymorphisms and lipid metabolism in patients with primary aldosteronism
  4264. Low ACTH and cortisol production following adrenalectomy for primary aldosteronism
  4265. Plasma Aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism
  4266. Effectiveness of Adrenalectomy and Aldosterone Antagonists for Long-Term Treatment of Primary Aldosteronism
  4267. Experimental study on the rationality of amiloride off-label use in treating primary aldosteronism
  4268. Immunohistochemical staining for histopathological subclassification of primary aldosteronism: nationwide 10-year results from Iceland
  4269. Role of adrenal vein sampling in primary aldosteronism: impact of different diagnostic criteria on subtype diagnosis
  4270. Episodic primary aldosteronism associated with a novel gain-of-function mutation in a cell adhesion molecule
  4271. OS 35-09 long-term outcome of surgically-and medically-treated patients of the primary aldosteronism prevalence in hypertensives (PAPY) study
  4272. New germline mutation in calcium channel CACNA1H causes late-onset primary aldosteronism
  4273. Application and evaluation of postural stimulation test and captopril challenge test in diagnosis of primary aldosteronism
  4274. PRIMARY ALDOSTERONISM AND SUBCLINICAL CUSHING’S FROM THE SAME ADENOMA: AN UNCOMMON VARIANT
  4275. Simultaneous assays of Aldosterone and renin concentrations in just ten minutes could change the clinical assessment for the diagnosis of primary aldosteronism
  4276. GW24-e3740 Comparison of biomarkers of endothelial dysfunction and risk of early organ damage between primary aldosteronism and essential hypertension
  4277. A Rare Case of Subclinical Primary Aldosteronism and Subclinical Cushing’s Syndrome without Cardiovascular Complications
  4278. MEDICAL MANAGEMENT OF MILD HYPERCORTISOLISM AND PRIMARY ALDOSTERONISM IN A PATIENT WITH ACTH-INDEPENDENT MACRONODULAR …
  4279. Post saline infusion test Aldosterone levels indicate severity and outcome in primary aldosteronism
  4280. First phase insulin secretion is impaired by Aldosterone excess in primary aldosteronism
  4281. Abstract P398: Screening of Primary Aldosteronism by Clinical Features and Daily Laboratory Tests: Combination of Urine pH, Sex, and Serum K+
  4282. It’s Complicated: How Often are Patients with Primary Aldosteronism Cured After Adrenalectomy?
  4283. The correlation between C171Tmutation of potassium inwardly-rectifying channel, subfamily J, member 5gene and hypokalemic in patients with primary aldosteronism
  4284. Is the adrenal vein sampling the gold standard diagnostic test for the subtyping of primary aldosteronism?
  4285. A case of subclinical primary aldosteronism and subclinical Cushing’s syndrome without risk factors of cardiovascular disease
  4286. Influence of Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism
  4287. GW24-e3533 Correlation between C171T mutation of KCNJ5 gene and hypokalemic in patients with primary aldosteronism
  4288. Ascending aorta dilatation in primary aldosteronism: a new deleterious consequence of Aldosterone excess
  4289. PRIMARY ALDOSTERONISM: UTILITY OF LEFT ADRENAL VEIN Aldosterone RATIO TO PREDICT UNILATERAL DISEASE
  4290. 5970 Who to test for primary aldosteronism: development of a decision tool to select the right patients
  4291. FP088 COMBINATION OF URINE PH AND FEMALE GENDER FOR SCREENING PRIMARY ALDOSTERONISM IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
  4292. Prevalence rate, characteristics and predictive factors of primary aldosteronism among hypertensive patients who had Aldosterone-renin ratio screening in Southern …
  4293. Mass spectrometry-based adrenal venous steroid profiling for subtyping primary aldosteronism
  4294. LATERALIZATION CRITERIA IN ADRENAL VEIN SAMPLING IN PATIENSWITH PRIMARY ALDOSTERONISM BY HIGH EFFECTIVE LIQUID CHROMATOGRAPHY
  4295. [PP. 27.23] GUIDELINES FOR PRIMARY ALDOSTERONISM: UPTAKE BY PRIMARY CARE PHYSICIANS IN EUROPE
  4296. Radiofrequency bipolar ablation therapy for primary aldosteronism patients: investigator-initiated exploratory clinical trial
  4297. … DAILY DOSE CAN ASSESS POSTOPERATIVE CHANGE IN ANTIHYPERTENSIVE DRUG CONSUMPTION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4298. Lb02. 07: effect of acute Da2 dopaminergic receptor blockade on performance of adrenal vein sampling for subtyping of primary aldosteronism
  4299. MP37-19 short-term impact on health-related quality of life of laparoscopic adrenalectomy for primary aldosteronism in Japanese patients
  4300. … of endoscopic ultrasound and other imaging techniques compared to adrenal vein sampling regarding therapeutic decisions in patients with primary aldosteronism
  4301. … -producing adenoma by histological, immunohistochemical and radiological features; a basis for individualised treatment strategies in primary aldosteronism?
  4302. … from Dr Catena, Dr Colussi and Dr Sechi to Preoperative masked renal damage in Japanese patients with primary aldosteronism: Identification of predictors for …
  4303. A Novel Score System for Primary Aldosteronism Screening, PUK2 score: Combination of Urine pH and Serum Uric Acid and K+ Levels
  4304. Are we missing patients with primary aldosteronism (PA) if we require both elevated Aldosterone: renin ratio (ARR) and elevated Aldosterone levels?
  4305. Comparison between Aldosterone and renin measurement by chemiluminescent immunoassay and RIA for the diagnosis of primary aldosteronism
  4306. … -Saline Infusion Plasma Aldosterone Concentrations are Well Correlated with the Lateralized Ratio of Adrenal Venous Sampling in Patients of Primary Aldosteronism
  4307. Cardiovascular outcome in patients with primary aldosteronism following adrenalectomy and mineralocorticoid antagonist treatment: prospective results of the Munich …
  4308. … Study on Steroidgenic Activity in Aldosterone-Producing Adenoma With ATPase or CACNA1D Gene Mutations in Japanese Patients With Primary Aldosteronism
  4309. Activated Intrarenal Renin Angiotensin System Contributes to the Development of Chronic Kidney Disease in Primary Aldosteronism
  4310. … Mutations and a Rare Coding Single Nucleotide Polymorphism Within KCNJ5 Potassium Channel in a Large Cohort of Sporadic Cases of Primary Aldosteronism.
  4311. PS 17-02 TARGET ORGAN DAMAGE OF PRIMARY ALDOSTERONISM DIFFERENT SUBTYPES
  4312. Evaluation of Chemiluminescence Immunoassay for Detecting Blood Levels of Aldosterone and Renin With its Diagnostic Value of Primary Aldosteronism
  4313. Activated Intrarenal Renin Angiotensin Systems Is the Primary Source of Progressing Renal Damage in Primary Aldosteronism
  4314. Impact of Aldosterone Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism
  4315. [LB. 01.32] URINARY METABOLIC SIGNATURE OF PRIMARY ALDOSTERONISM: GENDER AND SUBTYPE SPECIFIC ALTERATIONS
  4316. Adequate salt intake attenuates mineralocorticoid receptor antagonist-induced hyperkalemia in patients with primary aldosteronism
  4317. … Comment from Dr Catena, Dr Colussi and Dr Sechi to Preoperative masked renal damage in Japanese patients with primary aldosteronism: Identification of predictors …
  4318. … Association between the levels of carboxy-terminal propeptide of type I procollagen and Aldosterone in patients with primary aldosteronism and essential hypertension
  4319. Careful selection of patients with primary aldosteronism using combination of age, serum potassium and CT adrenal glands can avoid the need for adrenal venous …
  4320. [PP. 27.07] QUALITY OF LIFE IN PRIMARY ALDOSTERONISM IMPROVES MORE AFTER ADRENALECTOMY THAN AFTER MEDICAL THERAPY
  4321. Diagnostic Efficacy of CT/MR Imaging and Adrenal Vein Sampling for Localization of Aldosterone-producing Adrenal Adenomas in Primary Aldosteronism
  4322. MYOCARDIAL ULTRASOUND TISSUE CHARACTERIZATION OF PATIENTS WITH PRIMARY ALDOSTERONISM HSIU-HAO LEE,* y CHI-SHENG HUNG, z …
  4323. Immuno-phenotypic Characterization of Lateralized Primary Aldosteronism with New Monoclonal Antibodies against the Human Aldosterone Synthase (CYP11B2) …
  4324. PS 14-77 THE DIAGNOSIS OF PATIENTS WITH PRIMARY ALDOSTERONISM IN CARDIOLOGY DEPARTMENT OF MIE UNIVERSITY HOSPITAL IN JAPAN
  4325. PP. 09.16: 24-HOUR CENTRAL SYSTOLIC AORTIC BLOOD PRESSURE IN ALDOSTERONISM, ESSENTIAL hypertension AND NORMOTENSION
  4326. 8d. 02: Peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in primary aldosteronism patients
  4327. … 14-01 COMPARISON OF LEFT VENTRICULAR STRUCTURE AND FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension …
  4328. … induced galectin-3 secretion via MR/PI3K/Akt/NF-kB signaling in THP-1 cell: a possible mediator of myocardial fibrosis in patients with primary aldosteronism
  4329. Use of NP-59 (131I-iodocholesterol) scan as a potential alternative to adrenal venous sampling in the investigation of primary aldosteronism: a 5-year …
  4330. [PP. 25.11] GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM (GRA): A MODEL OF DISCREPANCY BETWEEN GENOTYPE AND CLINICAL PHENOTYPE
  4331. MP03-06 PATIENT SELECTION FOR CONFIRMATORY TESTS OF PRIMARY ALDOSTERONISM (PA) USING THE PA DISCRIMINATION SCORE
  4332. [BP. 05.01] THE CLINICAL CHARACTERISTICS OF PATIENTS WITH PRIMARY ALDOSTERONISM COMPLICATED WITH OBSTRUCTIVE SLEEP APNEA …
  4333. Os 35-08 Does Adrenocorticotropic Hormone (Acth) Administration Improve the Diagnostic Performance of Adrenal Vein Sampling for Primary Aldosteronism?
  4334. OS 35-03 LEFT VENTRICULAR CHANGES ARE AFFECTED BY DIETARY SALT INTAKE IN PRIMARY ALDOSTERONISM: A PROSPECTIVE STUDY
  4335. 0456 Relation between Primary Aldosteronism and Obstructive Sleep Apnea
  4336. PS 14-76 CLINICAL CHARACTERISTICS OF THE YOUNG (=< 40Y) WITH PRIMARY ALDOSTERONISM IN JAPAN
  4337. … Does Contralateral Suppression at Adrenal Venous Sampling Predict Outcome Following Unilateral Adrenalectomy for Primary Aldosteronism? A Retrospective Study
  4338. LBPS 02-37 ADRENAL HEMORRHAGE FOLLOWING ADRENAL VEIN SAMPLING IN PRIMARY ALDOSTERONISM: A SIX-CENTER EXPERIENCE.
  4339. Perioperative nursing of 44 patients with primary aldosteronism undergoing super-selective adrenal arterial embolization
  4340. P-158: Long-term evolution of blood pressure and kalemia in patients with primary aldosteronism: surgical treatment versus medical treatment
  4341. MP03-07 ADRENALECTOMY ATTENUATES THE RISK OF END STAGE RENAL DISEASE OF PRIMARY ALDOSTERONISM–A COMPETING RISK ANALYSIS
  4342. 5.4. 2. Primary Aldosteronism
  4343. [OP. 6B. 02] LONG-TERM EFFECTS OF ADRENALECTOMY OR SPIRONOLACTONE ON ARTERIAL STIFFNESS IN PRIMARY ALDOSTERONISM
  4344. MP03-08 POST ADRENALECTOMY RENAL FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4345. A14761 Random 24-hour urinary sodium and Aldosterone excretion in hypertensive patients may indicate underlying primary aldosteronism
  4346. [PP. 17.22] PRIMARY ALDOSTERONISM AND TWIN PREGNANCY WITH INTRAUTERINE DEATH OF ONE FOETUS: A CASE REPORT
  4347. Imaging mass spectrometry reveals co-accumulation of Aldosterone and 18-oxocortisol with CYP11B2 in pre-adenomatous states of primary aldosteronism
  4348. 11C-metomidate PET-CT in primary aldosteronism: five possible indications for a non-invasive alternative to adrenal vein sampling
  4349. … -TO-RENIN RATIO IS A PREDICTOR OF DECREMENT IN GLOMERULAR FILTRATION RATE AFTER ADRENALECTOMY FOR PRIMARY ALDOSTERONISM
  4350. S-322: Unmasked renal damage after unilateral adrenalectomy for primary aldosteronism: Report of two cases
  4351. PP. 09.07: THE NECESSITY OF ADRENAL VENOUS SAMPLING IN ALDOSTERONISM PATIENTS YOUNGER THAN AGE 45
  4352. [PP. 27.05] THE THERAPEUTIC EFFECT OF BROMOCRIPTINE IN COMBINATION WITH SPIRONOLACTONE IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4353. PS 14-73 SUBTYPE CLASSIFICATION OF PRIMARY ALDOSTERONISM WITH SUBCLINCAL CUSHING SYNDROME BY SUPER-SELECTIVE ADRENAL VEIN …
  4354. … ] COSYNTROPIN INFUSION SIGNIFICANTLY INFLUENCES THE RESULTS OF ADRENAL VENOUS SAMPLING IN PATIENTS WITH PRIMARY ALDOSTERONISM.
  4355. … -FOUR HOUR BLOOD PRESSURE PROFILE AND LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS WITH PRIMARY ALDOSTERONISM
  4356. [OP. 6B. 04] DEVELOPMENT OF A PREDICTION MODEL FOR PATIENTS WITH SUSPECTED PRIMARY ALDOSTERONISM AND AN INCONCLUSIVE SALT …
  4357. PP. 09.30: DIETARY SALT INTAKE AND RENAL DAMAGE IN PRIMARY ALDOSTERONISM
  4358. [BP. 08.05] SUBTYPING OF PRIMARY ALDOSTERONISM BY AVS: HORMONE-AND SIDE-SPECIFIC EFFECTS OF COSYNTROPIN AND METOCLOPRAMIDE
  4359. … BETWEEN T REGULATORY AND TH17 LYMPHOCYTE SUBSETS IN PATIENTS WITH RESISTANT hypertension AND PRIMARY ALDOSTERONISM
  4360. … COMPARISON OF LEFT VENTRICULAR STRUCTURE AND FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension
  4361. CYP11B2/CYP11B1 Immunophenotyping of 111 Adrenal Glands Excised from Primary Aldosteronism Patients leads to a Novel Classification of the Disease
  4362. PP. 09.13: COMPLIANCE WITH ANTIHYPERTENSIVE TREATMENT IN PRIMARY ALDOSTERONISM
  4363. PP. 09.29: AORTIC DILATATION IN PATIENTS WITH PRIMARY ALDOSTERONISM AFTER THERAPY WITH MINERALOCORTICOID RECEPTORS ANTAGONISTS
  4364. Abstract P212: A Meta Analysis of Somatic KCNJ5 Mutations in 1636 Primary Aldosteronism Patients
  4365. … ] SUPPRESSION OF Aldosterone SECRETION AFTER RECUMBENT SALINE INFUSION DOES NOT EXCLUDE LATERALIZED PRIMARY ALDOSTERONISM
  4366. Supplementary Fig. 3. Biochemical and clinical characteristics of patients with primary aldosteronism in the COAR and SIE cohorts. To compare the numbers of …
  4367. … : ASSOCIATION OF PLASMA Aldosterone CONCENTRATION WITH PREVALENCE OF DIABETES MELLITUS IN SUSPECTED PRIMARY ALDOSTERONISM
  4368. [PP. 27.21] hypertension AND PRIMARY ALDOSTERONISM
  4369. 44 IMPACT OF ADRENAL VENOUS SAMPLING (AVS) ON DETERMINATION OF RESPONSIBLE LESION OF PRIMARY ALDOSTERONISM (PA)
  4370. S-448: Bilateral Adrenal Adenomas in the Presence of Primary Aldosteronism
  4371. Melanocortin 2 Receptor Mutations and Clinical Significance in Case of Cushing Syndrome and Subclinical Cushing Syndrome and Primary Aldosteronism
  4372. PP. 23.22: CARDIAC REMODELING IN PATIENTS WITH PRIMARY AND SECONDARY ALDOSTERONISM
  4373. … RENIN-Aldosterone AXIS DEFICIENCY WITHOUT HYPERKALEMIA FOLLOWING UNILATERAL ADRENALECTOMY FOR PRIMARY ALDOSTERONISM
  4374. … BY PULSE WAVE VELOCITY PREDICTIVE OF THE IMPROVEMENT OF hypertension AFTER ADRENAL SURGERY FOR PRIMARY ALDOSTERONISM?
  4375. … PHASE OF THE MENSTRUAL CYCLE AFFECT THE RESULTS OF ADRENAL VENOUS SAMPLING AND SUBTYPING OUTCOME OF PRIMARY ALDOSTERONISM …
  4376. [OP. 3A. 05] THE USE OF PREDICTION SCORE TO DIAGNOSE UNILATERAL DISEASE IN CHINESE PATIENTS WITH PRIMARY ALDOSTERONISM
  4377. PP. 23.20: PRIMARY ALDOSTERONISM AND hypertension
  4378. S-445 Outcomes Analysis of Surgical and Medical Treatments for Patients with Primary Aldosteronism
  4379. [PP. 25.02] A NOVEL TREATMENT FOR BILATERAL HYPERPLASIA AS A CAUSE OF PRIMARY ALDOSTERONISM
  4380. [OP. LB01. 11] MEASUREMENT OF ANGIOTENSIN II AT EQUILIBRIUM IN THE DIAGNOSTIC WORKUP OF PRIMARY ALDOSTERONISM. IMPACT OF PATIENT …
  4381. [OP. 6D. 07] ASSESSMENT OF THE QUANTITATIVE VALUE OF THE Aldosterone-RENIN RATIO (ARR) FOR PRIMARY ALDOSTERONISM (AQUARR) STUDY
  4382. [LB. 03.20] APPLICATIONS OF RAS-EQUILIBRIUM-ANALYSIS IN THE DIAGNOSIS OF PRIMARY ALDOSTERONISM AND BIOCHEMICAL PROFILING OF …
  4383. LBPS 02-61 GUIDELINES FOR PRIMARY ALDOSTERONISM: UPTAKE BY PRIMARY CARE PHYSICIANS IN EUROPE
  4384. … -ANGIOTENSIN SYSTEMS AND OXIDATIVE STRESS IN TUBULAR CAN BE THE ORIGINAL MECHANISM OF RENAL DAMAGE IN PRIMARY ALDOSTERONISM
  4385. [PP. 25.13] PRIMARY ALDOSTERONISM AND LEFT VENTRICLE IN 2D ECHOCARDIOGRAPHY: NEW INSIGHTS
  4386. 9B. 01: CLINICAL SIGNIFICANCE OF CONTRALATERAL ADRENAL SUPPRESSION DURING ADRENAL VEIN SAMPLING IN PRIMARY ALDOSTERONISM.
  4387. PS 14-74 EVALUATION OF INSULIN SENSITIVITY AND SECRETION IN PRIMARY ALDOSTERONISM
  4388. SP 01-2 HYPERTENSIVE TARGET ORGAN DAMAGE IN PRIMARY ALDOSTERONISM
  4389. [PP. 25.15] THYROID ABNORMALITIES IN PRIMARY ALDOSTERONISM
  4390. … OF STRESS REACTION ON THE ASSESSMENT OF LATERALIZATION DURING SEQUENTIAL ADRENAL VEIN SAMPLING FOR PRIMARY ALDOSTERONISM
  4391. … TYPE: ORAL OR POSTER ABSTRACT SUBMISSION NO.: PN-2639; THE RELATIONSHIP BETWEEN PARATHYROID HORMONE AND PRIMARY ALDOSTERONISM
  4392. PD1-01 AORTIC CALCIFICATION INDEX (ACI) OF THE PATIENTS WITH PRIMARY ALDOSTERONISM (PA) IS AN INDEPENDENT PREDICTOR OF HYPERTENSIVE …
  4393. OS 05-06 IN PRIMARY ALDOSTERONISM, MINERALOCORTICOIDS AND POTASSIUM INFLUENCE ABUNDANCE OF THE THIAZIDE SENSITIVE SODIUM …
  4394. PP. 09.24: A META ANALYSIS OF 1504 PRIMARY ALDOSTERONISM PATIENTS WITH Aldosterone PRODUCING ADENOMA GENOTYPED FOR KCNJ5 …
  4395. PP. 09.22: POTENTIAL EFFECTS OF AGE ON SCREENING FOR PRIMARY ALDOSTERONISM
  4396. … POTASSIUM TO URINARY SODIUM DIVIDED BY SERUM POTASSIUM TO SERUM SODIUM (UPUSPS) AS A SCREENING TOOL FOR PRIMARY ALDOSTERONISM
  4397. [PP. 23.15] RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS, RISK FACTORS, FREQUENCY OF PRIMARY ALDOSTERONISM AND THE NUMBER OF …
  4398. … ANALYSIS OF THIAZIDE SODIUM COTRANSPORTER IN URINARY EXOSOMES FROM NORMAL CONTROLS AND PATIENTS WITH PRIMARY ALDOSTERONISM
  4399. [OP. LB01. 12] CACNA1H MUTATIONS ARE ASSOCIATED WITH YOUNG ONSET AND FAMILIAL FORMS OF PRIMARY ALDOSTERONISM
  4400. … AMONG DIETARY SALT, Aldosterone AND LEFT VENTRICULAR STRUCTURE IN PATIENT S WITH PRIMARY ALDOSTERONISM-A CASE-CONTROL STUDY
  4401. [PP. 07.12] ARMC5 MUTATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM AND BILATERAL ADRENAL LESIONS
  4402. … 23.18: POSTOPERATIVE DYNAMICS IN PULSE WAVE VELOCITY AND PARAMETERS OF LOCAL CAROTID ARTERY STIFFNESS IN PRIMARY ALDOSTERONISM
  4403. … -79 ROLE OF ENDOGENOUS ADRENOCORTICOTROPIC HORMONE ON CIRCADIAN Aldosterone RHYTHM IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4404. … ON MORNING AND EVENING BLOOD PRESSURE MEASURED BY SELF-MEASURED BLOOD PRESSURE MONITORING IN PRIMARY ALDOSTERONISM …
  4405. PS 14-84 PREDICTORS OF BLOOD PRESSURE OUTCOME FOLLOWING LAPAROSCOPIC UNILATERAL ADRENALECTOMY IN PRIMARY ALDOSTERONISM
  4406. PP. 09.26: AMBULATORY BLOOD PRESSURE MONITORING-DERIVED SHORT-TERM BLOOD PRESSURE VARIABILITY IN PRIMARY ALDOSTERONISM
  4407. … INDEX AND CONTRALATERAL RATIO PREDICT BLOOD PRESSURE OUTCOME FOLLOWING UNILATERAL ADRENALECTOMY IN PRIMARY ALDOSTERONISM
  4408. [PP. 25.16] FREQUENCY OF PRIMARY ALDOSTERONISM IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA–OSA-PA STUDY
  4409. [PP. 25.17] THE AA2-RATIO: IMPROVED SCREENING FOR PRIMARY ALDOSTERONISM IN hypertension
  4410. [PP. 25.07] EVOLUTION OF COMPUTED TOMOGRAPHY-DETECTABLE ADRENAL NODULES IN PATIENTS WITH BILATERAL PRIMARY ALDOSTERONISM
  4411. [OP. 3A. 04] ADRENAL HEMORRHAGE FOLLOWING ADRENAL VEIN SAMPLING IN PRIMARY ALDOSTERONISM: A SIX-CENTER EXPERIENCE
  4412. Circulating levels of miR24-1 cluster microRNAs are increased in primary aldosteronism
  4413. PP. 09.28: INCREASED URINARY RELEASE OF ENAC-ACTIVATING PROSTASIN IN PATIENTS AFFECTED BY PRIMARY ALDOSTERONISM
  4414. PP. 23.21: IMMUNO-PHENOTYPIC CHARACTERIZATION OF LATERALIZED PRIMARY ALDOSTERONISM WITH NOVEL MONOCLONAL ANTIBODIES AGAINST …
  4415. PD3-02 IN PRIMARY ALDOSTERONISM WITH BILATERAL ADRENAL ADNOMAS, LAPAROSCOPIC BILATERAL ADRENAL SURGERY COULD BE AN OPTIONAL …
  4416. … . 23.19: ACTIVATED INTRARENAL RENIN-ANGIOTENSIN-SYSTEM CONTRIBUTES TO THE DEVELOPMENT OF RENAL DAMAGE IN PRIMARY ALDOSTERONISM
  4417. PP. 23.24: THE AA2-RATIO: A NOVEL SCREENING TEST FOR PRIMARY ALDOSTERONISM IN HYPERTENSIVE PATIENTS
  4418. Measurement of Peripheral Blood 18-Oxocortisol as the Diagnostic Method of Primary Aldosteronism and Its Subtypes
  4419. GW24-e2292 The complement c1q tumor necrosis factor-related protein 1 level in patients with sleep apnea and primary aldosteronism
  4420. PP. 32.13: CAN 128-SLICE DUAL-SOURCE CT REPLACE ADRENAL VEIN SAMPLING FOR SUBTYPING PATIENTS WITH PRIMARY ALDOSTERONISM?
  4421. The Adrenal Vein Sampling International Study-2: Results in 1636 Primary Aldosteronism Patients
  4422. P1-10: Renin-Aldosterone axis deficiency without frank hyperkalemia following unilateral adrenalectomy for primary aldosteronism (PA): about 4 cases
  4423. MP12-06 MEDIUM-TERM OUTCOMES AFTER LAPAROSCOPIC ADRENALECTOMY FOR PRIMARY ALDOSTERONISM
  4424. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
  4425. The unrecognized prevalence of primary aldosteronism: a cross-sectional study
  4426. Primary aldosteronism: where are we now? Where to from here?
  4427. Genetic causes of primary aldosteronism
  4428. Evolution of the primary aldosteronism syndrome: updating the approach
  4429. Prevalence, diagnosis and outcomes of treatment for primary aldosteronism
  4430. Renal damage in primary aldosteronism: a systematic review and meta-analysis
  4431. Primary Aldosteronism: JACC State-of-the-Art Review
  4432. Primary aldosteronism is a public health issue: challenges and opportunities
  4433. Primary aldosteronism in patients in China with recently detected hypertension
  4434. Old and new genes in primary aldosteronism
  4435. Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives
  4436. Classification of microadenomas in patients with primary aldosteronism by steroid profiling
  4437. Genetic and genomic mechanisms of primary aldosteronism
  4438. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion
  4439. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism
  4440. Screening rates for primary aldosteronism in resistant hypertension: a cohort study
  4441. Primary aldosteronism: Treatment of the disease, and new therapeutic approaches
  4442. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit
  4443. Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization
  4444. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY …
  4445. Progress in primary aldosteronism 2019: new players on the block?
  4446. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism
  4447. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism
  4448. Pathogenesis and treatment of primary aldosteronism
  4449. Primary aldosteronism: at the tipping point
  4450. MANAGEMENT OF ENDOCRINE DISEASE: The role of confirmatory tests in the diagnosis of primary aldosteronism
  4451. Primary aldosteronism: cardiovascular risk, diagnosis, and management
  4452. Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta‐analysis
  4453. Endothelial dysfunction in primary aldosteronism
  4454. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism
  4455. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism
  4456. Primary aldosteronism
  4457. Primary aldosteronism in the elderly
  4458. Development and validation of prediction models for subtype diagnosis of patients with primary aldosteronism
  4459. Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study
  4460. Low quality of reports on blood pressure in patients adrenalectomized for unilateral primary aldosteronism
  4461. Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism
  4462. The effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism
  4463. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism
  4464. Left ventricular remodeling and dysfunction in primary aldosteronism
  4465. Primary Aldosteronism: Mutations, Mechanisms, Prevalence, and Public Health
  4466. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis
  4467. Safety of medical adjustment and confirmatory testing in the diagnostic work-up of primary aldosteronism
  4468. Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling
  4469. Predictors of clinical success after surgery for primary aldosteronism in the Japanese Nationwide Cohort
  4470. Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism–Findings From the German Conn’s Registry
  4471. Characterization and gene expression analysis of serum-derived extracellular vesicles in primary aldosteronism
  4472. Seated saline infusion test in predicting subtype diagnosis of primary aldosteronism
  4473. Developments in primary aldosteronism subtyping using steroid profiling
  4474. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension
  4475. Precise mapping of intra-adrenal Aldosterone activities provides a novel surgical strategy for primary aldosteronism
  4476. Long-Term mortality for patients of primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis
  4477. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism
  4478. Steroid profiling and immunohistochemistry for subtyping and outcome prediction in primary aldosteronism—a review
  4479. Age, gender, and body mass index as determinants of surgical outcome in primary aldosteronism
  4480. Hypokalemia and the prevalence of primary aldosteronism
  4481. Primary aldosteronism diagnosis and management: A clinical approach
  4482. Discordance between imaging and adrenal vein sampling in primary aldosteronism irrespective of interpretation criteria
  4483. Primary aldosteronism and obstructive sleep apnea: casual association or pathophysiological link?
  4484. Role of Aldosterone and potassium levels in sparing confirmatory tests in primary aldosteronism
  4485. Primary aldosteronism: present and future
  4486. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension
  4487. 11C‐Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice
  4488. Variability of Aldosterone measurements during adrenal venous sampling for primary aldosteronism
  4489. Low-grade Cortisol Cosecretion Has Limited Impact on ACTH-stimulated AVS Parameters in Primary Aldosteronism
  4490. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism
  4491. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth
  4492. Effects of mineralocorticoid and AT1 receptor antagonism on the Aldosterone-renin ratio in primary aldosteronism—the EMIRA study
  4493. Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism
  4494. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism
  4495. China nationwide screening and registry of primary aldosteronism in hypertensive patients
  4496. Targeted treatment of primary aldosteronism–The consensus of Taiwan Society of Aldosteronism
  4497. The potential pathophysiological role of Aldosterone and the mineralocorticoid receptor in anxiety and depression–Lessons from primary aldosteronism
  4498. Basal plasma Aldosterone concentration predicts therapeutic outcomes in primary aldosteronism
  4499. Primary aldosteronism subtype discordance between computed tomography and adrenal venous sampling
  4500. Circulating miRNA expression profiling in primary aldosteronism
  4501. KCNJ5 Somatic Mutation Is a Predictor of hypertension Remission After Adrenalectomy for Unilateral Primary Aldosteronism
  4502. Baseline plasma Aldosterone level and renin activity allowing omission of confirmatory testing in primary aldosteronism
  4503. Familial Aggregation and Heritability of Aldosteronism with Cardiovascular Events
  4504. Diverse pathological lesions of primary aldosteronism and their clinical significance
  4505. Vitamin D supplementation: a novel therapy for aldosteronism?
  4506. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than …
  4507. Functional imaging by 11C-metomidate PET: a really useless technique for primary aldosteronism subtyping?
  4508. The risk factors for hepatic steatosis in patients with primary aldosteronism
  4509. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine hypertension of …
  4510. Left Ventricular Dysfunction in Patients With Primary Aldosteronism: A Propensity Score–Matching Follow‐Up Study With Tissue Doppler Imaging
  4511. Adrenal insufficiency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact
  4512. Disease monitoring of Primary Aldosteronism
  4513. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism
  4514. Primary aldosteronism with nonlocalizing imaging
  4515. International histopathology consensus for unilateral primary aldosteronism
  4516. Aldosterone-potassium ratio predicts primary aldosteronism subtype
  4517. Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism
  4518. Cellular Pathophysiology of Mutant Voltage-Dependent Ca2+ Channel CACNA1H in Primary Aldosteronism
  4519. Outcomes after surgery for unilateral dominant primary aldosteronism in Sweden
  4520. The crosstalk between Aldosterone and calcium metabolism in primary aldosteronism: a possible calcium metabolism-associated aberrant “neoplastic” …
  4521. Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography
  4522. Renin-angiotensin-Aldosterone system triple-A analysis for the screening of primary aldosteronism
  4523. Primary aldosteronism: cardiovascular outcomes pre-and post-treatment
  4524. Aldosterone reduction rate after saline infusion test may be a novel prediction in patients with primary aldosteronism
  4525. Primary aldosteronism: does underlying pathology impact clinical presentation and outcomes following unilateral adrenalectomy?
  4526. Immunohistochemistry of the human adrenal CYP11B2 in normal individuals and in patients with primary aldosteronism
  4527. Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping
  4528. Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism
  4529. Primary Aldosteronism decreases insulin secretion and increases insulin clearance in humans
  4530. Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: an important tool for improved patient follow-up
  4531. MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism
  4532. Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system
  4533. Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism
  4534. Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS
  4535. Clinical outcomes after surgery for primary aldosteronism: Evaluation of the PASO-investigators’ consensus criteria within a worldwide cohort of patients
  4536. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the …
  4537. Salt appetite and its effects on cardiovascular risk in primary aldosteronism
  4538. Effects of ramipril on the Aldosterone/renin ratio and the Aldosterone/angiotensin II ratio in patients with primary aldosteronism
  4539. Aldosterone to renin ratio as screening tool in primary aldosteronism
  4540. Primary aldosteronism in a general population sample. The Czech post-MONICA study
  4541. … number of positive confirmatory tests is associated with the clinical presentation and incidence of cardiovascular and cerebrovascular events in primary aldosteronism
  4542. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension
  4543. Significance of Discordant Results Between Confirmatory Tests in Diagnosis of Primary Aldosteronism
  4544. Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling
  4545. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism
  4546. obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism
  4547. Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis
  4548. hypertension with primary aldosteronism is associated with increased carotid intima‐media thickness and endothelial dysfunction
  4549. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism
  4550. Impact of Victoria’s first dedicated Endocrine hypertension Service on the pattern of primary aldosteronism diagnoses
  4551. Cosyntropin stimulation in adrenal vein sampling improves the judgment of successful adrenal vein catheterization and outcome prediction for primary aldosteronism
  4552. Enigma of the origin of primary aldosteronism
  4553. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism
  4554. Simultaneous bilateral adrenal vein sampling for primary aldosteronism: useful tips to make it simple and safe
  4555. Development of a prediction score to avoid confirmatory testing in patients with suspected primary aldosteronism
  4556. Influence of Different Treatment Strategies on New‐Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort‐Based …
  4557. Risk of new-onset autoimmune diseases in primary aldosteronism: A nation-wide population-based study
  4558. Utility of microcatheter in adrenal venous sampling for primary aldosteronism
  4559. Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism
  4560. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function
  4561. Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of Aldosterone normalization
  4562. Primary aldosteronism in elderly, old, and very old patients
  4563. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism
  4564. Unilateral disease is common in patients with primary aldosteronism without adrenal nodules
  4565. Effects of primary Aldosteronism and different therapeutic modalities on glucose metabolism
  4566. Evaluation of biochemical conditions allowing bypass of confirmatory testing in the workup of primary aldosteronism: a retrospective study in a French hypertensive …
  4567. Clinical presentation and surgical outcomes in primary aldosteronism differ by race
  4568. Application of CT texture analysis to assess the localization of primary aldosteronism
  4569. Long-term blood pressure outcomes of patients with adrenal venous sampling-proven unilateral primary aldosteronism
  4570. Atrial fibrillation in primary aldosteronism
  4571. Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism
  4572. The prevalence of primary aldosteronism and evolving approaches for treatment
  4573. Primary Aldosteronism: Strike Two
  4574. A disease-specific Quality of Life questionnaire for primary aldosteronism
  4575. Serum-soluble (pro) renin receptor concentration as a biomarker for organ damage in primary aldosteronism
  4576. Primary Aldosteronism: Three Strikes and Out
  4577. The Aldosterone to renin ratio in the diagnosis of primary aldosteronism: promises and challenges
  4578. Quality of life in primary aldosteronism: A prospective observational study
  4579. Letter to the Editor from Zhu and Rossi:“Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism”
  4580. New advances in the diagnosis of primary aldosteronism
  4581. Impact of cone beam-CT on adrenal vein sampling in primary aldosteronism
  4582. Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection
  4583. Abdominal aortic calcification is more severe in unilateral primary aldosteronism patients and is associated with elevated Aldosterone and parathyroid hormone levels
  4584. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism
  4585. Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome
  4586. The Unrecognized Prevalence of Primary Aldosteronism
  4587. Higher prevalence of metabolic disorders in patients with bilateral primary aldosteronism than unilateral primary aldosteronism
  4588. Autonomous cortisol secretion influences psychopathological symptoms in patients with primary aldosteronism
  4589. The Aldosterone/renin ratio predicts cardiometabolic disorders in subjects without classic primary aldosteronism
  4590. The association of primary aldosteronism with glaucoma-related fundus abnormalities
  4591. Assessing the quality of guidelines for primary aldosteronism: which guidelines are worth applying in diverse settings?
  4592. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study
  4593. The impact of glucocorticoid co-secretion in primary aldosteronism on thyroid autoantibody titers during the course of disease
  4594. Surgical Outcomes Among Primary Aldosteronism Patients Without Visible Adrenal Lesions
  4595. Exploration Of The Seated Saline Suppression Test For The Diagnosis Of Primary Aldosteronism In The Chinese Population
  4596. Adrenalectomy for primary aldosteronism: significant variability in work-up strategies and low guideline adherence in worldwide daily clinical practice
  4597. Diabetes mellitus itself increases cardio-cerebrovascular risk and renal complications in primary aldosteronism
  4598. Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids
  4599. Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan
  4600. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among US Veterans: A Retrospective Cohort Study
  4601. Outcomes in unilateral primary aldosteronism after surgical or medical therapy
  4602. Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study
  4603. Adrenal venous sampling in young patients with primary aldosteronism. Extravagance or irreplaceable?
  4604. Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism
  4605. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism
  4606. Extracellular vesicles as biomarkers and biovectors in primary aldosteronism
  4607. Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism: A Prospective Cohort Study
  4608. Heterogenous Responses to Cosyntropin in Primary Aldosteronism: Commentary to: Three Discrete Patterns of Primary Aldosteronism Lateralization in Response to …
  4609. Surgical approach to patients with primary aldosteronism
  4610. Response to Letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping
  4611. Lateralizing asymmetry of adrenal imaging and adrenal vein sampling in patients with primary aldosteronism
  4612. Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT)
  4613. Comparisons of skin microvascular changes in patients with primary aldosteronism and essential hypertension
  4614. Primary aldosteronism complicated by hyperparathyroidism: report of one case and literature review
  4615. Proteomic profile of urinary extracellular vesicles identifies AGP1 as a potential biomarker of primary aldosteronism
  4616. Association of Adrenal Venous Sampling With Outcomes in Primary Aldosteronism for Unilateral Adenomas
  4617. Patients with primary aldosteronism respond to unilateral adrenalectomy with long-term reduction in salt intake
  4618. The quality of clinical practice guidelines and consensuses on the management of primary aldosteronism: A critical appraisal
  4619. Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtype‐Specific Alterations
  4620. Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met
  4621. Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism
  4622. CACNA1H Calcium Channel Mutations in Primary Aldosteronism – Is Sodium the Culprit?
  4623. Molecular mechanisms in primary aldosteronism
  4624. Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism
  4625. A speckle tracking echocardiographic study on right ventricular function in primary aldosteronism
  4626. Arterial Stiffness Is Associated with Clinical Outcome and Cardiorenal Injury in Lateralized Primary Aldosteronism
  4627. Timeline of Advances in Genetics of Primary Aldosteronism
  4628. The captopril challenge test for diagnosing primary Aldosteronism in a Chinese population
  4629. Using microwave thermal ablation to develop a subtotal, cortical-sparing approach to the management of primary aldosteronism
  4630. Dr. Conn Lives on: Insights Into Screening and Genetics of Primary Aldosteronism
  4631. Repeat adrenal vein sampling in aldosteronism: reproducibility and interpretation of persistently discordant results
  4632. Left-right differences in adrenal vein sampling for primary aldosteronism
  4633. Long-term outcome success after operative treatment for primary aldosteronism
  4634. Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review
  4635. Primary aldosteronism: Novel insights
  4636. Sleep-EEG in patients with primary aldosteronism in comparison to healthy controls and patients with depression
  4637. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension
  4638. Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism
  4639. Plasma Aldosterone after seated saline infusion test outperforms captopril test at predicting clinical outcomes after adrenalectomy for primary aldosteronism
  4640. Prediction of unilateral hyperaldosteronism on adrenal vein sampling using captopril challenge test in patients with primary aldosteronism
  4641. … concentration and response to ACTH during simultaneous bilateral adrenal veins sampling to predict the source of Aldosterone secretion in primary aldosteronism
  4642. The Unrecognized Prevalence of Primary Aldosteronism
  4643. Comparison of ambulatory blood pressure between patients with primary aldosteronism and other forms of hypertension
  4644. Comparison of the shortened and standard saline infusion tests for primary aldosteronism diagnostics
  4645. Diagnostic accuracy of adrenal imaging for subtype diagnosis in primary aldosteronism: systematic review and meta-analysis
  4646. Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test—Variability Between Immunoassay and HPLC-MS/MS
  4647. Primary aldosteronism is associated with decreased low‐density and high‐density lipoprotein particle concentrations and increased GlycA, a pro‐inflammatory …
  4648. A Multicenter Study of Neutrophil-to-Lymphocyte Ratio in Primary Aldosteronism
  4649. Aldosterone level after saline infusion test could predict clinical outcome in primary aldosteronism after adrenalectomy
  4650. Higher blood urea nitrogen and urinary calcium: new risk factors for diabetes mellitus in primary aldosteronism patients
  4651. High body fat percentage is associated with primary aldosteronism: a cross-sectional study
  4652. Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea
  4653. High efficiency of the Aldosterone-to-renin ratio in precisely detecting primary aldosteronism
  4654. Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia
  4655. Speckle-Tracking Echocardiographic Layer-Specific Strain Analysis on Subclinical Left Ventricular Dysfunction in Patients With Primary Aldosteronism
  4656. Simplifying the Diagnosis of Primary Aldosteronism
  4657. Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome
  4658. … levels in peripheral veins following intravenous sedation during adrenal vein sampling: implications for the concept of nonsuppressibility in primary aldosteronism
  4659. Screening for primary aldosteronism:’How to adjust existing antihypertensive medications to avoid diagnostic errors’
  4660. Association between plasma Aldosterone and markers of tubular and glomerular damage in primary aldosteronism
  4661. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism
  4662. Taiwan mini-frontier of primary aldosteronism: Updating detection and diagnosis
  4663. Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment
  4664. Impact of primary aldosteronism on renal function in patients with type 2 diabetes
  4665. Transtubular potassium gradient predicts kidney function impairment after adrenalectomy in primary aldosteronism
  4666. Treatment of primary aldosteronism with mTORC1 inhibitors
  4667. Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea—what do we know so far?
  4668. Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome
  4669. Renal impairment is closely associated with plasma Aldosterone concentration in patients with primary aldosteronism
  4670. Non-neoplastic/hyperplastic primary aldosteronism–Its histopathology and genotype
  4671. Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism
  4672. Can incomplete adrenal venous sampling data be used in predicting the subtype of primary aldosteronism?
  4673. Guideline Adherence for Primary Aldosteronism: Breaking the Vicious Cycle
  4674. Primary Aldosteronism: New Insights Into its Detection and Cardiac Involvement
  4675. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling
  4676. Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trio
  4677. Segmental Adrenal Vein Sampling in Patients With Primary Aldosteronism: Superlative or Superfluous?
  4678. The value of the post-captopril Aldosterone/renin ratio for the diagnosis of primary aldosteronism and the influential factors: A meta-analysis
  4679. Bilateral Aldosterone suppression in patients with right unilateral primary aldosteronism and review of the literature
  4680. Mass spectrometry imaging establishes 2 distinct metabolic phenotypes of Aldosterone-producing cell clusters in primary aldosteronism
  4681. Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension
  4682. Primary aldosteronism concurrent with subclinical Cushing’s syndrome: a case report and review of the literature
  4683. Clinical characteristics of snoring patients with primary aldosteronism and obstructive sleep apnea–hypopnea syndrome
  4684. Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
  4685. Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism
  4686. Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism
  4687. Treatment of primary aldosteronism reduces the probability of obstructive sleep apnea
  4688. The Unrecognized Prevalence of Primary Aldosteronism
  4689. Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A cross‐sectional study
  4690. Urinary sodium potassium ratio is associated with clinical success after adrenalectomy in patients with unilateral primary aldosteronism
  4691. Splice-variant-specific effects of primary aldosteronism point mutations on human CaV3. 2 calcium channels
  4692. Diverse responses of autoantibodies to the angiotensin II type 1 receptor in primary aldosteronism
  4693. Novel chemiluminescent immunoassay to measure plasma Aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism
  4694. Primary aldosteronism: a consensus statement
  4695. Primary aldosteronism: considerations about the evaluation of the Aldosterone to renin ratio during canrenone treatment
  4696. Molecular Mechanisms of Primary Aldosteronism
  4697. Minor Change of Plasma Renin Activity during the Saline Infusion Test Provide an Auxiliary Diagnostic Value for Primary Aldosteronism
  4698. Trends in blood pressure-related outcomes after adrenalectomy in patients with primary aldosteronism: A systematic review
  4699. Effects of chronically high levels of Aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism
  4700. … diagnosis and identification of the chimeric CYP11B1/CYP11B2 gene in two pediatric cases of a Japanese family with glucocorticoid-remediable aldosteronism
  4701. Primary aldosteronism subtyping in the setting of partially successful adrenal vein sampling
  4702. Parameters of captopril challenge test can predict results of other confirmatory tests for primary aldosteronism and propose the next test to be done
  4703. Basal contralateral Aldosterone suppression is rare in lateralized primary aldosteronism
  4704. Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in hypertensive patients with primary aldosteronism
  4705. Letter to the editor: primary aldosteronism: does underlying pathology impact clinical presentation and outcomes following unilateral adrenalectomy?
  4706. Clinical outcomes of primary aldosteronism based on lateralization index and contralateral suppression index after adrenal venous sampling in real-world …
  4707. Clinical characteristics of concurrent primary aldosteronism and renal artery stenosis: A retrospective case–control study
  4708. Molecular basis of Primary Aldosteronism and adrenal Cushing
  4709. Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: Aldosterone‐producing adenoma and idiopathic hyperaldosteronism
  4710. Predicting factors related with uncured hypertension after retroperitoneal laparoscopic adrenalectomy for unilateral primary aldosteronism
  4711. Atherosclerotic Burden and Arterial Stiffness are Not Increased in Patients with Milder Forms of Primary Aldosteronism Compared to Patients with Essential …
  4712. Influence of adrenal venous sampling on management in patients with primary aldosteronism independent of lateralization on cross-sectional imaging
  4713. Evaluation of Adrenal Vein Sampling Use and Outcomes in Patients With Primary Aldosteronism
  4714. Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling
  4715. Significance of Aldosterone gradient within left adrenal vein in diagnosing unilateral subtype of primary aldosteronism
  4716. Web Exclusive. The Unrecognized Prevalence of Primary Aldosteronism.
  4717. Quality of life of primary aldosteronism patients by mineralocorticoid receptor antagonists
  4718. Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity
  4719. Reassessment of urinary Aldosterone measurement after saline infusion in primary aldosteronism
  4720. Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in Aldosterone-producing adenomas
  4721. Adrenal (Pro) renin Receptor Expression and Serum Soluble (Pro) renin Receptor Concentration in Primary Aldosteronism
  4722. Hypercortisolism and primary aldosteronism caused by bilateral adrenocortical adenomas: a case report
  4723. Primary aldosteronism in young adults with acute stroke: Prevalence and clinical characteristics
  4724. Feasibility and effectiveness of a single-catheter approach for adrenal vein sampling in patients with primary aldosteronism
  4725. Suspected Borderline Aldosteronism in hypertension: The Next Target?
  4726. Reply: Suspected Borderline Aldosteronism in hypertension: The Next Target?
  4727. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
  4728. Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference
  4729. 10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy
  4730. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies) Cause or Consequence of Human Primary Aldosteronism?
  4731. Myocardial mechano-energetic efficiency in primary aldosteronism
  4732. PREVALENCE, SUBTYPE CLASSIFICATION, AND OUTCOMES OF TREATMENT OF PRIMARY ALDOSTERONISM: A PROSPECTIVE STUDY IN CHINA
  4733. Adrenal vein sampling for primary aldosteronism: a 15-year national referral center experience
  4734. The Outcomes of Primary Aldosteronism Patients in the AVIS-2 Study
  4735. Primary Aldosteronism Associated with Multiple Adrenocortical Micronodules in a Patient with Renal Cell Carcinoma
  4736. Haemodynamics of primary aldosteronism associated with adrenocortical adenoma: insights from bioimpedance cardiography measurements
  4737. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof‐of‐principle trial
  4738. The Role of the CYP11B2 Promoter Polymorphism in the Diagnosis of Primary Aldosteronism
  4739. The Association between eGFR and the Aldosterone-to-Renin Ratio and Its Effect on Screening for Primary Aldosteronism
  4740. The 2020 Italian Society of Arterial hypertension (SIIA) practical guidelines for the management of primary aldosteronism
  4741. Letter to the Editor:“Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion”
  4742. Primary Aldosteronism in Newly Diagnosed Hypertensive Patients: Lessons From China
  4743. Minimally Invasive Partial Versus Total Adrenalectomy for the Treatment of Primary Aldosteronism: Results of a Multicenter Series According to the PASO Criteria
  4744. Response to Letter to the Editor: Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
  4745. A patient with bilateral primary aldosteronism refractory to oral eplerenone who responded to esaxerenone with increased renin activity
  4746. High Efficiency and Problems of Chemiluminescence Assay-Detected Aldosterone-To-Renin Ratio in Practical Primary Aldosteronism Screening
  4747. Unilateral primary aldosteronism as an independent risk factor for vertebral fracture
  4748. Masking by hypokalemia—primary aldosteronism with undetectable Aldosterone
  4749. A combination of captopril challenge test after saline infusion test improves diagnostic accuracy for primary aldosteronism
  4750. MON-LB129 A Pilot Genome Wide Association Study (GWAS) on Primary Aldosteronism Patients in a Multi-Ethnic Malaysian Cohort
  4751. … SUPPRESSION TESTING IS COMPARABLE TO CAPTOPRIL CHALLENGE TEST FOR THE DIAGNOSIS OF PRIMARY ALDOSTERONISM: A PROSPECTIVE STUDY
  4752. Response to Letter to the Editor:“Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism”
  4753. Preoperative non-stimulated adrenal venous sampling index for predicting outcomes of adrenalectomy for unilateral primary aldosteronism
  4754. Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
  4755. Primary aldosteronism and pregnancy
  4756. Subclinical Primary Aldosteronism and Cardiometabolic Disorders
  4757. Primary aldosteronism associated with a germline variant in CACNA1H
  4758. Adrenal Venous Sampling in Primary Aldosteronism: The Usefulness of Contralateral Suppression Index
  4759. The role of adrenal venous sampling and computed tomography in the management of primary aldosteronism
  4760. PREVALENCE AND CHARACTERISTICS OF METABOLIC SYNDROME AND ITS COMPONENTS IN PRIMARY ALDOSTERONISM: INCREASED PREVALENCE OF …
  4761. Angiotensin II type 1 receptor autoantibodies in primary aldosteronism
  4762. Feasibility of screening primary aldosteronism by Aldosterone-to-direct renin concentration ratio derived from chemiluminescent immunoassay measurement …
  4763. Adrenal vein sampling with and without cosyntropin stimulation for detection of surgically remediable aldosteronism
  4764. Primary aldosteronism long-term outcome: Medical versus surgical therapy
  4765. Assessing outcomes after adrenalectomy for unilateral primary aldosteronism
  4766. Steroid Profiling as an Additional Tool to Confirm One-Sided Hormone Overproduction in Primary Aldosteronism: A Case Report
  4767. Letter to the Editor:“Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism”
  4768. Biochemical and clinical characteristics of patients with primary aldosteronism–single centre experience
  4769. Automated Mindray CL-1200i chemiluminescent assays of renin and Aldosterone for the diagnosis of primary aldosteronism
  4770. … AND Aldosterone LEVELS AND CHANGES IN KIDNEY FUNCTION AFTER TREATMENT FOR PRIMARY ALDOSTERONISM: A LARGE MULTICENTER …
  4771. A primary aldosteronism-like phenotype identified with the Aldosterone-to-angiotensin II ratio in black men: the SABPA study: cardiovascular topics
  4772. A speckle-tracking echocardiographic study on right ventricular function in primary aldosteronism
  4773. Mineralocorticoid receptor-dependent impairment of baroreflex contributes to hypertension in a mouse model of primary aldosteronism
  4774. Increased Prevalence of Diabetes in Elderly Patients with Primary Aldosteronism
  4775. Challenges in obesity and primary aldosteronism: Diagnosis and treatment
  4776. … Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism
  4777. Germline and somatic genetic basis of primary aldosteronism
  4778. SUN-LB96 Basal Contralateral Aldosterone Suppression Is Rare in Lateralized Primary Aldosteronism and Can Be Useful in Predicting Surgical Outcome
  4779. Plasma levels of the cardiovascular protective endogenous nucleoside adenosine are reduced in patients with primary aldosteronism without affecting ischaemia …
  4780. CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy
  4781. … and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
  4782. Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center …
  4783. U-shaped relationship between left ventricular mass index and estimated glomerular filtration rate in patients with primary aldosteronism
  4784. Secondary Aldosteronism
  4785. Primary aldosteronism in hypertension: more than a factoid
  4786. Primary Aldosteronism
  4787. Nadir Aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism
  4788. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
  4789. Primary aldosteronism: Aldosterone/renin ratio cut-off points
  4790. Application of CT texture analysis to assess the localization of primary aldosteronism
  4791. Microvascular and macrovascular endothelial function in two different types of primary aldosteronism
  4792. The Cl−/HCO 3− exchanger pendrin is downregulated during oral co-administration of exogenous mineralocorticoid and KCl in patients with primary aldosteronism
  4793. SUN-LB92 The Importance of Early Diagnosis and Treatment of Primary Aldosteronism on the Progression of Chronic Kidney Disease, Compared With Essential …
  4794. Can unilateral forms of primary aldosteronism be excluded with confidence preoperatively by methods other than adrenal venous sampling? The search continues
  4795. Pregnancy induced Cushing’s syndrome and primary aldosteronism: a case report
  4796. Primary aldosteronism due to bilateral micronodular hyperplasia and concomitant subclinical Cushing’s syndrome: A case report
  4797. Letter to the Editor: Very high cortisol concentration in adrenal venous sampling in primary aldosteronism—physiological or pathological
  4798. Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met
  4799. Oral salt loading test is associated with 24-hour blood pressure and organ damage in primary aldosteronism patients
  4800. Incidence of Acute Kidney Injury after Adrenalectomy in Patients with Primary Aldosteronism
  4801. The Aldosterone index could be used to diagnose the dominant gland in primary aldosteronism—a retrospective study
  4802. MON-217 New Methods for Primary Aldosteronism Screening by Exploring the Values of Different Indicators and in Combination with Predictive Model
  4803. A Case of Primary Aldosteronism Due to A Primary Adrenal Adenoma Diagnosed by Segmental Adrenal Venous Sampling (S-AVS) Using a Modified Catheter …
  4804. Unusual presentation of primary aldosteronism with advanced target organ damage: A case report
  4805. Improvement of Cardiac Function by Laparoscopic Adrenalectomy in a Patient with Severe Heart Failure Attributable to Primary Aldosteronism
  4806. Primary aldosteronism: The Mayo Clinic approach
  4807. Development and validation of a novel chemiluminescent immunoassay for diagnosing primary aldosteronism
  4808. Challenging aspects of Primary Aldosteronism
  4809. Age-Stratified Comparison of Clinical Outcomes Between Medical and Surgical Treatments in Patients with Unilateral Primary Aldosteronism
  4810. Effects of mineralocorticoid and AT-1 receptor antagonism on the Aldosterone–renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and …
  4811. Left-versus-right-adrenal-volume ratio as a screening index before adrenal venous sampling to identify unilateral primary aldosteronism patients
  4812. SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
  4813. Developing a Research Database of Primary Aldosteronism: Rationale and Baseline Characteristics
  4814. Diagnostic Accuracy of the Aldosterone–to–Active Renin Ratio for Detecting Primary Aldosteronism
  4815. SAT-547 Aldosterone-Potassium Ratio Predicts Primary Aldosteronism Subtype
  4816. NONALCOHOLIC FATTY LIVER DISEASE IN TWO SUBTYPES OF PRIMARY ALDOSTERONISM
  4817. Response to Letter to the Editor from Zhu and Rossi:“Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism”
  4818. Update on the Diagnosis and Management of Primary Aldosteronism
  4819. Primary aldosteronism: Genetics and pathology
  4820. Electrochemical Detection of Kallikrein Using a p-Methoxyaniline-conjugated Tripeptide towards Simple Diagnosis of Primary Aldosteronism
  4821. Annals On Call-Underdiagnosis of Primary Aldosteronism
  4822. 11 C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature
  4823. DRUG-RESISTANT hypertension: A COMMON PRESENTATION OF PRIMARY ALDOSTERONISM IN THE AVIS-2:*: STUDY
  4824. High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young‐onset hypertension
  4825. … -131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series
  4826. SEX SPECIFICITY OF METABOLIC CHANGES IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4827. Primary Aldosteronism
  4828. Association of Papillary Thyroid Carcinoma with Primary Aldosteronism
  4829. Possible causes of plasma Aldosterone reduction in primary aldosteronism
  4830. Primary Aldosteronism: the Results of the Treatment According to the Data of Renal Arteries Duplex Scanning
  4831. Aldosterone-induced cardiac damage in primary aldosteronism depends on its subtypes
  4832. Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical versus Surgical Treatment: A Meta-Analysis
  4833. OR34-03 Variable and Pulsatile Circulating Aldosterone Levels in Primary Aldosteronism: Implications for Diagnosis and Sub-Type Differentiation
  4834. MON-197 Developing a Research Database About Primary Aldosteronism: Rationale and Baseline Characteristics
  4835. SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
  4836. SURGICAL TREATMENT OF THE PATIENTS WITH PRIMARY ALDOSTERONISM
  4837. Update and Research Progress in the Diagnosis of Primary Aldosteronism
  4838. Primary Aldosteronism: A Glimpse into the Most Common Endocrine Cause of Arterial hypertension
  4839. MALIGNANT hypertension: A CLINICAL PRESENTATION OF PRIMARY ALDOSTERONISM
  4840. IS CONFIRMATORY TESTING NEEDED IN ALL PATIENTS WITH POSITIVE SCREENING TEST FOR PRIMARY ALDOSTERONISM?
  4841. CMR-Verified Myocardial Fibrosis is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients
  4842. OR34-02 Somatic Transmembrane Domain Mutations of a Cell Adhesion Molecule, CADM1, Cause Primary Aldosteronism by Preventing Gap Junction …
  4843. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study
  4844. Cardiovascular Events and All-Cause Mortality in Surgically or Medically Treated Primary Aldosteronism: A Meta-Analysis
  4845. Transient pseudohypo-aldosteronism
  4846. Primary aldosteronism-why is it still underdiagnosed in clinical practice?
  4847. Erythromelalgia Caused by Polycythemia Vera Combined with Primary Aldosteronism
  4848. PRIMARY ALDOSTERONISM
  4849. URINARY EXOSOMAL MRNA ANALYSIS OF NCC IN PRIMARY ALDOSTERONISM
  4850. Primary Aldosteronism: It’s Out There
  4851. A case of primary aldosteronism with resistant hypertension successfully treated by unilateral adrenalectomy after unsuccessful classification of subtype in adrenal …
  4852. Curative resection of an aldosteronoma causing primary aldosteronism in the second trimester of pregnancy
  4853. Clinical characteristics of primary aldosteronism in newly diagnosed diabetes mellitus with hypertensive patients.
  4854. Aldosterone to Potassium Ratio after Adrenocorticotropin Stimulation in Unilateral Primary Aldosteronism Diagnosis
  4855. Association of Outcome Definitions With Success Following Adrenalectomy for Primary Aldosteronism
  4856. Should all Hypertensive Patients be Screened for Primary Aldosteronism?
  4857. Clinical Presentation, Diagnosis, and Management of Primary Aldosteronism and Pheochromocytoma
  4858. Aldosteronism with elevated active renin concentration: Primary versus secondary? Importance of follow-up for the diagnosis
  4859. PRIMARY ALDOSTERONISM: LC-MS/MS ASSAY FOR 24-HOUR URINE Aldosterone DETERMINATION IMPROVES SCREENING
  4860. PREVALENCE OF PRIMARY ALDOSTERONISM IN A GENERAL POPULATION SAMPLE OF HYPERTENSIVE SUBJECTS. THE CZECH POST-MONICA STUDY
  4861. DIABETES MELLITUS AND THE METABOLIC SYNDROME IN PATIENTS WITH PRIMARY ALDOSTERONISM IN XIN JIANG IN NORTH-WEST CHINA: SEX SPECIAL …
  4862. Prevalence and Clinical Phenotype of Primary Aldosteronism in Primary Care Hypertensives
  4863. Spironolactone Chronotherapy of Hypertensive Patient with Aldosteronism: Case Report
  4864. SAT-545 Diabetes Mellitus Is the Risk Factor of Cardiovascular and Cerebrovascular Events in Primary Aldosteronism
  4865. Diagnostic Efficiency of Different Screening Indexes for Primary Aldosteronism
  4866. SUN-711 Association of Single Nucleotide Polymorphisms of CYP11B2, CYP11B1 and CYP17A1 with Primary Aldosteronism in a Multi-Ethnic Malaysian Cohort
  4867. Primary aldosteronism: follow up of 17 cases
  4868. SAT-540 Primary Aldosteronism Represents Earlier Myocardial Fibrosis Than Essential hypertension by T1 Mapping
  4869. MON-192 Comparison of the Seated and Recumbent Saline Infusion Test for the Diagnosis of Primary Aldosteronism in Chinese Population
  4870. Primary aldosteronism in Klinefelter’s syndrome: two cases
  4871. SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
  4872. MON-221 Seated Saline Suppression Testing Is Comparable to Captopril Challenge Test for the Diagnosis of Primary Aldosteronism: A Prospective Study
  4873. SAT-541 Difference in Aldosterone Dependency Between Cardiovascular Diseases and Renal Impairments in Patients with Primary Aldosteronism
  4874. SAT-556 Use of ACTH-Stimulated Lateralization Indices Underestimates Surgically Curable Primary Aldosteronism
  4875. … CUT-OFF PLASMA Aldosterone LEVEL MEASURED BY IMMUNOASSAY FOR THE DIAGNOSIS OF PRIMARY ALDOSTERONISM USING SEATED SALINE …
  4876. Stress the standardized diagnosis and management of primary aldosteronism
  4877. SUN-195 Bilateral Aldosterone-Producing Adenomas: A New Subtype of Bilateral Primary Aldosteronism?
  4878. Diagnosis and Treatment of Primary Aldosteronism in West China Hospital of Sichuan University from 2009 to 2018
  4879. Growth differentiation factor 15 levels are similar in primary aldosteronism and essential hypertension and do not predict arterial inflammation
  4880. SUN-378 Unilateral Primary Aldosteronism as an Independent Risk Factor for Vertebral Fracture
  4881. OR34-01 11C Metomidate PET-CT Identifies More Unilateral Primary Aldosteronism Than Adrenal Vein Sampling
  4882. Duplicate inferior vena cava complicating the evaluation of primary aldosteronism
  4883. Becoming of patients with primary aldosteronism according to their treatment
  4884. The Diagnostic Value of Captopril Challenge Test for Primary Aldosteronism
  4885. SUN-189 A Case of Delayed Hypoaldosteronism Following Unilateral Adrenalectomy for Primary Aldosteronism
  4886. … PRESSURE OUTCOME OF PATIENTS WITH ADRENAL VENOUS SAMPLING-PROVEN UNILATERAL PRIMARY ALDOSTERONISM: A RETROSPECTIVE STUDY …
  4887. OR34-04 Efficiency of Adrenal Venous Sampling in the Treatment Choice of Primary Aldosteronism (AVSTAT Study)
  4888. Aldosterone measurement in the Diagnosis of primary aldosteronism-comparison between two automated immunoassays and two liquid chromatography tandem …
  4889. … ON THE Aldosterone/RENIN RATIO AND Aldosterone/ANGIOTENSIN II RATIO IN PATIENTS WITH PRIMARY ALDOSTERONISM: A PILOT STUDY
  4890. SAT-LB76 Impact of Glucocorticoid Cosecretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease
  4891. Cardiovascular, cerebrovascular and metabolic risk in primary aldosteronism–beyond hypertension.
  4892. Non-sequential and non-stimulated bilateral adrenal vein sampling utility in primary aldosteronism: Case inform
  4893. SUN-175 Repeat Unstimulated AVS with Aid of Plasma Metanephrines Identifies Unilateral Primary Aldosteronism When Initial AVS and Metomidate PET-CT Fails To
  4894. Primary Aldosteronism
  4895. Cellular and Functional Defects in Aldosteronism-linked Cytosolic Domain Mutations in GIRK4 (KCNJ5)
  4896. SUN-161 Primary Aldosteronism and Klinefelter’s Syndrome: Two Cases
  4897. SAT-558 A Dedicated Endocrine hypertension Service Increases the Timely Diagnosis of Primary Aldosteronism
  4898. SAT-177 Relationship Between Visceral Fat and the Position of Adrenal Glands in Cranial-Caudal Direction in Patients with Primary Aldosteronism
  4899. Surgical treatment of hypertension: Preoperative work-up and surgical treatment of primary aldosteronism in current daily practice
  4900. Corrigendum: IRB Approval Number Correction. Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism
  4901. Clinical characteristics of primary aldosteronism with concurrent adrenal Cushing’s syndrome
  4902. Primary aldosteronism: Study of 09 cases
  4903. SAT-543 Human Hair Aldosterone Measurements for Evaluation of Primary Aldosteronism
  4904. Atrial Fibrillation is an Independent Predictor for Cardiovascular Events in Hypertensive Patients Due to Primary Aldosteronism
  4905. SUN-191 The Creatinine, the Crib and the Manometer-Navigating the Labyrinth of Primary Aldosteronism
  4906. Supplemental Data and Methods: Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralisation
  4907. Abstract P234: Pre-And Post-treatment Analysis Of Pendrin In The Urinary Exosome In Primary Aldosteronism
  4908. SAT-548 Significance of Adrenal Vein Aldosterone Gradient in the Diagnosis of Unilateral Subtype of Primary Aldosteronism
  4909. Primary Aldosteronism Complicated by Hypokalemic Rhabdomyolysis. A Clinical Case
  4910. Characterization and gene expression analysis of serum-derived extracellular vesicles in primary aldosteronism 2
  4911. SAT-551 Sparing Confirmatory Tests in Primary Aldosteronism
  4912. Reply to: Assessing outcomes after adrenalectomy for unliateral primary aldosteronism
  4913. Primary Aldosteronism due to a Sub Centimeter Unilateral Adrenal Adenoma.”. Endocrinology and Surgical Endocrinology, 1 (1); DOI: http
  4914. SAT-544 Primary Aldosteronism in Intracerebral Hemorrhage. Not Intracerebral Hemorrhage in Primary Aldosteronism
  4915. Normotensive primary aldosteronism in a young woman taking-minipill–case report
  4916. MON-207 Validating and Optimizing the Guideline Criterion for Skipping Confirmatory Tests of Primary Aldosteronism
  4917. SUN-LB36 Primary Aldosteronism Due Tosimultaneous Occurrence of Aldosteronoma in the Left Adrenal Gland and Ectopicaldosteronoma in the Liver: A Case …
  4918. Predictors of bilateral and unilateral primary aldosteronism: a retrospective observational study
  4919. ONLINE SUPPLEMENT Effect of Cosyntropin during Adrenal Venous Sampling on Subtype of Primary Aldosteronism: Analysis of Surgical Outcome
  4920. MON-200 Clinical Characterizations of Aldosterone-and Cortisol-Producing Adrenal Tumors in Primary Aldosteronism
  4921. Regression of left ventricular hypertrophy in primary aldosteronism after adrenalectomy: a meta-analysis of echocardiographic studies.
  4922. Application of Aldosterone/direct renin ratio before drug washout in the screening of primary aldosteronism
  4923. The effectiveness of treatment for primary aldosteronism in Iceland 2007–2016
  4924. Primary Aldosteronism is Under-Diagnosed, Partially Due to Insufficient Screening
  4925. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.
  4926. Development of radiofluorinated CYP11B2-Inhibitors for the differential diagnosis of primary aldosteronism
  4927. … : Dilated Cardiomyopathy With Electrocardiographic Changes And Coronary-Pulmonary Fistula: An Uncommon Presentation Of Primary Aldosteronism In The Covid …
  4928. Hypokalaemic cardiac arrest-a rare presentation of primary aldosteronism
  4929. Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism
  4930. EFFECTIVENESS OF RENAL DENERVATION IN SECONDARY ALDOSTERONISM RELATED hypertension FROM TAIWAN MULTICENTER EXPERIENCE
  4931. Primary aldosteronism (PA)-clinical and hormonal characteristics of a series of patients
  4932. Obstructive sleep apnea in primary aldosteronism is associated with cortisol cosecretion
  4933. Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS
  4934. Steroid profiling as an additional tool to confirm one-sided hormone overproduction in primary aldosteronism
  4935. Clinical and histopathologic phenotype of a single-center patient cohort operated for unilateral primary aldosteronism
  4936. Histopathological, biochemical and genetic characterization of different types of primary aldosteronism, including validation of a new angiotensin assay
  4937. Immunohistochemical characteristics of adrenal tumors in patients with primary aldosteronism
  4938. Intraoperative hypertensive crisis in a patient with normotensive primary aldosteronism. Lessons from a clinical case
  4939. The diagnostic accuracy of adjusted unconventional indices for adrenal vein sampling in the diagnosis of primary aldosteronism subtypes.
  4940. Analysis of circulating microRNAs in primary aldosteronism
  4941. Assessment of serum adropin concentrations in primary aldosteronism
  4942. A CASE OF PERSISTENT HYPOKALEMIA IN A NORMOTENSIVE PATIENT WITH PRIMARY ALDOSTERONISM
  4943. Evaluation of angiotensin II in primary aldosteronism and other forms of hypertension-a preliminary study
  4944. A Case of Giant Adrenal Adenoma Presenting Primary Aldosteronism
  4945. TARGET TREATMENT OF PRIMARY ALDOSTERONISM AFFECTS CARDIAC WORK AND BIOENERGETICS
  4946. Adrenal androgen measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism
  4947. Moderators of the psychotropic effect of Aldosterone in primary aldosteronism
  4948. Expression of CYP11B2 and CYP11B1 immunostaining in primary aldosteronism
  4949. Primary Aldosteronism due to a Sub Centimeter Unilateral Adrenal Adenoma
  4950. MON-LB062 A Preemptive Strike at Suspected Primary Aldosteronism in a Medically Underserved Patient
  4951. Measurement of metanephrine in adrenal venous sampling may help subtyping primary aldosteronism
  4952. SAT-LB41 Surgery Outcomes for Patients With Primary Aldosteronism Who Show Normal-Appearing Adrenals on Computed Tomography but Unilateral Disease on …
  4953. EHR-Based Modeling Specifically Identifies Patients With Primary Aldosteronism
  4954. High sensitive CRP and copeptin levels in patients with primary aldosteronism compared to hypertensive subjects: Data from the German Conn’s registry and the …
  4955. Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism
  4956. Intact endothelial epoxyeicosatrienoic acids pathway in primary aldosteronism–the route to new treatment strategies?
  4957. Adrenocortical hypofunction with simultaneous primary aldosteronism: A case report
  4958. Primary aldosteronism with an Aldosterone-producing adenoma and contralateral adrenal hyperplasia: A case report
  4959. Plasma metanephrines and normetanephrines: Alternative indices of avs in a patient with primary aldosteronism and endogenous hypercortisolemia
  4960. Impact of daily salt intake on the consistency between catopril challenge test and saline infusion test in patients with primary aldosteronism
  4961. Clinical presentation and management of primary aldosteronism in late childhood and adolescence: Experience in an outpatient hypertension clinic
  4962. Abstract P2025: Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans
  4963. Partially successful adrenal vein sampling can in some cases reveal the etiology of primary aldosteronism
  4964. The Aldosterone/renin ratio predicts cardiometabolic disorders in subjects without classic primary aldosteronism
  4965. Heparin-induced hypo-aldosteronism and hyperkalemia
  4966. ASSOCIATION OF LOW SODIUM-POTASSIUM RATIO WITH ATRIAL FIBRILLATION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4967. Possible protective influence of KCNJ5 and CACNA1D gene polymorphisms on lipid profile in primary aldosteronism and essential hypertensive patients
  4968. 11C-Metomidate PET/CT Identifies Unilateral Primary Aldosteronism in a Multi-ethnic Cohort
  4969. Biochemical and clinical cure of primary aldosteronism by ultrasound-guided endoscopic radiofrequency ablation
  4970. ANGIOTENSIN II TYPE 1 RECEPTOR AUTOANTIBODIES: CAUSE OR CONSEQUENCE OF HUMAN PRIMARY ALDOSTERONISM?
  4971. Diagnostic accuracy of captopril challenge test and saline infusion test in patients at high risk for primary aldosteronism
  4972. … OF SEVERE LEFT VENTRICLE HYPERTROPHY AFTER MEDICAL TREATMENT OF GLUCOCORTICOID-SUPPRESSIBLE PRIMARY ALDOSTERONISM
  4973. … imaging techniques, immunohistochemistry and genetic analysis to investigate the suitability of laparoscopic partial adrenalectomy in primary aldosteronism
  4974. Author’s Reply: Primary Aldosteronism: Does Underlying Pathology Impact Clinical Presentation and Outcomes Following Unilateral Adrenalectomy?
  4975. … RATIO AND LATERALIZATION INDEX ARE ASSOCIATED WITH ADVERSE RENAL OUTCOMES IN PRIMARY ALDOSTERONISM PATIENTS WHO UNDERWENT …
  4976. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as an alternative to left sided adrenalectomy in the treatment of primary aldosteronism
  4977. Evaluation of clinical and biochemical cure and adrenal CYP11B2 and CYP11B1 immunostaining in primary aldosteronism operated after adrenal venous sampling
  4978. SUN-367 Artificial Intelligence Systems for Predicting Primary Aldosteronism Subtype
  4979. Abstract MP11: Aldosterone Synthase Structure With Cushing’s Disease Drug Osilodrostat Provides Clues For Treatment Of Primary Aldosteronism
  4980. Somatic transmembrane domain mutations of a cell adhesion molecule, CADM1, cause primary aldosteronism by preventing gap junction communication between …
  4981. SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening
  4982. SUN-058 Concurrent Hypercortisolism in Primary Aldosteronism Patients at a Tertiary Care Center: 2007-2017
  4983. MP69-03 IMPACT OF LAPAROSCOPIC ADRENALECTOMY ON CARDIAC FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4984. MON-211 Prevalence, Characteristics and Outcomes of Primary Aldosteronism in Newly Diagnosed Hypertensives in China (Pa China)
  4985. SAT-016 The Influence of Aldosterone Values in the Tributary Veins of Unresected Adrenal Gland on Primary Aldosteronism Surgical Outcomes
  4986. MON-215 Clinical Factors Associated with Insulin Secretion and Sensitivity in Patients with Primary Aldosteronism
  4987. MON-198 Cosyntropin Stimulation on Adrenal Venous Sampling Obscure Surgically Curable Primary Aldosteronism
  4988. MON-213 Cardiac Damage and Related Risk Factors in Patients with Primary Aldosteronism
  4989. MON-193 Glucocorticoid Excess and Its Association with Metabolic and Cardiovascular Complications in Primary Aldosteronism
  4990. SUN-366 The Optimal Cutoff Value for Basal Plasma Aldosterone Concentration Suspected as Primary Aldosteronism Distributed According to Aldosterone-Renin …
  4991. SAT-059 Treatment Of Primary Aldosteronism With The mTORC1 Inhibitor Everolimus
  4992. SAT-563 The Unsuppressed Plasma Renin Activity May Not Enough for Management of Non-Surgically Treated Primary Aldosteronism
  4993. SUN-365 Characteristics of Primary Aldosteronism without Suppression of Plasma Renin Activity
  4994. SUN-144 High Prevalence of Diabetes in Patients with Primary Aldosteronism (PA) Associated with Subclinical Hypercortisolism and Prediabetes More Prevalent in …
  4995. SAT-060 Analysis of over 24,000 Aldosterone to Renin Ratio for Screening Hypertensive Patients for Primary Aldosteronism
  4996. PD31-03 FACTORS ASSOCIATED WITH RENAL FUNCTION DECLINE AFTER UNILATERAL ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM
  4997. SAT-075 Introduction of a Single Radiologist Improves the Performance of Adrenal Vein Sampling for Primary Aldosteronism, but Does Not Ameliorate Suboptimal …
  4998. SAT-058 Histopathological Analysis of Kidneys and Adrenal Glands in the Same Primary Aldosteronism (PA) Patients: Exploring the Mechanisms of Aldosterone …
  4999. OR02-3 Endocrinological Crosstalk between Calcium Metabolism and Steroidogenesis in Primary Aldosteronism
  5000. … TO PREDICT RENAL DAMAGE AFTER LAPAROSCOPIC ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM: MANAGEMENT OF UNMASKED …
  5001. SUN-364 In Search of Predictors of Concordance between Imaging and Adrenal Vein Sampling in Unilateral Primary Aldosteronism
  5002. OR31-6 Insulin Sensitivity and Pancreatic Beta-Cell Function in Patients with Primary Aldosteronism
  5003. MP69-01 VALIDATION OF PRIMARY ALDOSTERONISM (PA) DISCRIMINATION SCORE FOR CONFIRMATORY TESTS OF PA
  5004. SAT-067 Insights into Paradoxical Bilateral Aldosterone Suppression in the Adrenal Veins of Patients with Primary Aldosteronism
  5005. SAT-056 Primary Aldosteronism Has a Distinctive Twenty-four Hour Blood Pressure Profile
  5006. SAT-002 Measurement of Visceral Fat Using Computed Tomography in Two Subtypes of Primary Aldosteronism
  5007. SAT-061 Determinants of Cosyntropin Effect on Adrenal Vein Sampling Lateralization in Primary Aldosteronism
  5008. SAT-070 Clinical and Imaging Characteristics of Primary Unilateral Adrenal Hyperplasia in Primary Aldosteronism
  5009. 2445-PUB: Impact of Primary Aldosteronism on Renal Function in Type 2 Diabetes Patients
  5010. PD31-04 IMPACT OF NOCTURIA ON DETERIORATED RENAL FUNCTION AFTER ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM
  5011. SAT-076 The Effect of Body Mass Index on Diagnosis of Primary Aldosteronism
  5012. SAT-055 The Aldosterone-Renin Ratio Predicts Cardiometabolic Disorders in Subjects without Classic Primary Aldosteronism
  5013. SAT-062 National PA Registry as a Platform for Standardized Clinical Practice of Primary Aldosteronism in Japan
  5014. … OF PRE-OPERATIVE MODELS FOR PREDICTING PATHOLOGY OF PRIMARY ALDOSTERONISM-A JAPAN PRIMARY ALDOSTERONISM STUDY/JAPAN RARE …
  5015. SAT-052 Comparison of Echocardiographic Parameters between Pre-and Post-Adrenalectomy in Patients with Primary Aldosteronism
  5016. SAT-071 Usefulness of NP-59 SPECT/CT for Lateralization in Primary Aldosteronism
  5017. SAT-074 Using Ipsilateral and Contralateral Ratios from Adrenal Vein Samples to Identify Functioning Adrenal Adenoma in Patients with Primary Aldosteronism
Related Posts

Gut Brain Axis

Nootropics

Phytosterols

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping